Chemokine receptor antagonists and methods of use thereof

ABSTRACT

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 
     
       
         
         
             
             
         
       
     
     or physiologically acceptable salt thereof.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.12/436,271, filed May 6, 2009, which is a continuation of U.S.application Ser. No. 11/595,653, filed Nov. 10, 2006, which is acontinuation of U.S. application Ser. No. 10/487,168, filed Oct. 7,2004, which is the U.S. National Phase of International Application No.PCT/US02/36953, filed Nov. 13, 2002, published in English, which is acontinuation-in-part of U.S. application Ser. No. 09/989,086, filed Nov.21, 2001 (abandoned), the entire teachings of all above-referencedapplications are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Chemoattractant cytokines or chemokines are a family of proinflammatorymediators that promote recruitment and activation of multiple lineagesof leukocytes and lymphocytes. They can be released by many kinds oftissue cells after activation. Continuous release of chemokines at sitesof inflammation mediates the ongoing migration of effector cells inchronic inflammation. The chemokines characterized to date are relatedin primary structure. They share four conserved cysteines, which formdisulfide bonds. Based upon this conserved cysteine motif, the family isdivided into two main branches, designated as the C—X—C chemokines(α-chemokines), and the C—C chemokines (β-chemokines), in which thefirst two conserved cysteines are separated by an intervening residue,or adjacent respectively (Baggiolini, M. and Dahinden, C. A., ImmunologyToday, 15:127-133 (1994)).

The C—X—C chemokines include a number of potent chemoattractants andactivators of neutrophils, such as interleukin 8 (IL-8), PF4 andneutrophil-activating peptide-2 (NAP-2). The C—C chemokines includeRANTES (Regulated on Activation, Normal T Expressed and Secreted), themacrophage inflammatory proteins 1α and 1β (MIP-1α and MIP-1β), eotaxinand human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2, MCP-3), whichhave been characterized as chemoattractants and activators of monocytesor lymphocytes but do not appear to be chemoattractants for neutrophils.Chemokines, such as RANTES and MIP-1α, have been implicated in a widerange of human acute and chronic inflammatory diseases includingrespiratory diseases, such as asthma and allergic disorders.

The chemokine receptors are members of a superfamily of Gprotein-coupled receptors (GPCR) which share structural features thatreflect a common mechanism of action of signal transduction (Gerard, C.and Gerard, N. P., Annu Rev. Immunol., 12:775-808 (1994); Gerard, C. andGerard, N. P., Curr. Opin. Immunol., 6:140-145 (1994)). Conservedfeatures include seven hydrophobic domains spanning the plasma membrane,which are connected by hydrophilic extracellular and intracellularloops. The majority of the primary sequence homology occurs in thehydrophobic transmembrane regions with the hydrophilic regions beingmore diverse. The first receptor for the C—C chemokines that was clonedand expressed binds the chemokines MIP-1α and RANTES. Accordingly, thisMIP-1α/RANTES receptor was designated C—C chemokine receptor 1 (alsoreferred to as CCR-1; Neote, K., et al., Cell, 72:415-425 (1993); Horuk,R. et al., WO 94/11504, May 26, 1994; Gao, J.-I. et al., J. Exp. Med.,177:1421-1427 (1993)). Three receptors have been characterized whichbind and/or signal in response to RANTES: CCR3 mediates binding andsignaling of chemokines including eotaxin, RANTES, and MCP-3 (Ponath etal., J. Exp. Med., 183:2437 (1996)), CCR4 binds chemokines includingRANTES, MIP-1α, and MCP-1 (Power, et al., J. Biol. Chem., 270:19495(1995)), and CCR5 binds chemokines including MIP-1α, RANTES, and MIP-1β(Samson, et al., Biochem. 35: 3362-3367 (1996)). RANTES is a chemotacticchemokine for a variety of cell types, including monocytes, eosinophils,and a subset of T-cells. The responses of these different cells may notall be mediated by the same receptor, and it is possible that thereceptors CCR1, CCR4 and CCR5 will show some selectivity in receptordistribution and function between leukocyte types, as has already beenshown for CCR3 (Ponath et al.). In particular, the ability of RANTES toinduce the directed migration of monocytes and a memory population ofcirculating T-cells (Schall, T. et al., Nature, 347:669-71 (1990))suggests this chemokine and its receptor(s) may play a critical role inchronic inflammatory diseases, since these diseases are characterized bydestructive infiltrates of T cells and monocytes.

Many existing drugs have been developed as antagonists of the receptorsfor biogenic amines, for example, as antagonists of the dopamine andhistamine receptors. No successful antagonists have yet been developedto the receptors for the larger proteins such as chemokines and C5a.Small molecule antagonists of the interaction between C—C chemokinereceptors and their ligands, including RANTES and MIP-1α, would providecompounds useful for inhibiting harmful inflammatory processes“triggered” by receptor ligand interaction, as well as valuable toolsfor the investigation of receptor-ligand interactions.

SUMMARY OF THE INVENTION

It has now been found that a class of small organic molecules areantagonists of chemokine receptor function and can inhibit leukocyteactivation and/or recruitment. An antagonist of chemokine receptorfunction is a molecule which can inhibit the binding and/or activationof one or more chemokines, including C—C chemokines such as RANTES,MIP-1α, MCP-2, MCP-3 and MCP-4 to one or more chemokine receptors onleukocytes and/or other cell types. As a consequence, processes andcellular responses mediated by chemokine receptors can be inhibited withthese small organic molecules. Based on this discovery, a method oftreating a disease associated with aberrant leukocyte recruitment and/oractivation is disclosed as well as a method of treating a diseasemediated by chemokine receptor function. The method comprisesadministering to a subject in need an effective amount of a compound orsmall organic molecule which is an antagonist of chemokine receptorfunction. Compounds or small organic molecules which have beenidentified as antagonists of chemokine receptor function are discussedin detail hereinbelow, and can be used for the manufacture of amedicament for treating or for preventing a disease associated withaberrant leukocyte recruitment and/or activation. In one aspect, thecompound has the formula:

or a physiologically acceptable salt thereof, wherein Z, n, M, R⁷⁰, R⁷¹,R⁷² and R⁷³ are as described herein.

The invention also relates to the disclosed compounds and small organicmolecules for use in treating or preventing a disease associated withaberrant leukocyte recruitment and/or activation. The invention alsoincludes pharmaceutical compositions comprising one or more of thecompounds or small organic molecules which have been identified hereinas antagonists of chemokine function and a suitable pharmaceuticalcarrier. The invention further relates to novel compounds which can beused to treat an individual with a disease associated with aberrantleukocyte recruitment and/or activation and methods for theirpreparation.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic showing the preparation of the compoundsrepresented by Structural Formula (I).

FIG. 2 is a schematic showing the preparation of the compoundsrepresented by Compound (VI-b).

FIG. 3 is a schematic showing the preparation of the compoundsrepresented by Structural Formula (I)

FIG. 4 is a schematic showing the preparation of the compoundsrepresented by Structural Formula (I), wherein Z is represented byStructural Formula (III) and wherein Ring A and/or Ring B in Z issubstituted with R⁴⁰.

FIG. 5 is a schematic showing the preparation of the compoundsrepresented by Structural Formula (I), wherein Z is represented byStructural Formula (III) and wherein Ring A and/or Ring B in Z issubstituted with —(O)_(u)—(CH₂)_(t)—COOR²⁰, —(O)_(u)—(CH₂)_(t)—OC(O)R²⁰,—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²² or —(O)_(u)—(CH₂)_(t)—NHC(O)—R²⁰.

FIGS. 6A-6Z show the structures of exemplary compounds of the presentinvention.

FIG. 7 shows the preparation of compounds represented by StructuralFormula (I), where in Z is represented by Structural Formulas (III) andwherein Ring A or Ring B in Z is substituted with R⁴⁰.

FIG. 8A is a schematic showing the preparation of4-(4-chlorophenyl)-4-fluoropiperidine.

FIG. 8B is a schematic showing the preparation of4-4-azido-4-(4-chlorophenyl)piperidine.

FIG. 8C is a schematic showing the preparation of4-(4-chlorophenyl)-4-methylpiperidine.

FIG. 9A is a schematic showing the preparation of compounds representedby Structural Formulas (I), (VIII) and (VIII) wherein R¹ is an amine.

FIG. 9B is a schematic showing the preparation of compounds representedby Structural Formulas (I), (VIII) and (VIII) wherein R¹ is analkylamine.

FIG. 9C is a schematic showing the preparation of2-(4-chlorophenyl)-1-(N-methyl)ethylamine.

FIG. 9D is a schematic showing the preparation of3-(4-chlorophenyl)-3-chloro-1-hydroxypropane.

FIG. 9E is a schematic showing the preparation of3-(4-chlorophenyl)-1-N-methylaminopropane.

FIG. 10A is a schematic showing the preparation of3-(4-chlorophenyl)-3-hydroxyl-3-methyl-1-N-methylaminopropane.

FIG. 10B is a schematic showing the preparation of1-(4-chlorobenzoyl)-1,3-propylenediamine.

FIG. 10C is a schematic showing three procedures for the preparation ofcompounds represented by Structural Formulas (I), (VII), (VIII), (IX)and (XI) wherein Z is represented by Structural Formula (III) andwherein Ring A or Ring B in Z is substituted with R⁴⁰. In FIG. 10C, R⁴⁰is represented by —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²², u is one, t is zero.

FIG. 10D is a schematic showing the preparation of4-(4-chlorophenyl)-4-pyridine.

FIGS. 11A-11T show the structures of exemplary compounds of the presentinvention.

FIG. 12 is a schematic showing preparation of compounds of formula(VI-c).

FIG. 13 is a schematic showing preparation of compounds of formula(VI-e).

FIG. 14 is a schematic showing a procedure for the preparation ofExamples 434 and 435.

FIG. 15 is a schematic showing a procedure for the preparation ofExamples 436-438.

FIG. 16 is a schematic showing a procedure for the preparation ofcompounds of formula (I-f).

FIG. 17 is a schematic showing a procedure for the preparation ofExamples 441 and 442.

FIG. 18 is a schematic showing a procedure for the preparation ofExample 443.

FIG. 19 is a schematic showing a procedure for the preparation ofExamples 315, 455, 338 and 446.

FIGS. 20-28 show the structures of exemplary compounds of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to small molecule compounds which aremodulators of chemokine receptor function. In a preferred embodiment,the small molecule compounds are antagonists of chemokine receptorfunction. Accordingly, processes or cellular responses mediated by thebinding of a chemokine to a receptor can be inhibited (reduced orprevented, in whole or in part), including leukocyte migration, integrinactivation, transient increases in the concentration of intracellularfree calcium [Ca⁺⁺]_(i), and/or granule release of proinflammatorymediators.

The invention further relates to a method of treatment, includingprophylactic and therapeutic treatments, of a disease associated withaberrant leukocyte recruitment and/or activation or mediated bychemokines or chemokine receptor function, including chronicinflammatory disorders characterized by the presence of RANTES, MIP-1α,MCP-2, MCP-3 and/or MCP-4 responsive T cells, monocytes and/oreosinophils, including but not limited to diseases such as arthritis(e.g., rheumatoid arthritis), atherosclerosis, arteriosclerosis,restenosis, ischemia/reperfusion injury, diabetes mellitus (e.g., type 1diabetes mellitus), psoriasis, multiple sclerosis, inflammatory boweldiseases such as ulcerative colitis and Crohn's disease, rejection oftransplanted organs and tissues (i.e., acute allograft rejection,chronic allograft rejection), graft versus host disease, as well asallergies and asthma. Other diseases associated with aberrant leukocyterecruitment and/or activation which can be treated (includingprophylactic treatments) with the methods disclosed herein areinflammatory diseases associated with Human Immunodeficiency Virus (HIV)infection, e.g., AIDS associated encephalitis, AIDS relatedmaculopapular skin eruption, AIDS related interstitial pneumonia, AIDSrelated enteropathy, AIDS related periportal hepatic inflammation andAIDS related glomerulo nephritis. The method comprises administering tothe subject in need of treatment an effective amount of a compound(i.e., one or more compounds) which inhibits chemokine receptorfunction, inhibits the binding of a chemokine to leukocytes and/or othercell types, and/or which inhibits leukocyte migration to, and/oractivation at, sites of inflammation.

The invention further relates to methods of antagonizing a chemokinereceptor, such as CCR1, in a mammal comprising administering to themammal a compound as described herein.

According to the method, chemokine-mediated chemotaxis and/or activationof pro-inflammatory cells bearing receptors for chemokines can beinhibited. As used herein, “pro-inflammatory cells” includes but is notlimited to leukocytes, since chemokine receptors can be expressed onother cell types, such as neurons and epithelial cells.

While not wishing to be bound by any particular theory or mechanism, itis believed that compounds of the invention are antagonists of thechemokine receptor CCR1, and that therapeutic benefits derived from themethod of the invention are the result of antagonism of CCR1 function.Thus, the method and compounds of the invention can be used to treat amedical condition involving cells which express CCR1 on their surfaceand which respond to signals transduced through CCR1, as well as thespecific conditions recited above.

In one embodiment, the antagonist of chemokine receptor function isrepresented by Structural Formula (I):

and physiologically acceptable salts thereof.

Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one,two or more aromatic rings, wherein each ring in Z is independentlysubstituted or unsubstituted.

n is an integer, such as an integer from one to four. Preferably, n isone, two or three. More preferably n is two. In alternative embodiments,other aliphatic or aromatic spacer groups (L) can be employed for(CH₂)_(n).

M is >NR² or >CR¹R². M is preferably >C(OH)R².

R¹ is —H, —OH, —N₃, a halogen, an aliphatic group, a substitutedaliphatic group, an aminoalkyl group, —O-(aliphatic group),—O-(substituted aliphatic group), —SH, —S-(aliphatic group),—S-(substituted aliphatic group), —OC(O)-(aliphatic group),—O—C(O)-(substituted aliphatic group), —C(O)O-(aliphatic group),—C(O)O-(substituted aliphatic group), —COOH, —CN, —CO—NR³R⁴, —NR³R⁴; orR¹ can be a covalent bond between the ring atom at M and an adjacentcarbon atom in the ring which contains M. R¹ is preferably —H or —OH.

R² is —H, —OH, a halogen, an acyl group, a substituted acyl group,—NR⁵R⁶, an aliphatic group, a substituted aliphatic group, an aromaticgroup, a substituted aromatic group, a benzyl group, a substitutedbenzyl group, a non-aromatic heterocyclic group, a substitutednon-aromatic heterocyclic group, —O-(substituted or unsubstitutedaromatic group), —O-(substituted or unsubstituted aliphatic group) or—C(O)-(substituted or unsubstituted aromatic group) or—C(O)-(substituted or unsubstituted aliphatic group). R² is preferablyan aromatic group or a substituted aromatic group.

R³, R⁴, R⁵ and R⁶ are independently —H, an acyl group, a substitutedacyl group, an aliphatic group, a substituted aliphatic group, anaromatic group, a substituted aromatic group, a benzyl group, asubstituted benzyl group, a non-aromatic heterocyclic group or asubstituted non-aromatic heterocyclic group.

R¹ and R², R³ and R⁴, or R⁵ and R⁶ taken together with the atom to whichthey are bonded, can alternatively form a substituted or unsubstitutednon-aromatic carbocyclic or heterocyclic ring.

In embodiments where M is >CR¹R² and R¹ is a covalent bond between thecarbon atom at M and an adjacent carbon atom in the ring which containsM, the antagonist of chemokine function can be represented by StructuralFormula (Ia).

Z, n and R² are as described in Structural Formula (I).

In one embodiment, Z is a tricyclic ring system comprising twocarbocyclic aromatic groups fused to a five, six, seven or eightmembered cycloalkyl group or to a non-aromatic heterocyclic ring. In oneexample, Z is represented by Structural Formula (II):

The phenyl rings in Structural Formula (II), labeled with an “A” and“B”, are referred to herein as “Ring A” and “Ring B”, respectively. Thecentral ring, labeled with a “C”, is referred to as “Ring C” and can be,for example, a five, six, seven or eight membered non-aromaticcarbocyclic ring (e.g., a cycloheptane or cyclooctane ring) or anon-aromatic heterocyclic ring. When Ring C is a non-aromaticheterocyclic ring, it can contain one or two heteroatoms such asnitrogen, sulfur or oxygen. In particular embodiments, Ring c is When Zis represented by Structural Formula (II), the tricyclic ring system canbe connected to the remainder of the molecule by a covalent double bondbetween a carbon atom in Ring C and the carbon atom which, as depictedin Structural Formula (I), is bonded to Z.

Ring A and/or Ring B in Structural Formula (II) can be unsubstituted.Alternatively, Ring A and/or Ring B can have one or more substituents.Suitable substituents are as described hereinbelow. In one example, RingA or Ring B is substituted with —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²² or—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰.

u is zero or one.

t is an integer, such as an integer from zero to three, and themethylene group —(CH₂)_(t)— can be substituted, as described herein foraliphatic groups, or unsubstituted.

R²⁰, R²¹ or R²² are independently —H, an aliphatic group, a substitutedaliphatic group, an aromatic group, a substituted aromatic group or anon-aromatic heterocyclic group. Alternatively, R²¹ and R²², takentogether with the nitrogen atom to which they are bonded, can form anon-aromatic heterocyclic ring.

Ring C optionally contains one or more substituents, as describedhereinbelow. Examples of suitable tricyclic ring systems, Z, areprovided by Structural Formula (III):

Ring A and Ring B in Structural Formula (III) are as described forStructural Formula (II).

X₁ is a bond, —O—, —S—, —CH₂—, —CH₂—CH₂—, —CH₂—S—, —S—CH₂—, —O—CH₂—,—CH₂—O—, —NR_(c)—CH₂—, —CH₂—NR_(c)—, —SO—CH₂—, —CH₂—SO—, —S(O)₂—CH₂—,—CH₂—S(O)₂—, —CH═CH—, —NR_(c)—CO— or —CO—NR_(c)—. Preferably X₁ is—CH₂—O—, —CH₂—CH₂—, —CH₂—S—, —NR_(c)—CO— or —CO—NR_(c)—.

R_(c) is hydrogen, an aliphatic group, a substituted aliphatic group, anaromatic group, a substituted aromatic group, a benzyl group or asubstituted benzyl group.

In one example, R_(c) is —(CH₂)_(s)—COOR³⁰, —(CH₂)_(s)—C(O)—NR³¹R³² or—(CH₂)_(s)—NHC(O)—O—R³⁰, wherein s is an integer, such as an integerfrom one to three;

R³⁰, R³¹ and R³² are independently —H, an aliphatic group, a substitutedaliphatic group, an aromatic group, a substituted aromatic group or anon-aromatic heterocyclic group. Alternatively, R³¹ and R³², takentogether with the nitrogen atom to which they are bonded, form anon-aromatic heterocyclic ring.

Other examples of suitable tricyclic ring systems for Z includebenzodiazepines, benzooxazepines, benzooxazines, phenothiazines andgroups represented by the following structural formulas:

In other embodiments, Z is a tricyclic ring system comprising twoaromatic groups fused to a seven or eight membered cycloalkyl group orto a non-aromatic heterocyclic ring, wherein at least one of thearomatic groups is a heteroaryl group. In one example, Z is

Ring A in Structural Formula (IV) can be a substituted or unsubstitutedheteroaryl group. Ring B in Structural Formula (IV) can be a substitutedor unsubstituted aromatic group, e.g., a heteroaryl group or carbocyclicaryl group. Suitable substituents are as described hereinbelow. In oneexample, Ring A and/or Ring B is substituted with

—(O)_(u)—(CH₂)_(t)—C(O)OR²⁰, —(O)_(u)—(CH₂)_(t)—OC(O)R²⁰,—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²² or —(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰ asdescribed above. u, t, R²⁰, R²¹, and R²² are as described above. X₁ andR_(c) can be as described above for Structural Formula (III).

In another embodiment of the present invention Z is represented byStructural Formula (IV), wherein Ring A is a pyridyl group and Ring B isan aromatic or heteroaromatic group. In one example, Z is represented byStructural Formula (IVa):

In this embodiment Ring A and Ring B are independently substituted orunsubstituted, and Ring B is preferably a phenyl group. X₁ and R_(c) canbe as described above for Structural Formula (III).

In another embodiment, both Ring A and Ring B are pyridyl groups, and Zis represented by Structural Formula (IVb):

Ring A and Ring B can be independently substituted or unsubstituted asdescribed above in Structural Formula (II), and X₁ can be as describedabove for Structural Formula (III).

In preferred embodiments, Z is represented by Structural Formula (V):

Ring A and Ring B can be independently substituted or unsubstituted asdescribed above in Structural Formula (II), and X₁ can be as describedabove for Structural Formula (III).

In particularly preferred embodiments, Ring B in Structural Formula (V)is substituted para to the carbon atom of Ring B which is bonded to X₁of Ring C, and Z is represented by Structural Formula (VI):

X₁ can be as described above in Structural Formula (II). Preferably X₁is —CH₂—O—, —CH₂—CH₂— or —CH₂—S—.

R⁴⁰ is a substituent as described herein for aromatic groups. In oneembodiment, R⁴⁰ is —OH, —COOH, a halogen, —NO₂, an aliphatic group, asubstituted aliphatic group, an aromatic group, a substituted aromaticgroup, —NR²⁴R²⁵, —CONR²⁴R²⁵, —C(═NR⁶⁰)NR²¹R²², -Q-(aliphatic group),-Q-(substituted aliphatic group), —O-(aliphatic group), —O-(substitutedaliphatic group), —O-(aromatic group), —O-(substituted aromatic group),an electron withdrawing group, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²² or—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰. Q, R²⁰, R²¹, R²², R²⁴, R²⁵, R⁶⁰, u and tare as described herein.

Preferably R⁴⁰ is an aliphatic group, substituted aliphatic group,—O-(aliphatic group) or —O-(substituted aliphatic group). In certainembodiments, R⁴⁰ is an —O-alkyl, such as —O—CH₃, —O—C₂H₅, —O—C₃H₇ or—O—C₄H₉.

In another embodiment, R⁴⁰ can be represented by—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²², wherein u is one, t is zero, and R²¹and R²² are as described herein. In this embodiment, R²¹ and R²² caneach independently be —H, a substituted or unsubstituted aliphaticgroup, a substituted or unsubstituted aromatic group, or R²¹ and R²²taken together with the nitrogen atom to which they are bonded form asubstituted or unsubstituted nonaromatic heterocyclic ring (e.g.,pyrrolidine, piperidine, morpholine).

In another embodiment, R⁴⁰ can be represented by—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²², wherein u is zero, t is one to aboutthree, and R²¹ and R²² are as described herein.

In another embodiment, R⁴⁰ can be represented by—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²², wherein both u and t are zero, and R²¹and R²² are as described herein.

In another embodiment, R⁴⁰ is an aliphatic group (e.g., methyl, ethyl,propyl) that is substituted with —NR²⁴R²⁵ or —CONR²⁴R²⁵, wherein R²⁴ andR²⁵ are as described herein. For example, R⁴⁰ can be represented by

In another embodiment, R⁴⁰ is —O—C(O)—NR²¹R²⁶, wherein R²¹ is asdescribed herein, R²⁶ can be —H, an aliphatic group, a substitutedaliphatic group, an aromatic group, a substituted aromatic group, anon-aromatic heterocyclic group, —C(O)—O-(substituted or unsubstitutedaliphatic group), —C(O)—O-(substituted or unsubstituted aromatic group),—S(O)₂-(substituted or unsubstituted aliphatic group),—S(O)₂-(substituted or unsubstituted aromatic group) or R²¹ and R²⁶,taken together with the nitrogen atom to which they are bonded, can forma substituted or unsubstituted non-aromatic heterocyclic ring.

In additional embodiments, R⁴⁰ can be —S(O)₂—NR²¹R²² or —N—C(O)—NR²¹R²²,wherein R²¹ and R²² are as described herein.

In a preferred embodiment, the chemokine receptor antagonist can berepresented by Structural Formula I wherein n is three, M is C(OH)R², R²is a phenyl group or a halophenyl group (e.g., 4-chlorophenyl) and Z isrepresented by Structural Formula (VI) wherein X₁ is —CH₂—O—. In oneexample of this embodiment, R⁴⁰ can be —O-(substituted aliphatic group),such as

In particularly preferred embodiments, R⁴⁰ is

In other preferred embodiments, R⁴⁰ is a substituted aliphatic group, asubstituted aromatic group, —O-substituted aliphatic group or—O-substituted aromatic group. Preferably the aliphatic or aromaticmoiety of the substituted aliphatic group, substituted aromatic group,—O-substituted aliphatic group or —O-substituted aromatic group bears asubstituent selected from the group consisting of —OH, —COOR,-Q-aliphatic group or -Q-aromatic group substituent. Q is as describedherein. Preferably, Q is —C(O)O—. For example, R⁴⁰ can be a linear,branched or cyclic aliphatic group that contains 1 to 6 carbon atoms,such as a C₁-C₆ alkyl group, a C₂-C₆ alkenyl, C₂-C₆ alkynyl, that issubstituted with —OH, —COOH, —C(O)O—(C₁-C₆ aliphatic) or—C(O)O-(aromatic).

In another embodiment, the antagonist of chemokine activity can berepresented by Structural Formula (VII):

and physiologically acceptable salts thereof.

n is as described in Structural Formula (I). Z is as described herein,preferably as described in Structural Formula (V) or (VI).

M is >NR², >CR¹R², or —CH₂—CR¹R²—O—.

R¹ and R² are as described in Structural Formula (I).

q¹ is an integer, such as an integer from zero to about three, and q² isan integer from zero to about one. The ring containing M can besubstituted or unsubstituted.

Thus, the antagonist of chemokine function can be represent by, forexample, Structural Formulas (VIIa)-(VIIk):

and physiologically acceptable salts thereof, wherein Z, n and M are asdescribed in Structural Formula (VII), and the ring which contains M issubstituted or unsubstituted. The ring containing M can have one or moresuitable substituents which are the same or different. Suitablesubstituents for the ring which contains M and other nonaromaticheterocyclic rings are as described herein. For example, the ringcontaining M can be substituted with a methyl, ethyl, propyl, butyl oroxo group.

When the ring containing M is substituted, the compound can berepresented by Sturctural Formula (VIII):

or physiologically acceptable salt thereof.

R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶ and R⁷⁷ are independently —H, —OH,—N₃, a halogen, an aliphatic group, a substituted aliphatic group, anaminoalkyl group, —O-(aliphatic group), —O-(substituted aliphaticgroup), —SH, —S-(aliphatic group), —S-(substituted aliphatic group),—OC(O)-(aliphatic group), —O—C(O)-(substituted aliphatic group),—C(O)O-(aliphatic group), —C(O)O-(substituted aliphatic group), —COOH,—CN, —CO—NR³R⁴, —NR³R⁴, an acyl group, a substituted acyl group, abenzyl group, a substituted benzyl group, a non-aromatic heterocyclicgroup, a substituted non-aromatic heterocyclic group, —O-(substituted orunsubstituted aromatic group), or any two of R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴,R⁷⁵, R⁷⁶ and R⁷⁷ taken together with the atoms to which they are bondedform a three to eight membered ring.

n is as described in Structural Formula (I). Z is as described herein,preferably as described in Structural Formula (V) or (VI). M is asdescribed in Structural Formula (VII). Preferably, M is >NR² or >CR¹R².

In certain embodiments R⁷⁴, R⁷⁵, R⁷⁶ and R⁷⁷ are —H. In otherembodiments, R⁷⁴, R⁷⁵, R⁷⁶ and R⁷⁷ are —H, and at least one of R⁷⁰, R⁷¹,R⁷² and R⁷³ is an aliphatic group or a substituted aliphatic group.Preferred aliphatic groups at R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶ and R⁷⁷are C₁-C₆ alkyl, preferred substititued aliphatic groups are are C₁-C₆alkyl substituted with —OH, —(O)_(u)—(CH₂)_(t)—C(O)OR₂₀ or —O-(aliphaticgroup) wherein t is zero to three, u is zero or one, and R²⁰ is C₁-C₆alkyl. In more particular embodiments, the compound has the formula ofStructural Formula VIII wherein R⁷⁰, R⁷³, R⁷⁴, R⁷⁵, R⁷⁶ and R⁷⁷ are —H,and at least one of R⁷¹ and R⁷² is —CH₃.

In a preferred embodiment, the chemokine receptor antagonist isrepresented by Structural Formula VIII wherein n is two; M is >C(OH)R²;R² is a halophenyl group (e.g., 4-chlorophenyl);

R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶ and R⁷⁷ are —H and R⁷⁰ and R⁷¹ are independentlyC₁-C₆ alkyl or substituted C₁-C₆ alkyl; or R⁷⁰, R⁷¹, R⁷⁴, R⁷⁵, R⁷⁶ andR⁷⁷ are —H and R⁷² and R⁷³ are independently C₁-C₆ alkyl or substitutedC₁-C₆ alkyl; and

Z is represented by Structural Formula (VI) wherein X_(i) is —CH₂—O—.

When R⁷² and R⁷³ are each —CH₃, the compounds of this preferredembodiment can have the formula:

or a physiologically acceptable salt thereof, wherein R² is4-halophenyl. Preferably R² is selected from the group consisting of4-chlorophenyl, 4-bromophenyl and 4-fluorophenyl. Preferred groups atR⁴⁰ are as described herein. Particularly preferred at R⁴⁰ are aliphaticgroups (e.g., C₁-C₆ alkyl) and substituted aliphatic groups.

In a particularly preferred embodiment, the compound is the(S)-enantiomer of the compound of Formula (XII) and has the structure:

or a physiologically acceptable salt thereof, wherein R² is4-halophenyl.

Particularly preferred compounds of the invention have the structure ofFormula XIII wherein R² is 4-chlorophenyl and R⁴⁰ is selected from thegroup consisting of:

In another embodiment, the compound is represented by Structural FormulaVIII:

or a physiologically acceptable salt thereof, wherein n, R¹ and R² areas described in Structural Formula (I), and Z is as described inStructural Formula (V) or (VI).

In a certain embodiments, Z is represented by Structural Formula (VI)wherein X₁ is —CH₂—O—; n is two, R¹ is —H and R² is —NR⁵R⁶. Preferably,compounds of these embodiments have the structure:

or a physiologically acceptable salt thereof, wherein R⁵ and R⁶ are asdescribed in Structural Formula I, and preferred groups at R⁴⁰ are asdescribed herein.

In particular embodiments, R⁵ is aliphatic group (e.g., C₁-C₆ alkyl) orsubstituted aliphatic group, and R⁶ is benzyl or substituted benzyl; orR⁵ and R⁶ taken together with the atom to which they are bonded, form asubstituted or unsubstituted non-aromatic carbocyclic or heterocyclicring. In more particular embodiments, R⁵ is C₁-C₆ alkyl and R⁶ ishalo-substituted benzyl. In a preferred embodiment, R⁵ is ethyl and R⁶is chloro-substituted benzyl (e.g., 4-chlorobenzyl).

The nitrogen atom in the ring containing M can be a tertiary nitrogen asdepicted in Structural Formula (IV), or the nitrogen atom can bequaternized with a suitable substituent, such as a C₁ to about C₆ or aC₁ to about C₃ substituted or unsubstituted aliphatic group. Compoundswhich comprise a quaternary nitrogen atom can also contain acounteranion such as chloride, bromide, iodide, acetate, perchlorate andthe like.

The antagonist of chemokine function can be represented by StructuralFormula (VII) wherein the heterocyclic ring containing M is substitutedwith a suitable bivalent group which is bonded to two atoms that are inthe ring, thereby forming a bicyclic moiety. Suitable bivalent groupsinclude, for example, substituted or unsubstituted bivalent aliphaticgroups, such as a C₁-C₆ alkylene group.

The antagonist of chemokine receptor function can comprise a variety ofbicyclic moieties. In one embodiment, the antagonist of chemokinereceptor function can be represented by Structural Formula (VIII):

and physiologically acceptable salts thereof.

M is >NR², >CR¹R², —O—CR¹R²—O— or —CH₂—CR¹R²—O—. Preferably, M is >NR²or >CR¹R². R¹ and R² are as described in Structural Formula (I), and nand Z are as described in structural Formula (VII).

In another embodiment, the antagonist of chemokine receptor function isrepresented by Structural Formula (IX):

and physiologically acceptable salts thereof

Z is as described herein, preferably as described in Structural Formula(V) or (VI).

n is an integer, such as an integer from one to about four. Preferably,n is one, two or three. More preferably n is two. In alternativeembodiments, other aliphatic or aromatic spacer groups (L) can beemployed for (CH₂)_(n).

R⁵⁰ and R⁵¹ are each independently —H, an aliphatic group, a substitutedaliphatic group, an aminoalkyl group, —NR³R⁴, an aromatic group, asubstituted aromatic group, a benzyl group, a substituted benzyl group,a non-aromatic heterocyclic group, a substituted non-aromaticheterocyclic group or a covalent bond between the nitrogen atom anadjacent carbon atom.

R³ and R⁴ are independently —H, an acyl group, a substituted acyl group,an aliphatic group, a substituted aliphatic group, an aromatic group, asubstituted aromatic group, a benzyl group, a substituted benzyl group,a non-aromatic heterocyclic group or a substituted non-aromaticheterocyclic group.

R³ and R⁴ taken together with the atom to which they are bonded, canalternatively form a substituted or unsubstituted non-aromaticcarbocyclic or heterocyclic ring.

In a preferred embodiment R⁵⁰ is a substituted aliphatic group, such asa substituted C₁ to about C₁₋₂ alkyl group, and R⁵¹ is —H or asubstituted or unsubstituted aliphatic group. More preferably, R⁵⁰ is asubstituted linear or branched C₂ to about C₇ aliphatic group whereinone or more carbon atoms can be replaced by a heteroatom, such asnitrogen, oxygen or sulfur, and R⁵¹ is —H or a linear or branched C₁ toabout C₆ or a C₁ to about C₃ aliphatic group wherein one or more carbonatoms can be replaced by a heteroatom. R⁵⁰ and R⁵¹ can be substitutedwith one or more suitable substituents, as described herein, preferablyan aromatic group (e.g., phenyl, 4-halophenyl). For example, R⁵⁰ can beselected from the group consisting of:

The activity of chemokine receptor antagonists represented by StructuralFormula IX can be affected by the character of the nitrogen atom towhich R⁵⁰ and R⁵¹ are bonded. It is believed that compounds in whichsaid nitrogen atom is basic can have potent chemokine receptorantagonist activity. It is known that the basicity of a nitrogen atomcan be decreased when the nitrogen atom is bonded to a carbonyl group,sulfonyl group or a sulfinyl group. Therefore, it is preferred thatneither R⁵⁰ nor R⁵¹ comprise a carbonyl group, sulfonyl group orsulfinyl group that is directly bonded to the nitrogen atom.

In another aspect, the antagonist of chemokine receptor function isrepresented by Structural Formula (X):

and physiologically acceptable salts thereof.

Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one,two or more aromatic rings, wherein each ring in Z is independentlysubstituted or unsubstituted. Preferably, Z is as described inStructural Formula (VI).

n is an integer, such as an integer from one to about four. Preferably,n is one, two or three. More preferably n is two. In alternativeembodiments, other aliphatic or aromatic spacer groups (L) can beemployed for (CH₂)_(n).

M is >NR² or >CR².

R² is —H, —OH, an acyl group, a substituted acyl group, —NR⁵R⁶, analiphatic group, a substituted aliphatic group, an aromatic group, asubstituted aromatic group, a benzyl group, a substituted benzyl group,a non-aromatic heterocyclic group, a substituted non-aromaticheterocyclic group, —O-(substituted or unsubstituted aromatic group) or—O-(substituted or unsubstituted aliphatic group). R² is preferably anaromatic group or a substituted aromatic group.

R⁵ and R⁶ are independently —H, an acyl group, a substituted acyl group,an aliphatic group, a substituted aliphatic group, an aromatic group, asubstituted aromatic group, a benzyl group, a substituted benzyl group,a non-aromatic heterocyclic group or a substituted non-aromaticheterocyclic group.

R⁵ and R⁶ taken together with the atom to which they are bonded, canalternatively form a substituted or unsubstituted non-aromaticcarbocyclic or heterocyclic ring.

X⁻ is a physiologically acceptable anion. Preferably, X⁻ is Cl⁻ or Br⁻.

The chemokine receptor antagonist described herein can be prepared andadministered as active compounds or as prodrugs. Generally, prodrugs areanalogues of pharmaceutical agents which can undergo chemical conversionby metabolic processes to become fully active. For example, A prodrug ofthe invention can be prepared by selecting appropriate groups for R⁴⁰.In one embodiment, a prodrug can be represented by Structural Formula(XI):

wherein, R⁴⁰ is Q-substituted aliphatic group, and the aliphatic groupis substituted with —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰, wherein Q is —C(O)O—, uis one, t is zero and R²⁰ is a cyclic aliphatic group. For example, whenthe substituted aliphatic group is a substituted ethyl group, R⁴⁰ can berepresented by:

Such a prodrug can be converted to an active chemokine receptorantagonist represented by Structural Formula XI, wherein R⁴⁰ is —COOH.

Another embodiment of the present invention includes novel compoundsemployed in these methods.

The compounds disclosed herein can be obtained as E- andZ-configurational isomers. It is expressly pointed out that theinvention includes compounds of the E-configuration and theZ-configuration around the double bond connecting Ring C of Z to theremainder of the molecule, and a method of treating a subject withcompounds of the E-configuration, the Z-configuration, and mixturesthereof. Accordingly, in the structural formulas presented herein, thesymbol:

-   -   “        ”        is used to represent both the E-configuration and the        Z-configuration. Preferably Ring A and the alkylene chain bonded        to Ring C are in the cis configuration. For example, the        compounds can have the configuration of:

It is understood that one configuration can have greater activity thananother. The desired configuration can be determined by screening foractivity, employing the methods described herein.

Additionally, certain compounds of the invention may be obtained asdifferent stereoisomers (e.g., diastereomers and enantiomers). Thecompounds of the invention can be prepared as racemates or assubstantially pure stereoisomers. The stereoisomers of the invention(e.g., (S)- and (R)-enantiomers) can be prepared using any suitablemethod. For example, the enantiomers can be resolved from the racemateusing chiral chromatography or recrystallization. Preferably, thestereoisomers (e.g., (S)- and/or (R)-enantiomers) are prepared bystereospecific synthesis as described herein.

The optical configuration of the stereoisomers of the invention areassigned using the (R),(S) method of Cahn-Ingold-Prelog. (See, J. March,“Advanced Organic Chemistry,” 4^(th) Edition, Wiley Interscience, NewYork, pp. 109-111 (1992).)

The invention includes all isomeric forms and racemic mixtures of thedisclosed compounds and a method of treating a subject with both pureisomers and mixtures thereof, including racemic mixtures. Sterioisomerscan be separated and isolated using any suitable method, such aschromatography. Again, it is understood that one sterioisomer may bemore active than another. The desired isomer determined by screening.

Also included in the present invention are physiologically acceptablesalts of the compounds represented by Structural Formulas (I) through(XIII). Salts of compounds containing an amine or other basic group canbe obtained, for example, by reacting with a suitable organic orinorganic acid, such as hydrogen chloride, hydrogen bromide, aceticacid, citric acid, perchloric acid and the like. Compounds with aquaternary ammonium group also contain a counteranion such as chloride,bromide, iodide, acetate, perchlorate and the like. Salts of compoundscontaining a carboxylic acid or other acidic functional group can beprepared by reacting with a suitable base, for example, a hydroxidebase. Salts of acidic functional groups contain a countercation such assodium, potassium, ammonium, calcium and the like. (See, for example,Berge S. M. et al., “Pharmaceutical Salts,” J. Pharma. Sci., 66:1(1977).)

As used herein, aliphatic groups include straight chained, branched orcyclic C₁-C₂₀ hydrocarbons which are completely saturated or whichcontain one or more units of unsaturation. Preferred aliphatic groupsare C₁ to about C₁₀ hydrocarbons. More preferred are C₁ to about C₆ orC₁ to about C₃ hydrocarbons. One or more carbon atoms in an aliphaticgroup can be replaced with a heteroatom, such as nitrogen, oxygen orsulfur. For example, suitable aliphatic groups include substituted orunsubstituted linear, branched or cyclic C₁-C₂₀ alkyl, alkenyl oralkynyl groups.

An aminoalkyl group is an alkyl group substituted with —NR²⁴R²⁵, R²⁴ andR²⁵ are as described herein. Preferably the alkyl moiety comprises oneto about twelve, more preferably one to about six carbon atoms. Thealkyl moiety of an aminoalkyl group can be unsubstituted or substitutedas described herein for aliphatic groups. Examples of suitableaminoalkyl groups include aminomethyl, 2-aminoethyl, 3-aminopropyl,4-aminobutyl, dimethylaminoethyl, diethylaminomethyl, methylaminohexyl,aminoethylenyl and the like.

Aromatic groups include carbocyclic aromatic groups such as phenyl,1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl, and heterocyclicaromatic or heteroaryl groups such as N-imidazolyl, 2-imidazolyl,4-imidazolyl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl,2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl,4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl,4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl,5-thiazolyl, 5-tetrazolyl, 2-oxazolyl, 4-oxazolyl and 5-oxazolyl. Wherethese rings are fused, for example, to Ring C, the stated point ofattachment can be either of the two fused bonds.

Aromatic groups also include fused polycyclic aromatic ring systems inwhich a carbocyclic aromatic ring or heteroaryl ring is fused to one ormore other rings. Examples include tetrahydronaphthyl, 2-benzothienyl,3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl,2-quinolinyl, 3-quinolinyl, 2-benzothiazolyl, 2-benzooxazolyl,2-benzimidazolyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl,3-isoindolyl, acridinyl, 3-benzisoxazolyl, and the like. Also includedwithin the scope of the term “aromatic group”, as it is used herein, isa group in which one or more carbocyclic aromatic rings and/orheteroaryl rings are fused to a cycloalkyl or non-aromatic heterocyclicring, for example, benzocyclopentane, benzocyclohexane.

Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings whichinclude one or more heteroatoms such as nitrogen, oxygen or sulfur inthe ring. The ring can be five, six, seven or eight-membered and/orfused to another ring, such as a cycloalkyl on aromatic ring. Examplesinclude 1,3-dioxolan-2-yl, 3-1H-benzimidazol-2-one,3-1-alkyl-benzimidazol-2-one, 3-1-methyl-benzimidazol-2-one,2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahyrothiophenyl,3-tetrahyrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino,2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl,2-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl,2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl,diazolonyl, N-substituted diazolonyl, 1-phthalimidyl,1-3-alkyl-phthalimidyl, benzoxane, benzopyrrolidine, benzopiperidine,benzoxolane, benzothiolane, benzothiane, tetrahydrofuran-2-one-3-yl,2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl,2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl,

Suitable substituents on an aliphatic group, aromatic group (carbocyclicand heteroaryl), non-aromatic heterocyclic ring or benzyl group include,for example, an electron withdrawing group, a halogen (chloride,bromide, fluoride, iodide), azido, —CN, —COOH, —OH, —CONR²⁴R²⁵,OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, —S(O)₂NH₂, guanidino, ureido,oxalo, amidino, —C(═NR⁶⁰)NR²¹R²², ═NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²²,—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphatic group),-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group),-Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group) p is an integer from 1-5),-Q-(non-aromatic heterocyclic group) or -Q-(CH₂)_(p)-(non-aromaticheterocyclic group).

R²⁰, R²¹ and R²² are independently —H, an aliphatic group, a substitutedaliphatic group, an aromatic group, a substituted aromatic group, anon-aromatic heterocyclic group, —NHC(O)—O-(aliphatic group),—NHC(O)—O-(aromatic group) or —NHC(O)—O-(non-aromatic heterocyclicgroup) and wherein R²¹ and R²², taken together with the nitrogen atom towhich they are bonded, can form a substituted or unsubstitutednon-aromatic heterocyclic ring.

R⁶⁰ is a —H, —OH, —NH₂, an aromatic group or a substituted aromaticgroup.

t is an integer from zero to about three, and the methylene group,—(CH₂)_(t)—, can be substituted, as described herein for aliphaticgroups, or unsubstituted.

u is zero or one.

Q is —O—, —S—, —S(O)—, —S(O)₂—, —OS(O)₂—, —C(O)—, —OC(O)—, —C(O)O—,—C(O)C(O)—O—, —O—C(O)C(O)—, —C(O)NH—, —NHC(O)—, —OC(O)NH—, —NHC(O)O—,—NH—C(O)—NH—, —S(O)₂NH—, —NHS(O)₂—, —N(R²³)—, —C(NR²³)NHNH—,—NHNHC(NR²³)—, —NR²⁴C(O)— or —NR²⁴S(O)₂—.

R²³ is —H, an aliphatic group, a benzyl group, an aryl group ornon-aromatic heterocyclic group.

R²⁴ and R²⁵ are independently —H, —OH, an aliphatic group, a substitutedaliphatic group, a benzyl group, an aryl group, non-aromaticheterocyclic group or R²⁴ and R²⁵ taken together with the nitrogen atomto which they are bonded can form a substituted or unsubstitutednon-aromatic heterocyclic ring.

A substituted non-aromatic heterocyclic ring, benzyl group or aromaticgroup can also have an aromatic group, an aliphatic or substitutedaliphatic group, as a substituent. When a non-aromatic ring (carbocyclicor heterocyclic) or an aromatic ring (carbocyclic aromatic orheteroaryl) is substituted with another ring, the two rings can befused. A substituted aliphatic group can also have an oxo group, epoxygroup, non-aromatic heterocyclic ring, benzyl group, substituted benzylgroup, aromatic group or substituted aromatic group as a substituent. Asubstituted non-aromatic heterocyclic ring can also have ═O, ═S, ═NH or═N(aliphatic, aromatic or substituted aromatic group) as a substituent.A substituted aliphatic, substituted aromatic, substituted non-aromaticheterocyclic ring or substituted benzyl group can have more than onesubstituent, which can be the same or different.

Acyl groups include substituted and unsubstituted aliphatic carbonyl,aromatic carbonyl, aliphatic sulfonyl and aromatic sulfonyl.

Suitable electron withdrawing groups include, for example, alkylimines,alkylsulfonyl, carboxamido, carboxylic alkyl esters, —CH═NH, —CN, —NO₂and halogens.

In the structural formulas depicted herein, the single or double bond bywhich a chemical group or moiety is connected to the remainder of themolecule or compound is indicated by the following symbol:

-   -   “        ”        For example, the corresponding symbol in Structural Formulas        (II), (III) and (IV) indicates the double bond by which the        central ring of the tricyclic ring system is connected to the        remainder of the molecule represented by Structural Formula (I).

A “subject” is preferably a bird or mammal, such as a human, but canalso be an animal in need of veterinary treatment, e.g., domesticanimals (e.g., dogs, cats, and the like), farm animals (e.g., cows,sheep, fowl, pigs, horses, and the like) and laboratory animals (e.g.,rats, mice, guinea pigs, and the like).

An “effective amount” of a compound is an amount which results in theinhibition of one or more processes mediated by the binding of achemokine to a receptor in a subject with a disease associated withaberrant leukocyte recruitment and/or activation. Examples of suchprocesses include leukocyte migration, integrin activation, transientincreases in the concentration of intracellular free calcium [Ca²⁺]_(i),and granule release of proinflammatory mediators. Alternatively, an“effective amount” of a compound is a quantity sufficient to achieve adesired therapeutic and/or prophylactic effect, such as an amount whichresults in the prevention of or a decrease in the symptoms associatedwith a disease associated with aberrant leukocyte recruitment and/oractivation.

The amount of compound administered to the individual will depend on thetype and severity of the disease and on the characteristics of theindividual, such as general health, age, sex, body weight and toleranceto drugs. It will also depend on the degree, severity and type ofdisease. The skilled artisan will be able to determine appropriatedosages depending on these and other factors. Typically, an effectiveamount of the compound can range from about 0.1 mg per day to about 100mg per day for an adult. Preferably, the dosage ranges from about 1 mgper day to about 100 mg per day. An antagonist of chemokine receptorfunction can also be administered in combination with one or moreadditional therapeutic agents, e.g. theophylline, β-adrenergicbronchodilators, corticosteroids, antihistamines, antiallergic agents,immunosuppressive agents (e.g., cyclosporin A, FK-506, prednisone,methylprednisolone), hormones (e.g., adrenocorticotropic hormone(ACTH)), cytokines (e.g., interferons (e.g., IFNβ-1a, IFNβ-1b)) and thelike.

The compound can be administered by any suitable route, including, forexample, orally in capsules, suspensions or tablets or by parenteraladministration. Parenteral administration can include, for example,systemic administration, such as by intramuscular, intravenous,subcutaneous, or intraperitoneal injection. The compound can also beadministered orally (e.g., dietary), transdermally, topically, byinhalation (e.g., intrabronchial, intranasal, oral inhalation orintranasal drops), or rectally, depending on the disease or condition tobe treated. Oral or parenteral administration are preferred modes ofadministration.

The compound can be administered to the individual in conjunction withan acceptable pharmaceutical or physiological carrier as part of apharmaceutical composition for treatment of HIV infection, inflammatorydisease, or the other diseases discussed above. Formulation of acompound to be administered will vary according to the route ofadministration selected (e.g., solution, emulsion, capsule). Suitablecarriers may contain inert ingredients which do not interact with thecompound. Standard pharmaceutical formulation techniques can beemployed, such as those described in Remington's PharmaceuticalSciences, Mack Publishing Company, Easton, Pa. Suitable carriers forparenteral administration include, for example, sterile water,physiological saline, bacteriostatic saline (saline containing about0.9% benzyl alcohol), phosphate-buffered saline, Hank's solution,Ringer's-lactate and the like. Methods for encapsulating compositions(such as in a coating of hard gelatin or cyclodextran) are known in theart (Baker, et al., “Controlled Release of Biological Active Agents”,John Wiley and Sons, 1986).

The quantity of active ingredient (one or more compounds of theinvention) in the composition can range from about 0.1% to about 99.9%by weight. Preferably the quantity of active ingredient is about 10% toabout 90%, or about 20% to about 80% by weight. A unit dose preparationcan contain from 1 mg to about 1000 mg active ingredient, preferablyabout 10 mg to about 100 mg active ingredient. The composition can, ifdesired, also contain other compatible therapeutic agents, such astheophylline, β-adrenergic bronchodilators, corticosteroids,antihistamines, antiallergic agents, immunosuppressive agents (e.g.,cyclosporin A, FK-506, prednisone, methylprednisolone), hormones (e.g.,adrenocorticotropic hormone (ACTH)), cytokines (e.g., interferons (e.g.,IFNβ-1a, IFNβ-1b)) and the like.

In one embodiment, the pharmaceutical composition comprises the(S)-enantiomer of a compound of the invention (e.g., a compound ofStructural Formula (XIII)) and a physiologically acceptable carrier orexcipient. For example, in one embodiment, the composition comprises(S)-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-oland a physiologically acceptable carrier or excipient. In certainembodiments, the pharmaceutical composition comprises the (S)-enantiomerof a compound of the invention (e.g., a compound of Structural Formula(XIII)) and is substantially free of the corresponding (R)-enantiomer(contains at least about 98% or at least about 99% enantiomeric excessof (S)-enantiomer). In another embodiments, the composition comprisesthe (S)-enantiomer of a compound of the invention (e.g., a compound ofStructural Formula (XII)), the corresponding (R)-enantiomer and aphysiologically acceptable carrier or excipient. In a more particularembodiment, the composition comprises a racemic compound of StructuralFormula (XII), for example,racemic-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]propyl}-3,3-dimethyl-piperidin-4-olIn other embodiments, the ratio (5)-enantiomer(R)-enantiomer (w/w) inthe compositions is at least about 2:1 or about 5:1 or about 10:1 orabout 20:1 or about 50:1.

The activity of compounds of the present invention can be assessed usingsuitable assays, such as receptor binding assays and chemotaxis assays.For example, as described in the Exemplification Section, small moleculeantagonists of RANTES and MIP-1α binding have been identified utilizingTHP-1 cells which bind RANTES and chemotax in response to RANTES andMIP-1α as a model for leukocyte chemotaxis. Specifically, a highthrough-put receptor binding assay, which monitors ¹²⁵I-RANTES and¹²⁵I-MIP-1α binding to THP-1 cell membranes, was used to identify smallmolecule antagonists which block binding of RANTES and MIP-1α. Compoundsof the present invention can also be identified by virtue of theirability to inhibit the activation steps triggered by binding of achemokine to its receptor, such as chemotaxis, integrin activation andgranule mediator release. They can also be identified by virtue of theirability to block RANTES and MIP-1α mediated HL-60, T-cell, peripheralblood mononuclear cell, and eosinophil chemotactic response.

The compounds disclosed herein can be prepared accordingly to theschemes shown in FIGS. 1-5 and 7. The schemes are described in greaterdetail below.

FIG. 1 shows the preparation of compounds represented by StructuralFormula (I). L¹ is PPh₃Cl, PPh₃Br, PPh₃I or (EtO)₂P(O), L² is a suitableleaving group such as halogen, p-toluene sulfonate, mesylate, alkoxy,and phenoxy; Pg is a suitable protecting group such astetrahydropyranyl; and the other symbols are as defined above.

In Step 1 of FIG. 1, a Wittig reaction is carried out in a solvent suchas ether, or tetrahydrofuran (THF) in the presence of a base such assodium hydride, n-butyl lithium or lithium diisopropylamide (LDA) at 0°C. up to the reflux temperature for the solvent used for 5 minutes to 72h. Compounds represented by Formula II in FIG. 1 can be prepared bymethods disclosed in JP 61/152,673, U.S. Pat. No. 5,089,496, WO89/10369, WO 92/20681 and WO 93/02081, the entire teachings of which areincorporated herein by reference.

In Step 2 of FIG. 1, deprotection is carried out with an acid in asolvent such as methanol at room temperature up to the refluxtemperature for the solvent used for 5 minutes to 72 h. Alternatively, acompound of represented by Formula V in FIG. 1 can be prepared directlyfrom step 1 without isolating an intermediate. The reaction mixtureobtained after the work up of the reaction described in step 1 can bedissolved in the solvent and reacted with the acid.

In Step 3 of FIG. 1, the hydroxy group can be converted to a leavinggroup by known methods. Compounds represented by Formula VI in FIG. 1can be prepared by methods disclosed in J. Med. Chem., 1992 (35)2074-2084 and JP 61/152,673.

In Step 4 of FIG. 1, an alkylation reaction is carried out in a solventsuch as acetone, methyl ethyl ketone, ethyl acetate, toluene,tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of abase such as potassium carbonate or sodium hydride and a catalyst suchas an alkali metal iodide at room temperature up to the refluxtemperature for the solvent used for 5 minutes to 72 h.

FIG. 2 shows the preparation of compounds represented by Compound(VI-b). In Step 1 of FIG. 2, a Grignard reaction may be carried out in asolvent such as ether, or tetrahydrofuran (THF) at 0° C. up to thereflux temperature for the solvent used for 5 minutes to 72 h. CompoundVII is available commercially.

In Step 2 of FIG. 2, bromination may be carried out with brominateagents such as hydrobromic acid, bromotrimethylsilane or borontribromide-methyl sulfide complex in a solvent such as acetic acid,dichloromethane or dichloroethane at room temperature up to the refluxtemperature for the solvent used for 5 minutes to 72 h.

FIG. 3 shows the preparation of compounds represented by StructuralFormula (I). In FIG. 3, a reductive amination may be carried out withreducing regents such as sodium cyanoborohydride, sodiumacetoxyborohydride or sodium borohydride in a solvent such as methanol,ethanol, tetrahydrofuran (THF), dichloromethane or dichloroethane atroom temperature up to the reflux temperature for the solvent used for 5minutes to 72 h.

FIG. 4 shows the preparation of compounds represented by StructuralFormula (I), where in Z is represented by Structural Formulas (III) andwherein Ring A and/or Ring B in Z is substituted with R⁴⁰. In FIG. 4,the alkylation reaction can be carried out in a solvent such as acetone,methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) ordimethylformamide (DMF) in the presence of a base such as potassiumcarbonate or sodium hydride and a catalyst such as an alkali metaliodide at room temperature up to the reflux temperature for the solventused for 5 minutes to 72 h.

FIG. 5 is a schematic showing the preparation of the compoundsrepresented by Structural Formula (I), wherein Z is represented byStructural Formulas (III) and wherein Ring A and/or Ring B in Z issubstituted with —(O)_(u)—(CH₂)_(t)—COOR²⁰, —(O)_(u)—(CH₂)_(t)—OC(O)R²⁰,—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²² or —(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰. InFIG. 5, the hydrolysis reaction may be carried out in a mixture ofaqueous alkali metal hydroxide solution and a solvent such as methanol,ethanol, tetrahydrofuran (THF) or dioxane at room temperature up to thereflux temperature for the solvent used for 5 minutes to 72 h. Theacylation reaction can be carried out using dicyclohexylcarbodiimide(DCC) or (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (DEC) in asolvent such as tetrahydrofuran (THF), dimethylformamide (DMF) ormethylene chloride in the presence of a base such as pyridine ortriethylamine (when necessary) at temperatures of 0 to 100° C. for 5minutes to 72 h.

FIG. 7 shows the preparation of compounds represented by StructuralFormula (I), wherein Z is represented by Structural Formulas (III) andwherein Ring A or Ring B in Z is substituted with R⁴⁰. L⁴ is a suitableleaving group such as halogen or trifluoromethylsulfonate. In FIG. 7, apalladium coupling reaction such as Stille coupling, Suzuki coupling,Heck reaction, or carboxylation using carbon monoxide may be carried outusing a palladium catalyst such astetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladiumchloride, and palladium acetate in a solvent such as tetrahydrofuran(THF), 1,4-dioxane, toluene, dimethylformamide (DMF), ordimethylsufoxide (DMSO) in the presence of additive (when necessary)such as triphenylphosphine, 1,1′-bis(diphenylphosphino)ferrocene,triethylamine, sodium bicarbonate, tetraethylammonium chloride, orlithium chloride at room temperature up to the reflux temperature forthe solvent used for 5 minutes to 72 h.

FIG. 10C shows three procedures for the preparation of compoundsrepresented by Structural Formulas (I), (VII), (VIII) and (IX), whereinZ is represented by Structural Formula (III) and wherein Ring A or RingB in Z is substituted with R⁴⁰. In FIG. 10C, R⁴⁰ is represented by—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²², u is one, t is zero. In FIG. 10C acompound containing a phenol can be reacted with a carbonate equivalent,such as a carbamoyl chloride (method A), an isocyanate (method B) or anacylimidazole (method C), in the presence of a base such as sodiumhydroxide, potassium carbonate or sodium carbonate in a solvent such asdimethylformamide or tetrahydrofuran, at a temperature from 0° C. toreflux temperature for a period of about 5 minutes to about 72 hours.

Compounds represented by Structural Formula (I), wherein Z isrepresented by Structural Formulas (III) or (IV), X is —CO—NR_(c)— andR_(c) is —(CH₂)_(s)—COOR³⁰, —(CH₂)_(n)—C(O)—NR³¹R³² or—(CH₂)_(s)—NHC(O)—O—R³⁰, can be prepared by suitable modification of thescheme shown in FIGS. 1-5 and 7. One modification utilizes the startingmaterial shown in FIG. 1, wherein X is —CO—NH—. The amide is thenalkylated with L³-(CH₂)_(s)—COOR³⁰, wherein L³ is a suitable leavinggroup, using the alkylation procedures described above. The remainder ofthe synthesis is as described in FIGS. 1-5 and 7.

FIG. 12 shows the preparation of compounds of formula (VI-c). TheFriedel-Crafts acylation can be carried out using an acid chloride inthe presence of a Lewis acid, such as aluminum trichloride or titaniumtetrachloride, in a solvent such as dichloromethane, dichloroethane,nitrobenzene or carbon disulfide. The acylation reaction can be run at atemperature of about room temperature up to the reflux temperature ofthe chosen solvent, and for a period of about 5 minutes to about 72hours.

FIG. 13 shows the preparation of compounds of formula (VI-e). In Step 1of FIG. 13, a chlorosulfonylation can be carried out usingchlorosulfonic acid in a solvent, such as dichloromethane, or in theabsence of a solvent at a temperature of about 0° C. to about 60° C. fora period of about 5 minutes to about 72 hours. In Step 2 of FIG. 12, acoupling reaction can be carried out using an amine in the presence of abase, such as triethylamine, in a solvent such as dichloromethane,acetone, ethanol, THF or DMF. The reaction can be carried out at atemperature of about room temperature up to the reflux temperature ofthe selected solvent, and for a period of about 5 minutes to about 72hours.

Although FIGS. 1-5, 7, 12 and 13 show the preparation of compounds inwhich Rings A and B are phenyl rings, analogous compounds withheteroaryl groups for Rings A and B can be prepared by using startingmaterials with heteroaryl groups in the corresponding positions. Thesestarting materials can be prepared according to methods disclosed in JP61/152,673, U.S. Pat. No. 5,089,496, WO 89/10369, WO 92/20681 and WO93/02081.

The invention is illustrated by the following examples which are notintended to be limiting in any way.

EXEMPLIFICATION Example 14-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ylidene)propyl]piperidin-4-ol

To a solution of5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene(described in JP 48-030064)(200 mg) in DMF (10 ml) were added4-(4-chlorophenyl)-4-hydroxypiperidine (230 mg), potassium carbonate(360 mg), and potassium iodide (50 mg). The mixture was stirred at 70°C. for 24 hours. Water and ethyl acetate were added to the reactionmixture, the organic layer was separated and washed with saturatedaqueous sodium chloride, and dried with magnesium sulfate. The solventwas distilled off under reduced pressure. The residue was purified bysilica gel chromatography eluting with ethyl acetate-hexane (1:1) togive the titled compound (250 mg). ¹H-NMR (CDCl₃) d: 1.65-2.11 (5H, m),2.32-3.10 (8H, m), 3.22-3.67 (4H, m), 5.87 (1H, t), 7.03-7.44 (12H, m).MS m/z: 444(M+1).

Example 24-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-6,11-dihydrodibenz[b,e]oxepine. ¹H-NMR (CDCl₃)d: 1.61-2.16 (5H, m), 2.37-2.80 (8H, m), 5.22 (2H, brs), 5.70 (0.6×1H,t), 6.03 (0.4×1H, t), 6.73-6.90 (2H, m), 7.09-7.45 (10H, m). MS m/z:446(M+1)

Example 3 Membrane Preparations for Chemokine Binding and Binding Assays

Membranes were prepared from THP-1 cells (ATCC #TIB202). Cells wereharvested by centrifugation, washed twice with PBS (phosphate-bufferedsaline), and the cell pellets were frozen at −70 to −85° C. The frozenpellet was thawed in ice-cold lysis buffer consisting of 5 mM HEPES(N-2-hydroxyethylpiperazine-N′-2-ethane-sulfonic acid) pH 7.5, 2 mM EDTA(ethylenediaminetetraacetic acid), 5 μg/ml each aprotinin, leupeptin,and chymostatin (protease inhibitors), and 100 μg/ml PMSF (phenylmethane sulfonyl fluoride—also a protease inhibitor), at a concentrationof 1 to 5×10⁷ cells/ml. This procedure results in cell lysis. Thesuspension was mixed well to resuspend all of the frozen cell pellet.Nuclei and cell debris were removed by centrifugation of 400×g for 10minutes at 4° C. The supernatant was transferred to a fresh tube and themembrane fragments were collected by centrifugation at 25,000×g for 30minutes at 4° C. The supernatant was aspirated and the pellet wasresuspended in freezing buffer consisting of 10 mM HEPES pH 7.5, 300 mMsucrose, 1 μg/ml each aprotinin, leupeptin, and chymostatin, and 10μg/ml PMSF (approximately 0.1 ml per each 10⁸ cells). All clumps wereresolved using a minihomogenizer, and the total protein concentrationwas determined using a protein assay kit (Bio-Rad, Hercules, Calif., cat#500-0002). The membrane solution was then aliquoted and frozen at −70to −85° C. until needed.

Binding Assays utilized the membranes described above. Membrane protein(2 to 20 pg total membrane protein) was incubated with 0.1 to 0.2 nM¹²⁵I-labeled RANTES or MIP-1α with or without unlabeled competitor(RANTES or MIP-1α) or various concentrations of compounds. The bindingreactions were performed in 60 to 100 μl of a binding buffer consistingof 10 mM HEPES pH 7.2, 1 mM CaCl₂, 5 mM MgCl₂, and 0.5% BSA (bovineserum albumin), for 60 min at room temperature. The binding reactionswere terminated by harvesting the membranes by rapid filtration throughglass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3%polyethyleneimine. The filters were rinsed with approximately 600 μl ofbinding buffer containing 0.5 M NaCl, dried, and the amount of boundradioactivity was determined by scintillation counting in a Topcountbeta-plate counter.

The activities of test compounds are reported in the Table below as IC₅₀values or the inhibitor concentration required for 50% inhibition ofspecific binding in receptor binding assays using ¹²⁵I-RANTES or¹²⁵I-MIP-1α as ligand and THP-1 cell membranes. Specific binding isdefined as the total binding minus the non-specific binding;non-specific binding is the amount of cpm still detected in the presenceof excess unlabeled Rantes or MIP-1α.

TABLE BIOLOGICAL DATA IC50 Example (μM) 1 <1 2 <1 8 <1 12 <1 17 <10 18<1 19 <1 21 <1 22 <1 23 <1 24 <10 25 <1 26 <1 27 <1 28 <1 29 <1 30 <1 31<1 32 <1 33 <1 34 <1 35 <1 36 <1 38 <1 39 <10 40 <1 41 <1 42 <1 43 <1044 <1 45 <1 46 <1 47 <1 48 <1 49 <1 51 <1 52 <1 53 <1 54 <1 55 <1 56 <157 <10 59 <1 60 <1 61 <10 62 <10 63 <10 64 <1 65 <1 66 <1000 67 <1 68<10 69 <1 71 <1 72 <10 73 <10 74 <1000 75 <10 76 <10 77 <1 78 <1 79 <183 <1000 85 <1 86 >10 89 >10 90 <1 91 <1 111 <1 114 <1 117 <1 118 <1 120<1 122 <1 123 <1 128 <1 130 <1 131 <1 132 <1 133 <1 134 <1 135 <1 138 <1139 <1 140 >10 141 <1 142 <10 143 <1 144 <1 145 10 146 >10 147 <10 148<10 149 <1000 150 <10 151 <1 152 <1 153 <1 154 <1 155 <1 158 <1 159 <1160 <1 161 <10 162 <1 163 <1 166 <10 167 >1 168 1 172 <1 173 <1 174 <1175 <1 176 <1 178 <1 180 <1 181 <1 182 <1 183 <1 184 <10 185 <1000 186<1 187 <1 188 >10 190 >10 191 >10 192 >10 193 <1 194 <1 195 <10 197 <1198 <1 199 <1 200 <1 201 <1 203 <1 204 <1 205 <1 211 <1 212 <1 215 <1216 <1 218 <1 242 <1 248 10 249 <1 262 <1 263 <1 264 <1 265 <1 266 <1267 <1 268 <1 269 <1 270 <1 271 <1 272 <1 273 <1 277 <1 278 <1 279 <1280 <1 281 <1 282 <1 283 <1 284 <1 285 <1 286 <1 287 <1 288 <1 289 <1290 <1 291 <1 292 <1 306 <1 422 <1 423 <1 424 <1 425 <1 426 <1 427 <1428 <1 429 <1 430 <1 431 <1 432 <1 456 <1 457 <1 458 <10 459 <10 460 <1461 <10 462 <10 463 <10 464 <1 465 <1 466 <50 467 <1 468 <1 469 <1 470<1 471 <1 472 <1 473 <1 474 <1 475 <1 476 <1 477 <10 478 <10 479 <1 480<1 481 <1 482 <1 483-1 <1 483-2 <10 484 <1 485 <1 486 <1 487 <1 488 <1489 <10 490 <1 491 <1 492 <10 493 <10 494 <1 495 <1 496 <10 497 <10 498<10 499 <10 500 <10 501 <10 502 <1 503 <1 504 <1 505 <1 506 <1 507 <1508 <1 509 <1 510 <1 511 <1 512 <1 513 <1 514 <1 515 <1 516 <1 517 <1518 <1 519 <1 520 <1 521 <1 522 <1 523 <1 524 <1 525 <20 526 <1 527 <1528 <10 529 <20 530 <20 531 <1 532 <2 533 <10 534 <1 535 <10 536 <1 537<1 538 <10 539 <10 540 <10 541 <10 542 <10 543 <10 544 <10 545 <10 546<1 547 <1 548 <10 549 <1 550 <1 551 <1 552 <1 553 <1 554 <1 555 <1 556<1 557 <1 558 <10 559 <1 560 <10 561 <10 562 <10 563 <10 564 <10 565 <10566 <20 567 <1 568 <1 569 <1 570 <10 571 <10

Example 84-(4-Chlorophenyl)-1-[3-(6,11-dihydro-dibenz[b,e]thiepin-11-ylidene)propyl]piperidin-4-olStep 1

11-(3-Bromopropylidene)-6,11-dihydrodibenz[b,e]thiepine was prepared byfollowing the procedure of example 45, step 1 and 2, but replacing5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with6,11-dihydrodibenz[b,e]thiepin-11-one. ¹H-NMR (CDCl₃) δ: 2.50-2.64 (2H,m), 3.36-3.47 (3H, m), 4.99 (1H, d), 5.94 (1H, t), 6.98-7.31 (8H, m).

Step 2

The titled compound was prepared by following the procedure of example45, step 3 but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene withthe product of step 1.

¹H-NMR (CDCl₃) δ: 1.65-1.80 (3H, m), 1.95-2.70 (10H, m), 3.35 (1H, d),4.98 (1H, d), 5.96 (1H, t), 7.09-7.43 (12H, m).

MS m/z: 462(M+1)

Example 121-[3-(5-Benzyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

To a solution4-(4-chlorophenyl)-1-[3-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-olhydrochloride (Example 39)(300 mg) in DMF (5 ml) were added sodiumhydride (60% in oil, 200 mg), benzyl bromide (0.15 ml) and the mixturewas stirred at room temperature for 1 hour. Water and ethyl acetate wereadded to the reaction mixture, the organic layer was separated andwashed with saturated aqueous sodium chloride, and dried with magnesiumsulfate. The solvent was distilled off under reduced pressure. Theresidue was purified by silica gel chromatography eluting with ethylacetate to give the titled compound (180 mg).

¹H-NMR (CDCl₃) δ: 1.62-1.67 (2H, m), 1.99-2.20 (3H, m), 2.33-2.65 (8H,m), 5.10 (1H, d), 5.75 (1H, d), 5.94 (1H, t), 7.11-7.42 (16H, m), 7.91(1H, dd).

MS m/z: 549(M+1)

Example 171-[3-(5-Carboxymethyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-ethoxycarbonylmethyl-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-ol(Example 18)(1.0 g) was solved in 1M hydrogen chloride in diethyl etherand stirred at room temperature for 24 hours. Aqueous sodium hydroxideand ethyl acetate were added to the reaction mixture, the aqueous layerwas separated and neutralized with dilute hydrochloric acid. Theprecipitation was filtered to give the titled compound (250 mg).

¹H-NMR (DMSO-d₆) δ: 1.44-1.61 (2H, m), 2.07-2.17 (1H, m), 2.35-3.01 (9H,m), 4.28 (1H, d), 4.59 (1H, d), 5.83 (1H, t), 7.18-7.71 (12H, m).

MS m/z: 517(M+1)

Example 184-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-ethoxycarbonymethyl-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-5-ethoxycarbonymethyl-6-oxo-5H-dibenz[b,e]azepine.

¹H-NMR (CDCl₃) δ: 1.30 (3H, t), 1.64-1.69 (2H, m), 1.97-2.10 (3H, m),2.38-2.71 (8H, m), 4.27 (2H, q), 4.32 (1H, d), 4.84 (1H, d), 5.88 (1H,t), 7.16-7.45 (11H, m), 7.88 (1H, dd).

MS m/z: 545(M+1)

Example 194-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-methyl-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-5-methyl-6-oxo-5H-dibenz[b,e]azepin.

¹H-NMR (CDCl₃) δ: 1.58-2.06 (5H, m), 2.39-2.75 (8H, m), 3.53 (3H, s),5.84 (1H, t), 7.10-7.44 (11H, m), 7.85-7.89 (1H, m). MS m/z: 473(M+1).

Example 214-(4-Chlorophenyl)-1-[3-(5H-dibenzo[a,d]cycloheptene-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with5-(3-bromopropylidene)-5H-dibenzo[a,d]cycloheptene.

¹H-NMR (CDCl₃) δ: 1.58-1.63 (2H, m), 2.00-2.05 (2H, m), 2.26-2.46 (6H,m), 2.62-2.66 (2H, m), 5.55 (1H, t), 6.85 (2H, s), 7.24-7.40 (12H, m).

MS m/z: 442 (M+1).

Example 224-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-methoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-6,11-dihydro-2-methoxy-carbonyldibenz[b,e]oxepine.¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 2.01-2.13 (3H, m), 2.41-2.80 (7H,m), 3.85 (3H, s), 5.40 (2H, brs), 5.73 (0.6×1H, t), 6.09 (0.4×1H, t),6.76 (0.6×1H, d), 6.82 (0.4×1H, d), 7.21-7.43 (8H, m), 7.73 (1H, dd),7.87 (0.6×1H, d), 7.97 (0.4×1H, d).

MS m/z: 504 (M+1).

Example 231-[3-(2-Butoxycarbonyl-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-2-butoxy-6,11-dihydrodibenz[b,e]oxepine.

¹H-NMR (CDCl₃) δ: 0.96 (3H, t), 1.53 (2H, q), 1.70-1.77 (3H, m),2.02-2.14 (3H, m), 2.39-2.78 (5H, m), 4.27 (2H, t), 5.27 (2H, brs), 5.75(0.8×1H, t), 6.10 (0.2×1H, t), 6.78 (1H, d), 7.27-7.43 (8H, m), 7.76(1H, dd), 7.89 (0.8×1H, d), 7.98 (0.2×1H, d).

MS m/z: 546 (M+1).

Example 241-[3-(2-Carboxyl-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

To a solution of4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-methoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(Example 22)(100 mg) in ethanol (3 ml) were added 15% sodium hydroxideaqueous solution (0.6 ml) and the mixture was heated to reflux for 12hours. The solvent was distilled off under reduced pressure. Water andethyl acetate were added to the reaction mixture, the aqueous layer wasseparated and neutralized with dilute hydrochloric acid. Theprecipitation was filtered to give the titled compound (80 mg).

¹H-NMR (CD₃OD) δ: 1.73-1.79 (2H, m), 2.14-2.19 (2H, m), 2.80-2.93 (3H,m), 3.02-3.11 (3H, m), 3.24-3.29 (2H, m), 5.25 (2H, brs), 5.61 (0.7×1H,t), 6.05 (0.3×1H, t), 6.72 (1H, d), 7.22-7.40 (8H, m), 7.52-7.65 (1H,m), 7.75 (0.7×1H, d), 7.80 (0.3×1H, d).

MS m/z: 490 (M+1).

Example 254-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-dimethylaminocarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-2-dimethylaminocarbonyl-6,11-dihydrodibenz[b,e]oxepine.

¹H-NMR (CDCl₃) δ: 1.62-1.67 (2H, m), 2.00-2.12 (2H, m), 2.37-2.47 (8H,m), 2.89 (6H, s), 5.25 (2H, brs), 5.68 (0.7×1H, t), 6.03 (0.3×1H, t),6.71 (0.3×1H, d), 6.78 (0.7×1H, d), 7.13-7.40 (10H, m).

MS m/z: 517 (M+1).

Example 264-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxymethyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

To a solution of(4-chlorophenyl)-1-[3-(6,11-dihydromethoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(110 mg) in THF (8 ml) were added lithium aluminum hydride (1.0M, 0.42ml) dropwise at 0° C., and the mixture was stirred at room temperaturefor 1 hour. Aqueous sodium hydroxide (1M) was added to the reactionmixture to stir for 30 minutes, then ethyl acetate and brine was addedto the mixture. The organic layer was separated and washed withsaturated aqueous sodium chloride, and dried with magnesium sulfate. Thesolvent was distilled off under reduced pressure. The residue waspurified by silica gel chromatography eluting withdichloromethane-methanol (10:1) to give the titled compound (90 mg).

¹H-NMR (CDCl₃) δ: 1.61-1.66 (2H, m), 1.98-2.03 (2H, m), 2.39-2.48 (3H,m), 2.57-2.79 (6H, m), 4.52 (2H, s), 5.20 (2H, brs), 5.66 (0.8×1H, t),6.01 (0.2×1H, t), 6.67 (0.2×1H, d), 6.79 (0.8×1H, d), 7.06 (1H, dd),7.15-7.37 (9H, m).

MS m/z: 476 (M+1).

Example 274-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-(1-hydroxy-1-methyl)ethyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

To a solution of4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(60 mg) in THF (6 ml) were added methylmagnesium chloride (3.0M, 0.16ml) dropwise at 0° C., and the mixture was stirred at room temperaturefor 2 hour, the reaction mixture was quenched by saturated ammoniumaqueous, then ethyl acetate and water was added to the mixture. Theorganic layer was separated and washed with saturated aqueous sodiumchloride, and dried with magnesium sulfate. The solvent was distilledoff under reduced pressure. The residue was purified by silica gelchromatography eluting with ethyl acetate-methanol (95:5) to give thetitled compound (20 mg).

¹H-NMR (CDCl₃) δ: 1.54 (0.7×6H, s), 1.62 (0.3×6H, s), 1.63-1.70 (2H, m),2.03-2.10 (3H, m), 2.38-2.49 (3H, m), 2.62-2.82 (4H, m), 5.17 (2H, brs),5.68 (0.7×1H, t), 6.05 (0.3×1H, t), 6.75 (0.3×1H, d), 6.83 (0.7×1H, d),7.18-7.43 (10H, m).

MS m/z: 504 (M+1).

Example 284-(4-Chlorophenyl)-1-[3-(2-cyano-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-2-cyano-6,11-dihydrodibenz[b,e]oxepine.

¹H-NMR (CDCl₃) δ: 1.67-1.72 (2H, m), 2.02-2.13 (2H, m), 2.37-2.77 (8H,m), 5.35 (2H, brs), 5.75 (0.7×1H, t), 6.07 (0.3×1H, t), 6.78 (0.3×1H,d), 6.82 (0.7×1H, d), 7.25-7.51 (10H, m).

MS m/z: 471 (M+1).

Example 291-[3-(2-Aminomethyl-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

To a solution of4-(4-chlorophenyl)-1-[3-(2-cyano-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(380 mg) in EtOH (20 ml) were added Raney nickel (50% slurry in water,60 mg), and the mixture was hydrogenated at 15 psi for 2 hours. Themixture was filtered through the celite and distilled off under reducedpressure. The residue was purified by silica gel chromatography elutingwith dichloromethane-methanol-aqueous ammonium (95:5:1) to give thetitled compound (130 mg).

¹H-NMR (CDCl₃) δ: 1.76-1.94 (3H, m), 2.18-2.34 (2H, m), 2.85-3.10 (8H,m), 3.88 (2H, s), 5.30 (2H, brs), 5.59 (1H, t), 6.78 (1H, d), 7.13-7.40(10H, m).

MS m/z: 475 (M+1).

Example 304-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-nitrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example1, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with11-(3-bromopropylidene)-6,11-dihydro-2-nitorodibenz[b,e]oxepine.

¹H-NMR (CDCl₃) δ: 1.62-1.67 (2H, m), 1.80-2.12 (3H, m), 2.28-2.78 (8H,m), 5.05 (0.3×2H, brs), 5.40 (0.7×2H, brs), 5.90 (0.7×1H, t), 6.17(0.3×1H, t), 6.82 (0.3×1H, d), 6.92 (0.7×1H), 7.28-7.41 (8H, m), 7.82(1H, dd), 8.15 (0.7×1H, d), 8.22 (0.3×1H, d).

MS m/z: 491 (M+1).

Example 311-[3-(2-Amino-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

To a solution of4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-nitrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(120 mg) in EtOH (15 ml) were added tin (II) chloride (190 mg), and themixture was heated to reflux for 1 hour. The solvent was distilled offunder reduced pressure. To the residue was added ethyl acetate andsodium aqueous to neutralize. The organic layer was separated and washedwith saturated aqueous sodium chloride, and dried with magnesiumsulfate. The solvent was distilled off under reduced pressure. Theresidue was purified by silica gel chromatography eluting withdichloromethane-methanol (95:5) to give the titled compound (70 mg).

¹H-NMR (DMSO-d₆) δ: 1.54-1.60 (2H, m), 1.85-2.00 (2H, m), 2.30-2.80 (8H,m), 3.88 (2H, s). 5.07 (2H, brs), 5.66 (1H, t), 6.41-6.46 (2H, m), 6.59(1H, d), 7.24-7.49 (8H, m).

MS m/z: 461 (M+1).

Example 324-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-olStep 1

11-(3-Bromopropylidene)-6,11-dihydro-2-hydroxydibenz[b,e]oxepine wasprepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-one.

¹H-NMR (CDCl₃) δ: 2.69 (2H, q), 3.39 (2H, t), 5.20 (2H, brs), 5.92 (1H,t), 6.50-6.81 (4H, m), 7.17-7.37 (4H, m).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene withthe product of step 1.

¹H-NMR (CDCl₃) δ: 1.60-1.75 (3H, m), 1.95-2.10 (2H, m), 2.35-2.80 (8H,m), 5.10 (2H, brs), 5.93 (1H, t), 6.56 (2H, brs), 6.71 (1H, brs),7.11-7.35 (8H, m).

MS m/z: 462(M+1)

Example 334-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-olStep 1

11-(3-Bromopropylidene)-6,11-dihydro-2-methoxydibenz[b,e]oxepine wasprepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-one.

¹H-NMR (CDCl₃) δ: 2.74 (2H, q), 3.43 (2H, t), 3.77 (3H, s), 5.10 (2H,brs), 6.02 (1H, t), 6.70-6.83 (3H, m), 7.21-7.38 (4H, m).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene withthe product of step 1.

¹H-NMR (CDCl₃) δ: 1.59-1.65 (2H, m), 1.95-2.66 (11H, m), 3.75 (3H, s),5.10 (2H, brs), 6.03 (1H, t), 6.69 (2H, brs), 6.82 (1H, brs), 7.20-7.40(8H, m).

MS m/z: 476(M+1)

Example 344-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-ethoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol

To a solution of4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(Example 32)(200 mg) in DMF (5 ml) were added sodium hydride (60% inoil, 25 mg), ethyl iodide (0.052 ml) and the mixture was stirred at roomtemperature for 1 hour. Water and ethyl acetate were added to thereaction mixture, the organic layer was separated and washed withsaturated aqueous sodium chloride, and dried with magnesium sulfate. Thesolvent was distilled off under reduced pressure. The residue waspurified by silica gel chromatography eluting with ethyl acetate-hexane(1:1) to give the titled compound (170 mg).

¹H-NMR (CDCl₃) δ: 1.37 (3H, t), 1.60-1.65 (2H, m), 1.95-2.08 (3H, m),2.28-75 (8H, m), 3.96 (2H, q), 5.15 (2H, brs), 6.02 (1H, t), 6.68 (2H,brs), 6.82 (1H, brs), 7.19-7.42 (8H, m).

MS m/z: 490(M+1)

Example 35 1-[3-(3-Bromo-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol Step 1

3-Bromo-11-(3-bromopropylidene)-6,11-dihydrodibenz[b,e]oxepine wasprepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with3-bromo-6,11-dihydrodibenz[b,e]oxepin-11-one.

¹H-NMR (CDCl₃) δ: 2.74 (2H, q), 3.43 (2H, t), 3.77 (3H, s), 5.10 (2H,brs), 6.02 (1H, t), 6.70-6.83 (3H, m), 7.21-7.38 (4H, m).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene withthe product of step 1.

¹H-NMR (CDCl₃) δ: 1.63-1.70 (3H, m), 1.96-2.10 (2H, m), 2.32-2.69 (8H,m), 5.20 (2H, brs), 6.00 (1H, t), 6.92-7.00 (2H, m), 7.11-7.14 (1H, m),7.24-7.42 (8H, m).

MS m/z: 524, 526(M+1)

Example 364-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-methoxypiperidine

To a solution of4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(Example 2)(400 mg) in DMF (5 ml) were added sodium hydride (60% in oil,50 mg), methyl iodide (0.07 ml) and the mixture was stirred at roomtemperature for 1 hour. Water and ethyl acetate were added to thereaction mixture, the organic layer was separated and washed withsaturated aqueous sodium chloride, and dried with magnesium sulfate. Thesolvent was distilled off under reduced pressure. The residue waspurified by silica gel chromatography eluting with ethyl acetate-hexane(1:1) to give the titled compound (100 mg).

¹H-NMR (CDCl₃) δ: 1.90-2.04 (4H, m), 2.34-2.62 (8H, m), 2.93 (3H, s),5.25 (2H, brs), 6.04 (1H, t), 6.75-6.91 (3H, m), 7.09-7.37 (9H, m).

MS m/z: 460(M+1)

Example 374-Acetoxy-4-(4-chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidine

To a solution of4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol(Example 2)(200 mg) in dichloromethane (5 ml) were added acetyl chloride(0.06 ml), triethylamine (0.19 ml) and the mixture was stirred at roomtemperature for 1 hour. Aqueous sodium bicarbonate and ethyl acetatewere added to the reaction mixture, the organic layer was separated andwashed with saturated aqueous sodium chloride, and dried with magnesiumsulfate. The solvent was distilled off under reduced pressure. Theresidue was purified by silica gel chromatography eluting with ethylacetate-hexane (1:4) to give the titled compound (190 mg).

¹H-NMR (CDCl₃) δ: 1.98-2.85 (12H, m), 2.02 (3H, s), 2.93 (3H, s), 5.23(2H, brs), 6.01 (1H, t), 6.73-6.90 (3H, m), 7.11-7.40 (9H, m).

MS m/z: 488(M+1)

Example 381-[3-(8-Bromo-4,10-dihydrothieno[3,2-c][1]benzoxepin-10-ylidene)propyl]piperidin-4-(4-chlorophenyl)-4-olStep 1

8-Bromo-10-(3-bromopropylidene)-4,10-dihydrothieno[3,2-c][1]benzoxepinewas prepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with4,10-dihydrothieno[3,2-c][1]benzoxepin-10-one.

¹H-NMR (CDCl₃) δ: 2.84 (2H, q), 3.45 (2H, t), 5.10 (2H, s), 6.11 (1H,t), 6.65 (1H, d), 7.03-7.08 (2H, m), 7.38-7.43 (2H, m).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene withthe product of step 1.

¹H-NMR (CDCl₃) δ: 1.66-1.75 (3H, m), 2.03-2.16 (2H, m), 2.40-2.86 (8H,m), 5.09 (0.7×2H, s), 5.14 (0.3×2H, s), 5.90 (0.3×1H, t), 6.10 (0.7×1H,t), 6.64 (0.7×1H, d), 6.75 (0.3×1H, d), 6.90 (0.3×1H, d), 7.03-7.09 (2H,m), 7.21-7.45 (6H, m).

MS m/z: 532(M+1)

Example 394-(4-Chlorophenyl)-1-[3-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-olStep 1

11-(3-Bromopropylidene)-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepine wasprepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with6,11-dihydro-6-5H-dibenz[b,e]azepin-6,11-dione.

¹H-NMR (CDCl₃) δ: 2.70-2.92 (2H, m), 3.45 (2H, t), 5.92 (1H, t),7.08-7.58 (7H, m), 8.05 (1H, dd), 9.00 (1H, brs).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene withthe product of step 1.

¹H-NMR (CDCl₃) δ: 1.61-1.66 (2H, m), 1.97-2.20 (3H, m), 2.35-2.68 (8H,m), 5.80 (1H, t), 7.03-7.53 (11H, m), 8.02 (1H, dd), 9.27 (1H, brs). MSm/z: 459(M+1)

Example 404-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-ethyl-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example12, but replacing benzyl bromide with ethyl iodide.

¹H-NMR (CDCl₃) δ: 1.19-1.28 (3H, m), 1.63-1.69 (2H, m), 1.99-2.16 (3H,m), 2.37-2.70 (8H, m), 3.77-3.85 (1H, m), 4.40-4.48 (1H, m), 5.85 (1H,t), 7.12-7.45 (11H, m), 7.85 (1H, dd).

MS m/z: 487(M+1)

Example 411-[3-(5-n-Butyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example12, but replacing benzyl bromide with n-butyl iodide.

¹H-NMR (CDCl₃) δ: 0.90-0.98 (3H, m), 1.25-2.20 (9H, m), 2.40-2.87 (8H,m), 3.62-3.72 (1H, m), 4.52-4.64 (1H, m), 5.85 (1H, t), 7.16-7.45 (11H,m), 7.88 (1H, dd).

MS m/z: 515(M+1)

Example 424-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-(3-hydroxypropyl)-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-ol

To a solution4-(4-chlorophenyl)-1-[3-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-olhydrochloride (Example 39)(500 mg) in DMF (8 ml) were added sodiumhydride (60% in oil, 200 mg), 2-(3-bromopropoxy)tetrahydro-2H-pyran (0.5ml) and the mixture was stirred at room temperature for 6 hours. Waterand ethyl acetate were added to the reaction mixture, the organic layerwas separated and washed with saturated aqueous sodium chloride, anddried with magnesium sulfate. The solvent was distilled off underreduced pressure. The residue was solved in 1M hydrogen chloride indiehyl ether and stirred at room temperature for 1 hour. Aqueous sodiumbicarbonate and ethyl acetate were added to the reaction mixture, theorganic layer was separated and washed with saturated aqueous sodiumchloride, and dried with magnesium sulfate. The solvent was distilledoff under reduced pressure. The residue was purified by silica gelchromatography eluting with ethyl acetate to give the titled compound(250 mg).

¹H-NMR (CDCl₃) δ: 1.25-2.87 (15H, m), 3.51-3.56 (2H, m), 3.76-3.82 (1H,m), 4.81-4.87 (1H, m), 5.86 (1H, t), 7.16-7.45 (11H, m), 7.82 (1H, dd).

MS m/z: 517(M+1)

Example 431-[3-(5-tert-Butoxycarbonymethyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example12, but replacing benzyl bromide with tert-butyl bromoacetate.

¹H-NMR (CDCl₃) δ: 1.50 (9H, s), 1.65-1.70 (2H, m), 1.95-2.10 (3H, m),2.42-2.75 (8H, m), 4.24 (1H, d), 4.75 (1H, d), 5.88 (1H, t), 7.16-7.46(11H, m), 7.90 (1H, dd).

MS m/z: 573(M+1)

Example 44 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol Step 1

To a solution of the product of example 45, step 1 (4.3 g) indichloroethane (100 ml) was added boron tribromide-methyl sulfidecomplex (19.3 g) and the mixture was heated to reflux for 3 hour. Waterand ethyl acetate were added to the reaction mixture and neutralizedwith dilute NaOH solution. The organic layer was separated and washedwith saturated aqueous sodium chloride, and dried over magnesiumsulfate. The solvent was distilled off under reduced pressure. Theresidue was purified by silica gel chromatography eluting with ethylacetate-hexane (1:2) to give5-(3-bromopropylidene)-5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridine (3.2 g).

¹H-NMR (CDCl₃) δ: 2.72 (2H, q), 3.45 (2H, t), 5.28 (2H, brs), 6.03 (1H,t), 6.66-6.80 (3H, m), 7.26 (1H, dd), 7.58 (1H, dd), 8.51 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridine with the product of step 1.

¹H-NMR (DMSO-d₆) δ: 1.46-1.51 (2H, m), 1.74-1.85 (2H, m), 2.29-2.51 (8H,m), 5.15 (2H, brs), 6.07 (1H, t), 6.61-6.70 (3H, m), 7.33-7.48 (5H, m),7.73 (1H, dd), 8.47 (1H, dd), 9.06 (1H, s).

MS m/z: 463(M+1)

Example 454-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olStep 1

To a solution of 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one (5.0 g) in THF (50 ml) was added 1.1M cyclopropylmagnesium bromide THF solution (25 ml) at 0° C. Thereaction mixture was warmed to room temperature, and stirred for 30minutes. Aqueous ammonium chloride and ethyl acetate were added to thereaction mixture, the organic layer was separated and washed withsaturated aqueous sodium chloride, and dried with magnesium sulfate. Thesolvent was distilled off under reduced pressure. The residue wasfiltered and washed with ethyl acetate-hexane (1:2) to give5-cyclopropyl-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ol(5.0 g).

Step 2

To a solution of the product of step 1 (4.3 g) in acetic acid (30 ml)was added 48% aqueous HBr (25 ml) at 10° C. The reaction mixture waswarmed to room temperature, and stirred for 12 hours. Water and ethylacetate were added to the reaction mixture and neutralized with diluteNaOH solution. The organic layer was separated and washed with saturatedaqueous sodium chloride, and dried over magnesium sulfate. The solventwas distilled off under reduced pressure. The residue was purified bysilica gel chromatography eluting with ethyl acetate-hexane (1:4) togive 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridine (5.6 g).

¹H-NMR (CDCl₃) δ: 2.74 (2H, q), 3.46 (2H, t), 3.78 (3H, s), 5.25 (2H,brs), 6.07 (1H, t), 6.72-6.82 (3H, m), 7.21-7.42 (5H, m), 7.56 (1H, dd),8.45 (1H, dd).

Step 3

To a solution the product of step 2 (1.1 g) in DMF (15 ml) were added4-(4-chlorophenyl)-4-hydroxypiperidine (0.81 g) and potassium carbonate(0.53 g) and the mixture was stirred at room temperature for 3 hours.Water and ethyl acetate were added to the reaction mixture, the organiclayer was separated and washed with saturated aqueous sodium chloride,and dried with magnesium sulfate. The solvent was distilled off underreduced pressure. The residue was purified by silica gel chromatographyeluting with methylene chloride-methanol (10:1) to give the titledcompound as major regioisomer (0.86 g) and minor one (0.05 g).

Major Isomer

¹H-NMR (CDCl₃) δ: 1.64-1.69 (2H, m), 1.91-2.08 (3H, m), 2.34-2.69 (8H,m), 3.77 (3H, s), 5.25 (2H, brs), 6.07 (1H, t), 6.72-6.82 (3H, m),7.21-7.42 (5H, m), 7.56 (1H, dd), 8.45 (1H, dd).

MS m/z: 477(M+1)

Minor Isomer

1H-NMR (CDCl₃) d: 1.65-1.79 (3H, m), 2.01-2.13 (2H, m), 2.35-2.76 (8H,m), 3.76 (3H, s), 5.22 (2H, brs), 5.95 (1H, t), 6.72-6.80 (2H, m), 7.06(1H, d), 7.16 (1H, dd), 7.28 (2H, d), 7.42 (2H, d), 7.66 (1H, dd), 8.39(1H, dd).

MS m/z: 477(M+1)

Example 46 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example34, but replacing4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-olwith4-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol(example 44).

¹H-NMR (CDCl₃) δ: 1.38 (3H, t), 1.67-1.72 (3H, m), 2.05-2.16 (2H, m),2.40-2.80 (8H, m), 3.99 (2H, q), 5.26 (2H, brs), 6.05 (1H, t), 6.71-6.82(3H, m), 7.23-7.43 (5H, m), 7.57 (1H, dd), 8.47 (1H, dd).

MS m/z: 491(M+1)

Example 474-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-isopropoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with isopropyl bromide.

¹H-NMR (CDCl₃) δ: 1.30 (6H, d), 1.60-1.70 (3H, m), 1.99-2.09 (2H, m),2.33-2.69 (8H, m), 4.37-4.48 (1H, m), 5.26 (2H, brs), 6.06 (1H, t),6.73-6.82 (3H, m), 7.21-7.43 (5H, m), 7.55 (1H, dd), 8.47 (1H, dd).

MS m/z: 505(M+1)

Example 484-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxycarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with ethyl bromoacetate.

¹H-NMR (CDCl₃) δ: 1.28 (3H, t), 1.63-1.68 (2H, m), 1.97-2.02 (3H, m),2.33-2.68 (8H, m), 4.24 (2H, q), 4.55 (2H, s), 5.26 (2H, brs), 6.06 (1H,t), 6.73-6.88 (3H, m), 7.21-7.42 (5H, m), 7.55 (1H, dd), 8.44 (1H, dd).MS m/z: 549(M+1)

Example 494-(4-Chlorophenyl)-1-[3-(7-cyanomethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with bromoacetonitrile.

¹H-NMR (CDCl₃) δ: 1.62-1.67 (2H, m), 1.94-2.06 (2H, m), 2.21 (1H, brs),2.34-2.66 (8H, m), 4.70 (2H, s), 5.26 (2H, brs), 6.10 (1H, t), 6.80 (2H,brs), 6.92 (1H, brs), 7.22-7.41 (5H, m), 7.56 (1H, dd), 8.44 (1H, dd).

MS m/z: 502(M+1)

Example 50 1-[3-(7-(2-Acetoxyethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with 2-bromoethyl acetate.

¹H-NMR (CDCl₃) δ: 1.65-1.72 (3H, m), 1.97-2.09 (5H, m), 2.37-2.70 (8H,m), 4.11-4.14 (2H, m), 4.37-4.41 (2H, m), 5.25 (2H, brs), 6.07 (1H, t),6.75-6.84 (3H, m), 7.23-7.43 (5H, m), 7.56 (1H, dd), 8.47 (1H, dd).

MS m/z: 549(M+1)

Example 514-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of1-[3-(7-(2-acetoxyethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol(Example 50)(140 mg) in ethanol (5 ml) were added 15% sodium hydroxideaqueous solution (2 ml) and the mixture was heated to reflux for 1 hour.Water and ethyl acetate were added to the reaction mixture, the organiclayer was separated and washed with saturated aqueous sodium chloride,and dried with magnesium sulfate. The solvent was distilled off underreduced pressure. The residue was purified by silica gel chromatographyeluting with methylene chloride-methanol (10:1) to give the titledcompound (120 mg).

¹H-NMR (CDCl₃) δ: 1.64-1.69 (2H, m), 1.98-2.10 (3H, m), 2.36-2.79 (8H,m), 3.89-3.94 (2H, m), 3.99-4.04 (2H, m), 5.24 (2H, brs), 6.04 (1H, t),6.71-6.84 (3H, m), 7.23-7.41 (5H, m), 7.54 (1H, dd), 8.43 (1H, dd).

MS m/z: 507(M+1)

Example 524-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-morpholinoethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with 4-(2-chloroethyl)morpholinehydrochloride.

¹H-NMR (CDCl₃) δ: 1.62-1.67 (2H, m), 1.95-2.08 (2H, m), 2.20-2.67 (13H,m), 2.74 (2H, t), 3.67-3.71 (4H, m), 4.04 (2H, t), 5.23 (2H, brs), 6.05(1H, t), 6.73-6.82 (3H, m), 7.20-7.41 (5H, m), 7.53 (1H, dd), 8.42 (1H,dd).

MS m/z: 576(M+1)

Example 53 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol Step 1

5-(3-Bromopropylidene)-5,11-dihydro [1]benzoxepino[2,3-b]pyridine wasprepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro[1]benzoxepino [2,3-b]pyridin-5-one.

¹H-NMR (CDCl₃) δ: 2.71 (2H, q), 3.46 (2H, t), 5.33 (2H, brs), 6.04 (1H,t), 7.01-7.17 (3H, m), 7.29 (1H, dd), 7.56 (1H, dd), 8.53 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridine with the product of step 1.

¹H-NMR (CDCl₃) δ: 1.66-1.71 (2H, m), 2.00-2.20 (3H, m), 2.36-2.69 (8H,m), 5.34 (2H, brs), 6.10 (1H, t), 6.83-6.96 (3H, m), 7.17-7.44 (6H, m),7.60 (1H, dd), 8.46 (1H, dd).

MS m/z: 447(M+1)

Example 541-[3-(8-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

8-Bromo-5-(3-bromopropylidene)-5,11-dihydro[1]benzoxepino[2,3-b]pyridinewas prepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with8-bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.

¹H-NMR (CDCl₃) δ: 2.75 (2H, q), 3.50 (2H, t), 5.38 (2H, brs), 6.08 (1H,t), 6.85-6.98 (2H, m), 7.18-7.35 (3H, m), 7.59 (1H, dd), 8.54 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing5-(3-bromopropylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridinewith the product of step 1.

¹H-NMR (CDCl₃) δ: 1.64-1.69 (2H, m), 1.90-2.07 (3H, m), 2.30-2.67 (8H,m), 5.30 (2H, brs), 6.08 (1H, t), 7.00-7.07 (2H, m), 7.13 (1H, d),7.25-7.42 (5H, m), 7.56 (1H, dd), 8.47 (1H, dd).

MS m/z: 525, 527(M+1)

Example 554-(4-Chlorophenyl)-1-[3-(10,11-dihydro-10-oxo-5H-pyrido[2,3-c][2]benzazepin-5-ylidene)propyl]piperidin-4-olStep 1

5-(3-Bromopropylidene)-10,11-dihydro-10-oxo-5H-pyrido[2,3-c][2]benzazepinewas prepared by following the procedure of example 45, step 1 and 2, butreplacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with10,11-dihydro-5H-pyrido[2,3-c][2]benzazepin-5,10-dione.

¹H-NMR (CDCl₃) δ: 2.75-2.90 (2H, m), 3.45 (2H, t), 5.92 (1H, t),7.04-7.70 (5H, m), 8.10 (1H, dd), 8.48 (1H, dd), 10.00 (1H, brs).

Step 2

The titled compound was prepared by following the procedure of example45, step 3, but replacing5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene withthe product of step 1.

¹H-NMR (CDCl₃) δ: 1.64-1.69 (3H, m), 2.00-2.12 (2H, m), 2.35-2.70 (8H,m), 5.82 (1H, t), 7.08 (1H, dd), 7.23-7.62 (8H, m), 8.04 (1H, dd), 8.32(1H, dd), 8.76 (1H, brs).

MS m/z: 460(M+1)

Example 564-(4-Chlorophenyl)-1-[3-(10,11-dihydro-11-methyl-10-oxo-5H-pyrido[2,3-c][2]benzazepin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example36, but replacing of4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-1′-ylidene)propyl]piperidin-4-olwith5-(3-bromopropylidene)-10,11-dihydro-10-oxo-5H-pyrido[2,3-c][2]benzazepine.

¹H-NMR (CDCl₃) δ: 1.64-1.70 (3H, m), 2.00-2.10 (2H, m), 2.41-2.69 (8H,m), 3.62 (3H, s), 5.82 (1H, t), 7.07 (1H, dd), 7.25-7.54 (8H, m), 7.91(1H, dd), 8.34 (1H, dd).

MS m/z: 474(M+1)

Example 57 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)ethyl]piperidin-4-ol Step 1

To a solution of methyltriphenylphosphonium bromide (2.2 g) in THF (20ml) was added 1.6M n-butyl lithium hexane solution (2.9 ml) at 0° C. for30 minutes. To the reaction mixture cooled to 0° C. was added5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one (1.0 g)dropwise as THF solution (5 ml), and the mixture was warmed to roomtemperature, and stirred for 3 hours. Aqueous ammonium chloride andethyl acetate were added to the reaction mixture, the organic layer wasseparated and washed with saturated aqueous sodium chloride, and driedwith magnesium sulfate. The solvent was distilled off under reducedpressure. The residue was purified by silica gel chromatography elutingwith ethyl acetate-hexane (1:4) to give5,11-dihydro-7-methoxy-5-methylenepyrido[2,3-c][1]benzoxepine (0.14 g).

Step 2

To a solution of DMF (0.54 ml) was added phosphorus oxychloride (0.41ml) at 0° C. for 10 minutes. To the reaction mixture was added theproduct of step 1 (210 mg) in carbontetrachloride (5 ml) and the mixturewas heated to reflux for 5 hours. Aqueous sodium bicarbonate and ethylacetate were added to the reaction mixture, the organic layer wasseparated and washed with saturated aqueous sodium chloride, and driedwith magnesium sulfate. The solvent was distilled off under reducedpressure. The residue was purified by silica gel chromatography elutingwith ethyl acetate-hexane (1:4) to give3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)acetaldehyde(130 mg).

¹H-NMR (CDCl₃) δ: 3.77 (0.7×3H, s), 3.79 (0.3×3H, s), 5.31 (2H, s), 6.46(0.7×1H, d), 6.52 (0.3×1H, d), 6.78-7.40 (4H, m), 7.68 (0.3×1H, dd),7.78 (0.7×1H, dd), 8.55 (0.7×1H, dd), 8.64 (0.3×1H, dd), 9.62 (0.3×1H,d), 9.79 (0.7×1H, d).

Step 3

The titled compound was prepared by following the procedure of example58, step 2, but replacing of3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propanaldehydewith product of step 2.

¹H-NMR (CDCl₃) δ: 1.64-1.82 (2H, m), 1.92-2.22 (3H, m), 2.43-2.58 (2H,m), 2.79-3.45 (6H, m), 3.68 (0.3×3H, s), 3.70 (0.7×3H, s), 5.24 (2H,brs), 6.18 (0.7×1H, t), 6.21 (0.3×1H, t), 6.72-7.42 (8H, m), 7.78(0.3×1H, dd), 7.85 (0.7×1H, dd), 8.42 (0.7×1H, dd), 8.46 (0.3×1H, dd).

MS m/z: 463(M+1).

Example 584-(4-Chlorophenyl)-1-[4-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)butyl]piperidin-4-olStep 1

3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propenaldehydewas prepared by following the procedure of example 57, step 2, butreplacing5,11-dihydro-7-methoxy-5-methylene[1]benzoxepino[2,3-b]pyridine with5,11-dihydro-7-methoxy-5-(propyl-1-ene) [1]benzoxepino[2,3-b]pyridine(by-product of example 45, step 3).

¹H-NMR (CDCl₃) δ: 3.78 (0.3×3H, s), 3.80 (0.7×3H, s), −5.32 (2H, brs),6.34-6.39 (1H, m), 6.72-7.38 (6H, m), 7.58 (0.7×1H, dd), 7.77 (0.3×1H,dd), 8.49 (0.3×1H, dd), 8.60 (0.7×1H, dd), 9.51 (0.7×1H, d), 9.54(0.3×1H, d).

Step 2

To a solution of the product of step 1 (90 mg) in dichloromethane (6 ml)were added sodium triacetoxyborohydride (170 mg),4-(4-chlorophenyl)-4-hydroxypiperidine (70 mg) and acetic acid (0.02 ml)and the mixture stirred at room temperature for 24 hour. Water and ethylacetate were added to the reaction mixture, the organic layer wasseparated and washed with saturated aqueous sodium chloride, and driedwith magnesium sulfate. The solvent was distilled off under reducedpressure. The residue was purified by silica gel chromatography elutingwith dichloromethane-methanol (95:5) to give4-(4-chlorophenyl)-1-[4-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)buten-2-yl]piperidin-4-ol(110 mg).

¹H-NMR (CDCl₃) δ: 1.68-1.73 (2H, m), 2.04-2.16 (2H, m), 2.43-2.72 (3H,m), 2.77-2.81 (2H, m), 3.08-3.13 (2H, m), 3.73 (0.3×3H, s), 3.77(0.7×3H, s), 5.20 (2H, brs), 5.98-6.05 (1H, m), 6.23-7.43 (10H, m), 7.58(0.7×1H, dd), 7.65 (0.3×1H, dd), 8.37 (0.3×1H, dd), 8.45 (0.7×1H, dd).

MS m/z: 489(M+1).

Step 3

To a solution of the product of step 2 (8 mg) in ethanol (2 ml) wereadded 10% Pd—C (2 mg) was stirred under hydrogen (under a balloon) atroom temperature for 1 hour. The mixture was filtered through the celiteand distilled off under reduced pressure to give the titled compound (6mg).

¹H-NMR (CDCl₃) δ: 1.68-3.00 (15H, m), 3.77 (3H, s), 5.18-5.35 (2H, m),5.94 (0.4H, t, E isomer), 6.06 (0.6H, t, Z isomer), 6.65-6.88 (3H, m),7.05-7.73 (6H, m), 8.30-8.56 (1H, m).

MS m/z: 491(M+1)

Example 591-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-phenyl-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-phenyl-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.68-1.73 (2H, m), 2.02-2.15 (3H, m), 2.38-2.72 (8H,m), 3.77 (3H, s), 5.26 (2H, brs), 6.08 (1H, t), 6.72-6.83 (3H, m),7.21-7.36 (4H, m), 7.46-7.49 (2H, m), 7.58 (1H, dd), 8.46 (1H, dd).

MS m/z: 443 (M+1).

Example 604-(4-Bromophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-bromophenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.65-1.69 (2H, m), 2.00-2.10 (3H, m), 2.37-2.71 (8H,m), 3.76 (3H, s), 5.24 (2H, brs), 6.05 (1H, t), 6.70-6.82 (3H, m), 7.24(1H, dd), 7.38 (2H, d), 7.44 (2H, s), 7.52 (1H, dd), 8.44 (1H, dd).

MS m/z: 521,523 (M+1).

Example 611-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.43-1.60 (2H, m), 1.80-1.98 (2H, m), 2.00-2.18 (3H,m), 2.34-2.48 (4H, m), 2.63-2.76 (2H, m), 3.64-3.73 (1H, m), 3.70 (3H,s), 5.35 (2H, brs), 6.06 (1H, t), 6.74-6.84 (3H, m), 7.25 (1H, dd), 7.60(1H, dd), 8.50 (1H, dd).

MS m/z: 367 (M+1).

Example 624-Benzyl-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-benzyl-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.42-1.57 (3H, m), 1.62-1.75 (2H, m), 2.22-2.70 (8H,m), 2.79 (2H, s), 3.80 (3H, s), 5.25 (2H, brs), 6.08 (1H, t), 6.73-6.84(3H, m), 7.18-7.24 (6H, m), 7.57 (1H, dd), 8.50 (1H, dd).

MS m/z: 457 (M+1).

Example 634-Cyano-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-cyano-4-phenylpiperidine.

¹H-NMR (CDCl₃) δ: 1.97-2.06 (4H, m), 2.37-2.60 (6H, m), 2.85-2.90 (2H,m), 3.79 (3H, s), 5.27 (2H, brs), 6.08 (1H, t), 6.72-6.84 (3H, m),7.24-7.58 (7H, m), 8.49 (1H, dd).

MS m/z: 452 (M+1).

Example 641-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-phenylpiperidine.

¹H-NMR (CDCl₃) δ: 1.73-1.79 (4H, m), 1.96-2.03 (2H, m), 2.37-2.52 (5H,m), 2.86-2.94 (2H, m), 3.77 (3H, s), 5.26 (2H, brs). 6.08 (1H, t),6.72-6.83 (3H, m), 7.17-7.31 (6H, m), 7.56 (1H, dd), 8.49 (1H, dd).

MS m/z 426 (M+1).

Example 654-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)piperidine.

¹H-NMR (CDCl₃) δ: 1.68-1.74 (4H, m), 1.96-2.03 (2H, m), 2.36-2.48 (5H,m), 2.89-2.94 (2H, m), 3.77 (3H, s), 5.27 (2H, brs), 6.07 (1H, t),6.73-6.83 (3H, m), 7.10-7.27 (5H, m), 7.57 (1H, dd), 8.48 (1H, dd).

MS m/z: 461 (M+1).

Example 661-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-piperidinopiperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-piperidinopiperidine.

¹H-NMR (CDCl₃) δ: 1.40-2.00 (12H, m), 2.15-2.60 (9H, m), 2.80-2.92 (2H,m), 3.80 (3H, s), 5.28 (2H, brs), 6.05 (1H, t), 6.75-6.86 (3H, m), 7.30(1H, dd), 7.55 (1H, dd), 8.46 (1H, dd).

MS m/z 434 (M+1).

Example 671-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-keto-1-benzimidazolinyl)piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(2-keto-1-benzimidazolinyl)piperidine.

¹H-NMR (CDCl₃) δ: 1.75-1.79 (2H, m), 2.03-2.15 (2H, m), 2.38-2.52 (6H,m), 2.93-2.98 (2H, m), 3.78 (3H, s), 4.30-4.38 (1H, m), 5.30 (2H, brs),6.10 (1H, t), 6.73-6.84 (3H, m), 7.01-7.03 (3H, m), 7.21-7.28 (2H, m),7.59 (1H, dd), 8.48 (1H, dd).

MS m/z: 483 (M+1).

Example 681-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-keto-3-methyl-1-benzimidazolinyl)piperidine

The titled compound was prepared by following the procedure of example36, but replacing of4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-olwith1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-keto-1-benzimidazolinyl)piperidine.

¹H-NMR (CDCl₃) δ: 1.72-1.76 (2H, m), 2.09-2.14 (2H, m), 2.23-2.54 (6H,m), 2.91-2.96 (2H, m), 3.38 (3H, s), 3.77 (3H, s), 4.30-4.37 (1H, m),5.27 (2H, brs), 6.08 (1H, t), 6.71-6.83 (3H, m), 6.93-7.06 (3H, m),7.23-7.60 (2H, m), 8.08 (1H, dd), 8.48 (1H, dd). MS m/z: 497 (M+1).

Example 698-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one.

¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 2.36-2.41 (2H, m), 2.53-2.79 (8H,m), 3.76 (3H, s), 4.70 (2H, s), 5.25 (2H, brs), 6.10 (1H, t), 6.71-6.88(6H, m), 7.21-7.27 (3H, m), 7.58-7.61 (2H, m), 8.48 (1H, dd).

MS m/z: 497 (M+1).

Example 704-Anilino-4-carbamyl-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-anilino-4-carbamylpiperidine.

¹H-NMR (CDCl₃) d: 1.85-1.90 (2H, m), 2.03-2.08 (2H, m), 2.19-2.46 (6H,m), 2.62-2.67 (2H, m), 3.75 (3H, s), 3.97 (1H, brs), 5.27 (2H, brs),5.53 (1H, brs), 6.03 (1H, t), 6.60 (2H, d), 6.70-6.85 (4H, m), 7.12-7.25(4H, m), 7.53 (1H, dd), 8.46 (1H, dd).

MS m/z 485 (M+1).

Example 711-(4-Chlorophenyl)-4-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(4-chlorophenyl)piperazine.

¹H-NMR (CDCl₃) δ: 2.36-2.53 (8H, m), 3.07-3.09 (4H, m), 3.76 (3H, s),5.26 (2H, brs), 6.08 (1H, t), 6.72-6.81 (5H, m), 7.16-7.28 (3H, m), 7.56(1H, dd), 8.49 (1H, dd).

MS m/z: 462 (M+1).

Example 721-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-pyrimidyl)piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(2-pyrimidyl)piperazine.

¹H-NMR (CDCl₃) δ: 2.37-2.53 (8H, m), 3.74-3.83 (7H, m), 5.27 (2H, brs),6.08 (1H, t), 6.45 (1H, t), 6.72-6.83 (3H, m), 7.25 (1H, dd), 7.56 (1H,dd), 8.27 (2H, d), 8.49 (1H, dd).

MS m/z: 430 (M+1).

Example 731-Cyclohexyl-4-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-cyclohexylpiperazine.

¹H-NMR (CDCl₃) δ: 1.12-1.27 (6H, m), 1.74-1.86 (6H, m), 2.18-2.52 (11H,m), 3.76 (3H, s), 5.26 (2H, brs), 6.04 (1H, t), 6.74-6.81 (3H, m), 7.23(1H, dd), 7.55 (1H, dd), 8.48 (1H, dd).

MS m/z: 434 (M+1).

Example 741-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-furoyl)piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(2-furoyl)piperazine.

¹H-NMR (CDCl₃) δ: 2.34-2.48 (8H, m), 3.71-3.74 (7H, s), 5.24 (2H, brs),6.05 (1H, t), 6.42 (1H, dd), 6.70-6.80 (3H, m), 6.93 (1H, d), 7.23 (1H,dd), 7.42 (1H, d), 7.53 (1H, dd), 8.46 (1H, dd).

MS m/z: 446 (M+1).

Example 754-(3-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(3-chlorophenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.61-1.75 (2H, m), 1.98 (1H, brs), 1.99 (2H, dt), 2.25(3H, s), 2.30-2.76 (8H, m), 3.73 (3H, s), 5.22 (2H, brs), 5.95 (0.1H, t,E isomer), 6.04 (0.9H, t, Z isomer), 6.71-6.89 (3H, m), 6.95 (1H, dd),7.15-7.20 (0.3H, m, E isomer), 7.21-7.35 (2.7H, m, Z isomer), 7.53(0.9H, dd, Z isomer), 7.65 (0.1H, dd, E isomer), 8.35 (0.1H, dd, Eisomer), 8.45 (0.9H, dd, Z isomer).

MS m/z: 477(M+1)

Example 764-(2-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(2-chlorophenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.98-2.08 (2H, m), 2.24 (2H, dt), 2.38-2.78 (9H, m),3.77 (3H, s), 5.27 (2H, brs), 6.08 (1H, t), 6.82-6.75 (3H, m), 7.28-7.19(3H, m), 7.33 (1H, dd), 7.49 (1H, dd), 7.58 (1H, dd), 8.40 (0.1H, dd, Zisomer), 8.47 (0.9H, dd, E isomer).

MS m/z: 477(M+1)

Example 771-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-fluorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-fluorophenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.58-1.72 (2H, m), 2.04 (2H, dt), 2.22-2.78 (9H, m),3.75 (3H, s), 5.26 (2H, brs), 6.09 (1H, t), 6.70-6.88 (3H, m), 7.00 (2H,dd), 7.23 (1H, dd), 7.42 (2H, dd), 7.56 (1H, dd), 8.41 (1H, dd).

MS m/z: 461(M+1)

Example 781-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(p-toly)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(p-tolyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.65-1.78 (2H, m), 2.02 (2H, dt), 2.31 (3H, s),2.24-2.75 (9H, m), 3.75 (3H, s), 5.25 (2H, brs), 6.07 (1H, t), 6.72-6.84(3H, m), 7.13 (2H, d), 7.23 (1H, dd), 7.34 (1H, d), 7.56 (1H, dd), 8.43(1H, dd).

MS m/z: 457(M+1)

Example 794-(3,4-Dichlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(3,4-dichlorophenyl)-4-hydroxypiperidine.

¹HNMR (CDCl₃) d: 1.58-1.72 (2H, m), 1.84 (1H, brs), 2.02 (2H, td),2.32-2.72 (8H, m), 3.76 (3H, s), 5.27 (2H, brs), 5.95 (0.1H, t, Eisomer), 6.07 (0.9H, t, Z isomer), 6.72-6.85 (3H, M), 7.12-7.20 (0.2H,m, E isomer), 7.21-7.32 (0.18H, m, Z isomer), 7.32-7.45 (1H, m),7.52-7.56 (2H, m), 8.37 (0.9H, dd, E siomer), 8.45 (0.1H, dd, Z isomer).

MS m/z: 512(M+1)

Example 834-(5-Chloropyridin-2-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(5-chloropyridin-2-yl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.77-1.82 (2H, m), 2.36-2.94 (11H, m), 3.77 (3H, brs),5.26 (2H, brs), 6.07 (1H, t), 6.76-6.84 (3H, m), 7.26 (1H, dd), 7.57(1H, dd), 8.49-7.48 (1H, d), 8.42-8.53 (3H, m).

MS m/z: 478(M+1)

Example 854-(5-Chloro-2-keto-1-benzimidazolinyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(5-chloro-2-keto-1-benzimidazolinyl)piperidine.

¹H-NMR (CDCl₃) δ: 1.68-1.72 (2H, m), 2.03-2.60 (8H, m), 2.90-3.02 (2H,m), 3.78 (3H, s), 4.32-4.21 (1H, m), 5.29 (2H, brs), 5.95 (0.1H, t, Esiomer), 6.08 (0.9H, t, Z isomer), 6.70-6.92 (3H, m), 7.02 (1H, dd),7.08-7.20 (1H, m), 7.26 (1H, dd), 7.58 (0.9H, dd, Z isomer), 7.70 (0.1H,dd, E isomer), 8.42 (0.1H, dd, E isomer), 8.48 (0.9H, dd, Z isomer),10.5 (1H, s).

(NH is not observed in the spectrum)

MS m/z: 517(M+1)

Example 864-(p-Chloroanilino)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(p-chloroanilino)piperidine.

¹H-NMR (CDCl₃) δ: 1.20-1.54 (2H, m), 1.85-2.20 (4H, m), 2.24-2.60 (4H,m), 2.73 (2H, m), 3.18 (1H, m), 3.77 (3H, s), 5.27 (2H, brs), 6.06 (1H,t), 6.47 (2H, m), 6.68-6.90 (3H, m), 7.07 (2H, m), 7.24 (1H, dd), 7.57(1H, m), 8.48 (1Hdd). NH signal was not observed.

MS m/z: 476(M+1)

Example 891-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(p-tosyl)piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(p-tosyl)piperazine.

¹H-NMR (CDCl₃) δ: 2.20-2.54 (11H, m), 2.82-3.10 (4H, m), 3.73 (3H, s),5.16 (2H, brs), 6.00 (1H, t), 6.66-6.85 (3H, m), 7.21 (1H, dd), 7.31(2H, m), 7.51 (1H, dd), 7.61 (2H, m), 8.45 (1H, dd).

MS m/z: 506(M+1)

Example 901′-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4′-piperidine]

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine withspiro[isobenzofuran-1(3H), 4′-piperidine].

¹H-NMR (CDCl₃) δ: 1.62-1.82 (2H, m), 1.92 (2H, dt), 2.25-2.85 (8H, m),3.76 (3H, s), 5.03 (2H, s), 5.30 (2H, brs), 6.11 (1H, t), 6.68-6.90 (3H,m), 7.02-7.34 (5H, m), 7.58 (1H, dd), 8.48 (1H, dd).

MS m/z: 455(M+1)

Example 915-Chloro-1′-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4′-piperidine]

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with5-chlorospiro[isobenzofuran-1(3H), 4′-piperidine].

¹H-NMR (CDCl₃) δ: 1.69-1.74 (2H, m), 1.81-1.93 (2H, m), 2.30-2.44 (4H,m), 2.52-2.63 (2H, m), 2.71-2.75 (2H, m), 3.79 (3H, s), 5.00 (2H, s),5.28 (2H, brs), 6.09 (1H, t), 6.73-6.84 (3H, m), 7.03 (1H, d), 7.17-7.28(3H, m), 7.58 (1H, dd), 8.49 (1H, dd).

MS m/z: 489(M+1)

Example 1114-(4-Chlorophenyl)-1-[3-(5,11-dihydro[1]benzothiepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro[1]benzothiepino[2,3-b]pyridin-5-one.

1H-NMR (CDCl₃) d: 1.66-1.78 (3H, m), 2.04-2.65 (10H, m), 3.66 (1H, brd),5.05 (1H, brd), 6.03 (1H, t), 7.04-7.46 (10H, m), 8.44 (1H, dd).

MS m/z: 463(M+1)

Example 1144-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro-8-methoxy[1]benzoxepino[2,3-b]pyridin-5-one.

1H-NMR (CDCl₃) d: 1.66-1.70 (3H, m), 1.98-2.09 (2H, m), 2.34-2.70 (8H,m), 3.75 (3H, s), 5.32 (2H, brs), 6.02 (1H, t), 6.39 (1H, d), 6.51 (1H,dd), 7.19-7.44 (6H, m), 7.57 (1H, dd), 8.49 (1H, dd).

MS m/z: 477(M+1)

Example 1154-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro-7-methyl[1]benzoxepino[2,3-b]pyridin-5-one.

1H-NMR (CDCl₃) δ: 1.50 (1H, brs), 1.66-1.70 (2H, m), 1.98-2.10 (2H, m),2.28 (3H, s), 2.34-2.42 (4H, m), 2.52-2.57 (2H, m), 2.66-2.70 (2H, m),5.30 (2H, brs), 6.08 (1H, t), 6.76 (1H, d), 6.97 (1H, dd), 7.09 (1H, d),7.24-7.44 (5H, m), 7.57 (1H, dd), 8.49 (1H, dd).

MS m/z: 461(M+1)

Example 1171-[3-(7-Chloro-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with7-chloro-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.

1H-NMR (CDCl₃) δ: 1.66-1.71 (3H, m), 2.00-2.10 (2H, m), 2.36-2.44 (4H,m), 2.52-2.57 (2H, m), 2.66-2.70 (2H, m), 5.32 (2H, brs), 6.13 (1H, t),6.78 (1H, d), 7.11 (1H, dd), 7.26-7.44 (5H, m), 7.58 (1H, dd), 8.51 (1H,dd).

MS m/z: 481(M+1)

Example 1181-[3-(7-Carboxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

A mixture of the product of example 169 (500 mg), potassium acetate (330mg), palladium(II) diacetate (10 mg),1,1′-bis(diphenylphosphino)ferrocene (93 mg), in dimethylsulfoxide (10ml) was purged with carbon monoxide for 5 minutes and stirred under acarbon monoxide balloon at 60° C. for 3 hours. Water was added to thereaction mixture, the precipitation was filtered. The solid weredissolved with ethyl acetate and dilute sodium hydroxide solution. Theaqueous layer was separated and neutralized with dilute hydrochloricacid. The precipitation was filtered to give the titled compound (250mg).

1H-NMR (DMSO-d₆) δ: 1.45-1.55 (2H, m), 1.75-1.85 (2H, m), 2.36-2.62 (8H,m), 5.42 (2H, brs), 6.21 (1H, t), 6.90 (1H, d), 7.40-7.52 (5H, m), 7.75(1H, dd), 7.83 (1H, dd), 7.95 (1H, d), 8.56 (1H, dd).

MS m/z: 491(M+1)

Example 1204-(4-Chlorophenyl)-1-[3-(7-carboxymethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of product of Example 290 (3.7 g) in methanol (74 ml),acetic acid (6 ml), and water (37 ml) were added sodium periodate (1.7g) in water (15 ml) at 0° C., and the mixture was stirred at roomtemperature for 1 hour. To the reaction mixture were added amidosulfuricacid (1.2 g) and sodium chlorite (0.89 g) in water (10 ml), and themixture was stirred at room temperature for 15 minutes. The reactionmixture was distilled off under reduced pressure into half volume. Theresidue was neutralized with 1N sodium hydroxide. The precipitation wasfiltered and washed with water to give the titled compound (2.6 g).

¹H-NMR (DMSO-d₆) δ: 1.45-1.50 (2H, m), 1.73-1.82 (2H, m), 2.24-2.50 (8H,m), 3.50 (2H, s), 4.84 (1H, brs), 5.24 (2H, brs), 6.13 (1H, t), 6.74(1H, d), 7.06 (1H, dd), 7.21 (1H, d), 7.33-7.48 (5H, m), 7.74 (1H, dd),8.50 (1H, dd).

Example 1224-(4-Chlorophenyl)-1-[3-(7-dimethylaminocarbonylmethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing the product of example 133 with the product ofexample 120.

¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 1.95-2.06 (2H, m), 2.31-2.66 (9H,m), 2.93 (3H, s), 3.00 (3H, s), 3.61 (2H, s), 5.29 (2H, brs), 6.09 (1H,t), 6.78 (1H, d), 7.00 (1H, dd), 7.20-7.43 (6H, m), 7.56 (1H, dd), 8.42(1H, dd).

MS m/z: 532(M+1)

Example 1231-[3-(7-(2-Carboxy)ethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of example288.

1H-NMR (DMSO-d₆) δ: 1.44-1.49 (2H, m), 1.70-1.82 (2H, m), 2.22-2.48(10H, m), 2.75 (2H, t), 4.82 (1H, brs), 5.23 (2H, brs), 6.14 (1H, t),6.71 (1H, d), 7.04 (1H, dd), 7.17 (1H, d), 7.33-7.48 (5H, m), 7.72 (1H,dd), 8.49 (1H, dd).

MS m/z: 519(M+1)

Example 1284-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-propoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with propyl iodide.

1H-NMR (CDCl₃) δ: 1.03 (3H, t), 1.65-1.70 (2H, m), 1.78 (2H, q),1.98-2.09 (3H, m), 2.37-2.45 (4H, m), 2.51-2.56 (2H, m), 2.66-2.70 (2H,m), 3.88 (2H, t), 5.26 (2H, brs), 6.08 (1H, t), 6.72-6.84 (3H, m),7.23-7.43 (5H, m), 7.58 (1H, dd), 8.43 (1H, dd).

MS m/z: 505(M+1)

Example 130 4-(4-Chlorophenyl)-1-[3-(7-cyclopropylmethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with cyclopropylmethyl bromide.

1H-NMR (CDCl₃) δ: 0.31-0.37 (2H, m), 0.60-0.67 (2H, m), 1.21-1.28 (1H,m), 1.66-1.72 (3H, m), 2.01-2.11 (2H, m), 2.37-2.71 (8H, m), 3.77 (2H,d), 5.27 (2H, brs), 6.08 (1H, t), 6.73-6.86 (3H, m), 7.23-7.44 (5H, m),7.58 (1H, dd), 8.47 (1H, dd).

MS m/z: 517(M+1)

Example 1314-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-dimethylaminoethyl)oxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with 2-(dimethylamino)ethyl chloridehydrochloride.

¹H-NMR (CDCl₃) δ: 1.71-1.76 (2H, m), 2.12-2.21 (2H, m), 2.38 (6H, s),2.40-2.79 (11H, m), 4.07 (2H, t), 5.28 (2H, brs), 6.07 (1H, t),6.74-6.86 (3H, m), 7.27-7.46 (5H, m), 7.59 (1H, dd), 8.49 (1H, dd).

MS m/z: 534(M+1)

Example 1324-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(tetrazol-5-yl)methyloxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-triphenylmethyltetrazol-5-yl)methyloxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of example 46, but replacingethyl iodide with (2-triphenylmethyltetrazol-5-yl)methyl chloride.

¹H-NMR (CDCl₃) δ: 1.64-1.70 (3H, m), 2.02-2.15 (2H, m), 2.35-2.71 (8H,m), 5.29 (2H, brs), 5.33 (2H, s), 6.03 (1H, t), 6.77 (1H, d), 6.83 (1H,dd), 6.96 (1H, d), 7.04-7.08 (6H, m), 7.23-7.45 (14H, m), 7.54 (1H, dd),8.50 (1H, dd).

Step 2

A solution of the product of step 1 (530 mg) in acetone (2.5 ml), aceticacid (2.5 ml) and water (2.5 ml) was stirred at 55° C. for 30 minutes.The reaction mixture was distilled off under reduced pressure. Theresidue was washed with methanol to give the titled compound (280 mg).

¹H-NMR (DMSO-d₆) δ: 1.69-1.74 (2H, m), 1.99-2.09 (2H, m), 2.95-3.14 (8H,m), 5.18 (2H, brs), 5.20 (2H, s), 6.14 (1H, t), 6.76 (1H, d), 6.93 (1H,dd), 7.04 (1H, d), 7.39-7.48 (5H, m), 7.78 (1H, dd), 8.52 (1H, dd).

MS m/z: 545(M+1)

Example 1331-[3-(7-Carboxymethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

To a solution of product of example 48 (3.0 g) in methanol (50 ml) wasadded 1N sodium hydroxide solution (8 ml) and the mixture stirred atroom temperature for 1 hour. The reaction mixture was distilled offunder reduced pressure. The residue was dissolved with water andneutralized with 1N hydrochloric acid. The precipitation was filteredand washed with water to give the titled compound (2.6 g).

¹H-NMR (DMSO-d₆) δ: 1.48-1.53 (2H, m), 1.76-1.88 (2H, m), 2.32-2.60 (8H,m), 4.60 (2H, s), 5.18 (2H, brs), 6.16 (1H, t), 6.72-6.84 (3H, m),7.34-7.48 (5H, m), 7.73 (1H, dd), 8.50 (1H, dd).

MS m/z: 521(M+1)

Example 1344-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-dimethylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of product of example 133 (420 mg) in dimethylformamide(17 ml) were added 1-hydroxybenzotriazol hydrate (250 mg),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (310 mg),dimethylamine hydrochloride (270 mg) and triethylamine (0.45 ml), andthe mixture stirred at room temperature for 12 hours. Water andchloroform were added to the reaction mixture, the organic layer wasseparated and washed with saturated aqueous sodium chloride, and driedwith magnesium sulfate. The solvent was distilled off under reducedpressure to give the titled compound (380 mg).

¹H-NMR (CDCl₃) δ: 1.67-1.71 (2H, m), 1.95-2.11 (3H, m), 2.37-2.71 (8H,m), 2.97 (3H, s), 3.08 (3H, s), 4.64 (2H, s), 5.27 (2H, brs), 6.09 (1H,t), 6.74-6.82 (2H, m), 6.93 (1H, d), 7.24-7.44 (5H, m), 7.58 (1H, dd),8.47 (1H, dd).

MS m/z: 548(M+1)

Example 1354-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-morpholinocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing dimethylamine hydrochloride with morpholine.

¹H-NMR (CDCl₃) δ: 1.67-1.71 (2H, m), 1.87 (1H, brs), 2.00-2.11 (2H, m),2.38-2.71 (8H, m), 3.61-3.68 (8H, m), 4.65 (2H, s), 5.27 (2H, brs), 6.09(1H, t), 6.74-6.83 (2H, m), 6.90 (1H, d), 7.25-7.44 (5H, m), 7.58 (1H,dd), 8.48 (1H, dd).

MS m/z: 590(M+1)

Example 1384-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with ethyl 2-bromoisobutylate.

¹H-NMR (CDCl₃) δ: 1.27 (3H, t), 1.56 (6H, s), 1.63-1.71 (3H, m),2.01-2.10 (2H, m), 2.35-2.70 (8H, m), 4.24 (2H, q), 5.28 (2H, brs), 6.05(1H, t), 6.67-6.75 (2H, m), 6.87 (1H, d), 7.24-7.44 (5H, m), 7.56 (1H,dd), 8.49 (1H, dd).

MS m/z: 577(M+1)

Example 139 1-[3-(7-(1-Carboxy-1-methylethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing product of example 48 with product of example 138.

¹H-NMR (DMSO-d₆) δ: 1.45-1.52 (8H, m), 1.79-1.85 (2H, m), 2.28-2.53 (8H,m), 5.19 (2H, brs), 6.07 (1H, t), 6.69-6.73 (2H, m), 6.85 (1H, d),7.33-7.47 (5H, m), 7.71 (1H, dd), 8.48 (1H, dd).

MS m/z: 549(M+1)

Example 1401-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-methoxyphenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-methoxyphenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.62-1.75 (2H, m), 2.08 (2H, dt), 2.41-2.76 (9H, m),3.77 (3H, s), 3.78 (3H, s), 5.26 (2H, brs), 6.06 (1H, t), 6.75-6.871(5H, m), 7.23 (1H, dd), 7.38 (2H, d), 7.57 (1H, dd), 8.45 (1H, dd).

MS m/z: 473(M+1)

Example 1414-(4-Cyanophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-cyanophenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.58-1.70 (2H, m), 2.03 (2H, t), 2.31-2.64 (7H, m),2.65-2.78 (2H, m), 3.75 (3H, s), 5.26 (2H, brs), 5.95 (0.1H, t, Eisomer), 6.05 (0.9H, t, Z isomer), 6.70-6.80 (3H, m), 7.22 (1H, dd),7.54-7.68 (5H, m), 8.31 (0.1H, dd, E iosmer), 8.39 (0.9H, dd, Z isomer).

MS m/z: 468(M+1)

Example 1421-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-hydroxyphenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-hydroxyphenyl)-4-hydroxypiperidine.

¹HNMR (CDCl₃) δ: 1.76-1.88 (2H, m). 2.08-2.22 (2H, m), 2.45-2.95 (9H,m), 3.76 (3H, s), 5.28 (2H, brs), 5.95 (0.3H, t, E isomer), 6.04 (0.7H,t, Z iosmer), 6.69-6.72 (3H, m), 6.90 (2H, d), 7.20-7.30 (3H, m), 7.56(0.7H, dd, Z isomer), 7.67 (0.3H, dd, E isomer), 8.46 (0.7H, dd, Zisomer), 8.47 (0.3H, dd, E isomer). OH signal was not observed.

MS m/z: 473(M+1)

Example 1431-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-fluoro-3-methylphenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-fluoro-3-methylphenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.62-1.75 (2H, m), 2.05 (1H, brs), 2.09 (2H, dt), 2.25(3H, s), 2.30-2.76 (8H, m), 3.76 (3H, s), 5.26 (2H, brs), 5.96 (0.1H, t,E isomer), 6.07 (0.9H, t, Z isomer), 6.75-6.89 (3H, m), 6.93 (1H, t),7.11-7.20 (0.3H, m, E isomer), 7.21-7.35 (0.24H, m, Z isomer), 7.56(0.9H, dd, E isomer), 7.67 (0.1H, dd, E isomer), 8.38 (0.1H, dd, Eisomer), 8.45 (0.9H, dd, Z isomer).

MS m/z: 475(M+1)

Example 1444-(3,4-difluorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(3,4-difluorophenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.58-1.72 (2H, m), 1.96 (2H, dt), 2.33-2.71 (8H, m),3.73 (3H, s), 5.23 (2H, brs), 5.94 (0.1H, t, E isomer), 6.04 (0.9H, t, Zisomer), 8.38-8.36 (0.9H, m, Z isomer), 6.68-6.79 (3H, m), 6.98-7.38(4H, m), 7.50-7.62 (0.9H, m, Z isomer), 7.63-7.68 (0.1H, m, E isomer),8.29-8.32 (0.1H, m, E isomer), 8.32-8.44 (0.9H, m, Z isomer). OH signalwas not observed.

MS m/z: 479(M+1)

Example 1454-(4-Chloro-3-trifuluoromethylphenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chloro-3-trifluoromethylphenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.62-1.74 (2H, m), 2.10 (2H, dt), 2.35-2.80 (8H, m),2.42 (1H, brs), 3.76 (3H, s), 5.26 (2H, brs), 6.07 (0.9H, t, Z isomer),6.03 (0.1H, t, E isomer), 6.82-6.71 (3H, m), 7.24 (1H, dd), 7.43 (1H,d), 7.56 (1.8H, dd, Z isomer), 7.65 (0.2H, dd, E isomer) 7.83 (1H, d),8.36 (0.1H, dd, E isomer), 8.44 (0.9H, dd, Z iosmer),

MS m/z: 545(M+1)

Example 1464-(3,5-dichlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(3,5-dichlorophenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.58-2.22 (5H, m), 2.38-2.77 (8H, m), 3.76 (3H, s),5.26 (2H, brs), 5.92 (0.1H, t, E isomer), 6.07 (0.9H, t, Z isomer),6.83-6.71 (3H, m), 7.19-7.42 (4H, m), 7.56 (0.9H, dd, Z isomer), 7.68(0.1H, dd, E isomer), 8.38 (0.1H, dd, E isomer), 8.45 (0.9H, dd, Zisomer).

MS m/z: 512(M+1)

Example 1471-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-pyridyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(2-pyridyl)-4-hydroxypiperidine

¹H-NMR (CDCl₃) d: 1.54-1.65 (2H, m), 2.06 (2H, dt), 2.07 (1H, brs),2.35-2.62 (7H, m), 2.73-2.87 (2H, m), 3.78 (3H, s), 5.28 (2H, brs), 6.08(1H, t), 6.72-6.85 (3H, m), 7.14-7.29 (2H, m), 7.57 (1H, d), 7.70 (1H,dd), 8.48 (2H, dd).

MS m/z: 444(M+1)

Example 1481-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(3-pyridyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(3-pyridyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.65-1.78 (2H, m), 2.08 (2H, dt), 2.37-2.88 (7H, m),2.63-2.79 (2H, m), 3.78 (3H, s), 5.28 (2H, brs), 6.02 (0.1H, t, Eisomer), 6.07 (0.9H, t, Z isomer), 6.70-6.84 (3H, m), 7.22-7.32 (3H, m),7.56 (1H, dd), 7.77 (1H, dd), 8.46 (0.9H, d), 8.57 (0.1H, dd, E isomer),8.73 (1H, dd).

MS m/z: 444(M+1)

Example 1491-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-pyridyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-pyridyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.58-1.72 (2H, m), 2.03 (2H, dt), 2.34-2.89 (8H, m),2.96 (1H, brs), 3.76 (3H, s), 5.25 (2H, brs), 6.06 (1H, t), 6.72-6.83(3H, m), 7.24 (1H, dd), 7.37 (2H, dd), 7.56 (1H, dd), 8.45 (1H, dd),8.48 (2H, dd).

MS m/z: 444(M+1)

Example 1501-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-trifluoromethylphenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-trifluoromethylphenyl)-4-hydroxypiperidine.

¹H-NMR (CDCl₃) δ: 1.64-1.75 (2H, m), 2.01 (1H, brs), 2.16 (2H, dt),2.38-2.86 (8H, m), 3.76 (3H, s), 5.26 (2H, brs), 6.04 (1H, t), 6.72-6.84(3H, m), 7.23 (1H, dd), 7.56 (5H, m), 8.42 (1H, dd).

MS m/z: 511(M+1)

Example 1514-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)piperidine.

¹H-NMR (CDCl₃) δ: 1.62-1.92 (4H, m), 1.94-2.18 (2H, m), 2.28-2.64 (5H,m), 2.99 (2H, m), 5.25 (2H, brs), 6.00 (1H, t), 6.60-6.82 (3H, m),7.02-7.36 (5H, m), 7.50 (1H, dd), 8.47 (1H, dd).

OH signal was not observed.

MS m/z: 447(M+1)

Example 1524-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example46, but replacing the product of example 44 with the product of example151.

¹H-NMR (CDCl₃) δ: 1.40 (3H, t), 1.52-2.14 (6H, m), 2.30-2.57 (5H, m),2.94 (2H, m), 4.00 (2H, q), 5.28 (2H, brs), 6.07 (1H, t), 6.68-6.86 (3H,m), 7.05-7.36 (5H, m), 7.58 (1H, m), 8.49 (1H, m).

MS m/z: 475(M+1)

Example 1534-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-thoxycarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example48, but replacing the product of example 44 with the product of example151.

¹H-NMR (CDCl₃) δ: 1.29 (3H, t), 1.56-1.85 (4H, m), 1.99 (2H, dt),2.28-2.55 (5H, m), 2.91 (2H, m), 4.27 (2H, q), 4.58 (2H, s), 5.28 (2H,brs), 6.09 (1H, t), 6.68-6.95 (3H, m), 7.07-7.32 (5H, m), 7.58 (1H, dd),8.49 (1H, dd).

MS m/z: 533(M+1)

Example 1541-[3-(7-(Carboxymethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of example153.

¹H-NMR (CD₃OD) δ: 1.82-2.17 (4H, m), 2.69 (2H, m), 2.86 (1H, m), 3.07(2H, m), 3.30 (2H, m), 3.57 (2H, m), 4.57 (2H, s), 5.21 (2H, brs), 6.10(1H, t), 6.70-7.04 (3H, m), 7.16-7.38 (4H, m), 7.44 (1H, m), 7.77 (1H,m), 8.47 (1H, m). COOH signal was not observed.

MS m/z: 505(M+1)

Example 1554-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-dimethylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example134, but replacing the product of example 133 with the product ofexample 154.

¹H-NMR (CDCl₃) δ: 1.58-1.92 (4H, m), 2.04 (2H, m), 2.30-2.68 (5H, m),2.93 (2H, m), 2.98 (3H, s), 3.08 (3H, s), 4.65 (2H, s), 5.28 (2H, brs),6.07 (1H, t), 6.70-6.98 (3H, m), 7.08-7.36 (5H, m), 7.60 (1H, m), 8.50(1H, m).

MS m/z: 532(M+1)

Example 1561-[3-(7-(2-Acetoxyethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example50, but replacing the product of example 44 with the product of example151.

¹H-NMR (CDCl₃) δ: 1.55-1.88 (4H, m), 1.90-2.32 (2H, m), 2.10 (3H, s),2.28-2.60 (5H, m), 2.82-3.02 (2H, m), 4.14 (2H, dd), 4.41 (2H, dd), 5.29(2H, brs), 6.08 (1H, t), 6.72-6.90 (3H, m), 7.18-7.34 (5H, m), 7.57 (1H,m), 8.50 (1H, m).

MS m/z: 533(M+1)

Example 1574-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example51, but replacing the product of example 50 with the product of example156.

¹H-NMR (CD₃OD) δ: 1.66-1.98 (4H, m), 2.40-2.73 (5H, m), 2.82-2.94 (2H,m), 3.22 (2H, m), 3.84 (2H, dd), 4.01 (2H, dd), 5.23 (2H, brs), 6.13(1H, t), 6.64-6.98 (3H, m), 7.13-7.34 (4H, m), 7.45 (1H, m), 7.77 (1H,m), 8.47 (1H, m). OH signal was not observed.

MS m/z: 491(M+1)

Example 1584-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example138, but replacing the product of example 44 with the product of example151.

¹H-NMR (CDCl₃) d: 1.28 (3H, t), 1.56 (6H, s), 1.56-1.85 (4H, m), 1.97(2H, dt), 2.28-2.55 (5H, m), 2.93 (2H, m), 4.24 (2H, q), 5.28 (2H, brs),6.04 (1H, t), 6.62-6.95 (3H, m), 7.07-7.32 (5H, m), 7.57 (1H, dd), 8.50(1H, dd).

MS m/z: 561(M+1)

Example 1591-[3-(7-(1-Carboxy-1-methylethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of example158.

¹H-NMR (CD₃OD) d: 1.50 (6H, s), 1.82-2.18 (4H, m), 2.70 (2H, m), 2.87(1H, m), 3.12 (2H, m), 3.30 (2H, m), 3.60 (2H, m), 5.25 (2H, brs), 6.07(1H, t), 6.67-7.04 (3H, m), 7.16-7.38 (4H, m), 7.58 (1H, m), 7.96 (1H,m), 8.52 (1H, m). COOH signal was not observed.

MS m/z: 533(M+1)

Example 1601-[3-(8-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine

The titled compound was prepared by following the procedure of example65, but replacing the product of example 45, step 2 with the product ofexample 54, step 1.

¹H-NMR (CDCl₃) d: 1.50-1.86 (4H, m), 1.98 (2H, m), 2.26-2.60 (5H, m),2.88 (2H, m), 5.30 (2H, brs), 6.09 (1H, t), 6.96-7.36 (8H, m), 7.57 (1H,dd), 8.51 (1H, dd).

MS m/z: 509, 511(M+1)

Example 1611-[3-(8-Carboxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine

To a solution of1-[3-(8-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine(Example 160) (130 mg) in THF (1.0 ml) was added 1.6M n-butyllithiumhexane solution (0.17 ml) at −78° C. After stirring 10 minutes at thesame temperature, CO₂ (dry-ice) was added to the mixture. After beingwarmed to ambient temperature, the mixture was stirred for 30 minutes atthe same temperature. The mixture was concentrated in vacuo. Theresulting oil was purified by silica gel chromatography eluted withdichloromethane-methanol (5:1) to give the titled compound

¹H-NMR (CD₃OD) δ: 1.55-1.95 (4H, m), 2.17 (2H, dt), 2.32-2.78 (5H, m),3.00 (2H, m), 5.30 (2H, brs), 6.19 (1H, t), 7.08-7.54 (8H, m), 7.76 (1H,dd), 8.45 (1H, dd). COOH signal was not observed.

MS m/z: 475(M+1)

Example 1621-[3-(7-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with8-bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.

¹H-NMR (CDCl₃) δ: 1.60-1.71 (3H, m), 1.98-2.09 (2H, m), 2.34-2.69 (8H,m), 5.32 (2H, brs), 6.13 (1H, t), 6.73 (1H, d), 7.22-7.44 (7H, m), 7.57(1H, dd), 8.52 (1H, dd).

MS m/z: 525, 527(M+1)

Example 1634-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro-7-ethyl[1]benzoxepino[2,3-b]pyridin-5-one.

1H-NMR (CDCl₃) d: 1.23 (3H, t), 1.52 (1H, brs), 1.66-1.71 (2H, m),1.98-2.06 (2H, m), 2.35-2.70 (11H, m), 5.31 (2H, brs), 6.09 (1H, t),6.79 (1H, d), 7.01 (1H, dd), 7.11 (1H, d), 7.25-7.44 (5H, m), 7.58 (1H,dd), 8.49 (1H, dd).

MS m/z: 475(M+1)

Example 1644-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-vinyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro-8-vinyl[1]benzoxepino[2,3-b]pyridin-5-one.

1H-NMR (CDCl₃) d: 1.66-1.71 (3H, m), 2.00-2.10 (2H, m), 2.36-2.70 (8H,m), 5.22 (2H, d), 5.34 (2H, brs), 5.70 (1H, d), 6.11 (1H, t), 6.61 (1H,dd), 6.89 (1H, d), 6.99 (1H, dd), 7.24-7.44 (6H, m), 7.58 (1H, dd), 8.49(1H, dd).

MS m/z: 473(M+1)

Example 1654-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-ethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

A mixture of the product of example 164 (100 mg) and Pd—C (20 mg) inethanol (2 ml) stirred under a hydrogen balloon at room temperature for1 hour. The mixture was filtered through the celite and distilled offunder reduced pressure. The residue was purified by preparative thinlayer chromatography eluting with chloroform-methanol (15:1) to give thetitled compound (50 mg).

1H-NMR (CDCl₃) δ: 1.22 (3H, t), 1.55-1.77 (3H, m), 2.00-2.13 (2H, m),2.33-2.74 (10H, m), 5.32 (2H, brs), 6.07 (1H, t), 6.70 (1H, d), 6.78(1H, dd), 7.19-7.44 (6H, m), 7.57 (1H, dd), 8.49 (1H, dd).

MS m/z: 475(M+1)

Example 1664-(4-Chlorophenyl)-1-[3-(5,11-dihydro-9-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro-9-methoxy[1]benzoxepino[2,3-b]pyridin-5-one.

1H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 1.95-2.06 (2H, m), 2.15 (1H, brs),2.37-2.67 (8H, m), 3.83 (3H, s), 5.43 (2H, brs), 6.09 (1H, t), 6.79-6.91(3H, m), 7.22-7.43 (5H, m), 7.57 (1H, dd), 8.44 (1H, dd).

MS m/z: 477(M+1)

Example 1674-(4-Chlorophenyl)-1-[3-(5,11-dihydro[1]benzoxepino[4,3-c]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro[1]benzoxepino[4,3-c]pyridin-5-one.

1H-NMR (CDCl₃) δ: 1.67-1.71 (2H, m), 1.97-2.08 (2H, m), 2.16 (1H, s),2.40-2.69 (8H, m), 5.16 (2H, brs), 6.14 (1H, t), 6.80 (1H, dd),6.91-6.97 (1H, m), 7.13-7.19 (1H, m), 7.26-7.44 (6H, m), 7.50-8.54 (2H,m).

MS m/z: 447(M+1)

Example 168 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro[1]benzoxepino[4,3-d]pyrimidin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with5,11-dihydro[1]benzoxepino[4,3-d]pyrimidin-5-one.

1H-NMR (CDCl₃) δ: 1.68-1.72 (2H, m), 1.90 (1H, brs), 2.06-2.19 (2H, m),2.41-2.78 (8H, m), 5.20 (2H, s), 6.12 (1H, t), 7.14-7.45 (8H, m), 8.72(1H, s), 8.97 (1H, s).

MS m/z: 448(M+1)

Example 1694-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-trifluoromethanesulfonyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of product of example 44 (1.0 g) in pyridine (10 ml) wasadded trifluoromethanesulfonic acid anhydride (0.55 ml) at 0° C., andthe mixture was stirred at room temperature for 1 hour. Water anddiethyl ether were added to the reaction mixture, the organic layer wasseparated and washed with saturated aqueous sodium chloride, and driedwith magnesium sulfate. The solvent was distilled off under reducedpressure, and the residue was purified by silica gel chromatographyeluting with ethyl acetate-methanol (10:1) to give the titled compound(1.1 g).

¹H-NMR (CDCl₃) δ: 1.56 (1H, brs), 1.66-1.71 (2H, m), 1.97-2.09 (2H, m),2.35-2.69 (8H, m), 5.35 (2H, brs) 6.15 (1H, t), 6.88 (1H, d), 7.05 (1H,dd), 7.21-7.44 (6H, m), 7.60 (1H, dd), 8.54 (1H, dd).

MS m/z: 595(M+1)

Example 1701-[3-(7-Allyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

A mixture of the product of example 169 (240 mg), allyltributyltin (0.19ml), dichlorobis(triphenylphosphine)palladium(II) (30 mg) and lithiumchloride (76 mg), in dimethylformamide (3 ml) was heated under argon at120° C. for 2 hours. Aqueous ammonium fluoride solution and ethylacetate were added to the reaction mixture, the organic layer wasseparated and washed with saturated aqueous sodium chloride, and driedwith magnesium sulfate. The solvent was distilled off under reducedpressure, and the residue was purified by silica gel chromatographyeluting with chloroform-methanol (10:1) to give the titled compound (180mg).

1H-NMR (CDCl₃) δ: 1.62-1.72 (3H, m), 2.03-2.11 (2H, m), 2.39-2.73 (8H,m), 3.31 (2H, d), 5.04-5.11 (2H, m), 5.29 (2H, brs), 5.87-6.02 (1H, m),6.06 (1H, t), 6.77 (1H, d), 6.99 (1H, dd), 7.10 (1H, d), 7.23-7.43 (5H,m), 7.57 (1H, dd), 8.40 (1H, dd).

Example 1711-[3-(7-(2-t-Butoxycarboxy)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

A mixture of the product of example 169 (1.7 g), t-butyl acrylate (0.85ml), triethylamine (2.5 ml), 1,1′-bis(diphenylphosphino)ferrocene (250mg) and palladium(II) diacetate (33 mg) in dimethylformamide (3 ml) washeated under argon at 90° C. for 24 hours. Water ethyl acetate wereadded to the reaction mixture, the organic layer was separated andwashed with saturated aqueous sodium chloride, and dried with magnesiumsulfate. The solvent was distilled off under reduced pressure, and theresidue was purified by silica gel chromatography eluting with ethylacetate-methanol (30:1) to give the titled compound (780 mg).

1H-NMR (CDCl₃) δ: 1.45 (9H, s), 1.63-1.71 (3H, m), 1.98-2.10 (2H, m),2.35-2.72 (8H, m), 5.35 (2H, brs), 6.15 (1H, t), 6.26 (1H, d), 6.83 (1H,d), 7.22-7.44 (7H, m), 7.53 (1H, d), 7.58 (1H, dd), 8.52 (1H, dd).

Example 1721-[3-(7-(2-Carboxy)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The product of example 171 (330 mg) was dissolved with 4N hydrochloricacid 1,4-dioxane solution (4 ml), and stirred at room temperature for 1hour. The solvent was distilled off under reduced pressure. Water wasadded to the residue, and neutralized with sodium hydroxide solution.The precipitation was filtered to give the titled compound (190 mg).

1H-NMR (DMSO-d₆) δ: 1.45-1.52 (2H, m), 1.72-1.84 (2H, m), 2.25-2.58 (8H,m), 5.25 (2H, brs), 6.28 (1H, t), 6.43 (1H, d), 6.82 (1H, d), 7.34-7.60(8H, m), 7.75 (1H, dd), 8.52 (1H, dd).

Example 1734-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-propargyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with propargyl chloride.

1H-NMR (CDCl₃) δ: 1.66-1.71 (2H, m), 1.79 (1H, brs), 1.99-2.10 (2H, m),2.35-2.71 (9H, m), 4.66 (2H, d), 5.28 (2H, brs), 6.10 (1H, t), 6.80-6.93(3H, m), 7.24-7.46 (5H, m), 7.59 (1H, dd), 8.48 (1H, dd).

MS m/z: 501(M+1)

Example 1744-(4-Chlorophenyl)-1-[3-(7-cyclopentoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with cyclopentyl bromide.

1H-NMR (CDCl₃) δ: 1.54-2.18 (13H, m), 2.41-2.72 (8H, m), 4.66-4.73 (1H,m), 5.27 (2H, brs), 6.08 (1H, t), 6.70-6.87 (3H, m), 7.23-7.44 (5H, m),7.58 (1H, dd), 8.49 (1H, dd).

MS m/z: 531(M+1)

Example 1754-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-methoxyethyl)oxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with 2-methoxyethyl chloride.

1H-NMR (CDCl₃) δ: 1.66-1.75 (3H, m), 2.00-2.11 (2H, m), 2.36-2.71 (8H,m), 3.45 (3H, s), 3.71-3.75 (2H, m), 4.07-4.11 (2H, m), 5.27 (2H, brs),6.09 (1H, t), 6.75-6.91 (3H, m), 7.23-7.44 (5H, m), 7.57 (1H, dd), 8.48(1H, dd).

MS m/z: 521(M+1)

Example 1764-(4-Chlorophenyl)-1-[3-(7-(1-dimethyaminocarbonyl-1-methyl)ethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing the product of example 133 with the product ofexample 139.

1H-NMR (CDCl₃) δ: 1.59 (6H, s), 1.67-1.72 (2H, m), 1.99-2.09 (2H, m),2.36-2.70 (9H, m), 2.96 (3H, s), 3.21 (3H, s), 5.25 (2H, brs), 6.02 (1H,t), 6.60-6.77 (3H, m), 7.24-7.44 (5H, m), 7.58 (1H, dd), 8.44 (1H, dd).

MS m/z: 576(M+1)

Example 1774-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with ethyl 2-bromopropionate.

1H-NMR (CDCl₃) δ: 1.25 (3H, t), 1.59 (3H, d), 1.65-1.70 (2H, m),1.98-2.08 (2H, m), 2.35-2.68 (8H, m), 2.80 (1H, brs), 4.21 (2H, q), 4.68(1H, q), 5.24 (2H, brs), 6.07 (1H, t), 6.68-6.79 (2H, m), 6.88 (1H, d),7.22-7.44 (5H, m), 7.56 (1H, dd), 8.40 (1H, dd).

Example 1781-[3-(7-(1-Carboxyethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing product of example 48 with product of example 177.

1H-NMR (DMSO-d₆) δ: 1.46 (3H, d), 1.58-1.63 (2H, m), 1.98-2.06 (2H, m),2.41-2.45 (2H, m), 2.72-2.86 (6H, m), 4.74 (1H, q), 5.18 (2H, brs), 6.11(1H, t), 6.73 (2H, s), 6.84 (1H, s), 7.36-7.47 (5H, m), 7.73 (1H, dd),8.50 (1H, dd).

MS m/z: 535(M+1)

Example 1794-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonyl)cyclobutoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with ethyl 2-bromocyclobutanecarboxylate.

1H-NMR (CDCl₃) δ: 1.19 (3H, t), 1.67-1.71 (2H, m), 1.92-2.11 (5H, m),2.33-2.77 (12H, m), 4.21 (2H, q), 5.25 (2H, brs), 6.05 (1H, t), 6.47(1H, dd), 6.70 (1H, d), 6.73 (1H, d), 7.23-7.44 (5H, m), 7.55 (1H, dd),8.44 (1H, dd).

Example 1801-[3-(7-(1-Carboxy)cyclbutoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing product of example 48 with product of example 179.

1H-NMR (DMSO-d₆) δ: 1.60-1.65 (2H, m), 1.86-2.08 (4H, m), 2.24-2.90(12H, m), 5.17 (2H, brs), 6.05 (1H, t), 6.50 (1H, dd), 6.66 (1H, d),6.73 (1H, d), 7.37-7.48 (5H, m), 7.74 (1H, dd), 8.51 (1H, dd).

MS m/z: 561(M+1)

Example 1811-[3-(7-Carbamoylmethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing dimethylamine hydrochloride with ammonium hydroxide.

1H-NMR (CDCl₃) δ: 1.66-1.71 (2H, m), 1.98-2.09 (2H, m), 2.21 (1H, brs),2.38-2.70 (8H, m), 4.45 (2H, s), 5.28 (2H, brs), 6.09 (1H, t), 6.11 (1H,brs), 6.58 (1H, brs), 6.74-6.85 (3H, m), 7.24-7.44 (5H, m), 7.58 (1H,dd), 8.47 (1H, dd).

MS m/z: 520(M+1)

Example 1824-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing dimethylamine hydrochloride with methylamine.

1H-NMR (CDCl₃) δ: 1.67-1.72 (2H, m), 1.99-2.10 (2H, m), 2.36-2.70 (9H,m), 2.89 (3H, d), 4.45 (2H, s), 5.28 (2H, brs), 6.08 (1H, t), 6.66 (1H,brs), 6.73-6.84 (3H, m), 7.25-7.45 (5H, m), 7.58 (1H, dd), 8.47 (1H,dd).

MS m/z: 534(M+1)

Example 1831-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-hydroxyphenyl)piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-hydroxyphenyl)piperidine.

¹H-NMR (CDCl₃) δ: 1.52-1.88 (4H, m), 2.01 (2H, dt), 2.28-2.60 (5H, m),2.93 (2H, m), 3.79 (3H, s), 5.28 (2H, brs), 6.08 (1H, t), 6.68-6.88 (3H,m), 7.05-7.36 (5H, m), 7.58 (1H, dd), 8.50 (1H, dd).

MS m/z: 461(M+1)

Example 1841-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-hydroxyphenyl)piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(2-hydroxyphenyl)piperidine.

¹H-NMR (CDCl₃) δ: 1.78-1.92 (4H, m), 2.12-2.25 (2H, m), 2.32-2.70 (4H,m), 2.80-2.97 (1H, m), 3.01-3.15 (2H, m), 3.77 (3H, s), 3.78 (1H, brs),5.28 (2H, brs), 6.03 (1H, t), 6.74-6.86 (4H, m), 7.05 (1H, dd), 7.11(1H, dd), 7.23-7.28 (2H, m), 7.56 (1H, dd), 8.48 (1H, dd), OH signal wasnot observed.

MS m/z: 443(M+1)

Example 1854-(7-Chloro-1,2-benzisoxazol-3-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(7-chloro-1,2-benzisoxazol-3-yl)piperidine. This tetrahydropyridinewas prepared by the same method described in J. Med. Chem. 28:761-769(1985).

¹H-NMR (CDCl₃) δ: 1.94-2.20 (6H, m), 2.30-2.60 (4H, m), 2.86-3.14 (3H,m), 3.79 (3H, s), 5.29 (2H, brs), 6.10 (1H, t), 6.70-6.88 (3H, m), 7.22(1H, t), 7.27 (1H, dd), 7.50 (1H, dd), 7.57-7.68 (2H, m), 8.49 (1H, dd).

Example 1864-(7-Chloroindol-3-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(7-chloroindol-3-yl)piperidine. This piperidine was prepared by thesame method described in J. Med. Chem. 36:4006-4014 (1993) and followinghydrogenation described in Example 58, step 3.

¹H-NMR (CDCl₃) δ: 1.66-1.88 (2H, m), 1.92-2.22 (4H, m), 2.32-2.63 (4H,m), 2.78 (1H, m), 2.97 (2H, m), 3.79 (3H, s), 5.29 (2H, brs), 6.09 (1H,t), 6.70-6.87 (3H, m), 6.97-7.07 (2H, m), 7.12-7.30 (2H, m), 7.52 (1H,m), 7.59 (1H, dd), 8.45 (1H, brs), 8.50 (1H, dd).

Example 1874-Azido-4-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidineStep 1 4-azido-4-(4-chlorophenyl)piperidine (15): FIG. 8 b

To a cold (0° C.) solution of 1 (3.0 g, 14 mmol) in anhydrous dioxane(15 mL) under an inert atmosphere was added NaN₃ (1.0 g, 15.4 mmol)followed by the slow dropwise addition of and BF₃.OEt (4.4 mL, 35 mmol).The reaction was stirred at 0° C. for 3 hrs and was quenched at 0° C. bythe slow careful addition of saturated aqueous NaHCO₃ to basicity. Theorganic layer was separated and dried over Na₂SO₄. The reaction mixturewas purified via silica gel flash chromatography eluting a 2 g 1:3mixture of azidopiperidine 2 and olefin 3 with 2% MeOH/CH₂Cl₂. Themixture was taken directly on to the next reaction.

Step 2

The titled compound was prepared by then following the procedure ofexample 45, step 3, with the above reaction mixture (thereby replacing4-(4-chlorophenyl)-4-hydroxypiperidine with4-azido-4-(4-chlorophenyl)piperidine)), but limiting the amount ofbromide to 0.25 equivalents.

¹H-NMR (CDCL₃) δ: 1.88 (2H, m), 2.55-2.85 (4H, m), 3.00-3.30 (6H, m).3.75 (3H, s), 5.19 (2H, brs), 5.97 (1H, t), 6.68-6.65 (3H, m), 7.20-7.46(5H, m), 7.63 (1H, dd), 8.35 (1H, dd).

MS m/z: 477(M+1−N₂+H₂)

Example 188 Methyl1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidin-4-carboxylate

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine withmethyl 4-phenylpiperidin-4-carboxylate.

¹H-NMR (CDCl₃) δ: 1.82-2.15 (4H, m), 2.28-2.60 (6H, m), 2.78-2.82 (2H,m), 3.62 (3H, s), 3.68 (3H, s), 5.26 (2H, brs), 5.95 (0.1H, t, Eisomer), 6.05 (0.9H, t, Z isomer), 6.82-6.70 (3H, m), 7.33-7.22 (6H, m),7.65 (0.1H, dd, Z isomer), 7.55 (0.9H, dd, Z isomer), 8.39 (0.1H, dd, Eisomer), 8.48 (0.9H, dd, Z isomer).

MS m/z: 485(M+1)

Example 1891-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidin-4-carboxylicacid

The titled compound was prepared by following the procedure of example133, but replacing product of example 48 with product of example 188.

¹H-NMR (CD₃OD) δ: 2.16-2.23 (2H, m), 2.69-2.91 (4H, m), 3.00-3.16 (2H,m), 3.37-3.25 (2H, m), 3.68-3.73 (2H, m), 3.76 (3H, s), 5.34 (2H, brs),6.24 (1H, t), 6.70-7.04 (3H, m), 7.26-7.55 (5H, m), 7.79-7.89 (1H, m),8.21-8.34 (1H, m), 8.56-8.62 (0.1H, m), 8.63-8.77 (0.9H, m),

MS m/z: 471(M+1)

Example 1901-(2-Chlorophenylsulfonyl)-4-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(2-chlorophenylsulfonyl)piperazine.

¹H-NMR (CDCl₃) δ: 2.20-2.58 (8H, m), 3.12-3.38 (4H, m), 3.76 (3H, s),5.22 (2H, brs), 6.03 (1H, t), 6.64-6.90 (3H, m), 7.23 (1H, dd),7.32-7.60 (4H, m), 8.01 (1H, dd), 8.48 (1H, dd).

MS m/z: 526(M+1)

Example 1911-(3-Chlorophenylsulfonyl)-4-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(3-chlorophenylsulfonyl)piperazine.

¹H-NMR (CDCl₃) δ: 2.20-2.60 (8H, m), 2.82-3.12 (4H, m), 3.76 (3H, s),5.18 (2H, brs), 6.00 (1H, t), 6.64-6.90 (3H, m), 7.23 (1H, dd),7.42-7.78 (5H, m), 8.48 (1H, dd).

MS m/z: 526(M+1)

Example 1921-(4-Chlorophenylsulfonyl)-4-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(4-chlorophenylsulfonyl)piperazine.

¹H-NMR (CDCl₃) δ: 2.20-2.56 (8H, m), 2.82-3.10 (4H, m), 3.76 (3H, s),5.18 (2H, brs), 5.99 (1H, t), 6.62-6.92 (3H, m), 7.23 (1H, dd),7.42-7.78 (5H, m), 8.48 (1H, dd).

MS m/z: 526(M+1)

Example 1934-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine

The titled compound was prepared by following the procedure of example44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine.

¹H-NMR (CDCl₃) d: 2.37-2.72 (8H, m), 3.07 (2H, m), 5.25 (2H, brs), 6.00(1H, m), 6.07 (1H, t), 6.60-6.78 (3H, m), 7.18-7.47 (5H, m), 7.56 (1H,dd), 8.50 (1H, dd). OH signal was not observed.

MS m/z: 445(M+1)

Example 1944-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine.

¹H-NMR (CDCl₃) δ: 2.37-2.72 (8H, m), 3.06 (2H, m), 3.78 (3H, s), 5.27(2H, brs), 5.99 (1H, m), 6.10 (1H, t), 6.72-6.90 (3H, m), 7.20-7.44 (5H,m), 7.60 (1H, dd), 8.50 (1H, dd).

MS m/z: 459(M+1)

Example 1954-(7-Chloroindol-3-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(7-chloroindol-3-yl)-1,2,3,6-tetrahydropyridine. This piperidine wasprepared by the same method described in J. Med. Chem. 36:4006-4014(1993).

¹H-NMR (CDCl₃) δ: 2.37-2.76 (8H, m), 3.14 (2H, m), 3.78 (3H, s), 5.29(2H, brs), 6.02-6.23 (2H, m), 6.67-6.90 (3H, m), 7.05 (1H, dd),7.12-7.33 (3H, m), 7.60 (1H, dd), 7.77 (1H, m), 8.50 (1H, dd), 9.06 (1H,br s).

Example 1965-Chloro-1′-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4′-piperidine]

The titled compound was prepared by following the procedure of example44, step 2, but replacing-4-(4-chlorophenyl)-4-hydroxypiperidine with5-chlorospiro[isobenzofuran-1(3H), 4′-piperidine].

1H-NMR (CDCl₃) δ: 1.66-1.71 (2H, m), 1.79-1.91 (2H, m), 2.26-2.73 (8H,m), 4.99 (2H, s), 5.22 (2H, brs), 6.07 (1H, t), 6.63-6.70 (2H, m), 6.76(1H, d), 7.06 (1H, d), 7.19-7.32 (3H, m), 7.60 (1H, dd), 8.47 (1H, dd),8.63 (1H, s).

MS m/z: 475(M+1)

Example 1975-Chloro-1′-[3-(5,11-dihydro-7-(2-methoxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4′-piperidine]

The titled compound was prepared by following the procedure of example175, but replacing the product of example 44 with the product of example196.

1H-NMR (CDCl₃) δ: 1.69-1.74 (2H, m), 1.83-1.94 (2H, m), 2.31-2.76 (8H,m), 3.45 (3H, s), 3.72-3.75 (2H, m), 4.08-4.11 (2H, m), 5.00 (2H, s),5.28 (2H, brs), 6.09 (1H, t), 6.74-6.82 (2H, m), 6.89 (1H, d), 7.04 (1H,d), 7.17-7.28 (3H, m), 7.57 (1H, dd), 8.49 (1H, dd).

MS m/z: 531(M+1)

Example 1984-(4-Chlorophenyl)-1-[3-(7-dimethylaminocarbonyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing the product of example 133 with the product ofexample 118.

1H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 1.99-2.09 (3H, m), 2.32-2.69 (8H,m), 2.17 (3H, s), 5.35 (2H, brs), 6.15 (1H, t), 6.82 (1H, d), 7.19 (1H,dd), 7.28-7.46 (6H, m), 7.58 (1H, dd), 8.49 (1H, dd).

Example 1994-(4-Chlorophenyl)-1-[3-(7-(2-(1-hydroxy-2-methyl)propyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of product of example 138 (500 mg) in methanol (5 ml) wasadded sodium borohydride (330 mg), and the mixture was heated to refluxfor 1 hour. The mixture was distilled off under reduced pressure. Waterand ethyl acetate were added to the residue, the organic layer wasseparated and washed with saturated aqueous sodium chloride, and driedwith magnesium sulfate. The solvent was distilled off under reducedpressure, and the residue was purified by silica gel chromatographyeluting with chloroform-methanol (10:1) to give the titled compound (440mg).

1H-NMR (CDCl₃) δ: 1.26 (6H, s), 1.66-1.70 (2H, m), 1.79 (1H.brs),2.00-2.08 (2H, m), 2.37-2.70 (9H, m), 3.58 (2H, s), 5.30 (2H, brs), 6.05(1H, t), 6.75-6.84 (2H, m), 6.91 (1H, d), 7.26-7.44 (5H, m), 7.58 (1H,dd), 8.49 (1H, dd).

MS m/z: 535(M+1)

Example 2004-(4-Chlorophenyl)-1-[3-(7-(1-(2-methyl-2-hydroxy)propyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of product of example 48 (500 mg) in tetrahydrofuran (5ml) was added 0.95M methylmagnesium bromide tetrahydrofuran solution(3.8 ml) at 0° C., and the mixture was stirred at room temperature for20 minutes. Aqueous ammonium chloride solution and ethyl acetate wereadded to the mixture, the organic layer was separated and washed withsaturated aqueous sodium chloride, and dried with magnesium sulfate. Thesolvent was distilled off under reduced pressure, and the residue waspurified by silica gel chromatography eluting with chloroform-methanol(10:1) to give the titled compound (360 mg).

1H-NMR (CDCl₃) δ: 1.34 (6H, s), 1.58 (1H, brs), 1.66-1.71 (2H, m),1.99-2.10 (2H, m), 2.25 (1H, brs), 2.36-2.71 (8H, m), 3.77 (2H, s), 5.28(2H, brs), 6.09 (1H, t), 6.74-6.86 (3H, m), 7.24-7.44 (5H, m), 7.57 (1H,dd), 8.49 (1H, dd).

MS m/z: 535(M+1)

Example 2034-(4-Chlorophenyl)-1-[3-(7-(2-ethoxy)ethyloxy)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with 2-ethoxyethyl bromide.

¹H-NMR (CDCl₃) δ: 1.24 (3H, t), 1.66-1.75 (3H, m), 2.00-2.11 (2H, m),2.36-2.71 (8H, m), 3.59 (2H, q), 3.71-0.75 (2H, m), 4.07-4.11 (2H, m),5.27 (2H, brs), 6.09 (1H, t), 6.75-6.91 (3H, m), 7.23-7.44 (5H, m), 7.57(1H, dd), 8.48 (1H, dd).

MS m/z: 535(M+1)

Example 2054-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-(2,3-dihydroxy)propyloxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with glycidol.

¹H-NMR (CDCl₃) δ: 1.66-1.75 (2H, m), 2.00-2.11 (2H, m), 2.36-2.71 (8H,m), 3.62-3.76 (2H, m), 3.94-4.02 (4H, m), 4.21 (2H, brs), 5.27 (2H,brs), 6.09 (1H, t), 6.76-6.86 (3H, m), 7.23-7.44 (5H, m), 7.57 (1H, dd),8.48 (1H, dd).

MS m/z: 537(M+1)

Example 211 1-[3-(7-(1-Carbamoyl-1-methyl)ethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example176, but replacing dimethylamine hydrochloride with ammonium hydroxide.

¹H-NMR (CDCl₃) δ: 1.50 (6H, s), 1.67-1.72 (2H, m), 1.96-2.09 (3H, m),2.36-2.70 (8H, m), 5.30 (2H, brs), 5.70 (1H, brs), 6.05 (1H, t),6.75-6.90 (4H, m), 7.25-7.44 (5H, m), 7.58 (1H, dd), 8.49 (1H, dd).

MS m/z: 548(M+1)

Example 2124-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-methylaminocarbonyl-1-methyl)ethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example176, but replacing dimethylamine hydrochloride with methylamine.

¹H-NMR (CDCl₃) δ: 1.47 (6H, s), 1.67-1.72 (2H, m), 1.96-2.09 (2H, m),2.20 (1H, brs), 2.36-2.70 (8H, m), 2.87 (3H, d), 5.29 (2H, brs), 6.04(1H, t), 6.72-6.86 (4H, m), 7.27-7.44 (5H, m), 7.58 (1H, dd), 8.47 (1H,dd).

MS m/z: 562(M+1)

Example 2154-(4-Chlorophenyl)-1-[3-(7-(2-dimethylaminocarboxy)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing the product of example 133 with the product ofexample 172.

¹H-NMR (CDCl₃) δ: 1.63-1.71 (3H, m), 1.98-2.10 (2H, m), 2.35-2.72 (8H,m), 3.07 (3H, s), 3.17 (3H, s), 5.36 (2H, brs), 6.16 (1H, t), 6.76 (1H,d), 6.84 (1H, d), 7.28-7.45 (7H, m), 7.59-7.65 (2H, m), 8.52 (1H, dd).

MS m/z: 544(M+1)

Example 2181-[3-(7-(2-Carbamoyl)ethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example181, but replacing the product of example 133 with the product ofexample 123.

¹H-NMR (CDCl₃) δ: 1.65-1.90 (3H, m), 2.10-2.22 (2H, m), 2.40-2.80 (10H,m), 2.91 (2H, t), 5.31-5.46 (4H, m), 6.11 (1H, t), 6.78 (1H, d), 7.01(1H, dd), 7.16 (1H, d), 7.28-7.46 (5H, m), 7.57 (1H, dd), 8.49 (1H, dd).

MS m/z: 518(M+1)

Example 2341-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]-4-(indol-3-yl)-piperidine

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(indol-3-yl)-piperidine. This piperidine was prepared by the samemethod described in J. Med. Chem. 36:4006-4014 (1993) and followhydrogenation described in Example 58, step 3.

¹H-NMR (CDCl₃) d: 1.65-1.93 (2H, m), 1.94-2.28 (4H, m), 2.34-2.70 (4H,m), 2.81 (1H, m), 2.96 (2H, m), 3.78 (3H, s), 5.28 (2H, brs), 6.09 (1H,t), 6.70-7.42 (8H, m), 7.53-7.72 (2H, m), 8.28 (1H, brs), 8.49 (1H, m).

Example 235

1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]-4-(indol-3-yl)-1,2,3,6-tetrahydropyridine.

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(indol-3-yl)-1,2,3,6-tetrahydropyridine. This piperidine was preparedby the same method described in J. Med. Chem. 36:4006-4014 (1993).

¹H-NMR (CDCl₃) d: 2.35-2.77 (8H, m), 3.06-3.26 (2H, m), 3.78 (3H, s),5.29 (2H, brs), 6.05-6.22 (2H, m), 6.70-6.88 (3H, m), 7.07-7.38 (5H, m),7.60 (1H, dd), 7.87 (1H, m), 8.42 (1H, brs), 8.50 (1H, m).

Example 2364-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-(ethoxycarbonyl)propyloxy[1]benzoxipino[2,3-b]pyridin-5-ylidine)propyl]piperidine

The titled compound was prepared by following the procedure of example153, but replacing ethyl bromoacetate with ethyl 4-bromobutyrate.

¹H-NMR (CDCL₃) δ: 1.26 (3H, t), 1.56-1.85 (4H, m), 2.01 (2H, dt), 2.09(2H, quint), 2.30-2.60 (7H, m), 2.93 (2H, m), 3.98 (2H, t), 4.15 (2H,q), 5.28 (2H, brs), 6.07 (1H, t), 6.68-6.86 (3H, m), 7.07-7.33 (5H, m),7.58 (1H, dd), 8.50 (1H, dd).

MS m/z: 561(M+1)

Example 2371-[3-(7-(3-Carboxypropyl)oxy-5,11-dihydro-[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]-4-(4-chlorophenyl)-piperidine

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of example236.

¹H-NMR (CD₃OD) δ: 1.92-2.20 (6H, m), 2.48 (2H, t), 2.70-3.02 (3H, m),3.06-3.45 (4H, m), 3.66 (2H, m), 4.01 (2H, t), 5.48 (2H, brs), 6.36 (1H,t), 6.85 (2H, s), 7.00 (1H, s), 7.20-7.40 (4H, m), 8.11 (1H, dd), 8.64(1H, d), 8.81 (1H, d). COOH signal was not observed.

MS m/z: 533(M+1)

Example 2424-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-hydroxy-1-methyl)ethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example200, but replacing the product of example 48 with the product of example273.

¹H-NMR (CDCl₃) δ: 1.58 (6H, s), 1.65-1.70 (3H, m), 1.93-2.21 (2H, m),2.28-2.73 (8H, m), 5.32 (2H, brs), 6.13 (1H, t), 6.82 (1H, d), 7.20-7.50(7H, m), 7.59 (1H, dd), 8.50 (1H, dd)

MS m/z: 505(M+1)

Example 243 1-[3-(7-(1-Carboxy-1-methyl)ethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4(4-chlorophenyl)piperidin-4-ol Step 1

To a solution of Example 363, step 2 (2.4 g) in toluene (30 ml) wasadded DIBAL (1 mol/L toluene solution, 9.2 ml) at −78° C., and themixture stirred at 0° C. for 1 hour, and at room temperature for 30minutes. The reaction mixture was added saturated aqueous ammoniumchloride. 1 N aqueous hydrochloric acid, saturated sodium chloride andethyl acetate were added to the mixture, the organic layer was separatedand washed with saturated aqueous sodium chloride, and dried withmagnesium sulfate. The solvent was distilled off under reduced pressure.The residue was purified by silica gel chromatography eluting with ethylacetate-hexane (1:4) to give5-(3-bromopropylidene)-5,11-dihydro-7-(1-hydroxy-1-methyl)ethyl[1]benzoxepino[2m30b]pyridine(2.0 g).

¹H-NMR (CDCl₃) δ: 1.45 (H, s), 2.75 (2H, q), 3.47 (1H, t), 5.33 (2H,brs), 6.04 (1H, t), 6.87 (1H, d), 7.09-7.14 (2H, m), 7.30 (1H, dd), 7.57(1H, dd), 8.53 (1H, dd), 9.46 (1H, s).

Step 2

5-(3-bromopropylidene)-7-(1-carboxy-1-methyl)ethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridinewas prepared by following the procedure of Example 382, step 2, butreplacing the product of Example 382, step 1 with the product of step 1above.

Step 3

The titled compound was prepared by following the procedure of example44, step 2, but replacing the product of example 44, step 1 with theproduct of step 2.

¹H-NMR (DMSO-d₆) δ: 1.46 (6H, s), 1.63-1.84 (2H, m), 2.17-2.37 (4H, m),2.37-2.53 (4H, m), 3.20-3.43 (2H, m), 4.83 (1H, s), 5.23 (2H, brs), 6.13(1H, t), 6.76 (1H, d), 7.16 (1H, dd), 7.25 (1H, d), 7.35 (2H, d),7.42-7.48 (3H, m), 7.76 (1H, dd), 8.50 (1H, dd).

MS m/z: 533(M+1)

Example 2481′-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]-6-methylspiro[4H-3,1-benzoxazine-4,4′-piperidine]-2(1H)-one

The titled compound was prepared by following the procedure of example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with6-methylspiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one.

¹H-NMR (CDCl₃) δ: 1.99-2.06 (2H, m), 2.29 (3H, s), 2.32-2.69 (10H, m),3.77 (3H, s), 5.27 (2H, brs), 6.08 (1H, t), 6.69-6.83 (4H, m), 6.94 (1H,s), 7.02 (1H, d), 7.25 (1H, dd), 7.55 (1H, dd), 8.48 (1H, dd), 8.56 (1H,s).

MS m/z: 498(M+1)

Example 2495-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4,6-dioxazacane

5-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4,6-diazacyclooctylamine

Step 1

5-(3-(N,N′-Bis(2-hydroxyethyl)amino)propylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridinewas prepared by following the procedure of example 45, step 3, butreplacing 4-(4-chlorophenyl)-4-hydroxypiperidine with diethanolamine.

¹H-NMR (CD₃OD) δ: 2.46 (2H, m), 2.84 (4H, t), 2.98 (2H, m), 3.67 (4H,t), 3.75 (3H, s), 5.20 (2H, brs), 6.16 (1H, t), 6.68-6.80 (2H, m), 6.87(1H, d), 7.46 (1H, dd), 7.81 (1H, dd), 8.45 (1H, dd).

Step 2

To a mixture of product of step 1 (78 mg) and 4-chlorobenzaldehydedimethyl acetal (0.1 ml) in 1,2-dichloroethane (60 ml) was addedp-toluenesulfonic acid monohydrate (5 mg) at room temperature, and themixture was stirred at reflux for 12 hours. Dichloromethane andsaturated aqueous sodium bicarbonate was added to the cooled reactionmixture, the organic layer was separated and washed with saturatedaqueous sodium chloride, and dried with magnesium sulfate. The solventwas distilled off under reduced pressure, and the residue was purifiedby silica gel chromatography eluting with dichloromethane-methanol(20:1) to give the titled compound (40 mg).

¹H-NMR (CDCl₃) δ: 2.35 (2H, m), 2.64-2.94 (6H, m), 3.52-3.68 (2H, m),3.78 (3H, s), 3.72-3.90 (2H, m), 5.27 (2H, brs), 5.66 (1H, s), 6.08 (1H,t), 6.68-6.88 (3H, m), 7.18-7.46 (5H, m), 7.58 (1H, dd), 8.50 (1H, dd).

Example 252 Step 1

To a cold (0° C.) stirred solution of 4-oxohomopiperidine.HCl (0.6 g,4.05 mmol), K₂CO₃ (0.615 g, 4.46 mmol) in anhydrous THF (10 mL) will beethyl chloroformate (0.44 mL, 4.05 mmol) dropwise. The reaction waswarmed to RT for 2 hrs then quenched with H₂O, extracted with EtOAc, andthe organic layer dried over Na₂SO₄. Pure1-ethylcarbonyl-4-oxohomopiperidine will be isolated via silica gelflash chromatography

Step 2

To a cold (0° C.) stirred solution of1-ethylcarbonyl-4-oxohomopiperidine (1.42 g, 6.07 mmol) in anhydrous THF(50 mL) under argon can be added dropwise 1.0 mM 4-chlorophenylmagnesiumbromide in diethyl ether (10 mL, 10 mmol). The reaction can be warmed toRT for 2 hrs then quenched with saturated aqueous NH₄Cl 95 mL). Thereaction mixture can then be extracted with EtOAc (2×50 mL), the organiclayers combined and dried over Na₂SO₄. Pure1-ethoxycarbonyl-4-(4-chlorophenyl)-4-hydroxyhomopeperidine (2.1 g, 96%)can be isolated via silica gel flash chromatography eluting with 50%ETOAc/hexane.

4-(4-chlorophenyl)-4-hydroxyhomopiperidine can be prepared by reacting1-ethoxycarbonyl-4-(4-chlorophenyl)-4-hydroxyhomopeperidine with anucleophilic hydroxide equivalent such as LiOH in a solvent such as THF,methanol or ethanol. Removal of the solvent can afford4-(4-chlorophenyl)-4-hydroxyhomopeperidine.

Step 4

The compound was prepared by following the procedure for Example 44, butreplacing 4-(4-chlorophenyl)-4-hydroxypeperidine with4-(4-chlorophenyl)-4-hydroxyhomopeperidine.

Examples 253 and 254 Step 1

To a stirred solution of 4-oxohomopiperidine.HCl (1.2 g, 8.05 mmol),NaOH (0.68 g, 16.9 mmol) in t-BuOH/H₂O (1:1, 10 mL) was addedt-butyldicarbonate (1.93 mL, 8.9 mmol) drop-wise. The reaction wasstirred at RT overnight, extracted with EtOAc (2×10 mL) and the organiclayer separated. The organic layer was dried over Na₂SO₄ andconcentrated under vacuo. Pure 1-t-butoxycarbonyl-4-oxohomopiperidine(1.42 g, 84%) was isolated via silica gel flash chromatography elutingwith 50% EtOAc/hexane.

¹H NMR CDCl₃ δ: 44 (9H, s), 1.72-1.84 (2H, m), 2.60-2.65 (4H, m),3.55-3.61 (4H, m).

Step 2

To a cold (0° C.) stirred solution of1-t-butoxycarbonyl-4-oxohomopiperidine (1.42 g, 6.07 mmol) in anhydrousTHF (50 mL) under argon was added dropwise 1.0 M 4-chlorophenylmagnesiumbromide in diethyl ether (10 mL, 10 mmol). The reaction was warmed to RTfor 2 hrs then quenched with sat'd aqueous NH₄Cl (5 mL). The reactionmixture was extracted with EtOAc (2×50 mL), the organic layers combinedand dried over Na₂SO₄. Pure1-t-butoxycarbonyl-4-(4-chlorophenyl)-4-hydroxyhomopiperidine (2.1 g,96%) was isolated via silica gel flash chromatography eluting with 50%EtOAc/hexane. ¹H NMR CDCl₃ δ 1.43 (9H, s), 1.61-2.22 (6H, m), 3.21-3031(2H, m), 3.48-3.82 (2H, m).

Step 3

To a stirred solution of1-t-butoxycarbonyl-4-(4-chlorophenyl)-4-hydroxyhomopiperidine (2.1 g) atRT in CH₂Cl₂ (48 mL) was added TFA (2.0 mL). The reaction was stirred atRT for 2 hrs. Excess solvent and TFA was removed affording 2.0 g (92%yield) 1:1 mixture of 3-(4-chlorophenyl)-2,3-dehydrohomopiperidine and3-(4-chlorophenyl)-3,4-dehydrohomopiperidine. ¹H NMR (MeOD, isomer A) δ2.01-2.11 (2H, m, 4), 2.60-2.71 (2H, m, 5), 2.81-2.92 (2H, m, 4),2.83-3.05 (2H, m, 5), 3.66-3.92 (4H, m, 5), 6.16-6.21 (1H, t, 5). ¹H NMR(MeOD, isomer B) 3.44-3.56 (2H, m, 4), 3.88-3.97 (2H, m, 4), 6.01-6.12(1H, t, 4), 7.32-7.44 (1H, t, 4).

Step 4

The compounds can be prepared by following the procedure for Example 44but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with3-(4-chlorophenyl)-3,4-dehydrohomopiperidine and3-(4-chlorophenyl)-4,5-dehydrohomopiperidine.

Example 2551-(4-Chlorophenyl)-4-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazinone

The titled compound was prepared by following the procedure of example44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(4-chlorophenyl)piperazinone.

¹H-NMR (DMSO-d₆) δ: 2.30-2.34 (2H, m), 2.49-2.57 (2H, m), 2.68 (2H, t),3.06 (2H, s), 3.58 (2H, t), 5.12 (2H, brs), 6.06 (2H, t), 6.57-6.69 (3H,m), 7.35-7.71 (5H, m), 7.72 (1H, dd), 8.48 (1H, dd).

Example 2561-(4-Chlorophenyl)-4-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]homopiperazdine

The titled compound was prepared by following the procedure of example44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(4-chlorophenyl)homopiperazdine.

¹H-NMR (CDCl₃) δ: 1.89 (2H, brs), 2.27-2.35 (2H, m), 2.51-2.70 (6H, m),3.37-3.53 (4H, m), 5.23 (2H, brs), 5.98 (1H, t), 6.48-6.74 (6H, m),7.05-7.26 (2H, m), 7.52 (1H, dd), 8.45 (1H, dd).

MS m/z: 462(M+1)

Example 2603-(4-Chlorophenyl)-8-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-8-azabicyclo[3.2.1]octan-3-ol

The titled compound was prepared by following the procedure of example44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with3-(4-chlorophenyl)-8-azabicyclo[3.2.1]octan-3-ol

¹H-NMR (CDCl₃) δ: 1.65-2.10 (4H, m), 2.1-2.7 (8H, m), 3.32 (2H, bs),3.78 (3H, s), 5.24 (2H, bs), 6.10 (1H, dd), 6.70-6.90 (3H, m), 7.15-7.31(3H, m), 7.45 (bd, 2H), 7.64 (dd, 1H) 8.46 (dd, 1H)

MS m/z: 503(M+1)

Example 2611′-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[5-chloro-1,3-benzodioxole-2,4′-piperidine]

The titled compound was prepared by following the procedure of example44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine withspiro[5-chloro-1,3-benzodioxole-2,4′-piperidine] (Journal of MedicinalChemistry. 1995, 38, 2009-2017).

¹H-NMR (DMSO-d₆) δ: 1.78-2.02 (4H, m), 2.18-2.63 (8H, m), 4.97-5.27 (2H,brs), 6.06 (1H, t), 6.58-6.67 (3H, m), 6.79-6.87 (2H, m), 6.99 (1H, d),7.42 (1H, dd), 7.72 (1H, dd), 8.49 (1H, dd), 9.07 (1H, s).

Example 2621-[3-(7-(1-Carbamoyl-1-methyl)ethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)-4-hydroxy-1-methylpiperidiniumiodide

To a solution of the product of example 211 (330 mg) and in acetonitrile(1.2 ml) was added iodomethane (0.07 ml), and the reaction mixture wasstirred at room temperature for 2 hours. The precipitation was filteredand washed with acetonitrile to give the titled compound (250 mg).

¹H-NMR (DMSO-d₆) δ: 1.39 (6H, s), 1.65-1.85 (2H, m), 2.20-2.64 (4H, m),3.09 (3H, s), 3.30-3.65 (6H, m), 5.20 (2H, m), 5.61 (1H, s), 6.01 (1H,t), 6.75-6.92 (3H, m), 7.27 (1H, s), 7.38-7.64 (6H, m), 7.83 (1H, dd),8.56 (1H, dd)

MS m/z: 562[(M−I)+]

Example 2634-(4-Chlorophenyl)-1-[3-(7-diethylaminocarbonylmethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing dimethylamine hydrochloride with diethylamine.

¹H-NMR (CDCl₃) δ: 1.67-1.72 (2H, m), 1.99-2.10 (2H, m), 2.36-2.70 (9H,m), 2.89 (3H, d), 4.45 (2H, s), 5.28 (2H, brs), 6.08 (1H, t), 6.66 (1H,brs), 6.73-6.84 (3H, m), 7.25-7.45 (5H, m), 7.58 (1H, dd), 8.47 (1H,dd).

MS m/z: 534(M+1)

Example 2684-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methylaminocarbonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example198, but replacing dimethylamine hydrochloride with methylamine.

¹H-NMR (DMSO-d₆) δ: 1.75-1.80 (2H, m), 2.38-2.50 (2H, m), 2.63-2.73 (2H,m), 2.78 (3H, d), 3.17-3.50 (6H, m), 5.38 (2H, brs), 6.36 (1H, t), 6.87(1H, d), 7.41-7.50 (4H, m), 7.55-7.99 (4H, m), 8.48-8.50 (1H, m), 8.61(1H, dd).

MS m/z: 504(M+1)

Example 2691-[3-(7-Carbamoyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example198, but replacing dimethylamine hydrochloride with ammonium hydroxide.

¹H-NMR (CDCl₃) δ: 1.67-1.79 (2H, m), 2.01-2.10 (2H, m), 2.17-2.71 (8H,m), 5.38 (2H, brs), 6.21 (1H, t), 6.85 (1H, d), 7.27-7.57 (9H, m), 7.90(1H, dd), 8.50 (1H, dd).

MS m/z: 490(M+1)

Example 2704-(4-Chlorophenyl)-1-[3-(7-diethylaminocarbonyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example198, but replacing dimethylamine hydrochloride with diethylamine.

MS m/z: 546(M+1)

Example 2734-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(methoxycarbonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

A mixture of the product of example 169 (15.0 g), palladium(II)diacetate (170 mg), 1,3-bis(diphenylphosphino)propane (310 mg), andtriethylamine (7.0 ml) in methanol (100 ml) and dimethylformamide (150ml) was purged with carbon monoxide for 5 minutes and stirred under acarbon monoxide balloon at 70° C. for 8 hours. The reaction mixture wasevaporated under reduced pressure. The residue was added water andextracted with ethyl acetate. The extract was dried over magnesiumsulfate, and the solvent was evaporated under reduced pressure. Theresidue was purified by silica gel column chromatography (ethylacetate:methanol=10:1) to give the titled compound (13.1 g).

¹H-NMR (CDCl₃) δ: 1.45-1.80 (3H, m), 1.90-2.15 (2H, m), 2.28-2.48 (4H,m), 2.50-2.75 (4H, m), 3.89 (3H, s), 5.25-5.50 (2H, m), 6.20 (1H, dd),6.85 (1H, d), 7.20-7.37 (3H, m), 7.42 (2H, d), 7.58 (1H, d), 7.80 (1H,dd), 8.01 (1H, dd), 8.52 (1H, dd)

MS m/z: 505(M+1)

Example 2744-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxymethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To an ice-cooled solution of the product of example 273 (2.0 g) intetrahydrofuran (100 ml) was added lithium aluminum hydride (300 mg),and the reaction mixture was stirred at room temperature for 12 hours.After the reaction mixture was cooled to 0° C., water (0.3 ml), 15%sodium hydroxide aqueous solution (0.3 ml), and water (0.9 ml) wereadded. The reaction mixture was filtered, and the filtrate was driedover magnesium sulfate. The solvent was evaporated under reducedpressure and the residue was purified by silica gel columnchromatography (chloroform:methanol: 28% ammonia in water=100:5:1) togive the titled compound (1.6 g).

¹H-NMR (CDCl₃) δ: 1.55-1.71 (3H, m), 1.95-2.25 (2H, m), 2.34-2.70 (8H,m), 4.62 (2H, s), 5.20-5.45 (2H, brs), 6.13 (1H, t), 6.84 (1H, d), 7.16(1H, dd), 7.23-7.43 (6H, m), 7.58 (1H, dd), 8.51 (1H, dd)

MS m/z: 477(M+1)

Example 2754-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-propylamino)methyl[1]benzoxepino [2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of example 314 (300 mg) and 1-propylamine(0.26 ml) in tetrahydrofuran (6 ml) was added acetic acid (0.36 ml), andthe reaction mixture was stirred at 60° C. for 30 minutes. Then thereaction mixture was added sodium triacetoxyborohydride (670 mg) at 0°C., and stirred for 1.5 hours at room temperature. Sodium bicarbonate,water, and chloroform were added to the reaction mixture. The organiclayer was extracted, and dried over potassium carbonate, and evaporatedunder reduced pressure. The residue was recrystallized with ethylacetate to give titled compound (130 mg).

¹H-NMR (CDCl₃) δ: 0.92 (3H, t), 1.49-1.70 (6H, m), 1.98 (2H, m),2.34-2.42 (4H, m), 2.51-2.70 (6H, m), 3.71 (2H, s), 5.32 (2H, brs), 6.12(1H, t), 6.81 (1H, d), 7.11 (1H, dd), 7.25-7.45 (6H, m), 7.57 (1H, dd),8.49 (1H, dd).

MS m/z: 518(M+1)

Example 2764-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-hydroxy-1-propylamino)methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example275, but replacing 1-propylamine with 3-amino-1-propanol.

MS m/z: 534(M+1)

Example 2774-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-piperidino)methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example275, but replacing 1-propylamine with piperidine.

MS m/z: 544(M+1)

Example 2784-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(4-morpholino)methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example275, but replacing 1-propylamine with morpholine.

MS m/z: 546(M+1)

Example 2794-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-pyrrolidino)methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example275, but replacing 1-propylamine with 4-aminobutyric acid.

¹H-NMR (CDCl₃) δ: 1.70-1.75 (2H, m), 1.98 (2H, m), 2.12-2.23 (2H, m),2.40-2.86 (10H, m), 3.27 (2H, t), 4.36 (2H, s), 5.29 (2H, brs), 6.07(1H, t), 6.80 (1H, d), 7.04 (1H, dd), 7.19 (1H, d), 7.28-7.32 (3H, m),7.50 (1H, t), 7.61 (1H, dd), 8.51 (1H, dd).

MS m/z: 544(M+1)

Example 2804-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxy)ethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example273, but replacing the product of example with the product of example274.

¹H-NMR (CDCl₃) δ: 1.60-1.70 (4H, m), 2.01-2.12 (2H, m), 2.37-2.70 (8H,m), 2.81 (2H, t), 3.84 (2H, t), 5.31 (2H, brs), 6.09 (1H, t), 6.81 (1H,d), 7.03 (1H, dd), 7.15 (1H, d), 7.26-7.43 (5H, m), 7.57 (1H, dd), 8.49(1H, dd).

MS m/z: 491(M+1)

Example 2811-[3-(7-Carbamoylmethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example122, but replacing dimethylamine hydrochloride with ammonium hydroxide.

¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 1.98-2.06 (2H, m), 2.27-2.70 (9H,m), 3.46 (2H, s), 5.30 (2H, brs), 5.74 (1H, brs), 6.04 (1H, brs), 6.09(1H, t), 6.79 (1H, d), 7.02 (1H, dd), 7.18-7.41 (6H, m), 7.54 (1H, dd),8.43 (1H, dd).

MS m/z: 504(M+1)

Example 2884-(4-Chlorophenyl)-1-[3-(7-(2-ethoxycarboxy)ethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example165, but replacing the product of example 164 with the product ofexample 310.

¹H-NMR (CDCl₃) δ: 1.23 (3H, t), 1.63-1.71 (3H, m), 1.98-2.10 (2H, m),2.35-2.71 (10H, m), 2.89 (2H, t), 4.13 (2H, q), 5.31 (2H, brs), 6.08(1H, t), 6.78 (1H, d), 7.00 (1H, dd), 7.12 (1H, d), 7.26-7.44 (5H, m),7.57 (1H, dd), 8.49 (1H, dd).

MS m/z: 548(M+1)

Example 2894-(4-Chlorophenyl)-1-[3-(7-(1-(3-hydroxy)propyl)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of example288.

¹H-NMR (DMSO-d₆) δ: 1.45-1.50 (2H, m), 1.66-1.80 (4H, m), 2.26-2.57(10H, m), 3.41 (2H, q), 4.46 (1H, t), 4.83 (1H, s), 5.23 (2H, brs), 6.14(1H, t), 6.71 (1H, d), 7.01 (1H, dd), 7.13 (1H, d), 7.34-7.48 (5H, m),7.72 (1H, dd), 8.49 (1H, dd).

MS m/z: 505(M+1)

Example 2904-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2,3-dihydroxy)propyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of product of example 170 (6.9 g) in tetrahydrofuran (70ml) and water (14 ml) were added N-methylmorpholine oxide (1.7 g) andosmium tetraoxide at 0° C., and the mixture was stirred at roomtemperature for 3 hours. Ethyl acetate was added to the mixture, theaqueous layer was separated. Chloroform-isopropanol (4:1) was added tothe aqueous layer, the organic layer was extracted, and dried withmagnesium sulfate. The solvent was distilled off under reduced pressureto give the titled compound (7.0 g).

¹H-NMR (CDCl₃) δ: 1.65-1.73 (2H, m), 1.95-2.10 (2H, m), 2.30-2.75 (13H,m), 3.45-3.50 (1H, m), 3.60-3.65 (1H, m), 3.83-3.90 (1H, m), 5.28 (2H,brs), 6.06 (1H, t), 6.84 (1H, d), 7.03 (1H, dd), 7.15 (1H, d), 7.26-7.43(5H, m), 7.57 (1H, dd), 8.49 (1H, dd).

MS m/z: 521(M+1)

Example 2914-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-phenyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example170, but replacing allyltributyltin with phenyltributyltin.

¹H-NMR (CDCl₃) δ: 1.84-1.92 (2H, m), 2.85-3.40 (10H, m), 5.33 (2H, brs),6.05 (1H, t), 6.95 (1H, d), 7.30-7.58 (12H, m), 7.63-7.66 (1H, m),8.56-8.58 (1H, m)

MS m/z: 523(M+1)

Example 2924-(4-Chlorophenyl)-1-[3-(7-(2-furyl)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example170, but replacing allyltributyltin with ethyl (2-furyl)tributyltin.

¹H-NMR (CDCl₃) δ: 1.70-1.80 (3H, m), 1.97-2.16 (2H, m), 2.3-2.8 (8H, m),5.36 (2H, m), 6.19 (1H, t), 6.45 (1H, dd), 6.55 (1H, d), 6.87 (1H, d),7.20-7.50 (7H, m), 7.60-7.65 (2H, m), 8.52 (1H, dd)

MS m/z: 513(M+1)

Example 2934-(4-Chlorophenyl)-1-[3-(7-ethoxycarbonylamino-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]piperidin-4-ol

A mixture of product of example 118 (490 mg) and diphenylphosphonicazide (0.28 ml) was stirred at 110° C. for 30 minutes. After the mixturewas cooled, and triethylamine (0.14 ml) and ethanol (5 ml) were added,and the mixture was heated to reflux for 8 hours. The reaction mixturewas diluted with ethyl acetate and filterd through Celite. The filtratewas washed with saturated aqueous sodium bicarbonate, and dried overmagnesium sulfate. The solvent was removed under reduced pressure andthe residue was purified by silica gel column chromatography(chloroform:methanol=10:1) to give the titled compound (210 mg).

1H-NMR (CDCl₃) δ 1.31 (3H, t), 1.65-1.70 (2H, m), 2.01-2.09 (2H, m),2.36-2.70 (8H, m), 4.21 (2H, q), 5.30 (2H, brs), 6.13 (1H, t), 6.46 (1H,brs), 6.80 (1H, d), 7.02 (1H, dd), 7.28-7.50 (6H, m), 7.57 (1H, dd),8.50 (1H, dd).

MS m/z: 534(M+H)

Example 2941-[Bis(ethoxycarbonylmethyl)methoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with diethyl bromomalonate.

¹H-NMR (CDCl₃) δ: 1.30 (3H, t), 1.66-1.71 (2H, m), 1.98-2.09 (2H, m),2.35-2.69 (9H, m), 4.30 (2H, q), 5.14 (1H, s), 5.26 (2H, brs), 6.10 (1H,t), 6.78 (2H, d), 7.00 (1H, t), 7.26-7.45 (5H, m), 7.57 (1H, dd), 8.43(1H, dd).

MS m/z: 621(M+1)

Example 2951-[1,1-Bis(ethoxycarbonylmetyl)ethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with diethyl 2-bromo-2-methylmalonate.

¹H-NMR (CDCl₃) δ: 1.27 (6H, t), 1.65-1.70 (5H, m), 1.99-2.08 (3H, m),2.31-2.69 (8H, m), 4.28 (4H, q), 5.27 (2H, brs), 6.06 (1H, t), 6.72 (1H,d), 6.80 (1H, dd), 7.00 (1H, d), 7.27-7.45 (5H, m), 7.56 (1H, dd), 8.46(1H, dd).

Example 2964-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxy-1-hydroxymethyl)ethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example199, but replacing the product of example 138 with the product ofexample 294.

¹H-NMR (CDCl₃) δ: 1.70-1.75 (2H, m), 2.10-2.80 (11H, m), 3.90 (4H, d),4.36 (1H, quint), 5.28 (2H, brs), 6.13 (1H, t), 6.71-6.87 (2H, m), 7.00(1H, d), 7.29-7.45 (5H, m), 7.58 (1H, dd), 8.51 (1H, dd).

MS m/z: 537(M+1)

Example 2971-[1,1-Bis(hydroxymetyl)ethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-ol

The titled compound was prepared by following the procedure of example199, but replacing the product of example 138 with the product ofexample 295.

¹H-NMR (CDCl₃) δ: 1.09 (3H, s), 1.66-1.71 (2H, m), 1.90-2.10 (3H, m),2.37-2.75 (8H, m), 3.72-3.82 (4H, m), 5.29 (2H, brs), 6.05 (1H, t), 6.77(1H, d), 6.88 (1H, dd), 7.03 (1H, d), 7.26-7.43 (5H, m), 7.56 (1H, dd),8.48 (1H, dd).

MS m/z: 551(M+1)

Example 2994-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(5-ethoxycarbonylpropyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with ethyl 4-bromobutyrate.

¹H-NMR (CDCl₃) δ: 1.24 (3H, t), 1.65-1.69 (2H, m), 1.96-2.12 (4H, m),2.26-2.67 (10H, m), 3.96 (2H, t), 4.12 (2H, q), 5.24 (2H, brs), 6.08(1H, t), 6.70-6.83 (3H, m), 7.21-7.59 (6H, m), 8.39 (1H, dd).

Example 3001-[3-(7-(3-Carboxy-1-propyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of example299.

¹H-NMR (DMSO-d₆) δ: 1.41-1.95 (2H, m), 1.41-1.95 (4H, m), 2.20-2.72(10H, m), 3.95 (2H, t), 5.18 (2H, brs), 6.17 (1H, t), 6.72-6.84 (3H, m),7.36-7.48 (5H, m), 7.77 (1H, dd), 8.50 (1H, dd).

MS m/z: 549(M+1)

Example 3014-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(4-methoxycarbonylphenyl)methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with methyl 4-bromomethylbenzoate.

¹H-NMR (CDCl₃) δ: 1.66-1.70 (2H, m), 1.93-2.09 (3H, m), 2.37-2.70 (8H,m), 3.91 (3H, s), 5.09 (2H, s), 5.27 (2H, brs), 6.06 (1H, t), 6.80-6.91(3H, m), 7.24-7.60 (8H, m), 8.01-8.07 (2H, m), 8.47 (1H, dd).

Example 3021-[3-(7-(4-Carboxyphenyl)methoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of example301.

¹H-NMR (DMSO-d6) δ: 1.44-1.49 (2H, m), 1.67-1.87 (2H, m), 2.26-2.56 (8H,m), 4.85 (1H, brs), 5.15-5.25 (4H, m), 6.17 (1H, t), 6.72-6.95 (3H, m),7.30-7.75 (8H, m), 7.92-7.99 (2H, m), 8.48 (1H, dd).

MS m/z: 597(M+1)

Example 3034-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-((1-hydroxymethyl)cyclopropyl)methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olStep 1

1-[3-(7-((1-Benzoyloxymethyl)cyclopropyl)methoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olwas prepared by following the procedure of example 46, but replacingethyl iodide with (1-benzoyloxymethyl)cyclopropylmethylmethanesulfonate.

¹H-NMR (CDCl₃) δ: 0.70-0.81 (4H, m), 1.65-1.70 (3H, m), 1.98-2.07 (2H,m), 2.35-2.70 (8H, m), 3.91 (2H, s), 4.39 (2H, s), 5.25 (2H, brs), 6.06(1H, t), 6.72-6.84 (3H, m), 7.23-7.59 (9H, m), 8.02-8.06 (2H, m), 8.48(1H, dd).

Step 2

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of step 1.

¹H-NMR (CDCl₃) δ: 0.62 (4H, s), 1.67-1.72 (2H, m), 1.96-2.06 (2H, m),2.34-2.69 (8H, m), 3.39 (1H, brs), 3.91 (2H, s), 3.91 (2H, s), 5.26 (2H,brs, 6.09 (1H, t), 6.72-6.86 (3H, M), 7.27-7.60 (6H, m), 8.48 (1H, dd).

MS m/z: 547(M+1)

Example 3051-[3-(5,11-dihydro-7-(2-hydroxyethyl)aminocarbonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example198, but replacing dimethylamine hydrochloride with 2-hydroxyehylamine.

¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 2.03-2.06 (2H, m), 2.21 (1H, d),2.32-2.68 (8H, m), 3.63 (2H, dt), 3.83 (2H, t), 5.37 (2H, brs), 6.18(1H, t), 6.67 (1H, brs), 7.25-7.54 (7H, m), 7.86 (1H, dd), 8.50 (1H,dd).

MS m/z: 534(M+1)

Example 3064-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-cyclohexyloxycarbonyloxy)ethyloxycarbonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-oldihydrochloride

To a solution of product of example 118 (1.1 g) in dimethylformamide (15ml) were added sodium iodide (0.17 g), potassium carbonate (0.38 g) andcyclohexyl 1-chloroethyl carbonate (J. Antibiotics, 1987, 40, 81.) (0.57g) at room temperature. The mixture was stirred at 70° C. for 1 hour.Water and ethyl acetate were added to the reaction mixture, the organiclayer was separated and washed with saturated aqueous sodium chloride,and dried with magnesium sulfate. The solvent was distilled off underreduced pressure and the residue was purified by silica gel columnchromatography (ethyl acetate:methanol=100:3). The obtained oil wasdissolved with ethyl acetate, and 4 N hydrochloric acid ethyl acetatesolution (0.8 ml) was added. The precipitation was filtered to give thetitled compound (0.96 g).

¹H-NMR (DMSO-d₆) δ: 1.22-1.47 (6H, m), 1.58 (3H, d), 1.63-1.81 (6H, m),2.38-3.30 (10H, m), 4.07-4.59 (1H, m), 5.80 (2H, brs), 6.28 (1H, t),6.87 (1H, q), 6.97 (1H, d), 7.40-7.49 (4H, m), 7.64 (1H, dd), 7.79 (1H,dd), 7.96 (1H, d), 8.03 (1H, dd), 8.65 (1H, dd), 11.07 (1H, brs).

MS m/z: 661[(M−2HCl)+1]

Example 3074-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7(1-ethoxycarbonyloxy)ethyloxycarbonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example307, but replacing cyclohexyl 1-chloroethyl carbonate with ethyl1-chloroethyl carbonate.

MS m/z: 607(M+1)

Example 3084-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(5-hydroxyfuran-2-yl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(5-formylfuran-2-yl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol was prepared by followingthe procedure of example 170, but replacing allyltributyltin with(5-formylfuran-2-yl)tributyltin.

1H-NMR (CDCl₃) δ: 1.40-1.80 (2H, m), 1.89-2.12 (2H, m), 2.20-2.75 (8H,m), 5.28 (2H, brs), 6.16 (1H, t), 6.69 (1H, d), 6.84 (1H, d), 7.22-7.55(8H, m), 7.76 (1H, d), 8.42 (1H, dd), 9.52 (1H, s).

Step 2

The titled compound was prepared by following the procedure of example199, but replacing the product of example 138 with the product of step1.

MS m/z: 543(M+1)

Example 3091-[3-(7-(5-Carboxyfuran-2-yl)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of Example382, step 2, butreplacing the product of Example 382, step 1 with theproduct of example 307, step 1.

MS m/z: 557(M+1)

Example 3104-(4-Chlorophenyl)-1-[3-(7-(2-ethoxycarboxy)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example171, but replacing t-butyl acrylate with ethyl acrylate.

¹H-NMR (CDCl₃) δ: 1.33 (3H, t), 1.63-1.71 (3H, m), 1.98-2.10 (2H, m),2.35-2.72 (8H, m), 4.25 (2H, q), 5.36 (2H, brs), 6.10 (1H, t), 6.33 (1H,d), 6.85 (1H, d), 7.22-7.44 (7H, m), 7.58-7.65 (2H, m), 8.53 (1H, dd).

Example 3114-(4-Chlorophenyl)-1-[3-(7-(1-(2-ethyl-2-hydroxy)butyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example200, but replacing ethylmagnesium bromide with methylmagnesium bromide.

1H-NMR (CDCl₃) δ: 0.93 (6H, t), 1.60-1.70 (6H, m), 1.95-2.10 (3H, m),2.36-2.70 (8H, m), 3.79 (2H, s), 5.28 (2H, brs), 6.09 (1H, t), 6.77-6.86(3H, m), 7.24-7.43 (5H, m), 7.57 (1H, dd), 8.47 (1H, dd).

MS m/z: 563(M+1)

Example 3124-(4-Chlorophenyl)-1-[3-(7-(2-(2,3-dimethyl-3-hydroxy)butyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example200, but replacing the product of example 48 with the product of example138.

1H-NMR (CDCl₃) δ: 1.22 (6H, s), 1.32 (6H, s), 1.66-1.71 (2H, m),1.99-2.10 (2H, m), 2.35-2.85 (9H, m), 3.77 (2H, s), 5.28 (2H, brs), 6.04(1H, t), 6.74-6.89 (3H, m), 7.26-7.43 (5H, m), 7.57 (1H, dd), 8.44 (1H,dd).

MS m/z: 563(M+1)

Example 3134-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-oxopropyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propl]piperidin-4-ol

The titled compound was prepared by following the procedure of example146, but replacing ethyl iodide with chloracetone.

1H-NMR (CDCl₃) δ: 1.62-1.71 (3H, m), 1.99-2.10 (2H, m), 2.27 (3H, s),2.35-2.70 (8H, m), 4.51 (2H, s), 5.28 (2H, brs), 6.08 (1H, t), 6.70-6.84(3H, m), 7.25-7.32 (3H, m), 7.41-7.44 (2H, m), 7.58 (1H, dd), 8.50 (1H,dd).

MS m/z: 519(M+1)

Example 3144-(4-Chlorophenyl)-1-[3-(7-formyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of example 274 (1.0 g) in methylenechloride (200 ml) was added manganese(IV) oxide (3.0 g), and thesuspension was stirred at ambient temperature for 12 hours. The reactionmixture was diluted with ethyl acetate and filtered through Celite. Thesolvent was evaporated under reduced pressure to give the titledcompound (930 mg).

¹H-NMR (CDCl₃) δ: 1.71-1.80 (3H, m), 1.98-2.09 (2H, m), 2.35-2.43 (4H,m), 2.53-2.69 (4H, m), 5.30 (2H, brs), 6.24 (1H, t), 6.95 (1H, d),7.27-7.44 (5H, m), 7.61 (1H, dd), 7.67 (1H, dd), 7.85 (1H, d), 8.54 (1H,dd), 9.88 (1H, s).

Example 3151-[3-(7-Acetyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

To a solution of example 53, step 1 (7.2 g) in dichloromethane (70 ml)was added aluminum chloride (9.1 g) and acetyl chloride (3.2 ml), andthe mixture stirred at 0° C. for 10 minutes. The reaction mixture waspoured into ice. The aqueous layer was extracted with ethyl acetate, andthe organic layer was washed with saturated aqueous sodium chloride, anddried with magnesium sulfate. The solvent was distilled off underreduced pressure. The Residue was purified by silica gel chromatography,eluting with ethyl acetate-hexane (1:2) to give7-acetyl-5-(3-bromopropylidene)-5,11-dihydro[1]benzoxepino[2,3-b]pyridine(7.9 g).

¹H-NMR (CDCl₃) δ: 2.57 (3H, s), 2.77 (2H, m), 3.49 (2H, t), 5.40 (2H,brs), 6.16 (1H, t), 6.88 (1H, d), 8.33 (1H, dd), 7.58 (1H, dd), 7.77(1H, dd), 7.96 (1H, d), 8.56 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example44, step 2, but replacing the product of example 44, step 1 with theproduct of step 1.

¹H-NMR (CDCl₃) δ: 1.52-1.79 (2H, m), 1.93-2.11 (2H, m), 2.27-2.49 (4H,m), 2.49-2.60 (5H, m), 2.60-2.73 (2H, m), 5.40 (2H, brs), 6.22 (1H, t),6.87 (1H, d), 7.29-7.34 (3H, m), 7.42 (2H, d), 7.59 (1H, dd), 7.75 (1H,dd), 7.96 (1H, d), 8.53 (1H, dd).

MS m/z: 489(M+1)

Example 316

To a stirred solution of phenol containing the product of Example 44(1.0 mmol) and K₂CO₃ (1.5 mmol) in THF (10 mL) at RT was addedN,N-dimethylcarbamoylchloride (1.2 mmol). The reaction was stirred atreflux for 24 hrs. Excess solvent was removed and pure compound wasisolated via silica gel chromatography eluting with 5% MeOH/CH₂Cl₂. MSm/z: (M+535)

Example 317

To a stirred solution of phenol containing the product of Example 44(1.0 mmol) and K₂CO₃ (1.5 mmol) in THF (10 mL) at RT was addedmorpholinocarbamoylchloride (1.2 mmol). The reaction was stirred atreflux for 24 hrs. Excess solvent was removed and pure compound wasisolated via silica gel chromatography eluting with 5% MeOH/CH₂Cl₂. MSm/z: (M+577)

Example 318

To a stirred solution of phenol containing the product of Example 44(1.0 mmol) in DMF at RT was added NaH (1.5 mmol) followed by theaddition of N-isopropylisocyanate (1.5 mmol). The reaction was heated to60° C. for 6 hrs. The reaction was quenched with 1.5 equivalents of H₂Oand excess DMF was removed under reduced pressure. Residue was chargedon a silica gel column and eluted off with 5% MeOH/CH₂Cl₂. MS m/z:(M+548)

Example 319

To a stirred solution of phenol containing the product of Example 44(1.0 mmol) and K₂CO₃ (1.5 mmol) in THF (10 mL) at RT was addedN-methyl-N-phenylcarbamoylchloride (1.2 mmol). The reaction was stirredat reflux for 24 hrs. Excess solvent was removed and pure compound wasisolated via silica gel chromatography eluting with 5% MeOH/CH₂Cl₂. MSm/z: (M+597)

Example 320

To a stirred solution of phenol containing the product of Example 44(1.0 mmol) in DMF at RT was added NaH (1.5 mmol) followed by theaddition of N-phenyl]socyanate (1.5 mmol). The reaction was heated to60° C. for 6 hrs. The reaction was quenched with 1.5 equivalents of H₂Oand excess DMF was removed under reduced pressure. Residue was chargedon a silica gel column and eluted off with 5% MeOH/CH₂Cl₂. MS m/z:(M+583)

Example 321

To a stirred solution of phenol containing the product of Example 44(1.0 mmol) in DMF at RT was added NaH (1.5 mmol) followed by theaddition of N-(3-pyridyl)isocyanate (1.5 mmol). The reaction was heatedto 60° C. for 6 hrs. The reaction was quenched with 1.5 equivalents ofH₂O and excess DMF was removed under reduced pressure. Residue wascharged on a silica gel column and eluted off with 5% MeOH/CH₂Cl₂. MSm/z: (M+584)

Example 322

To a stirred solution of phenol containing the product of Example 44(1.0 mmol) and K₂CO₃ (1.5 mmol) in THF (10 mL) at RT was addedpyrrolidinylcarbamoylchloride (1.2 mmol). The reaction was stirred atreflux for 24 hrs. Excess solvent was removed and pure compound wasisolated via silica gel chromatography eluting with 5% MeOH/CH₂Cl₂. MSm/z: (M+560)

Example 323

The compound was prepared by following the procedure for example 45,step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-4-cyanopiperidine. MS m/z: (M+486).

Example 324

To a cold (0° C.) stirred solution of Example 323 (0.50 g, 0.104 mmol)in anhydrous THF (5 mL) was added lithium aluminum hydride (8 mg, 0.21mmol). The reaction was stirred at RT for 2 hrs. The reaction was thenquenched by the careful addition of H₂O (0.21 mL), 15% aqueous KOH (0.21mL), then H₂O (0.21 mL). The organic layer was separated and dried overNa₂SO₄. The compound was purified via silica gel flash chromatographyeluting with 10% methanol/methylene chloride. MS m/z: (M+490).

Example 325

The compound can be obtained by the reduction of the azido functionalityof Example 187 with a reducing agent, such as triphenyl phoshine,lithium aluminum hydride, sodium borohydride, in a solvent such astetrahydrofuran or diethyl ether in reaction temperature ranges from 0°C. to reflux with a reaction time between 5 minutes and 72 hours.

Example 326

The compound was prepared by following the procedure for example 45,step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-4-methylpiperidine provide in Example 329, steps 1-3.MS m/z: (M+475)

Example 328 Step 1 N-benzyl-4-(4-chlorophenyl)-4-hydroxypiperidine: FIG.8 a

To a stirred solution of commercially available4-(4-chlorophenyl)-4-hydroxypiperidine (10 g, 47 mmol., 1) in anhydrousDMF (10 mL) was added benzyl bromide (5.6 mL, 47 mmol) and K₂CO₃ (7.4 g,94 mmol.) and stirred at RT overnight. Excess solvent was removed underreduced pressure, brought up into CH₂Cl₂ (100 mL) washed with H₂O (2×50mL). Organic layer separated, dried over Na₂SO₄ and charged on a silicagel flash column. Eluting off with 2% MeOH/CH₂Cl₂ 10 g 2 (80% yield) wasobtained as a viscous liquid. MS m/z: (M+303)

Step 2 N-benzyl-4-(4-chlorophenyl)-4-fluoropiperidine: FIG. 8 a

To a cold (−78° C.) solution of 2 (10 g, 33 mmol) in CH₂Cl₂ (20 mL) wasslowly added DAST (diethylaminosulfur trifluoride, 5.3 mL, 39.8 mmol)under an inert atmosphere. The reaction was stirred at −78° C. for anadditional 45 min. The reaction was quenched at −78° C. by the slowaddition of enough saturated aqueous sodium bicarbonate solution toafford a pH>8. This reaction resulted a quantitative conversion of thestarting material to a 1:1 mixture of fluoropiperidine 3 and4-(4-chlorophenyl)tetrahydropyridine 4. The mixture of 3 and 4 (3.5 g,mixture, ˜35% yield) was purified via silica gel flash chromatography,eluting with 2% MeOH/CH₂Cl₂. This mixture proved to be inseparable bysilica gel flash chromatography. In order to separate out the desiredproduct, the mixture of 3 and 4 were subjected to osmium tetroxideoxidation.

To a stirred solution of the mixture of 3 and 4 (1.8 g) in acetone/H₂O(5:1, 10 mL) was added a catalytic amount of OsO₄ in isopropanol (2.5mol %, 1 mL) and N-methylmorpholine-N-oxide (0.69 g, 6.56 mmol). Thereaction was stirred at RT overnight. The reaction was then evaporatedto dryness, brought up into CH₂Cl₂ and washed with NaHSO₃. This reactionresulted in the dihydroxylation of the undesired 4 to 5 and the cleanseparation of the desired fluoropiperidine 3 (1.0 g, 55% yield) from thebyproduct by silica gel flash chromatography eluting with 2%MeOH/CH₂Cl₂. MS m/z: (M+306)

Step 3 4-(4-chlorophenyl)-4-fluoropiperidine: FIG. 8 a

To a cold (0° C.) solution of 3 (1.07 g, 3.5 mmol) in 1,2-dichloroethanewas added 1,1-chloroethylchloroformate (0.45 mL, 4.2 mmol). The reactionwas then heated to reflux for 2 hrs. Excess solvent was removed and theresidue was brought up into 5 mL methanol. The mixture was refluxed for2 hrs and excess methanol was removed under reduced pressure.Precipitation of the hydrochloride salt of 6 by the addition ofCH₂Cl₂/hexane (1:1) followed by filtration resulted in the quantitativeisolation of the desired crystalline product 6 (80%, 0.70 g). MS m/z:(M+215)

Step 4

The compound was prepared by following the procedure for example 44, butreplacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-4-fluoropiperidine. MS m/z: (M+466).

Example 329 Step 1 N-benzyl-4-methylpiperidine: FIG. 8 c

To a cold (−78° C.) stirred solution of 1.4 M methyllithium in THF (39mL, 54 mmol) under an inert atmosphere was addedN-benzyl-4-oxopiperidine (1, 5.1 g, 27 mmol). The reaction was stirredat −78° C. for 2 hrs. The reaction was quenched by the slow addition ofsaturated aqueous NH₄Cl, the organic layer was separated and dried overNa₂SO₄. Pure methylpiperidine (2) was isolated via silica gel flashchromatography eluting with 5% MeOH/CH₂Cl₂. MS m/z: (M+206)

Step 2 N-benzyl-4-(4-chlorophenyl)-4-methylpiperidine: FIG. 8 c

To a flask containing chlorobenzene (10 mL, excess) and methylpiperidine(0.42 g, 2.06 mmol, 2) was added aluminum trichloride (1.65 mL, 12.4mmol). The reaction was heated to reflux for 24 hrs. Excesschlorobenzene was removed under reduced pressure and pure 3 was obtainedvia silica gel flash chromatography eluting with % EtOAc/hexane. MS m/z:(M+300)

Step 3 4-(4-chlorophenyl)-4-methylpiperidine: FIG. 8 c

To a cold (0° C.) solution ofN-benzyl-4-(4-chlorophenyl)-4-methylpiperidine (3) (0.41 g, 1.4 mmol) inCH₂Cl₂ was 1.1 equivalent of 1-chloroethylchloroformate. The reactionwas then heated to reflux for 2 hrs. Excess solvent was removed and theresidue was brought up into methanol. The mixture was refluxed for 2 hrsand excess methanol was removed under reduced pressure. Precipitation ofthe hydrochloride salt 4 by the addition of CH₂Cl₂ followed byfiltration resulted in the quantitative isolation of the desiredcrystalline product 4 (100%, 0.34 g). MS m/z: (M+210)

Step 4

The compound was prepared by following the procedure for example 44,step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-4-methylpiperidine. MS m/z: (M+461)

Example 330

The compound was prepared by following the procedure for example 199,but replacing the resultant compound of example 44 with the resultantcompound of Example 329. MS m/z: (M+533)

Example 331 Step 1

A mixture of epichlorohydrin (5.92 g, 64 mmol) and benzhydrylamine (11.7g, 64 mmol) in MeOH (120 mL) was stirred under the protection of argonat room temperature for 48 hours. The mixture was then stirred at 50° C.for 72 hours. The reaction mixture was then stirred at room temperaturefor 72 hours. The reaction mixture was concentrated in vacuo andpartitioned between EtOAc and H₂O. The aqueous layer was extracted withEtOAc (200 mL×3), dried over MgSO₄ and concentrated in vacuo.Chromatographic purification on silica gel (CH₂Cl₂/MeOH=95/5) provided10.0 g (65%) of 1-benzhydril-3-hydroxyazetidine. m/z 240 (m+1)

Step 2

A mixture 1-benzhydril-3-hydroxyazetidine (2.6 g, 11 mmol) and palladiumhydroxide on active carbon (0.26 g, w/w 20%) in EtOH (40 mL) was shakenin hydrogenation parr under 60 psi for 24 hours. The reaction mixturewas filtered through celite and concentrated under vacuum. Concentrationin vacuo provided 0.75 (95%) 3-hydroxyazetidine. ¹H NMR (250 MHz, CD₃OD)3.81-3.92 (2H, m), 4.14-4.25 (2H, m), 4.61-4.69 (1H, m).

Step 3

The compound1-[3-(5,11-dihydro-7-(methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]azetidin-3-olwas prepared by following the procedure for example 45, step 3, butreplacing 4-(4-chlorophenyl)-4-hydroxypiperidine with3-hydroxyazetidine. m/z 339 (m+1).

Step 4

To a mixture of morpholine N-oxide (0.028 g, 0.244 mmol), crushedmolecular sieves (0.066 g) and Pr₄N⁺RO₄ (0.01 g, 0.024 mmol) in CH₂Cl₂was added the1-[3-(5,11-dihydro-7-(methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]azetidin-3-ol(0.055 g, 0.16 mmol) under the protection of argon. The mixture wasstirring over night at room temperature. The reaction mixture wasfiltered off through celite and concentrated under vacuum.Chromatographic purification on silica gel (CH₂Cl₂/MeOH=95/5 to 9/1)provided 0.033 g1-[3-(5,11-dihydro-7-(methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]azetidin-3-one(60%) of the desired product. m/z 337 (m+1)

Step 5

To a solution of1-[3-(5,11-dihydro-7-(methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]azetidin-3-one(0.06 g, 0.18 mmol) in THF (8 mL) was added dropwise a solution of4-chlorophenyl magnesium bromide in diethyl ether (1.0 M, 0.27 mL) underthe protection of argon at 0° C. The reaction was stirred at roomtemperature for 1.5 hours and quenched by the addition of saturatedaqueous NH₄OH (4 mL). The aqueous layer was extracted with EtOAc (10mL×2), dried over MgSO₄ and concentrated in vacuo. Chromatographicpurification on silica gel (CH₂Cl₂/MeOH=95/5) provided 0.048 g3-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-(methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]azetidine(51%) m/z 449 (m+1)

Example 332 Step 1 tert-Butyl 3-(4-chlorobenzoyl)-1-(2-aminoethyl)carbamate: FIG. 10 b

tert-Butyl N-(2-aminoethyl) carbamate (1, 0.50 g g, 3.12 mmol) was addedto the mixture of 4-chlorobenzoic acid chloride (0.547 g, 3.12 mmol) andEt₃N (1.74 mL, 12.5 mmol) in CH₂Cl₂ (20 mL) under the protection ofargon. Stirring at room temperature for 2 hours. The reaction mixturewas diluted with H₂O (25 mL), extracted with CH₂Cl₂ (50 mL×2), driedover MgSO₄ and concentrated in vacuo. Chromatographic purification onsilica gel (CH₂Cl₂/MeOH=95/5) to provide 0.86 g (2, 93%) of the desiredproduct tert-Butyl 3-(4-chlorobenzoyl)-1-(2-aminoethyl) carbamate. MSm/z: (M+299).

Step 2 1-(4-chlorobenzoyl)-1,2-ethylenediamine: FIG. 10 b

Trifluoroacetic acid (7.5 mL) was added to the solution of tent-Butyl3-(4-chlorobenzoyl)-1-(2-aminoethyl)carbamate (2, 0.86 g, 2.89 mmol) inCH₂Cl₂ (35 mL) at 0° C. Stirring at room temperature for 30 minutes.Concentration in vacuo provided 0.88 g (95%) of the desired product1-(4-chlorobenzoyl)-1,2-ethylenediamine (3). MS m/z: (M+199).

Step 3

The compound was prepared by following the procedure for example 45,step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with1-(4-chlorobenzoyl)-1,3-propylenediamine. MS m/z: (M+465).

Example 333 Step 1 2-(4-Chlorophenyl)-1-bromoethylene: FIG. 9 c

To a solution of AlCl₃ (1.96 g, 14.7 mmol) in anhydrous CH₂Cl₂ (50 mL),Borane-tert-butyl amine complex (2.57 g, 29.6 mmol) was added at 0° C.under argon protection, stirred for 10 minutes and clear solution wasformed. 4-Chlorophenacyl bromide (1, 1.11 g, 4.91 mmol) in CH₂Cl₂ (5 mL)was added to the resulted mixture at 0° C. The reaction was stirred for1.5 hours and then quenched by the addition of 0.1 N HCl (25 mL). Themixture was extracted with EtOAc (80 mL×3), dried over MgSO₄ andconcentrated in vacuo. Chromatographic purification on silica gel(Hexane/EtOAc=9:1) provided 0.85 g (84%) of2-(4-chlorophenyl)-1-bromoethylene (2). MS m/z: (M+219).

Step 2 2-(4-chlorophenyl)-1-(N-methyl)ethylamine: FIG. 9 c

A mixture of 2-(4-chlorophenyl)-1-bromoethylene (2, 1.02 g, 4.62 mmol),EtOH (3 mL) and H₂NMe in H₂O (6 mL, 40% w/w) was heated at 135 0° C.over night. The mixture was cooled down to room temperature. The mixturewas extracted with Et₂O (5 mL×2), dried over MgSO₄ and concentrated invacuo. Chromatographic purification on silica gel(CH₂Cl₂/MeOH/NH₄OH=9/1/0.1) provided 0.61 g2-(4-chlorophenyl)-1-(N-methyl)ethylamine (3, 79%). MS m/z: (M+170).

Step 3

The compound was prepared by following the procedure for example 45,step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with2-(4-chlorophenyl)-1-(N-methyl)ethylamine. MS m/z: (M+451).

Example 334 Step 1 3-(4-chlorophenyl)-1-N-methylaminopropane: FIG. 9 e

A mixture of 3-(4-chlorophenyl)-1-bromoropane (1, 0.70 g, 3.73 mmol),EtOH (3 mL) and H₂NMe in H₂O (6 mL, 40% w/w) was heated at 135 0° C.overnight. The mixture was then cooled down to room temperature. Themixture was extracted with Et₂O (5 mL×2), dried over MgSO₄ andconcentrated in vacuo. Chromatographic purification on silica gel(CH₂Cl₂/MeOH/NH₄OH=9/1/0.1) provided 0.5 g (76%) of3-(4-chlorophenyl)-1-N-methylaminopropane (2). MS m/z: (M+189).

Step 2

The compound was prepared by following the procedure for example 45,step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with3-(4-chlorophenyl)-1-N-methylaminopropane.

MS m/z: (M+450).

Example 335 Step 1 3-(4-chlorophenyl)-3-chloro-1-hydroxypropane: FIG. 9d

To 3,4′-Dichloropropylphenone (0.52 g, 2.53 mmol) in anhydrous MeOH (10mL) at 0° C. under the protection of argon, NaBH₄ (0.23 g, 3.03 mmol)was added to the solution by several portions. The reaction was stirredunder the same condition for 15 minutes. The mixture was warmed up toroom temperature, stirred an additional 30 minutes, then concentrationin vacuo. The residue was partitioned between EtOAc and H₂O. The aqueouslayer was re-extracted with EtOAc (30 mL×2), dried over MgSO₄ andconcentrated in vacuo. Chromatographic purification on silica gel(Hexane/EtOAc=(1/1) provided 0.52 g (99%) of3-(4-chlorophenyl)-3-chloro-1-hydroxypropane. MS m/z: (M+205).

Step 2

The compound was prepared by following the procedure for example 45,step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with3-(4-chlorophenyl)-3-chloro-1-hydroxypropane. MS m/z: (M+481).

Example 336 Step 13-(4-chlorophenyl)-3-hydroxy-3-methyl-1-chloropropane: FIG. 10 a

To 3,4′-Dichloropropylphenone (1, 1.10 g, 5.40 mmol) in anhydrous THF at0° C. under the protection of argon, was added MeMgBr (2.50 mL, 7.35mmol) dropwise at 0° C. The reaction was stirred at room temperature foran additional hour. The reaction was quenched by adding saturatedaqueous NH₄Cl. The reaction was then extracted with Et₂O (60 mL×2),dried over MgSO₄ and concentrated in vacuo. Chromatographic purificationon silica gel (Hexane/EtOAc=10/1) provided 1.0 g (85%) of3-(4-chlorophenyl)-3-hydroxy-3-methyl-1-bromoropane (2). MS m/z:(M+219).

Step 2 3-(4-chlorophenyl)-3-hydroxyl-3-methyl-1-N-methylaminopropane:FIG. 10 a

A mixture of 3,3,3-(4-Chlorophenyl)-hydroxylmethyl-1-bromoropane (2,1.04 g, 4.74 mmol), EtOH (5 mL) and H₂NMe in H₂O (10 mL, 40% w/w) washeated at 135 0° C. for 3 hours. The mixture was cooled down to roomtemperature. The mixture was extracted with Et₂O (5 mL×2), dried overMgSO₄ and concentrated in vauco. Chromatographic purification on silicagel (CH₂Cl₂/MeOH/NH₂OH=9/1/0.1) provided 1.01 g3-(4-chlorophenyl)-3-hydroxyl-3-methyl-1-N-methylaminopropane (3, 99%).

MS m/z: (M+214).

Step 3

The compound was prepared by following the procedure for example 45,step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with3-(4-chlorophenyl)-3-hydroxyl-3-methyl-1-N-methylaminopropane. MS m/z:(M+480).

Example 345

Using the procedure of Example 45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with1-azaxanthone, gives the desired compound.

Example 346

Using the procedure of Example 45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with1-4-azafluorene, gives the desired compound.

Example 347

Using the procedure of Example 45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with7-amino-1-azaxanthone, gives the desired compound.

Example 348

Using the procedure of Example 45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with4,5-diazafluorene, gives the desired compound.

Example 349

Using the procedure of Example 45, but replacing5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with1-aza-7-nitroxanthone, gives the desired compound.

Example 3503-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-(methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]pyrrolidineStep 1

A mixture of 1-benzyl-3-pyrrolidinone (10.0 g, 57 mmol), di-tert-butyldicarbonate (13.7 g, 63 mmol) and palladium on active carbon (2.5 g, w/w20%) in MeOH was shaken in a Parr hydrogenation vessel (50 psi H₂) for48 hours. The reaction mixture was filtered through celite andconcentrated in vacuo. Chromatographic purification on silica gel(Hexane/EtOAc=1/1) provided 6.21 g 1-t-butoxycarbonyl-3-pyrrolidinone(59%). ¹H NMR (250 MHz, CDCl₃) δ: 1.46 (9H, s), 2.57 (2H, t, J=7.8 Hz),3.71-3.75 (4H, m)

Step 2

To a stirred solution of 1-t-butoxycarbonyl-3-pyrrolidinone (0.57 g,3.23 mmol) in THF (10 mL) was added 4-chlorophenyl magnesium bromide(1.0 M, 5.2 mL) under the protection of argon at 0° C. The reaction wasstirred at room temperature for 1 hour then quenched by the addition ofsaturated aqueous NH₄OH (8 mL). The aqueous layer was extracted withEtOAc (50 mL×2), dried over MgSO₄ and concentrated in vacuo.Chromatographic purification on silica gel (Hexane/EtOAc=3/1) provided0.57 g 1-t-butoxycarbonyl-3-(4-chlorophenyl)-3-hydroxypyrrolidine (60%).m/z 298 (m+1)

Step 3

To a stirred solution of1-t-butoxycarbonyl-3-(4-chlorophenyl)-3-hydroxypyrrolidine (0.335 g,1.28 mmol) in CH₂Cl₂ (8 mL) was added trifluoroacetic acid (2 mL) at 0°C. slowly. The reaction was stirred at room temperature for 30 minutesand concentrated in vacuo. This provided 0.355 g3-(4-chlorophenyl)-3-hydroxypyrrolidine (100%) the desired product. m/z198 (m+1)

Step 4

The titled compound was prepared by following the procedure for example44 but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with3-(4-chlorophenyl)-3-hydroxypyrrolidine. m/z 432 (m+1).

Example 351 Step 1 4-(4-chlorophenyl)-4-pyridine: FIG. 10 d

To a solution of 4-bromopyridine (1, 1.94 g, mmol),4-chlorophenylboronic acid (2, 1.56 g, mmol) and K₂CO₃ (2.76 g, 2.0equiv) in ethanol/toluene (5 mL/100 mL) was added Pd(PPh₃)₃. Thereaction was refluxed for 1 hr, cooled back down to RT and quenched withH₂O (15 mL). The reaction mixture was extracted with EtOAc and theorganic layer was dried over Na₂SO₄. Pure 4-(4-chlorophenyl)-4-pyridine2 (1.3 g, 68% yield) was isolated after silica gel flash columnpurification eluting with 50% EtOAc/hexane. MS m/z: (M+191).

Step 2

The titled compound was prepared by following the procedure for example45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-4-pyridine. MS m/z: (M+456).

Example 352

The compound was prepared by following the procedure for example 44, butreplacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-chlorophenyl)-4-pyridine.

MS m/z: (M+442).

Example 3535-(2-(N-(4-(4-Chlorophenyl)-4-hydroxycyclohexyl)-N-methyl)ethylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridine

The compound was prepared by the procedure of Example 57, step 3, butreplacing 4-(4-chlorophenyl)-4-hydroxypiperidine with4-(4-N-methyl-(4-chlorophenyl)-4-hydroxycyclohexylamin. The startingmaterial can be prepared according to methods disclosed in Journal ofMedicinal Chemistry, Vol. 15, No. 12, pp. 1239-1243 (1972).

Example 3541-[3-(7-(4-Carboxyphenoxy)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 14-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(4-ethoxycarbonylphenoxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of example 46, but replacingethyl iodide with ethyl 4-fluorobenzoate

¹H-NMR (CDCl₃) δ: 1.36 (3H, t), 1.65-2.07 (4H, m), 2.32-2.63 (8H, m),4.34 (2H, q), 5.33 (2H, brs), 6.07 (1H, t). 6.88-7.10 (5H, m), 7.27-7.51(5H, m), 7.58 (1H, dd), 7.97-8.00 (2H, m), 8.49 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of step 1.

¹H-NMR (DMSO-d₆) δ: 1.44-1.49 (2H, m), 1.67-1.87 (2H, m), 2.26-2.56 (8H,m), 4.85 (1H, brs), 5.29 (2H, brs), 6.17 (1H, t), 6.88-7.09 (5H, m),7.33-7.48 (5H, m), 7.75 (1H, dd), 7.89-7.93 (2H, m), 8.52 (1H, dd).

MS m/z: 582(M)

Example 3554-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-(hydroxyimino)propyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of example 313 (300 mg) in ethanol (3 ml)was added hydroxylammonium chloride (80 mg) at room temperature, and themixture was stirred for 1 hour. The precipitation was filtered andwashed with ethanol to give the titled compound (300 mg).

¹H-NMR (DMSO-d6) δ: 1.75-1.80 (2H, m). 2.23-2.42 (2H, m), 2.53 (3H, s)3.16-3.48 (8H, m), 4.54 (2H, s), 5.19 (2H, brs), 5.57 (1H, s), 6.14 (1H,t), 6.76-6.98 (3H, m), 7.41-7.48 (5H, m), 7.79 (1H, dd), 8.53 (1H, dd),10.93 (1H, s).

MS m/z: 515(M+1)

Example 3561-[3-(7-(2-Carboxy-2-methyl-1-propyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-ethoxycarbonyl-2-methylproyl)oxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of example 46, but replacingethyl iodide with ethyl 2-bromo-1,1-dimethyl propionate.

¹H-NMR (CDCl₃) δ: 1.31 (6H, s), 1.67-1.72 (2H, m), 1.96-2.15 (2H, m),2.39-2.78 (8H, m), 3.69 (3H, s), 3.93 (2H, s), 5.27 (2H, brs), 6.09 (1H,t), 6.70-6.83 (3H, m), 7.23-7.59 (6H, m), 8.46 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of step 1.

¹H-NMR (DMSO-d6) δ: 1.46-1.50 (2H, m), 1.74-1.85 (2H, m), 2.22-2.38 (8H,m), 3.92 (2H, s), 4.58 (1H, brs), 5.19 (2H, brs), 6.18 (1H, t),6.71-6.83 (3H, m), 7.33-7.48 (5H, m), 7.72 (1H, dd), 8.49 (1H, dd).

MS m/z: 514(M+1)

Example 3574-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-(hydroxyimino)propyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example354, but replacing the product of example 313 with the product ofexample 315.

¹H-NMR (DMSO-d6) δ: 1.39-1.54 (2H, m), 1.64-1.86 (2H, m), 2.13 (3H, s),2.19-2.36 (4H, m), 2.36-2.52 (4H, m), 4.83 (1H, s), 5.28 (2H, brs), 6.20(1H, t), 6.80 (1H, d), 7.35 (2H, d), 7.43-7.49 (4H, m), 7.58 (1H, d),7.76 (1H, d), 8.51 (1H, dd), 11.04 (1H, s).

MS m/z: 504(M+1)

Example 3584-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-propionyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example315, but replacing acetyl chloride with propionyl chloride.

¹H-NMR (CDCl₃) δ: 1.22 (3H, t), 1.63-1.77 (2H, m), 1.97-2.13 (2H, m),2.25-2.48 (4H, m), 2.48-2.60 (2H, m). 2.60-2.73 (2H, m), 2.96 (2H, q),5.41 (2H, brs), 6.21 (1H, t), 6.86 (1H, d), 7.30-7.34 (3H, m), 7.43 (2H,d), 7.59 (1H, d), 7.75 (1H, dd), 7.97 (1H, d), 8.53 (1H, d).

MS m/z: 503(M+1)

Example 3594-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-isobutyry[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example315, but replacing acetyl chloride with isobutyryl chloride.

¹H-NMR (CDCL₃) δ: 1.21-1.33 (2H, m), 1.76-2.00 (2H, m), 2.46-3.47 (8H,m), 3.53 (1H, m), 5.47 (2H, brs), 6.09 (1H, t), 6.89 (1H, d), 7.32-7.45(6H, m), 7.64 (1H, d), 7.79 (1H, dd), 7.94 (1H, d), 8.57 (1H, d).

MS m/z: 517(M+1)

Example 3604-(4-Chlorophenyl)-1-[3-(7-cyclopropylacetyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example315, but replacing acetyl chloride with cyclopropylacetyl chloride.

¹H-NMR (CDCl₃) δ: 0.98-1.05 (2H, m), 1.20-1.24 (2H, m), 1.58-1.70 (2H,m), 1.99-2.09 (2H, m), 2.34-2.55 (4H, m), 2.58-2.68 (5H, m), 5.40 (2H,brs), 6.23 (1H, t), 6.89 (1H, d), 7.30-7.34 (3H, m), 7.43 (2H, d), 7.59(1H, dd), 7.86 (1H, dd), 8.00 (1H, d), 8.53 (1H, dd).

MS m/z: 515(M+1)

Example 3611-[3-(7-(3-Carboxypropionyl)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 14-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-methoxycarbonylpropionyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)piperidin-4-olwas prepared by following the procedure of Example 315, but replacingacetyl chloride with methyl succinyl chloride.

¹H-NMR (CDCl₃) δ: 1.57-1.77 (4H, m), 1.94-2.14 (4H, m), 2.27-2.61 (6H,m) 2.61-2.73 (2H, m), 3.67 (3H, s), 4.70 (1H, t), 5.30 (2H, brs), 6.11(1H, t), 6.83 (1H, d), 7.14 (1H, d), 7.29-7.32 (4H, m), 7.42 (2H, d),7.58 (1H, d), 8.50 (1H, d).

Step 2

The titled compound was prepared by following the procedure of Example133, but replacing the product of example 48 with the product of step 1.

¹H-NMR (DMSO-d₆) δ: 1.37-1.57 (2H, m), 1.63-1.86 (2H, m), 2.13-2.37 (4H,m), 2.45-2.63 (4H, m), 3.17-3.28 (4H, m), 4.85 (1H, brs), 5.36 (2H,brs), 6.30 (1H, t), 6.91 (1H, d), 7.35 (2H, d), 7.46-7.50 (3H, m),7.78-7.83 (2H, m), 7.95 (1H, d), 8.53 (1H, dd).

MS m/z: 547(M+1)

Example 3624-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethyl-1-hydroxy)propyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by flowing the procedure of example242, but replacing methylmagnesium bromide with ethylmagnesium bromide.

¹H-NMR (CDCl₃) δ: 0.79 (6H, t), 1.65-2.04 (9H, m), 2.35-2.66 (8H, m),5.37 (2H, brs), 6.09 (1H, t), 6.81 (1H, d), 7.10 (1H, dd), 7.26-7.51(6H, m), 7.59 (1H, dd), 8.49 (1H, dd).

MS m/z: 533(M+1)

Example 3634-(4-Chlorophenyl)-1-[3-(7-(1-cyano-1-methypethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olStep 1

5-(3-bromopropylidene)-7-(1-hydroxy-1-methyl)ethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridinewas prepared by following the procedure of Example 200, but replacingthe product of example 48 with the product of example 315, step 1.

¹H-NMR (CDCl₃) δ: 1.58 (6H, s), 2.74 (2H, q), 3.47 (2H, t), 5.34 (2H,brs), 6.09 (1H, t), 6.82 (1H, d), 7.25-7.31 (2H, m), 7.45 (1H, d), 7.57(1H, dd), 8.52 (1H, dd).

Step 2

To a solution of the product of step 1 (3.8 g) in dichloromethane (40ml) was added trimethylsilyl cyanide (4.1 ml) and boron trifluoridediethyl etherate (2.5 ml) at 0° C., and the mixture stirred at roomtemperature for 10 minutes. The reaction mixture was poured intosaturated aqueous sodium bicarbonate. The aqueous layer was extractedwith ethyl acetate, and the organic layer was washed with saturatedaqueous sodium chloride, and dried with magnesium sulfate. The solventwas distilled off under reduced pressure. The residue was purified bysilica gel chromatography eluting with ethyl acetate-hexane (1:3) togive5-(3-bromopropylidene)-7-(−1-cyano-1-methyl)ethyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridine(3.4 g).

¹H-NMR (CDCl₃) δ: 1.58 (6H, s), 2.76 (2H, m), 3.48 (2H, t), 5.34 (2H,brs), 6.09 (1H, t), 6.87 (1H, d), 7.22 (1H, dd), 7.32 (1H, dd), 7.42(1H, d), 7.58 (1H, dd), 8.55 (1H, dd).

Step 3

The titled compound was prepared by following the procedure of example44, step 2, but replacing the product of example 44, step 1 with theproduct of step 2.

¹H-NMR (CDCl₃) δ: 1.58 (6H, s), 1.60-1.70 (2H, m), 1.93-2.12 (2H, m),2.30-2.47 (4H, m), 2.50-2.74 (4H, m), 5.31 (2H, brs, 6.15 (1H, t), 6.86(1H, d), 7.19 (1H, dd), 7.28-7.32 (3H, m), 7.41-7.43 (3H, m), 7.61 (1H,d), 8.53 (1H, dd).

MS m/z: 514(M+1)

Example 364 4-(4-Chlorophenyl)-1-[3-(7-cyano-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example44, step 2, but replacing the product of example 44, step 1 with5-(3-bromopropylidene)-7-cyano-5,11-dihydro[1]benzoxepino[2,3-b]pyridine.

¹H-NMR (CDCL₃) δ: 1.62-1.75 (2H, m), 1.98-2.09 (2H, m), 2.36-2.69 (8H,m), 5.36 (2H, brs), 6.19 (1H, t), 6.89 (1H, d), 7.29-7.62 (8H, m), 8.55(1H, d).

MS m/z: 472(M+1)

Example 3654-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(tetrazol-5-yl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of Example 364 (1.0 g) in DMF (10 ml) wereadded sodium azide (0.69 g) and ammonium chloride (0.56 g) and themixture stirred at 100° C. for 36 hour. Water was added to the reactionmixture, and the precipitate was filtered and washed with ethanol togive the titled compound (800 mg).

¹H-NMR (DMSO-d₆) δ: 1.66-1.71 (2H, m), 1.91-2.01 (2H, m), 2.86-3.09 (8H,m), 5.33 (2H, brs), 6.22 (1H, t), 6.91 (1H, d), 7.39-7.51 (5H, m),7.79-7.84 (2H, m), 8.03 (1H, d), 8.55 (1H, dd).

MS m/z: 515(M+1)

Example 3664-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(hydroxyiminomethyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example357, but replacing the product of example 315, step 2 with the productof example 314.

¹H-NMR (DMSO-d₆) δ: 141-1.52 (2H, m), 1.70-1.82 (2H, m), 2.27-2.46 (8H,m), 4.83 (1H, s), 5.37 (2H, brs), 6.20 (1H, t), 6.83 (1H, d), 7.34-7.53(7H, m), 7.76 (2H, dd),

MS m/z: 490(M+1)

Example 3671-(4-Chlorophenyl)-4-[3-(5,11-dihydro-7-(1-hydroxy-1-methyl)ethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine

The titled compound was prepared by following the procedure of example71, but replacing the product of example 45, step 2 with the product ofExample 363, step 1.

¹H-NMR (CDCl₃) δ: 1.58 (6H, s), 2.31-2.63 (8H, m), 3.02-3.20 (4H, m),5.32 (2H, brs), 6.12 (1H, t), 6.79-6.83 (3H, m), 7.17-7.31 (6H, m), 7.45(1H, d), 7.58 (1H, dd), 8.51 (1H, dd).

MS m/z: 490(M+1)

Example 3684-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-sulfamoyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olStep 1

To the product of example 53, step 1 (5.4 g) was added chlorosulfonicacid (50 ml) and the mixture stirred at 0° C. for 1 hour. The reactionmixture was poured to ice, and ethyl acetate was added to the mixture,the organic layer was separated and washed with saturated aqueous sodiumchloride, and dried with magnesium sulfate. The solvent was distilledoff under reduced pressure. To the residue were added THF (250 ml) andammonium hydroxide (30 ml) and the mixture stirred at room temperaturefor 10 minutes. Ethyl acetate and water were added to the mixture, theorganic layer was separated and washed with saturated aqueous sodiumchloride, and dried with magnesium sulfate. The solvent was distilledoff under reduced pressure. The residue was purified by silica gelchromatography eluting with ethyl acetate-hexane (1:1) to give5-(3-bromopropylidene)-5,11-dihydro-7-sulfamoyl[1]benzoxepino[2,3-b]pyridine(5.0g).

¹H-NMR (CDCl₃) δ: 2.70-2.75 (2H, m), 3.48 (2H, t), 5.39-5.49 (4H, m),6.16 (1H, t), 6.88 (1H, d), 7.25-7.34 (2H, m), 7.53 (1H, dd), 7.68 (1H,dd), 7.93 (1H, d), 8.53 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example44, step 2, but replacing the product of example 44, step 1 with theproduct of step 1.

¹H-NMR (DMSO-d₆) δ: 1.65-1.70 (3H, m), 1.98-2.07 (2H, m), 2.35-2.64 (8H,m), 4.98 (2H, brs), 5.39 (2H, brs), 6.22 (1H, t), 6.92 (1H, d) 7.26-7.43(5H, m), 7.55-7.69 (2H, m), 7.91 (1H, d), 8.53 (1H, dd).

MS m/z: 526(M+1)

Example 3691-[-3-(7-(2-Aminothiazol-4-yl)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

7-bromoacetyl-5-(3-bromopropylidene)-5,11-dihydro[1]benzoxepino[2,3-b]pyridinewas prepared by following the procedure of example 315, step 1, butreplacing acetyl chloride with bromoacetyl chloride.

¹H-NMR (CDCl₃) δ: 2.77 (2H, m), 3.50 (2H, m), 4.40 (2H, s), 5.45 (2H,brs), 6.17 (1H, t), 6.90 (1H, d), 7.35 (1h, dd), 7.60 (1H, dd), 7.79(1H, dd), 8.01 (1H, d), 8.57 (1H, dd).

Step 2

To a solution of the product of step 1 (1.1 g) in ethanol (11 ml) wasadded thiourea (193 mg) at room temperature, and the mixture stirred at70° C. for 30 minutes. The reaction mixture was cooled to roomtemperature and poured into saturated aqueous sodiumbicarbonate. Theaqueous layer was extracted with ethyl acetate, and the organic layerwas washed with saturated aqueous sodium chloride, and dried withmagnesium sulfate. The solvent was distilled off under reduced pressure.The residue was purified by silica gel chromatography eluting with ethylacetate to give7-(2-aminothiazol-4-yl)-5-(3-bromopropylidene)-5,11-dihydro[1]benzoxepino[2,3-b]pyridine(749 mg).

¹H-NMR (CDCl₃) δ: 2.74 (2H, m), 3.47 (2H, t), 5.02 (2H, brs), 5.39 (2H,brs), 6.16 (1H, t), 6.62 (1H, s), 6.85 (1H, d), 7.30 (1H, dd), 7.54-7.57(2H, m), 7.77 (1H, d), 8.53 (1H, dd).

Step 3

The titled compound was prepared by following the procedure of example44, step 2, but replacing the product of example 44, step 1 with theproduct of step 2.

¹H-NMR (CDCl₃) δ: 1.57-1.70 (2H, m), 1.83-2.13 (2H, m), 2.30-2.46 (4H,m), 2.46-2.60 (2H, m), 2.60-2.73 (2H, M), 5.02 (2H, s), 5.37 (2H, brs),6.20 (1H, t), 6.61 (1H, s), 6.85 (1H, d), 7.27-7.32 (3H, m), 7.42 (2H,d), 7.50-7.58 (2H, m), 7.76 (1H, d), 8.50 (1H, dd).

MS m/z: 545(M+1)

Example 3701-[3-(7-(3-Carboxy-1-hydroxy)propyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-methoxycarbony-1-hydroxy)propyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of example 199, but replacingthe product of example 138 with the product of Example 361, step 1.

¹H-NMR (CDCl₃) δ: 1.57-1.77 (4H, m), 1.94-2.14 (4H, m), 2.27-2.61 (6H,m), 2.61-2.73 (2H, m), 3.67 (3H, s), 4.70 (1H, t), 5.30 (2H, brs), 6.11(1H, t), 6.83 (1H, d), 7.14 (1H, d), 7.29-7.32 (4H, m), 7.42 (2H, d),7.58 (1H, d), 8.50 (1H, d).

Step 2

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product step 1.

¹H-NMR (DMSO-d₆) δ: 1.44-1.63 (2H, m), 1.69-1.90 (2H, m), 2.17-2.29 (2H,m), 2.29-2.82 (6H, m), 3.24-3.53 (4H, m), 4.49 (1H, t), 5.03 (1H, brs),5.20 (2H, brs), 6.13 (1H, t), 6.76 (1H, d), 7.12 (1H, dd), 7.27 (1H, d),7.37 (2H, d), 7.43-7.48 (3H, m), 7.76 (1H, d), 8.32 (1H, s), 8.51 (1H,dd).

MS m/z: 549(M+1)

Example 3714-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-fluoroethylamino)carbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example134, but replacing dimethylamine hydrochloride with 2-fluoroethylamine.

¹H-NMR (CDCl₃) δ: 1.62-1.71 (3H, m), 1.98-2.10 (2H, m), 2.36-2.71 (8H,m), 3.63 (1H, q), 3.73 (1H, q), 4.46 (1H, t), 4.49 (2H, s), 4.63 (1H,t), 5.29 (2H, brs), 6.10 (1H, t), 6.75-6.96 (4H, m), 7.28-7.44 (5H, m),7.60 (1H, dd), 8.51 (1H, dd).

MS m/z: 566(M+1)

Example 3724-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(N-methylsulfamoyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example368, but replacing ammonium hydroxide with methylamine.

¹H-NMR (CDCl₃) δ: 1.57-1.70 (3H, m), 1.93-2.08 (2H, m), 2.34-2.73 (11H,m), 4.33 (1H, q), 5.36 (2H, brs), 6.21 (1H, t), 6.91 (1H, d), 7.29-7.45(6H, m), 7.58-7.65 (2H, m), 7.83 (1H, dd), 8.53 (1H, dd).

MS m/z: 540(M+1)

Example 3734-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(N,N-dimethylsulfamoyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example368, but replacing ammonium hydroxide with dimethylamine.

¹H-NMR (CDCl₃) δ: 1.55-1.75 (3H, m), 1.96-2.07 (2H, m), 2.35-2.67 (8H,m), 2.71 (6H, s), 5.51 (2H, brs), 6.19 (1H, t), 6.92 (1H, d), 7.29-7.73(8H, m), 8.55 (1H, dd).

MS m/z: 554(M+1)

Example 3741-[3-(7-(1-Carboxy-2-hydroxyethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

4-(4-Chlorophenyl-1-[3-(5,11-dihydro-7-(1-ethoxycarboxy-2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of example 199, but replacingthe product of example 138 with the product of example 294.

¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 2.01-2.11 (2H, m), 2.35-2.70 (8H,m), 3.76 (3H, s), 3.97-4.08 (2H, m), 4.71 (1H, t), 5.25 (1H, brs) 6.02(1H, t) 6.70-6.91 (3H, m), 7.23-7.56 (6H, m), 8.44 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of Step 1.

¹H-NMR (DMSO-d₆) δ: 1.51-1.56 (2H, m), 1.86-1.94 (2H, m), 2.33-2.67 (8H,m), 3.65-3.82 (2H, m), 4.58 (1H, t), 5.17 (2H, brs), 6.10 (1H, t),6.71-6.89 (3H, m), 7.34-7.47 (5H, m), 7.72 (1H, dd), 8.48 (1H, dd).

MS m/z: 551(M+1)

Example 3754-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ureidomethy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of example 314 (800 mg) in acetic acid (20ml) were added urea (2 g) and trimethylsilyl chloride (0.24 ml) at roomtemperature, and the mixture stirred for 2 hours. Sodium borohydride wasadded to the reaction mixture at room temperature, and the mixture wasstirred for 1 hour. The solvent was distilled off under reducedpressure, and, chloroform, 2-propanol and water were added. The organiclayer was extracted, and the solvent was distilled off under reducedpressure. The residue was purified by silica gel chromatography elutingwith chloroform-methanol-ammonium hydroxide (100:10:1) to give thetitled compound (250 mg).

¹H-NMR (CDCl₃) δ: 1.62-2.04 (5H, m), 2.35-2.69 (8H, m), 4.26 (2H, d),4.40 (2H, s), 4.48 (1H, t), 5.32 (2H, brs), 6.12 (1H, t), 6.80 (1H, d),7.07 (1H, dd), 7.23-7.58 (7H, m), 8.49 (1H, dd).

MS m/z: 519(M+1)

Example 3764-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methylthio[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example44, step 2, but replacing the product of example 44, step 1 with5-(3-bromopropylidene)-5,11-dihydro-7-methylthio[1]benzoxepino[2,3-b]pyridine.

¹H-NMR (CDCl₃) δ: 1.53-1.70 (3H, m), 1.98-2.16 (2H, m), 2.17 (3H, s),2.34-2.70 (8H, m), 5.32 (2H, brs), 6.12 (1H, t), 6.81 (1H, d), 7.11-7.44(7H, m), 7.57 (1H, dd), 8.50 (1H, dd).

MS m/z: 493(M+1)

Example 3774-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-furanon-3-yl)oxy[1]benzoxepino[2,3]b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example46, but replacing ethyl iodide with 3-bromotetrahydro-2-franon.

¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 1.97-2.13 (2H, m), 2.25-2.73 (10H,m), 4.25-4.53 (2H, m), 4.82 (1H, t), 5.27 (2H, brs), 6.09 (1H, t),6.73-6.91 (2H, m), 7.03 (1H, d), 7.22-7.59 (6H, m), 8.43 (1H, dd).

MS m/z: 547(M+1)

Example 3784-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(N-methoxycarbonylmethylsulfamoyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example368, but replacing ammonium hydroxide with glycine methyl esterhydrochloride.

¹H-NMR (CDCl₃) δ: 1.66-1.74 (3H, m), 1.97-2.15 (2H, m), 2.37-2.80 (8H,m), 3.63 (3H, s), 3.78 (2H, s) 5.40 (2H, brs), 6.22 (1H, t), 6.92 (1H,d), 7.28-7.45 (5H, m), 7.62 (2H, dd), 7.83 (1H, d), 8.53 (1H, dd).

MS m/z: 598(M+1)

Example 3791-[3-(7-(N-Carboxymethylsulfamoyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of example133, but replacing the product of example 48 with the product of Example378.

¹H-NMR (DMSO-d₆) δ: 1.60-1.65 (2H, m), 2.16-2.25 (2H, m), 2.43-3.03 (8H,m), 3.45 (2H, s), 5.33 (2H, brs), 6.39 (1H, t), 6.94 (1H, d), 7.41-7.57(6H, m), 7.83 (1H, dd), 8.00 (1H, d), 8.54 (1H, dd).

Example 3804-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-furanon-5-yl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example249, step 2, but replacing the product of example 249, step 1 with theproduct of Example 370, step 1.

¹H-NMR (CDCl₃) δ: 1.45-1.78 (4H, m), 1.93-2.12 (2H, m), 2.30-2.50 (4H,m), 2.50-2.78 (6H, m), 5.33 (2H, brs), 5.46 (1H, t), 6.12 (1H, t), 6.86(1H, d), 7.09 (1H, dd), 7.27-7.32 (4H, m), 7.42 (2H, d), 7.58 (1H, dd),8.51 (1H, dd).

MS m/z: 531(M+1)

Example 3811-[3-(7-Amino-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl[-4-(4-chlorophenyl)piperidin-4-ol

To a solution of the produce of example 293 (3.7 g) in ethanol (130 ml)was added 5N sodium hydroxide solution (100 ml) and the mixture stirredat 90° C. for 1 hour. The reaction mixture was distilled off underreduced pressure. The residue was dissolved with water and neutralizedwith 1N hydrochloric acid. Ethyl acetate was added to the mixture, theorganic layer was separated and washed with saturated aqueous sodiumchloride, and dried with magnesium sulfate to give the titled compound(3.0 g).

¹H-NMR (CDCl₃) δ: 1.62-1.72 (2H, m), 1.96-2.08 (2H, m), 2.27-2.72 (8H,m), 3.48 (2H, brs), 5.23 (2H, brs), 6.01 (1H, t), 6.49-6.73 (3H, m),7.18-7.59 (6H, m), 8.49 (1H, dd).

MS m/z: 462(M+1)

Example 3821-[3-(7-(2-Carboxyphenyl)-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-formylphenyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the similar procedure of example 170, butreplacing allyltributyltin with 2-formylphenylboronic acid.

¹H-NMR (CDCl₃) δ: 1.65-1.91 (3H, m), 1.99-2.04 (2H, m), 2.37-2.65 (8H,m), 5.39 (2H, brs), 6.15 (1H, t), 6.95 (1H, d), 7.19-7.65 (10H, m),7.97-8.05 (2H, m), 8.52 (1H, dd), 10.03 (1H, s).

Step 2

To a solution of the product of step 1 (270 mg) in acetic acid (2.2 ml)and water (0.5 ml) were added amidosulfuric acid (67 mg) and sodiumchlorite (68 mg) in water (0.1 ml), and the mixture was stirred at roomtemperature for 15 minutes. The reaction mixture was distilled off underreduced pressure into half volume. The residue was neutralized with 1Nsodium hydroxide. The precipitation was filtered and washed with waterto give the titled compound (80 mg).

¹H-NMR (DMSO-d₆) δ: 1.41-1.57 (2H, m), 1.74-1.92 (2H, m), 2.21-2.58 (8H,m), 5.32 (2H, brs), 6.20 (1H, t), 6.82 (1H, d), 7.15 (1H, dd), 7.31-7.78(11H, m), 8.52 (1H, dd).

MS m/z: 567(M+1)

Example 3834-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(N-(2,2,2-trifluoroethyl)sulfamoyl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example368, but replacing ammonium hydroxide with 2,2,2-trifluoroethylaminehydrochloride.

¹H-NMR (CDCl₃) δ: 1.64-1.77 (2H, m), 1.97-2.18 (2H, m), 2.35-2.80 (8H,m), 3.63 (2H, q), 5.41 (2H, brs), 6.21 (1H, t), 6.91 (1H, d), 7.22-7.65(7H, m), 7.84 (1H, d), 8.57 (1H, dd).

MS m/z: 608(M+1)

Example 3844-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methylsulfonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example44, step 2, but replacing the product of Example 44, step 1 with5-(3-bromopropylidene)-5,11-dihydro-7-methylsulfonyl[1]benzoxepino[2,3-b]pyridine.

¹H-NMR (CDCl₃) δ: 1.54-1.71 (3H, m), 1.99-2.08 (2H, m), 2.34-2.68 (8H,m), 3.04 (3H, s), 5.43 (2H, brs), 6.24 (1H, t), 6.97 (1H, d), 7.22-7.70(7H, m), 7.89 (1H, d), 8.55 (1H, dd).

MS m/z: 525(M+1)

Example 3854-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ureido[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olStep 14-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-pheoxycarbonylamino[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example293, but replacing ethanol with phenol.

¹H-NMR (CDCl₃) δ: 1.62-1.68 (2H, m), 1.96-2.08 (2H, m), 2.35-2.65 (8H,m), 5.28 (2H, brs), 6.10 (1H, t), 6.78 (1H, m), 7.08-7.40 (6H, m), 7.52(1H, dd), 7.62 (1H, s), 8.44 (1H, dd).

MS m/z: 582(M+1)

Step 2

To a solution of the product of Step 1 (300 mg) in DMF (3 ml) was addedammonium hydroxide (1.5 ml) and the mixture was stirred at roomtemperature for 2 hours. Ethyl acetate and water were added to themixture, the organic layer was separated and washed with saturatedaqueous sodium chloride, and dried with magnesium sulfate. The solventwas distilled off under reduced pressure. The residue was purified bysilica gel chromatography eluting with (chloroform:methanol=10:1) togive the titled compound (140 mg).

¹H-NMR (DMSO-d6) δ: 1.45-1.50 (2H, m), 1.72-1.88 (2H, m), 2.28-2.51 (8H,m), 4.82 (1H, s), 5.19 (1H, brs), 5.74 (2H, brs), 6.09 (1H, t), 6.69(1H, d), 7.12 (1H, dd), 7.32-7.48 (6H, m), 7.74 (1H, dd), 8.37 (1H, s),8.50 (1H, dd).

MS m/z: 505(M+1)

Example 3864-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-morpholinocarbonylamino[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example385, step 2, but replacing ammonium hydroxide with morpholine.

¹H-NMR (CDCl₃) δ: 1.62-1.67 (2H, m), 1.95-2.16 (2H, m), 2.28-2.64 (8H,m), 3.41 (4H, t), 3.69 (4H, t), 5.26 (2H, brs), 6.08 (1H, t), 6.69-6.76(2H, m), 6.98 (1H, dd), 7.21-7.51 (7H, m), 8.42 (1H, dd).

MS m/z: 575(M+1)

Example 3874-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-(2-ethoxy)carbonylethyl)ureido[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example385, step 2, but replacing ammonium hydroxide with beta-alanine ethylester hydrochloride.

¹H-NMR (CDCl₃) δ: 1.18-1.39 (3H, t), 1.62-1.66 (2H, m), 1.92-2.01 (2H,m), 2.21-2.62 (10H, m), 3.47-3.50 (2H, m), 4.08 (2H, q), 5.22 (2H, brs),5.98-6.03 (2H, m), 6.68-6.92 (2H, m), 7.15-7.42 (7H, m), 7.62 (1H, s),8.36 (1H, dd).

MS m/z: 605(M+1)

Example 3881-[3-(7-(E)-(2-Carboxy-1-methyl)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(7-(E)-(2-ethoxycarboxy-1-methyl)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of Example 411, but replacingethyl cyanoformate with ethyl (trimethylsilyl)acetate.

¹H-NMR (CDCl₃) δ: 1.30 (3H, t), 1.67-1.72 (3H, m), 1.98-2.05 (2H, m),2.42-2.67 (11H, m), 4.23 (2H, q), 5.36 (2H, brs), 6.14-6.19 (2H, m),6.85 (1H, d), 7.20-7.61 (8H, m), 8.52 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of Example133, but replacing the product of Example 48 with the product of step 1.

¹H-NMR (DMSO-d₆) δ: 1.50-1.55 (2H, m), 1.87-1.99 (2H, m), 2.34-2.61(11H, m), 5.29 (2H, brs), 6.12 (1H, s), 6.31 (1H, t), 6.83 (1H, d),7.35-7.49 (7H, m), 7.76 (1H, dd), 8.52 (1H, dd).

MS m/z: 530(M+1)

Example 3894-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-oxalo[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example361, but replacing methyl succinyl chloride with methyl oxalyl chloride.

¹H-NMR (DMSO-d₆) δ: 1.66-1.86 (2H, m), 2.08-2.34 (2H, m), 2.46-2.77 (2H,m), 3.00-3.68 (6H, m), 5.10 (2H, brs), 5.53 (1H, s), 6.15 (1H, t), 6.89(1H, d), 7.34-7.49 (5H, m), 7.68 (1H, dd), 7.75 (1H, dd), 7.87 (1H, d),8.53 (1H, dd).

MS m/z: 519(M+1)

Example 3901-[3-(7-(3-(2-Carboxy)ethyl)ureido-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of Example133, but replacing the product of Example 48 with the product of Example387.

¹H-NMR (DMSO-d6) δ: 1.45-1.55 (2H, m), 1.72-1.85 (2H, m), 2.32-2.49(10H, m), 3.29 (2H, q), 4.88 (1H, s), 5.19 (2H, brs), 6.06-6.14 (2H, m),6.69 (1H, d), 7.07 (1H, dd), 7.33-7.48 (6H, m), 7.73 (1H, dd), 8.43 (1H,s), 8.49 (1H, dd).

MS m/z: 577(M+1)

Example 3911-[3-(7-(3-(2-Hydroxy)ethyl)ureido-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of Example385, step 2, but replacing ammonium hydroxide with 2-aminoethanol.

¹H-NMR (DMSO-d6) δ: 1.45-1.51 (2H, m), 1.72-1.84 (2H, m), 2.24-2.51 (8H,m), 3.11-3.46 (4H, m), 4.71 (1H, t), 4.83 (1H, s), 5.19 (2H, brs), 6.08(1H, t), 6.69 (1H, d), 7.08 (1H, dd), 7.33-7.48 (6H, m), 7.73 (1H, dd),8.41 (1H, s), 8.50 (1H, dd).

MS m/z: 549(M+1)

Example 3921-[3-(5,11-Dihydro-7-(1-hydroxy-1-methyl)ethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-keto-1-imidazolinyl)piperidine

The titled compound was prepared by following the procedure of Example67, but replacing the product of Example 45, step 2 with the product ofExample 363, step 1.

¹H-NMR (CDCl₃) δ: 1.59 (6H, s), 1.71-1.87 (2H, m), 2.01-2.18 (2H, m),2.28-2.61 (6H, m), 2.86-3.00 (2H, m), 4.32 (1H, m), 5.36 (2H, brs), 6.15(1H, t), 6.84 (1H, d), 7.02-7.07 (3H, m), 7.24-7.31 (3H, m), 7.47 (1H,d), 7.60 (1H, dd), 8.51 (1H, dd), 8.97 (1H, s).

MS m/z: 511(M+1)

Example 3934-(4-Chlorophenyl)-1-[3-(7-(E)-(2-ethoxycarboxy-2-methyl)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of sodium hydride (60% in oil, 100 mg) in THF (6 ml) wereadded triethyl 2-phosphonopropionate (0.3 ml) and the product of Example314 (300 mg) at 0° C., and the mixture was stirred at room temperaturefor 30 minutes. Water and ethyl acetate were added to the reactionmixture. The organic layer was extracted, and the solvent was distilledoff under reduced pressure. The residue was purified by silica gelchromatography eluting with chloroform-methanol (30:1) to give thetitled compound (310 mg).

¹H-NMR (CDCl₃) δ: 1.34 (3H, t), 1.58-1.71 (3H, m), 1.98-2.15 (5H, m),2.37-2.70 (8H, m), 2.27 (2H, q), 5.37 (2H, brs), 6.14 (1H, t), 6.86 (1H,d), 7.25-7.44 (7H, m) 7.58-7.63 (2H, m), 8.52 (1H, dd).

MS m/z: 559(M+1)

Example 3941-[3-(7-(E)-(2-Carboxy-2-methyl)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of Example133, but replacing the product of Example 48 with the product of step 1.

¹H-NMR (DMSO-d6) δ: 1.62-1.67 (2H, m), 1.91-2.05 (5H, m), 2.50-2.94 (8H,m), 5.28 (2H, brs), 6.23 (1H, t), 6.87 (1H, d), 7.34-7.55 (8H, m), 7.79(1H, dd), 8.54 (1H, dd).

MS m/z: 531(M+1)

Example 3951-[3-(7-(5-Carboxy-1-pentyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(7-(5-ethoxycarbonyl-1-pentyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of Example 46, but replacingethyl iodide with ethyl 6-bromohexanoate.

¹H-NMR (CDCl₃) δ: 1.21 (3H, t), 1.42-1.79 (8H, m), 1.98-2.03 (2H, m),2.26-2.67 (10H, m), 3.87 (2H, t), 4.16 (2H, q), 5.23 (2H, brs), 6.09(1H, t), 6.67-6.81 (3H, m), 7.21-7.63 (6H, m), 8.16 (1H, dd).

Step 2

The titled compound was prepared by following the procedure of Example133, but replacing the product of Example 48 with the product of step 1.

¹H-NMR (DMSO-d6) δ: 1.41-1.95 (10H, m), 2.20-2.72 (10H, m), 3.92 (2H,t), 5.18 (2H, brs), 6.17 (1H, t), 6.72-6.84 (3H, m), 7.36-7.48 (5H, m),7.77 (1H, dd), 8.50 (1H, dd).

MS m/z: 577(M+1)

Example 3961-[3-(7-(1-(2-Carboxy)ethyl)aminocarbonyl-1-methyl)ethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

4-(4-Chlorophenyl)-1-[3-(7-(1-(2-ethoxycarbonyl)ethyl)aminocarbonyl-1-methyl)ethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-olwas prepared by following the procedure of Example 176, but replacingdimethylamine hydrochloride with beta-alanine ethyl ester hydrochloride.

¹H-NMR (CDCl₃) δ: 1.42 (3H, s), 1.62-1.67 (2H, m), 1.95-2.10 (3H, m),2.35-2.59 (10H, m), 3.51-3.53 (2H, m), 4.00 (2H, q), 5.23 (2H, brs),6.00 (1H, t), 6.68-6.81 (3H, m), 7.24-7.56 (6H, m), 8.39 (1H, dd).

Step 2

The title compound was prepared by following the procedure of Example133, but replacing the product of Example 48 with the product of step 1.

¹H-NMR (DMSO-d₆) δ: 1.37 (6H, s), 1.41-1.52 (2H, m), 1.79-1.87 (2H, m),2.28-2.41 (10H, m), 3.33 (2H, q), 5.21 (2H, brs), 6.12 (1H, t),6.70-6.87 (3H, m), 7.34-7.48 (5H, m), 7.74 (1H, dd), 8.08 (1H, t), 8.50(1H, dd).

MS m/z: 620(M+1)

Example 3974-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(thiazoline-2,4-dione-5-ylidene)methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of Example 314 (590 mg) in ethanol (6 ml)were added 2,4-thiazolinedione (440 mg) and piperidine (0.36 ml), andthe mixture was heated to reflux for 3 hours. The solvent was distilledoff under reduced pressure, and, chloroform, 2-propanol and water wereadded. The organic layer was extracted, and the solvent was distilledoff under reduced pressure. The residue was purified by silica gelchromatography eluting with chloroform-methanol (5:1) to give the titledcompound (510 mg).

¹H-NMR (DMSO-d6) δ: 1.61-1.66 (2H, m), 1.97-2.12 (2H, m), 2.79-2.99 (8H,m), 5.21 (2H, brs), 6.25 (1H, t), 6.90 (1H, d), 7.34-7.52 (7H, m), 7.81(1H, dd), 8.54 (1H, dd).

MS m/z: 574(M+1)

Example 3984-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methanesulfonamido[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example402, but replacing trifluoromethanesulfonic acid anhydride withmethanesulfony chloride.

¹H-NMR (CDCl₃) δ: 1.64-1.69 (2H, m), 1.89-2.05 (2H, m), 2.24-2.77 (8H,m), 2.95 (3H, s), 5.29 (2H, brs), 6.10 (1H, t), 6.84 (1H, d), 7.06 (1H,dd), 7.18-7.40 (6H, m), 7.56 (1H, dd), 8.42 (1H, dd).

MS m/z: 540(M+1)

Example 3994-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-phenylureido)sulfonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example320, but replacing compound of Example 44, step 2 with compound ofExample 368, step 2.

¹H-NMR (DMSO-d₆) δ: 1.65-1.69 (2H, m), 1.95-2.05 (2H, m), 2.89-3.06 (8H,m), 5.31 (2H, brs), 6.14 (1H, t), 6.74-6.85 (2H, m), 7.08-7.12 (2H, m),7.37-7.64 (8H, m), 7.80-7.84 (2H, m), 8.44 (1H, s), 8.54 (1H, dd).

MS m/z: 645(M+1)

Example 4004-(4-Chlorophenyl)-1-[3-(7-(3-cyclohexylureido)sulfonyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example399, but replacing phenyl isocyanate with cyclohexyl isocyanate.

¹H-NMR (DMSO-d₆) δ: 1.07-1.81 (14H, m), 2.23-2.58 (8H, m), 3.22-3.35(1H, m), 4.91 (1H, s), 5.38 (2H, brs), 6.17-6.29 (2H, m), 6.96 (1H, d),7.34-7.51 (5H, m), 7.62-7.84 (3H, m), 8.53 (114, dd).

MS m/z: 651(M+1)

Example 4014-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-propylureido)sulfonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example399, but replacing phenyl isocyanate with propyl isocyanate.

¹H-NMR (DMSIO-d6) δ: 0.74 (3H, t), 1.25-1.53 (4H, m), 1.81-1.91 (2H, m),2.33-2.59 (10H, m), 2.89 (211, q), 4.92 (1H, s), 5.35 (2H, brs), 6.20(1H, t), 6.44 (1H, brs), 6.96 (1H, d), 7.34-7.51 (5H, m), 7.64 (1H, dd),7.78-7.85 (2H, m), 8.54 (1H, dd).

MS m/z: 611(M+1)

Example 4024-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-trifluoromethanesulfonamido[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The title compound was prepared by following the procedure of Example169, but replacing the product of Example 44, step 2 with the product ofExample 381.

¹H-NMR (DMSO-d₆) δ: 1.75-1.80 (2H, m), 2.02-2.07 (2H, m), 2.49-2.54 (2H,m), 3.10-3.40 (6H, m), 5.15 (2H, brs), 5.52 (1H, s), 5.97 (1H, t), 6.58(1H, d), 6.80 (1H, dd), 6.96 (1H, d), 7.43-7.47 (5H, m), 7.78 (1H, dd),8.51 (1H, dd).

MS m/z: 593(M+1)

Example 4031-[3-(7-(3-carboxy)propyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-olStep 1

To a solution of the product of Example 361, step 1 (820 mg) in TFA (8.0ml) was added triethyl silane (0.92 ml) at 0° C., and the mixturestirred at room temperature for 4 hour. The solvent was distilled offunder reduced pressure. The residue was poured into saturated aqueoussodium bicarbonate, and the aqueous layer was extracted with ethylacetate. The organic layer was washed with saturated aqueous sodiumchloride, and dried with magnesium sulfate. The solvent was distilledoff under reduced pressure. The residue was purified by silica gelchromatography eluting with ethyl acetate-hexane (1:4) to give4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-methoxycarbonyl)propyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol(636 mg).

¹H-NMR (CDCl₃) δ: 1.93 (2H, m), 2.34 (2H, t), 2.59 (2H, t), 2.74 (2H,q), 3.47 (2H, t), 3.67 (3H, s), 5.33 (2H, brs), 6.05 (1H, t), 6.78 (1H,d), 7.00 (1H, dd), 7.09 (1H, d), 7.29 (1H, dd), 7.57 (1H, dd), 8.52 (1H,dd).

Step 2

The titled compound was prepared by following the procedure of Example133, but replacing the product of Example 48 with the product of step 1.

¹H-NMR (DMSO-d₆) δ: 1.37-1.57 (2H, m), 1.63-1.87 (4H, m), 2.10-2.36 (6H,m), 2.36-2.61 (6H, m), 4.83 (1H, brs), 5.24 (2H, brs), 6.14 (1H, t),6.72 (1H, d), 7.00 (1H, dd), 7.12 (1H, d), 7.35 (2H, d), 7.41-7.48 (3H,m), 7.73 (1H, dd), 8.49 (1H, dd).

MS m/z: 533(M+1)

Example 4041-[3-(7-Benzoylsulfamoyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure of Example399, but replacing phenyl isocyanate with benzoyl chloride.

MS m/z: 630(M+1)

Example 4054-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)methyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of Example 407 (1.7 g) in DMF (20 ml) wasadded 2-ethylhexyl chloroformate (0.62 ml) and the mixture was stirredat 0° C. for 1 hour. Chloroform and water were added to the reactionmixture. The organic layer was extracted, and the solvent was distilledoff under reduced pressure. The residue was purified by silica gelchromatography eluting with chloroform-methanol (30:1) and dissolved inxylene (50 ml). The solution was heated to reflux for 4 hours. Thesolvent was distilled off under reduced pressure. The residue wasreslurried with ethanol to the titled compound (490 mg).

¹H-NMR (DMSO-d6) δ: 1.60-1.65 (2H, m), 1.91-1.99 (2H, m), 2.41-2.52 (2H,m), 2.70-2.89 (6H, m), 4.90 (2H, s), 5.19 (2H, brs), 6.16 (1H, t),6.75-7.05 (3H, m), 7.37-7.48 (5H, m), 7.75 (1H, dd), 8.52 (1H, dd).

MS m/z: 561(M+1)

Example 4064-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example405, but replacing the product of Example 407 with the product ofExample 408.

¹H-NMR (DMSO-d6) δ: 1.58-1.63 (2H, m), 1.87-1.96 (2H, m), 2.40-2.51 (2H,m), 2.63-2.85 (6H, m), 5.14 (2H, brs), 6.23 (1H, t), 6.92 (1H, d),7.36-7.62 (6H, m), 7.77-7.81 (2H, m), 8.54 (1H, dd).

MS m/z: 531(M+1)

Example 4074-(4-Chlorophenyl)-1-[3-(7-hydroxyamidinomethoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example355, but replacing the product of Example 313 with the product ofExample 49.

¹H-NMR (DMSO-d6) δ: 1.45-1.50 (2H, m), 1.70-1.82 (2H, m), 2.27-2.51 (8H,m), 4.37 (2H, s), 4.83 (1H, s), 5.20 (1H, brs), 5.57 (2H, brs), 6.17(1H, t), 6.72-6.94 (3H, m), 7.33-7.48 (5H, m), 7.72 (1H, dd), 8.49 (1H,dd), 9.26 (1H, s).

MS m/z: 535(M+1)

Example 4084-(4-Chlorophenyl)-1-[3-(7-hydroxyamidino-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

The titled compound was prepared by following the procedure of Example355, but replacing the product of Example 313 with the product ofExample 364.

¹H-NMR (DMSO-d6) δ: 1.45-1.50 (2H, m), 1.73-1.81 (2H, m), 2.28-2.51 (8H,m), 4.83 (1H, s), 5.79 (2H, brs), 6.25 (1H, t), 6.81 (1H, d), 7.33-7.49(6H, m), 7.63-7.76 (2H, m), 8.51 (1H, dd), 9.48 (1H, s).

MS m/z: 505(M+1)

Example 409 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl)methyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of Example 407 (700 mg) in THF (20 ml) wereadded pyridine (0.21 ml) and thionyl chloride (0.1 ml) at 0° C., and themixture was stirred at 0° C. for 1 hour and the mixture was stirred atroom temperature for 30 minutes. Water, chloroform and 2-propanol wereadded to the reaction mixture. The organic layer was extracted and thesolvent was distilled off under reduced pressure. The residue waspurified by silica gel chromatography eluting with chloroform-methanol(5:1) to give the titled compound (170 mg).

MS m/z: 581(M+1)

Example 4104-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl)methyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of Example 407 (700 mg) in THF (20 ml) wasadded thiocarbonyldiimidazole (280 mg) and the mixture was stirred atroom temperature for 30 minutes. Water and ethyl acetate were added tothe reaction mixture. The organic layer was extracted, and the solventwas distilled off under reduced pressure. To the residue were added THF(50 ml) and boron trifluoride diethyl etherate (0.8 ml), and the mixturewas stirred at room temperature for 1 hour. Chloroform, 2-propanol andwater were added to the reaction mixture. The organic layer wasextracted, and the solvent was distilled off under reduced pressure. Theresidue was reslurried with acetone to the titled compound (180 mg).

MS m/z: 577(M+1)

Example 4114-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxycarbonylacetyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol

To a solution of the product of Example 315 (250 mg) in THF (3.0 ml) wasadded LDA (0.51 mol/L THF-hexane solution, 3.0 ml) at −78° C., and themixture stirred at room temperature for 20 minutes. The reaction mixturewas cooled to −78° C. again, and added ethyl cyanoformate (76 μl),stirred at room temperature for 1 hour. Saturated aqueous ammoniumchloride and aqueous sodium chloride were added to the mixture, and theaqueous layer was extracted with ethyl acetate. The organic layer waswashed with saturated aqueous sodium chloride, and dried with magnesiumsulfate. The solvent was distilled off under reduced pressure. Theresidue was purified by silica gel chromatography eluting withchloroform-methanol (10:1) to give the titled compound (280 mg).

¹H-NMR (CDCl₃) δ: 1.26 (3H, t), 1.67-1.85 (2H, m), 1.93-2.13 (2H, m),2.28-2.47 (4H, m), 2.47-2.60 (2H, m), 2.60-2.76 (2H, m), 3.94 (2H, s),4.21 (2H, q), 5.60 (2H, brs), 6.22 (1H, t), 6.88 (1H, d), 7.29-7.34 (3H,m), 7.43 (2H, d), 7.59 (1H, d), 7.71 (1H, dd), 7.97 (1H, d), 8.53 (1H,d).

MS m/z: 561(M+1)

Example 4124-(4-fluorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

To a solution of5-(3-bromopropylidene)-5,11-dihydro-7-hydroxy-[1]benzoxepino[2,3-b]pyridine(2.59 g) in DMF (10 ml) was added 4-(4-Fluorophenyl)-4-hydroxypiperidine(1.02 g) and triethylamine (835 μM). The solution was stirred at roomtemperature for 23 hours. The reaction was quenched with water,extracted with ethyl acetate, and evaporated in vacuo. The residue waspurified by silica gel chromatography (87:10:3 ethylacetate:methanol:triethylamine) to yield 0.9 g (39%) of the titlecompound. ¹H-NMR (DMSO) d: 1.64-1.69 (2H, m), 1.74-1.85 (2H, m),2.27-2.52 (8H, m), 4.81 (1H, s), 5.16 (2H, brs), 6.08 (1H, t), 6.62-6.71(3H, m), 7.12 (2H, t), 7.40-7.51 (3H, m), 7.72 (1H, dd), 8.48 (1H, dd),9.09 (1H, s).

ESI-MS m/z: 447 (M+1).

Example 4134-(4-fluorophenyl)-1-[3-(5,11-dihydro-7-carboxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of example118, but replacing the compound of Example 169 with the triflate derivedfrom compound 412.

¹H-NMR (MeOD) δ: 1.78-1.85 (2H, m), 2.25-2.40 (2H, m), 2.57-2.70 (2H,m), 3.06-3.35 (7H, m), 5.06-5.81 (2H, brs), 6.23 (1H, t), 6.77 (1H, d),7.00-7.11 (2H, m), 7.37-7.56 (3H, m), 7.65-7.80 (2H, m), 8.01 (1H, d),8.48 (1H, dd).

MS m/z: 475

Example 4144-(4-fluorophenyl)-1-[3-(5,11-dihydro-7-(1-hydroxy-1-methylethyl)-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example27, but starting with the methyl ester of the compound of Example 413.

¹H-NMR (CDCl₃) δ: 1.57-2.14 (12H, m), 2.34-2.45 (4H, m), 2.50-2.61 (2H,m), 2.63-2.78 (2H, m), 5.22-5.43 (2H, brs), 6.14 (1H, t), 6.95-7.10 (2H,m), 7.25-7.35 92H, m), 7.40-7.60 (4H, m), 8.50 (1H, dd).

MS m/z: 489

Example 4154-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-diethylcarbamoyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example316, but replacing dimethylamine with diethylamine.

¹H-NMR (CDCl₃) δ: 1.18-1.30 (6H, m), 1.65 (2H, d), 1.80 (1H, s), 2.05(2H, dt), 2.30-2.45 (4H, m), 2.50 (2H, t), 2.60-2.70 (2H, m), 3.35-3.50(4H, m), 5.30 (2H, brs), 6.15 (1H, t), 6.83 (1H, d), 6.90 (1H, dd), 7.10(1H, dd), 7.23-7.35 (3H, m), 7.40 (2H, d), 7.56 (1H, dd), 8.50 (1H, dd).

MS m/z: 563

Example 4164-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-phenylsulfonylcarbamoyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

To a solution of the compound of Example 44 (0.511 g, 1.1 mmol) in dryTHF (20 mL) was added sodium hydride (60% in mineral oil, 48 mg, 1.2mmol), and the slurry heated at 40° C. under argon with stirring for 20minutes. Phenylsulfonylisocyanate (160 μL, 1.2 mmol) was added and themixture was stirred for 14 hours. The solvent was then removed by rotaryevaporation to give the crude product. The solid material was washedtwice with 20 mL CH₂Cl₂, and then twice with 20 mL MeoH: CH₂Cl₂ (1:1) togive the title compound (274 mg).

MS m/z: 647

Example 4174-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxycarbonyl-carbamoyl-[1]benzoxepono[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

To a solution of the compound of Example 44 (0.214 g, 0.46 mmol) in dryTHF (5 mL) was added sodium hydride (60% in mineral oil, 28 mg, 0.7mmol), and the slurry heated at 50° C. under argon with stirring for 20minutes. Methyl isocyanatoformate (56 μl, 0.7 mmol) was added and themixture was stirred for 14 hours. The solvent was then removed by rotaryevaporation to give the crude product. The residue was purified bysilica gel chromatography eluting with a dichloromethane/2.0 M ammoniain methanol gradient (0 to 4% MeOH over 1 hour) to give the titlecompound (102 mg).

¹H-NMR (CDCl₃) δ: 1.60-1.65 (2H, m), 1.80 (1H, s), 2.05 (2H, dt),2.30-2.45 (4H, m), 2.50 (2H, t), 2.60-2.70 (2H, m), 3.35 (3H, s), 5.30(2H, brs), 6.15 (1H, t), 6.83 (1H, d), 6.90 (1H, dd), 7.10 (1H, dd),7.23-7.35 (3H, m), 7.40 (2H, d), 7.56 (1H, dd), 8.50 (1H, dd).

MS m/z: 565

Example 4184-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(R-3-ethoxycarbonyl-piperidine-1-yl)-carbamoyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol Step 1

R-ethyl nipecotate-L-tartrate (1.53 g) was freebased with aqueous sodiumhydroxide and ethyl acetate. The organic layers were evaporated, and theresulting amine was redissolved in THF (10 mL) and treated withcarbonyl-diimidazole (0.81 g). The resulting solution was stirred atroom temperature for 23 hours, concentrated in vacuo, and redissolved inacetonitrile (5 mL). This solution was treated with methyl iodide (0.347mL) and stirred for 18 hours at room temperature.

Step 2

The compound of Example 44 (0.7 g) was suspended in THF (25 mL) andtreated with sodium hydride (0.036 g) and stirred at room temperaturefor one hour. The resulting anion was added to the imidazolium saltprepared in Step 1, and the solution was heated to reflux for 18 hr. Thecrude material was then loaded on silica gel and purified by silica gelchromatography (87:10:3 ethyl acetate:methanol:triethylamine) to yield0.278 g (64%) of the title compound.

¹H-NMR (DMSO) δ: 1.11-1.21 (3H, m), 1.45-2.0 (8H, m), 2.15-2.40 (6H, m),3.05-3.15 (2H, m), 3.31 (2H, m), 3.95-4.15 (3H, m), 5.31 (2H, brs), 6.14(1H, t), 6.78 (1H, d), 6.92 (1H, dd), 7.05 (1H, d), 7.33 (2H, d),7.42-7.47 (3H, m), 7.72 (1H, dd), 8.50 (1H, dd).

ESI-MS m/z: 646 (M+1).

Example 4194-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(R-3-ethoxycarbonyl-piperidine-1-yl)-carbamoyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The compound of Example 418 (0.195 g) was dissolved in THF (1 mL) andtreated with aqueous lithium hydroxide (0.0084 g) and stirred at roomtemperature for 18 hours. The resulting solution was concentrated invacuo, and the residue was purified by chromatography on a reverse-phasesolid-phase-extraction column, eluting with water-acetonitrile, 0.1%formic acid, to yield 0.153 g (77%) of the title compound.

¹H-NMR (DMSO) δ: 1.55-2.25 (8H, m), 2.30-2.80 (10H, m), 3.22 (1H, m),4.15-4.35 (2H, m), 5.41 (2H, brs), 6.35 (1H, t), 6.98 (1H, d), 7.13 (1H,dd), 7.25 (1H, d), 7.54 (2H, d), 7.64 (3H, m), 7.90 (1H, dd), 8.50 (1H,s), 8.70 (1H, dd).

ESI-MS m/z: 618 (M+1).

Example 4204-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(4-ethoxycarbonyl-piperidine-1-yl)-carbamoyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example418, but replacing R-ethyl nipecotate-L-tartrate with ethylisonipecotate.

¹H-NMR (CDCl₃) δ: 1.25 (3H, t), 1.60-1.80 (4H, m), 1.90-2.05 (4H, m),2.25-2.65 (10H, m), 2.90-3.15 (2H, m), 4.05-4.25 (4H, m), 5.30 (2H,brs), 6.15 (1H, t), 6.75-6.90 (2H, m), 7.05 (1H, d), 7.20-7.40 (3H, m),7.40 (2H, d), 7.56 (1H, dd), 8.45 (1H, dd).

MS m/z: 647

Example 4214-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(4-carboxy-piperidine-1-yl)-carbamoyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene) propyl]piperidine-4-ol

A solution of the compound of Example 420 (91 mg, 0.14 mmol) in MeOH (5mL) was treated with a 0.4 M solution of lithium hydroxide (5 mL, 2mmol) and stirred for 3 hours. After addition of 5 mL of 0.4 N HCl, thesolvent was removed under reduced pressure to give the crude product.The residue was purified using silica gel chromatography eluting with adichloromethane:methanol gradient (0 to 50% MeOH over 1 hour) to givethe title compound (48 mg).

¹H-NMR (MeOD) δ: 1.60-1.65 (2H, m) 2.10-2.70 (10H, m), 5.30 (2H, brs),6.15 (1H, t), 6.80-6.90 (2H, m), 7.20-7.50 (6H, m), 7.62 (1H, dd), 8.48(1H, dd).

MS m/z: 619

Example 4224-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(S-3-ethoxycarbonyl-piperidine-1-yl)-carbamoyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example418, but replacing R-ethyl nipecotate-L-tartrate with ethyl(S)-nipecotate-D-tartrate.

¹H-NMR (CDCl₃) δ: 1.25 (3H, t), 1.30-1.70 (5H, m), 1.94-2.05 (3H, m),2.25-2.65 (11H, m), 3.05-3.15 (1H, m), 4.05-4.25 (4H, m), 5.30 (2H,brs), 6.15 (1H, t), 6.75-6.90 (2H, m), 7.05 (1H, d), 7.20-7.40 (3H, m),7.40 (2H, d), 7.56 (1H, dd), 8.45 (1H, dd).

MS m/z: 647

Example 4234-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The compound of Example 169 (0.166 g) was dissolved in DMF (1 mL) andtreated with palladium (II) acetate (0.007 g),1,3-bis-diphenylphosphinopropane (0.012 g), triethylamine (0.1 mL) andethanol (1 mL), and stirred at 60° C. for 18 hours under a CO balloon.The resulting solution was quenched with water, extracted with ethylacetate, concentrated in vacuo, and purified by silica gelchromatography (87:10:3 ethyl acetate:methanol:triethylamine). Theresidue was further purified by chromatography on a reverse-phasesolid-phase-extraction column, eluting with water-acetonitrile, 0.1%formic acid, to yield 0.114 g (73%) of the title compound.

¹H-NMR (DMSO) δ: 1.28 (3H, t), 1.40-1.55 (2H, m), 1.71-1.85 (2H, m),2.20-2.60 (6H, m), 3.22 (2H, m), 4.28 (2H, q), 5.00-5.60 (2H, brs), 6.21(1H, t), 6.92 (1H, d), 7.40-7.80 (8H, m), 8.50 (1H, d).

ESI-MS m/z: 519 (M+1).

Example 4244-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(ethoxycarbonylmethyl)-oxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The procedure of Example 423 was followed, but replacing ethanol withethyl glyoxylate to yield 0.041 g (26%) of the title compound.

¹H-NMR (DMSO) δ: 1.10-1.30 (3H, m), 1.35-1.55 (2H, m), 1.60-1.85 (2H,m), 2.20-2.60 (6H, m), 3.32 (2H, m), 4.05-4.25 (2H, m), 4.87 (2H, s),5.00-5.60 (2H, brs), 6.21 (1H, t), 6.92 (1H, d), 7.2-7.90 (8H, m), 8.50(1H, d).

ESI-MS m/z: 577 (M+1).

Example 4254-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-cyclohexyloxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The procedure of Example 423 was followed, but replacing ethanol withcyclohexanol to yield 0.050 g (32%) of the title compound.

¹H-NMR (MeOD) δ: 1.30-2.20 (14H, m), 2.53-2.60 (2H, m), 2.95-3.32 (6H,m), 5.00 (1H, m), 5.00-5.60 (2H, brs), 6.28 (1H, t), 6.92 (1H, d),7.40-7.55 (8H, m), 7.95 (2H, m), 8.05 (1H, s), 8.50 (2H, m).

ESI-MS m/z: 573 (M+1).

Example 4264-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-propoxy)carbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

To a solution of the compound of Example 118 (109 mg, 0.22 mmol) in dryDMF (5 mL) was added potassium carbonate (91 mg) followed by propyliodide (24 μL, 0.66 mmol). The mixture was heated to 55° C. for 14hours. The mixture was diluted with ethyl acetate (200 mL), washed twicewith water (200 mL) and then with brine (100 mL), and dried with sodiumsulfate. The organic solvent was removed under reduced pressure and theresidue subjected to silica gel chromatography using adichloromethane:methanol gradient (0 to 5% MeOH over 1 hour) to give thetitle compound (103 mg).

¹H-NMR (CDCl₃) δ: 1.06 (3H, t), 1.50-2.10 (4H, m), 2.14-2.25 (2H, m),2.31-2.75 (10H, m), 4.28 (2H, t), 6.15 (1H, t), 6.83 (1H, d), 7.24-7.38(3H, m), 7.42 (2H, d), 7.59 (1H, dd), 7.78 (1H, dd), 8.00 (1H, d), 8.50(1H, dd).

MS m/z: 533

Example 4274-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-butoxy)carbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The procedure of Example 423 was followed, but replacing ethanol withn-butanol to yield 0.065 g (45%) of the title compound.

¹H-NMR (MeOD) δ: 0.85-0.91 (3H, m), 1.25-1.45 (2H, m), 1.55-1.70 (2H,m), 1.70-1.85 (2H, m), 2.10-2.28 (2H, m), 2.53-2.60 (2H, m), 3.15-3.38(6H, m), 4.12-4.21 (2H, m), 5.00-5.60 (2H, brs), 6.10 (1H, t), 6.76 (1H,d), 7.22-7.40 (3H, m), 7.71 (1H, m), 7.95 (1H, m), 8.05 (1H, s), 8.30(1H, s), 8.41 (1H, m).

ESI-MS m/z: 547 (M+1).

Example 4284-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-propoxy)carbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example426, but replacing propyl iodide with 2-bromopropane.

¹H-NMR (CDCl₃) δ: 1.30-2.10 (8H, m), 2.14-2.25 (2H, m), 2.31-2.75 (10H,m), 5.15-5.60 (2H, m), 6.15 (1H, t), 6.83 (1H, d), 7.24-7.38 (3H, m),7.44 (2H, d), 7.59 (1H, dd), 7.80 (1H, dd), 8.02 (1H, d), 8.50 (1H, dd).

MS m/z: 533

Example 4294-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-cyclopentyl-oxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example426, but replacing propyl iodide with cyclopentyl bormide.

¹H-NMR (MeOD) δ: 1.23-1.33 (1H, m), 1.50-2.04 (10H, m), 2.27-2.41 (2H,m), 2.70-2.90 (2H, m), 3.30-3.62 (5H, m), 5.21-5.85 (3H, m), 6.15 (1H,t), 6.85 (1H, d), 7.38 (2H, d), 7.42 (2H, d), 7.60-7.82 (2H, m), 8.04(1H, d), 8.61 (1H, dd).

MS m/z: 559

Example 4304-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-morpholinoethyl-1-yl)-oxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example426, but replacing propyl iodide with 2-morpholinoethyl chloride.

¹H-NMR (CDCl₃) δ: 1.62-1.70 (2H, m) 1.90-2.13 (2H, m), 2.30-2.80 (14H,m), 3.62-3.75 (4H, m), 4.41 (2H, t), 5.11-5.62 (2H, brs), 6.19 (1H, t),6.83 (1H, d), 7.23-7.38 (3H, m), 7.42 (2H, d), 7.59 (1H, dd), 7.78 (1H,dd), 8.00 (1H, d), 8.50 (1H, dd).

MS m/z: 604

Example 4314-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2,2-diethylaminoethyl-1-yl)-oxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The titled compound was prepared by following the procedure of Example426, but replacing propyl iodide with 2-(N,N-diethylamino)ethylchloride.

¹H-NMR (CDCl₃) δ: 1.06 (6H, t), 1.62-1.71 (2H, m), 1.93-2.10 (2H, m),2.30-2.75 (12H, m), 2.85 (2H, t), 4.38 (2H, t), 5.20-5.58 (2H, brs),6.15 (1H, t), 6.83 (1H, d), 7.24-7.38 (3H, m), 7.42 (2H, d), 7.59 (1H,dd), 7.78 (1H, dd), 8.00 (1H, d), 8.50 (1H, dd).

MS m/z: 590

Example 4324-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-2,2-dimethylpropionyl-oxymethyl)-oxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The procedure of Example 426 was followed, but replacing withchloromethyl pivalate to yield 0.36 g (77%) of the title compound.

¹H-NMR (CDCl₃) δ: 1.18 (9H, s), 1.58-1.72 (2H, m), 1.85-2.85 (10H, m),5.00-5.60 (2H, brs), 5.94 (2H, s), 6.17 (1H, t), 6.82 (1H, d), 7.22-7.42(5H, m), 7.56 (1H, dd), 7.80 (1H, dd), 7.99 (1H, d), 8.05 (1H, d), 8.46(1H, dd).

ESI-MS m/z: 605 (M+1).

Example 4334-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxyethyl-1-yl)-oxycarbonyl-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine-4-ol

The procedure of Example 423 was followed, but replacing ethanol withethylene glycol to yield 0.076 g (42%) of the title compound.

¹H-NMR (MeOD) δ: 1.80-2.00 (4H, m), 2.25-2.35 (2H, m), 2.55-2.65 (2H,m), 3.15-3.45 (5H, m), 3.75 (2H, dd), 4.24 (2H, dd), 5.00-5.60 (2H,brs), 6.10 (1H, t), 6.76 (1H, d), 7.18-7.42 (5H, m), 7.71 (2H, m), 7.99(1H, m), 8.05 (1H, s), 8.30 (1H, s), 8.41 (1H, m).

ESI-MS m/z: 535 (M+1).

Example 4345-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-olStep 1: 3-Methyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester

In a Parr shaker flask, 1-benzyl-3-methyl-4-piperidone (19 g, 93 mmol),di-tert-butyl dicarbonate (27 g, 121 mmol) and palladium hydroxide (2.6g) were suspended in methanol (75 mL) and then purged with argon. Thereaction mixture was then purged with hydrogen and placed on a Parrshaker apparatus for about 16 hours at about 44 psi of hydrogen. Thecatalyst was filtered over celite and washed with methanol. The crudeproduct was chromatographed on silica gel, eluting with EtOAc/hexane(1:5) to give a white crystalline solid.

¹H-NMR (CDCl₃) δ: 0.97 (3H, d), 1.45 (9H, s), 2.37-2.53 (3H, m), 2.80(1H, brs), 3.16-3.26 (1H, m), 4.11-4.18 (2H, m).

ESI-MS m/z: 158 [M−CH═C(CH₃)₂+1].

Step 2: 4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidine-1-carboxylicacid tert-butyl ester

To 4-chlorophenyl magnesium bromide (49 mL, 49 mmol, 1M in diethylether) at about 0° C. under argon, was added3-Methyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester (7 g, 32.8mmol) in THF (50 mL) over a period of about 1 hour. The reaction wasallowed to warm to room temperature and stirred overnight. The reactionwas quenched with saturated ammonium chloride solution and extractedwith ethyl acetate. The organic layer was washed with water, then brineand dried over sodium sulfate. The solvent was evaporated and the cruderesidue was recrystallized in EtOAc to give a white solid.

¹H-NMR (CDCl₃) δ: 0.58 (3H, d), 1.45 (9H, s), 1.50-1.69 (2H, m),1.76-2.13 (2H, m), 2.80 (1H, t), 3.10 (1H, t), 3.96 (2H, brs), 7.29 (4H,m).

ESI-MS m/z: 252 [M−CH═C(CH₃)₂—H₂O+1].

Step 3: 4-(4-Chloro-phenyl)-3-methyl-piperidin-4-ol

To a solution of4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidine-1-carboxylic acidtert-butyl ester (1.5 g, 4.6 mmol) in dichloromethane (40 mL) at about0° C. was added trifluoroacetic acid (10 mL). The solution was stirredfor about 2 hours. The solvent was evaporated and the residue wasdissolved in ethyl acetate. The solution was neutralized with saturatedsodium bicarbonate, and washed with brine and dried over magnesiumsulfate. The solvent was removed to give a yellow solid. No purificationwas needed.

¹H-NMR (CDCl₃) δ: 0.65 (3H, d), 1.85 (1H, d), 2.52 (2H, m), 3.05 (1H,t), 3.27 (1H, dd), 3.34 (2H, d), 7.40 (4H, m).

ESI-MS m/z: 240 [M+1].

5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol

To a solution of 4-(4-Chloro-phenyl)-3-methyl-piperidin-4-ol (1.0 g, 4.6mmol) in DMF (10 mL) with triethylamine (1.75 mL, 12.54 mmol), was added5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol(1.38 g, 4.18 mmol) dropwise for over a period of about 1.5 hours atabout 50° C. The reaction was stirred overnight at about 50° C. Thereaction was quenched with water, extracted with ethyl acetate, andevaporated in vacuo. The residue was purified by silica gelchromatography (87:10:3 ethyl acetate:methanol:triethylamine) to yield abrown solid of the title compound.

¹H-NMR (CDCl₃) δ: 0.53 (3H, d), 1.60-1.69 (2H, m), 2.07-2.30 (3H, m),2.34-2.51 (3H, m), 2.56-2.75 (3H, m), 2.76-2.87 (1H, m), 2.98-3.11 (1H,m), 5.25 (2H, brs), 6.12 (1H, t), 6.64-6.79 (3H, m), 7.20-7.40 (5H, m),7.53 (1H, d), 8.50 (1H, d).

ESI-MS m/z: 477 [M+1].

Example 435

Trifluoro-methanesulfonic acid5-{3-[4-(4-chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ylester

The title compound was prepared according to the procedure of Example169 and obtained as a brown solid.

¹H-NMR (CDCl₃) δ: 0.55 (3H, d), 1.55-1.68 (2H, m), 1.92-2.18 (2H, m),2.24-2.69 (7H, m), 5.36 (2H, brs), 6.15 (1H, t), 6.88 (1H, d), 7.05 (1H,dd), 7.19-7.43 (6H, m), 7.60 (1H, d), 8.54 (1H, d).

ESI-MS m/z: 609 [M+1].

Example 4365-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cycloheptene-7-carboxylicacid methyl ester

The title compound was prepared according to the procedure of Example423 and obtained as a brown solid (formate salt).

¹H-NMR (CDCl₃) δ: 0.62 (3H, d), 1.75 (1H, d), 2.41-2.71 (5H, m),2.90-3.14 (4H, m), 3.27 (1H, d), 3.89 (3H, s), 5.00-5.70 (2H, brs), 6.08(1H, t), 6.86 (1H, d), 7.26-7.39 (5H, m), 7.59 (1H, d), 7.83 (1H, d),7.98 (1h, s), 8.34 (1H, s), 8.56 (1H, d).

ESI-MS m/z: 519 [M+1].

Example 4374-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidin-4-ol

The title compound was prepared according to the procedure of Example27. The racemic compound was resolved using preparative chiral HPLC(ChiralPak AD, 20 mm×250 mm, isocrati elution with 10% ethano1:90%hexane, 15 mL/min., 35 minute run time). The more active enantiomereluted first, at 17 minutes. The less active enantiomer eluted second,at 23 minutes. white solid (formate salt).

¹H-NMR (CDCl₃) δ: 0.61 (3H, d), 1.57 (6H, s), 1.76 (1H, d), 2.43-2.72(5H, m), 2.91-3.12 (4H, m), 3.25 (1H, d), 5.04-5.46 (2H, brs), 6.01 (1H,t), 6.82 (1H, d), 7.22-7.37 (5H, m), 7.46 (1H, s), 7.55 (1H, d),8.30-8.40 (1H, brs), 8.52 (1H, d).

ESI-MS m/z: 519 [M+1].

Example 4385-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cycloheptene-7-carboxylicacid

The title compound was prepared according to the procedure of Example118 and obtained as a brown solid (formate salt).

¹H-NMR (CDCl₃) δ: 0.49 (3H, d), 1.63 (1H, d), 2.29-2.43 (2H, m),2.45-2.63 (3H, m), 2.78-3.18 (5H, m), 4.82-5.85 (2H, brs), 6.13 (1H, t),6.67 (1H, d), 7.19-7.31 (5H, m), 7.55 (1H, d), 7.67 (1H, d), 7.87 (1h,s), 8.19 (1H, s), 8.40 (1H, d).

ESI-MS m/z: 505 [M+1].

Example 4395-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,5-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-olStep 1: 1-Benzyl-3,5-dimethyl-piperidin-4-one

To 1-benzyl-3-methyl-4-piperidone (2.0 g, 9.8 mmol) in THF at about −78°C. under argon, was added Lithium diisopropylamide (7.35 mL, 14.7 mmol,2 M in heptane/THF/ethylbenzene). After stirring for about 1 hour atabout −78° C., iodomethane (0.73 mL, 11.8 mmol) was added. The reactionmixture was stirred for about 1 hour at about −78° C., then warmed toroom temperature. Stirring was continued overnight at room temperature.The reaction was quenched with saturated ammonium chloride solution, andextracted with ethyl acetate. The organic layer was washed with water,then brine and dried over magnesium sulfate. The crude product waschromatographed on silica gel, eluting with EtOAc/hexane (3:10) to givea yellow oil of the title compound.

¹H-NMR (CDCl₃) δ: 0.96 (6H, d), 2.04 (2H, t), 2.62-2.78 (2H, m),3.12-3.17 (2H, m), 3.59 (2H, s), 7.23-7.38 (5H, m).

ESI-MS m/z: 218 [M+1].

Step 2: 3,5-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester

The title compound was prepared according to the procedure of Example434, step 1 and obtained as a white crystalline solid.

¹H-NMR (CDCl₃) δ: 1.02 (6H, d), 1.5 (9H, s), 2.47-2.75 (4H, m),4.25-4.54 (2H, brs).

ESI-MS m/z: 172 [M−CH═C(CH₃)₂+1].

Step 3:4-(4-Chloro-phenyl)-4-hydroxy-3,5-dimethyl-piperidine-1-carboxylic acidtert-butyl ester

The title compound was prepared according to the procedure of Example434, step 2 and obtained as a white solid.

¹H-NMR (CDCl₃) δ: 0.57 (6H, d), 1.49 (9H, s), 1.98-2.08 (2H, m),2.71-2.98 (2H, m), 3.79-4.10 (2H, m), 7.29-7.36 (4H, m).

ESI-MS m/z: 266 [M−CH═C(CH₃)₂—H₂O+1].

Step 4: 4-(4-Chloro-phenyl)-3,5-dimethyl-piperidin-4-ol

The title compound was prepared according to the procedure of Example434, step 3 and obtained as a light yellow solid.

¹H-NMR (CDCl₃) δ: 0.54 (6H, d), 1.97-2.11 (4H, m), 2.75 (2H, t), 2.88(2H, d), 7.27-7.32 (4H, m).

ESI-MS m/z: 240 [M+1].

5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,5-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol

The title compound was prepared according to the procedure of Example434, and obtained as a yellow solid.

¹H-NMR (CDCl₃) δ: 0.58 (6H, d), 2.50-2.80 (6H, m), 2.94-3.06 (2H, m),3.17 (2H, d), 5.14-5.29 (2H, brs), 5.87 (1H, t), 6.75-6.90 (2H, m),7.10-7.45 (6H, m), 8.44 (1H, d), 8.52 (1H, s).

ESI-MS m/z: 491[M+1].

Example 4404-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,5-dimethyl-piperidin-4-ol

The title compound was prepared according to the procedure of Example439 but using2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol,and was obtained as a white solid (formate salt).

¹H-NMR (CDCl₃) δ: 0.59 (6H, d), 1.58 (6H, s), 2.49-2.74 (6H, m),2.97-3.10 (2H, m), 3.16 (2H, d), 5.20-5.45 (2H, brs), 6.06 (1H, t), 6.83(1H, d), 7.12-7.43 (6H, m), 7.49 (1H, s), 7.60 (1H, d), 8.38 (1H, s),8.54 (1H, m).

ESI-MS m/z: 533 [M+1].

Examples 441 and 4424-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidin-4-oland4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-azadibenzo[a,d]cyclohepten-5-ylidene]-propyl}-4-methyl-piperidin-3-olStep 1: 4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acidtert-butyl ester

To a solution of di-tert-butyl-dicarbonate (3.27 g, 15.0 mmol) in CH₂Cl₂(50 mL) was added 4-(4-chlorophenyl)-1,2,3,6-tetrahydropiperidinehydrochloride (3.02 g, 13.1 mmol) and triethylamine (3.6 mL, 20 mmol).The solution was stirred at about room temperature for about 15 hours.Gas evolution was observed. The reaction was quenched with aqueousammonium chloride, extracted with CH₂Cl₂, and the organic layers wereevaporated in vacuo. The residue was purified by plug filtration throughsilica gel to yield the title compound as a colorless oil.

¹H-NMR (CDCL₃) d: 1.50 (9H, s), 2.46 (2H, br s), 3.62 (2H, br s), 4.05(2H, br s), 6.01 (1H, br s), 7.25 (4H, s).

Step 2:6-(4-Chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acidtert-butyl ester

To a solution of4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylester (3.8 g, 13 mmol) in CH₂Cl₂ (50 mL) was added 3-chloroperbenzoicacid (3.8 g, 17.0 mmol) and triethylamine (3.6 mL, 20 mmol). Thesolution was stirred at room temperature for about 4 hours. A whiteprecipitate was observed. The reaction was quenched with aqueous sodiumbicarbonate, extracted with CH₂Cl₂, and the organic layers wereevaporated in vacuo. The residue was purified by flash chromatography onsilica gel (35 g SiO₂, gradient elution from 100% hexane to 100% ethylacetate) to yield the title compound as a colorless oil.

¹H-NMR (CDCL₃) δ: 1.50 (9H, s), 2.15 (1H, m), 3.15 (2H, m), 3.6-4.2 (4H,m), 7.31 (4H, s).

Step 3: 4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidine-1-carboxylicacid tert-butyl ester and4-(4-Chloro-phenyl)-3-hydroxy-4-methyl-piperidine-1-carboxylic acidtert-butyl ester

A suspension of copper(I) iodide (0.38 g, 2 mmol) in THF (20 mL) wascooled to about 4° C., and treated with methylmagnesium bromide (6 mL of3M solution in diethyl ether, 18 mmol). To the cooled suspension ofcuprate was added6-(4-Chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acidtert-butyl ester (1.9 g, 6.1 mmol) in THF (5 mL). The solution wasstirred and allowed to warm to about room temperature for about 4 hours.The reaction was quenched with aqueous ammonium chloride, extracted withethyl acetate, and the organic layers were evaporated in vacuo. Theresidue was purified by flash chromatography on silica gel (35 g SiO₂,gradient elution from 100% hexane to 50% ethyl acetate) to yield amixture of the title compounds as a white foam. This mixture was carriedon to the next step.

Step 4: Synthesis of 4-(4-Chloro-phenyl)-3-methyl-piperidin-4-ol and4-(4-Chloro-phenyl)-4-methyl-piperidin-3-ol

The BOC-protected amino-alcohol mixture (0.8 g, 2.5 mmol) was dissolvedin 4M HCl/Dioxane (5 mL, 20 mmol). The solution was stirred at roomtemperature for about 1 hour. The solvent was removed in vacuo. Theresidue was quenched with aqueous sodium hydroxide, extracted with ethylacetate, and the organic layers were dried over sodium sulfate andevaporated in vacuo to yield the title compound as a brown solid.

ESI-MS m/z: 226 (M+1), 208 (M+1-H₂O). The mixture was carried on to thenext step without further purification.

4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidin-4-oland

4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-azadibenzo[a,d]cyclohepten-5-ylidene]-propyl}-4-methyl-piperidin-3-ol

To a solution of the amino alcohol mixture (0.53 g, 2.3 mmol) inisopropanol (10 mL) was added 2,6-lutidine (0.23 mL, 2.0 mmol) andcatalytic potassium iodide.

This mixture was heated to about 80° C., and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.37 g, 1.0 mmol), added in portions over about 2 hours. The solutionwas then stirred at about 80° C. for about an additional 2 hours. Thereaction was concentrated in vacuo, then purified by flashchromatography on silica gel (35 g SiO₂, gradient elution from 100%ethyl acetate to 87% ethyl acetate:10% methanol:3% triethylamine) toyield the title compounds.

The faster eluting isomer:4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]propyl}-3-methyl-piperidin-4-ol,a brown semisolid. ¹H-NMR (CDCL₃) δ: 0.70 (3H, d, J=7.2 Hz), 1.53 (6H,s), 1.92 (3H, m), 2.28-2.69 (8H, m), 5.30 (2H, br s), 6.15 (1H, t, J=1.4Hz), 6.79 (2H, d, J=8.4 Hz), 7.18-7.45 (7H, m), 7.59 (1H, d, J=8 Hz),8.45 (1H, m). ESI-MS m/z: 519(M+1).

The slower eluting isomer:4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-, a brownsemisolid. ¹H-NMR (CDCL₃) δ: 1.16 (3H, s), 1.55 (6H, s), 2.28-2.69 (5H,m), 3.86 (1H, br s), 5.30 (2H, br s), 6.07 (1H, t, J=1.4 Hz), 6.79 (2H,d, J=8.4 Hz), 7.18-7.45 (7H, m), 8.45 (1H, m). ESI-MS m/z: 519(M+1).

Example 4434-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol Step 1:1-Benzyl-3,3-dimethyl-piperidin-4-one

To a solution of 1-Benzyl-3-methyl-piperidin-4-one (2.03 g, 10 mmol) inTHF (10 mL) was added potassium t-Butoxide (1.1 g, 10 mmol) and methyliodide (0.62 mL, 10 mmol). The solution was then stirred at roomtemperature for about 72 hours. The reaction was quenched with brine andextracted with ethyl acetate. The combined organic layers wereconcentrated in vacuo, then purified by flash chromatography on silicagel (35 g SiO₂, gradient elution from 100% hexane to 100% ethyl acetate)to yield the title compound as a colorless oil.

¹H-NMR (CDCL₃) δ: 1.12 (6H, s), 2.41 (2H, s), 2.52 (2H, m), 2.73 (2H,m), 3.56 (2H, s), 7.20-7.40 (5H, m). ESI-MS m/z: 218 (M+1).

Step 2: 3,3-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester

To a solution of 1-Benzyl-3,3-dimethyl-piperidin-4-one (2.48 g, 11 mmol)in ethanol (100 mL) was added di-tert-butyl dicarbonate (2.18, 10 mmol)and palladium hydroxide (0.10 g), The suspension was then shaken under ahydrogen atmosphere (40 PSI) at room temperature for about an additional12 hours. The reaction was filtered through celite and evaporated invacuo to yield the title compound as a white solid.

¹H-NMR (CDCL₃) δ: 1.12 (61-1, br s), 1.48 (9H, s), 2.45-2.80 (3H, m),3.12 (1H, m), 3.42 (1H, br s), 3.70 (1H, m).

Step 3:4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acidtert-butyl ester

To an ice-cooled solution 3,3-Dimethyl-4-oxo-piperidine-1-carboxylicacid tert-butyl ester (1.6 g, 7.2 mmol) in THF (20 mL) was added4-chlorophenylmagnesium bromide (1 M in ether, 15 mL, 15 mmol). Thesolution was allowed to warm to about room temperature, then stirred atroom temperature for about 22 hours. The reaction was quenched withaqueous ammonium chloride and extracted with ethyl acetate. The combinedorganic layers were concentrated in vacuo, then purified by flashchromatography on silica gel (35 g SiO₂, gradient elution from 100%hexane to 100% ethyl acetate) to yield the title compound as a colorlessoil.

¹H-NMR (CDCL₃) δ: 1.12 (6H, s), 1.50 (11H, m), 2.60 (1H, m), 3.20 (2H,m), 3.56 (1H, m), 4.20 (1H, m), 7.20-7.40 (4H, m). ESI-MS m/z: 218(M+1).

Step 4: 4-(4-Chloro-phenyl)-3,3-dimethyl-piperidin-4-ol

4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acidtert-butyl ester (0.25 g, 0.73 mmol) was dissolved in 4M HCl/Dioxane (2mL, 8 mmol). The solution was stirred at room temperature for about 4hours. The solvent was removed in vacuo. The residue was quenched withaqueous sodium hydroxide, extracted with ethyl acetate, and the organiclayers were dried over sodium sulfate and evaporated in vacuo to yieldthe title compound as a yellow solid. The mixture was carried on to thenext step without further purification.

4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol

To a solution of the amino alcohol mixture (0.17 g, 0.7 mmol) inisopropanol (5 mL) was added 2,6-lutidine (0.23 mL, 2.0 mmol) andcatalytic potassium iodide. This mixture was heated to about 80° C., andtreated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.19 g, 0.5 mmol), added in portions over about 2 hours. The solutionwas then stirred at about 80° C. for an additional 2 hours. The reactionwas concentrated in vacuo, then purified by flash chromatography onsilica gel (10 g SiO₂, gradient elution from 100% ethyl acetate to 87%ethyl acetate:10% methanol:3% triethylamine) to yield the title compoundas a brown semisolid.

¹H-NMR (CDCL₃) δ: 0.78 (3H, s), 0.90 (3H, s), 1.45 (2H, m), 1.53 (6H,s), 2.28-2.80 (9H, m), 5.30 (2H, br s), 6.15 (1H, t, J=1.4 Hz), 6.79(2H, d, J=8.4 Hz), 7.18-7.45 (7H, m), 7.59 (1H, d, J=8 Hz), 8.45 (1H,m). ESI-MS m/z: 533 (M+1).

Example 4564-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo-[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carbonitrileStep 1: Bis-(2-chloroethyl)-carbamic acid tert-butyl ester

To a solution of bis-(2-chloroethyl)-amine hydrochloride (7.12 g, 40mmol) in dichloromethane (65 ml) was added N,N-diisopropylethylamine(34.8 ml, 200 mmol) and catalytic amount of 4-dimethylaminopyridine,followed by portionwise addition of di-tert-butyl dicarbonate (8.72 g,40 mmol). The solution was stirred at room temperature for 72 hours. Thereaction mixture was concentrated and triturated with ether (70 ml). Thesolid was filtered and the filtrate was concentrated under vacuum. Theresidue was purified by silica gel chromatography eluting withhexane-ethyl acetate (9:1) to give the title compound (2.02 g, 21%).

¹H-NMR (CDCl₃) δ: 1.5 (9H, s), 3.5-3.6 (8H, m).

Step 2: 4-(4-Chloro-phenyl)-4-cyano-piperidine-1-carboxylic acidtert-butyl ester

To 1.26 g (8.37 mmol) 4-chloro-benzylcyanide was addedbis-(2-chloroethyl)-carbamic acid tert-butyl ester (2.02 g, 8.37 mmol)in 25 ml N,N-dimethylformamide. The resulting mixture was stirred andcooled in an ice bath, then sodium hydride (60% suspension in mineraloil) (1.1 g, 42 mmol) was added portionwise. The reaction was brought toroom temperature and then heated in an oil bath at 60° C. for 16 hours.The reaction mixture was quenched by addition of ice water and theaqueous phase was extracted with ethyl acetate. The combined organiclayers were washed twice with water, once with brine, dried withmagnesium sulfate and concentrated in vacuo. The residual brown oil waspurified by silica gel chromatography eluting with hexane-ethyl acetate(9:1) to give the title compound (1.44 g, 54%).

¹H-NMR (CDCl₃) δ: 1.5 (9H, s), 1.8-2.0 (2H, m), 2.1 (2H, d), 3.2 (2H,t), 4.3 (2H, brs), 7.4 (4H, m).

MS m/z: 221 (M+1-100)

Step 3: 4-(4-Chloro-phenyl)-piperidine-4-carbonitrile

To a chilled solution of4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid tert-butylester (315 mg, 1 mmol) in 5 ml dichloromethane was added 1 mltrifluoroacetic acid. The reaction was stirred at 0° C. for 3 hours,then concentrated under vacuum. The resulting oil was diluted withdichloromethane and washed twice with saturated aqueous sodiumbicarbonate. The aqueous washings were extracted three times withdichloromethane. The combined organic layers were dried with magnesiumsulfate and concentrated under vacuum to yield the title compound (180mg, 82%).

¹H-NMR (CDCl₃) δ: 1.9-2.1 (4H, m), 3.0-3.2 (4H, m), 7.3-7.5 (4H, m).

MS m/z: 221 (M+1)

Step 4

To a suspension of 4-(4-chloro-phenyl)-piperidine-4-carbonitrile (180mg, 0.8 mmol) in acetonitrile/water (4/1) was added potassium carbonate(221 mg, 1.6 mmol), followed by2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(150 mg, 0.4 mmol). The reaction mixture was stirred at room temperaturefor 48 hours and then concentrated in vacuo. The resulting residue wastreated with water and extracted with ethyl acetate. Solvent wasevaporated from the combined dried (MgSO₄) organic extracts, and theresidue was purified by column chromatography on silica gel usinghexane-ethyl acetate (6:4) to afford the title compound.

¹H-NMR (CDCl₃) δ: 1.5 (6H, s), 1.8-2.0 (4H, m), 2.4 (4H, m), 2.55 (2H,m), 2.8 (2H, d), 5.3 (2H, brs), 6.1 (1H, t), 6.8 (1H, d), 7.27-7.4 (7H,m), 7.5 (1H, d), 8.5 (1H, d)

MS m/z: 514 (M+1)

Example 4571-(4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-ethanoneStep 1: 1-[4-(4-Chloro-phenyl)-piperidin-4-yl]-ethanone

To a dry round bottom flask was added via syringe 10 ml methyl magnesiumbromide in toluene/tetrahydrofuran (75:25, 1.4 M). The flask was cooledin an ice bath under a stream of nitrogen. A solution of4-(4-Chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid tert-butylester (357 mg, 1.11 mmol) in 4 ml tetrahydrofuran was added dropwise tothe flask over 20 minutes and the resulting mixture was stirred at 0° C.for 8 hours. The reaction mixture was warmed to room temperature andstirred for 5 days. The reaction was quenched by slowly pouring 150 mlsaturated aqueous ammonium chloride and extracted with ethyl acetate.The combined organic phases were dried over magnesium sulfate andconcentrated under vacuum. The yellow residue was purified by reversephase HPLC to get the formate salt of the title compound (106 mg, 40%).

MS m/z: 238 (M+1)

Step 2

To a suspension of 1-[4-(4-chloro-phenyl)-piperidin-4-yl]-ethanone inacetonitrile/water (4/1) was added potassium carbonate (221 mg, 1.6mmol), followed by2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(150 mg, 0.4 mmol). The reaction mixture was stirred at room temperaturefor 48 hours and then concentrated in vacuo. The resulting residue wastreated with water and extracted with ethyl acetate. Solvent wasevaporate from the combined dried (MgSO₄) organic extracts. Purificationon silica gel chromatography using dichloromethane-methanol (9.5:0.5)afforded the title compound.

¹H-NMR (CDCl₃) δ: 1.3 (2H, m), 1.5 (6H, s), 1.9 (3H, s), 2.1-2.5 (10H,m), 5.3 (2H, brs), 5.9 (1H, t), 6.8 (1H, d), 7.3 (6H, m), 7.4 (1H, d),7.6 (1H, d), 8.5 (1H, d)

MS m/z: 531 (M+1)

Example 4584-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carboxylicacid methyl ester Step 1:4-(4-Chloro-phenyl)-piperidine-1,4-dicarboxylic acid mono-tert-butylester

To a solution of 4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylicacid tert-butyl ester (1.1 g, 3.44 mmol) in 40 ml ethanol was added 10ml 10 N aqueous sodium hydroxide. The resulting solution was warmed toreflux for 48 hours, cooled to room temperature, poured into 1 N aqueoushydrochloric acid, and extracted into ethyl acetate. The organicextracts were washed with brine, dried over magnesium sulfate, andconcentrated in vacuo. Recovered orange oil was purified by silica gelchromatography, eluting with dichloromethane-methanol (9.5:0.5) to givethe title compound (1.0 g, 86%).

MS m/z: 338 (M−1)

Step 2: 4-(4-Chloro-phenyl)-piperidine-1,4-dicarboxylic acid1-tert-butyl ester 4-methyl ester

To a stirred 4-(4-chloro-phenyl)-piperidine-1,4-dicarboxylic acidmono-tert-butyl ester (852 mg, 2.5 mmol) in methanol (5 ml)-benzene(17.5 ml) was added 15 ml (trimethylsilyl)diazomethane (2.0 M solutionin hexanes) at room temperature. The mixture was stirred for 16 hours atroom temperature and concentrated in vacuo. The residual yellow oil waspurified by silica gel chromatography eluting with hexane-ethyl acetate(9:1) to give the corresponding ester (780 mg, 88%).

¹H-NMR (CDCl₃) δ: 1.5 (9H, s), 2.8-2.9 (2H, m), 2.5 (2H, d), 3.0 (2H,t). 3.7 (3H, s), 4.0 (2H, d), 7.4 (4H, m).

MS m/z: 354 (M+1)

Step 3: 4-(4-Chloro-phenyl)-piperidine-4-carboxylic acid methyl ester

The title compound was prepared by following the procedure of Example456, Step 3, but replacing4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid tert-butylester with 4-(4-chloro-phenyl)-piperidine-1,4-dicarboxylic acid1-tert-butyl ester 4-methyl ester.

¹H-NMR (CDCl₃) δ: 1.9 (2H, t), 2.55 (2H, d), 2.9 (2H, t), 3.25 (2H, d),3.8 (3H, s), 7.2 (4H, m)

MS m/z: 254 (M+1)

Step 4

To a suspension of 4-(4-chloro-phenyl)-piperidine-4-carboxylic acidmethyl ester in acetonitrile/water (4/1) was added potassium carbonate(221 mg, 1.6 mmol), followed by2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(150 mg, 0.4 mmol). The reaction mixture was stirred at room temperaturefor 48 hours and then concentrated in vacuo. The resulting residue wastreated with water and extracted with ethyl acetate. Solvent wasevaporate from the combined dried (MgSO₄) organic extracts. Purificationon silica gel chromatography using dichloromethane-methanol (9.6:0.4)afforded the title compound.

¹H-NMR (CDCl₃) δ: 1.5 (6H, s), 1.8-2.0 (4H, m), 2.1 (2H, m), 2.4-2.5(7H, m), 2.6 (2H, m), 5.3 (2H, brs), 6.1 (1H, t), 6.8 (1H, d), 7.3 (6H,m), 7.4 (1H, d), 7.6 (1H, d), 8.5 (1H, d)

MS m/z: 547 (M+1)

Example 4594-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carboxylicacid

To a solution4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carboxylicacid methyl ester (110 mg, 0.2 mmol) in methanol (5 ml) was added 1 ml 1N aqueous sodium hydroxide. The resulting solution was warmed to 50° C.for 16 hours, cooled to room temperature, and concentrated under astream of nitrogen. The residue was purified by reverse phase HPLC toget the formate salt of the title compound (96 mg. 90%).

¹H-NMR (CDCl₃) δ: 1.5 (6H, s), 1.8-1.9 (2H, m), 2.4 (4H, m), 2.55 (2H,m), 2.6-2.8 (4H, d), 5.3 (2H, brs), 5.9 (1H, t), 6.8 (1H, d), 7.27-7.4(7H, m), 7.5 (1H, m), 8.5 (1H, d)

MS m/z: 533 (M+1)

Example 4604-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carboxylicacid amide Step 1:4-Carbamoyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butylester

To a solution of 4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylicacid tert-butyl ester (500 mg, 1.56 mmol) in ethanol (15 ml) was added 2ml 10 N aqueous sodium hydroxide. The resulting solution was warmed toreflux for 2 hours, cooled to room temperature, poured into 1 N aqueoushydrochloric acid, and extracted into ethyl acetate. The organicextracts were washed with brine, dried over magnesium sulfate, andconcentrated in vacuo. Recovered yellow oil was purified by silica gelchromatography, eluting with dichloromethane-methanol (9.6:0.4) to givethe title compound (306 mg, 58%). MS m/z: 339 (M+1)

Step 2: 4-(4-Chloro-phenyl)-piperidine-4-carboxylic acid amide

The title compound was prepared by following the procedure of Example456, step 3, but replacing4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid tert-butylester with 4-carbamoyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acidtert-butyl ester.

MS m/z: 239 (M+1)

Step 3

The title compound was prepared by following the procedure of Example456, step 4 but replacing 4-(4-chloro-phenyl)-piperidine-4-carbonitrilewith 4-(4-chloro-phenyl)-piperidine-4-carboxylic acid amide.Purification on silica gel chromatography using dichloromethane-methanol(9:1) afforded the title compound.

¹H-NMR (CDCl₃) δ: 1.5 (6H, s), 1.8-2.0 (6H, m), 2.3-2.6 (6H, m), 5.3(2H, brs), 6.1 (1H, t), 6.8 (1H, d), 7.3 (6H, m), 7.4 (1H, d), 7.5 (1H,d), 8.5 (1H, d)

MS m/z: 532 (m+1)

Example 4612-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxymethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: 4-(4-Chloro-phenyl)-4-hydroxymethyl-piperidine-1-carboxylic acidtert-butyl ester

To a chilled solution of 4-(4-chloro-phenyl)-piperidine-1,4-dicarboxylicacid 1-tert-butyl ester 4-methyl ester (700 mg, 1.98 mmol) in 6 ml etherwas added dropwise 2 ml lithium aluminium hydride 1M solution in ether.The reaction was stirred at 0° C. for 3 hours, then water (100 ml) wasslowly added. The resulting gel was filtered and the aqueous filtratewas extracted three times with ether. The combined organic layers weredried with magnesium sulfate and concentrated under vacuum. Recoveredoil was purified by silica gel chromatography, eluting with hexane-ethylacetate (6:4) to give the title compound (297 mg, 46%).

¹H-NMR (CDCl₃) δ: 1.5 (9H, s), 1.7-1.8 (2H, m), 2.1 (2H, d), 3.0 (2H,m), 3.5 (2H, s), 3.7 (2H, d), 7.4 (4H, m)

MS m/z: 324 (M−1)

Step 2: [4-(4-Chloro-phenyl)-piperidin-4-yl]-methanol

The title compound was prepared by following the procedure of Example456, step 3, but replacing4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid ten-butyl esterwith 4-(4-chloro-phenyl)-4-hydroxymethyl-piperidine-1-carboxylic acidtert-butyl ester.

MS m/z: 224 (M−1)

Step 3

The title compound was prepared by following the procedure of Example456, step 4, but replacing 4-(4-chloro-phenyl)-piperidine-4-carbonitrilewith [4-(4-chloro-phenyl)-piperidin-4-yl]-methanol. Purification onsilica gel chromatography using dichloromethane-methanol (9.5:0.5)afforded the title compound.

¹H-NMR (CDCl₃) δ: 1.5 (6H, s), 2.0 (2H, m), 2.2-2.3 (4H, m) 2.4 (2H, m),2.55 (2H, m), 2.8 (2H, d), 3.5 (2H, s), 5.3 (2H, brs), 6.0 (1H, t), 6.8(1H, d), 7.27-7.4 (7H, m), 7.5 (1H, d), 8.5 (1H, d)

MS m/z: 517 (M−1)

Example 4622-(5-{3-[4-(4-chloro-phenyl)-4-(1-hydroxy-ethyl)-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

To a chilled solution of1-(4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-ethanone(70 mg, 0.13 mmol) in 5 ml methanol was added sodium borohydride (20 mg,0.53 mmol). The reaction mixture was stirred at 0° C. for 4 hours, thenconcentrated down under a stream of nitrogen. The residue was purifiedby reverse phase HPLC to get the formate salt of the title compound (39mg, 56%).

¹H-NMR (CDCl₃) δ: 0.8 (4H, d), 1.5 (6H, s), 2.1-2.7 (10H, m), 3.1 (2H,m), 5.3 (2H, brs), 5.95 (1H, t), 6.8 (1H, d), 7.27-7.4 (7H, m), 7.5 (1H,d), 8.5 (H, d)

MS m/z: 533 (M+1)

Example 4632-(5-{3-[4-(4-Chloro-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-piperidin-1-yl]propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: 4-Acetyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acidtert-butyl ester

To a chilled solution of 1-[4-(4-chloro-phenyl)-piperidin-4-yl]-ethanone(540 mg, 1.98 mmol) in dichloromethane (10 ml) was added triethylamine(0.6 ml, 3.82 mmol), followed by portionwise addition of di-tert-butyldicarbonate (470 mg, 1.98 mmol). The solution was stirred at roomtemperature for 16 hours. The reaction mixture was concentrated down,quenched with 1 N aqueous hydrochloric acid, and extracted intodichloromethane. The organic extracts were washed with saturated aqueoussodium bicarbonate solution, brine, dried over magnesium sulfate, andconcentrated in vacuo. Recovered oil was purified by silica gelchromatography, eluting with hexane-ethyl acetate (8:2) to give thetitle compound (445 mg, 67%).

¹H-NMR (CDCl₃) δ: 1.5 (9H, s), 1.9 (5H, m), 2.3-2.4 (2H, m), 3.1 (2H,t), 3.7-3.8 (2H, m), 7.4 (4H, m)

MS m/z: 338 (M+1)

Step 2:4-(4-Chloro-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-piperidine-1-carboxylicacid tert-butyl ester

To a dry round bottom flask was added via syringe 16 ml methyl magnesiumbromide in toluene/tetrahydrofuran (75:25, 1.4 M). The flask was cooledin an ice bath under a stream of nitrogen. A solution4-acetyl-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butylester (337 mg, 1.02 mmol) in 5 ml tetrahydrofuran was added dropwise tothe flask over 20 minutes and the resulting mixture was stirred at 0° C.for 8 hours. The reaction mixture was warmed to room temperature andstirred for 5 days. The reaction was quenched by slow addition of 150 mlsaturated aqueous ammonium chloride and extracted with ethyl acetate.The combined organic phases were washed with brine, dried over magnesiumsulfate and concentrated under vacuum. The yellow residue was purifiedby silica gel chromatography, eluting with hexane-ethyl acetate(7.5:2.5) to give the title compound (242 mg, 67%).

¹H-NMR (CDCl₃) δ: 1.1 (6H, s), 1.4 (9H, s), 1.8-1.9 (2H, m), 2.3-2.4(2H, d), 2.6 (2H, t), 3.9 (2H, d), 7.3 (4H, m)

MS m/z: 354 (M+1)

Step 3: 2-[4-(4-Chloro-phenyl)-piperidin-4-yl]-propan-2-ol

The title compound was prepared by following the procedure of Example456, step 3, but replacing4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid tert-butylester with:4-(4-chloro-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-piperidine-1-carboxylicacid tert-butyl ester.

MS m/z: 254 (M+1)

Step 4

The title compound was prepared by following the procedure of Example456, step 4, but replacing 4-(4-chloro-phenyl)-piperidine-4-carbonitrilewith 2-[4-(4-chloro-phenyl)-piperidin-4-yl]-propan-2-ol. Purification onsilica gel chromatography using dichloromethane-methanol (9:1) affordedthe title compound.

¹H-NMR (CDCl₃) δ: 1.1 (6H, s), 1.5 (6H, s), 1.8 (2H, m), 2.3-2.6 (10H,m), 5.3 (2H, brs), 5.95 (1H, t), 6.8 (1H, d), 7.27-7.4 (7H, m), 7.5 (1H,d), 8.5 (1H, d)

MS m/z: 547 (M+1)

Example 4644-(4-Chloro-phenylamino)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carbonitrileStep 1: 1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carbonitrile

To a solution of 1-Benzyl-piperidin-4-one (2.68 g, 14.20 mmol) in aceticacid (13 ml, glacial) was added 4-Chloro-phenylamine (1.99 g, 15.6mmol). The reaction was cooled in a cool temperature water bath.Trimethylsilylcyanide (1.89 ml, 14.20 mmol) was added slowly. Thereaction mixture was allowed to warm to room temperature and stirovernight under N₂. The reaction was cooled to 0° C. Concentratedammonium hydroxide (15 ml) was added slowly. Next added was cold water.The pH of the mixture was 10. The mixture was extracted three times withmethylene chloride, and the organic layers were dried over magnesiumsulfate, filtered, and concentrated under reduced pressure. Ether wasadded to the residue, and the white solid was filtered off and driedunder high vacuum to give the titled compound (3.73 g, 81%)

¹H-NMR (CDCl₃) δ 1.90-2.01 (2H, t), 2.3-2.4 (2H, m), 2.45-2.55 (2H, t),2.81-2.93 (2H, m), 3.61 (2H, s), 3.68 (1H, s) 6.87 (1H, s), 6.90 (1H, s)7.2-7.38 (7H, m).

MS m/z: 326 (M+1).

Step 2: 4-(4-Chloro-phenylamino)-piperidine-4-carbonitrile

To 1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carbonitrile (163 mg,0.5002 mmol) in dichloroethane (5 ml) was added 1-chloroethylchloroformate (65 μl, 0.600 mmol). The mixture was heated to reflux andstirred under N₂. After 1 hour 15 minutes, an additional 86 μl (0.800mmol) of the chloroformate was added to the reaction and stirred for anadditional 2 hours at reflux. After cooling to room temperature thereaction was concentrated under reduced pressure. To this residue wasadded methanol (5 ml) and the reaction was heated at reflux for 2 hours.Next, the reaction was allowed to cool to room temperature andconcentrated under reduced pressure. The residue was diluted with ethylacetate and water. The organic layer was removed and sodium hydroxide(1N) was added to the aqueous layer until pH≈9. The aqueous layer wasextracted with ethyl acetate 2 times and dried over magnesium sulfate.The solvent was distilled off under reduced pressure to obtain the titlecompound (84 mg, 71%).

¹H-NMR (CDCl₃) δ: 1.66-1.68 (1H, d), 1.70-1.75 (2H, d), 2.22-2.28 (2H,d), 2.87-3.12 (4H, m), 3.61 (1H, bs), 6.53-7.27 (4H, m)

MS m/z: 236 (M+1).

Step 3

The title compound was prepared by dissolving2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(106.7 mg, 0.285 mmol) in water (4 ml) and acetonitrile (1 ml). To thiswas added potassium carbonate (82.7 mg, 0.599 mmol) and4-(4-Chloro-phenylamino)-piperidine-4-carbonitrile (84.0 mg, 0.356mmol). The reaction was heated to 50° C. and stirred overnight. The nextday the reaction was allowed to cool to room temperature and dilutedwith ethyl acetate and water. The organic layer was washed twice withwater, dried over magnesium sulfate, and concentrated under reducedpressure. The crude residue was purified by reverse phase HPLC to givethe title compound (11.5 mg, 8% yield, 88% pure by LC/MS).

¹H-NMR (CDCl₃): δ 1.52 (6H, bs), 2.2-2.8 (12H, m), 3.4 (1H, b),5.16-5.36 (2H, b), 6.00-6.10 (1H, m), 6.75-6.80 (2H, m), 6.95-7.55 (7H,m), 8.45-8.76 (1H, m)

MS m/z: 529 (M+1).

Example 4654-(4-Chloro-phenylamino)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carboxylicacid methyl ester Step 1:1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carboxylic acid amide

To 1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carbonitrile (1.97 g,6.05 mmol) was added concentrated sulfuric acid (50 ml). The reactionstirred at room temperature as an orange homogeneous solution. After 24hours the reaction was cooled to 0° C. and very slowly poured intoconcentrated ammonium hydroxide in ice. The precipitate was filtered andwashed with water to give a white solid (202 mg, 71%).

¹H-NMR (CDCl₃): δ 1.87-1.92 (2H, bd), 2.06-2.14 (2H, t) 2.27-2.38 (2H,m), 2.70-2.78 (2H, bd), 3.50 (2H, s), 3.05 (1H, s), 5.42-5.44 (1H, bs),6.55-6.57 (2H, d), 6.76-6.82 (1H, bs), 7.10-7.15 (2H, d), 7.24-7.31 (5H,m)

MS m/z: 344 (M+1).

Step 2: 1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carboxylic acidmethyl ester

To a solution of1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carboxylic acid amide(1.19 g 3.46 mmol) in methanol (10 ml) in a sealed tube was addedtoluene sulfonic acid (2.33 g, 12.11 mmol). The reaction was heated to120° C., and stirred at that temperature behind a blast shield for 5days. The reaction was then allowed to cool to room temperature at whichtime it was worked up by diluting with water, then by addingconcentrated ammonium hydroxide until the pH≈8. The mixture wasextracted three times with ethyl acetate and dried over magnesiumsulfate. The solvent was distilled off under reduced pressure. Theyellow oil was used crude (744 mg, 60%).

¹H-NMR (CDCl₃): δ 1.93-2.03 (2H, bd), 2.19-2.28 (2H, dt), 2.32-2.48 (2H,m), 2.55-2.64 (2H, m), 3.51 (2H, s), 3.68 (3H, s), 3.85 (1H, s)6.47-6.51 (2H, bd), 7.07-7.10 (2H, bd), 7.21-7.35 (5H, m)

MS m/z: 359(M+1)

Step 3: 4-(4-Chloro-phenylamino)-piperidine-4-carboxylic acid methylester

The titled compound was prepared by following the procedure of Example464, step 2, but replacing1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carbonitrile with1-Benzyl-4-(4-chloro-phenyl amino)-piperidine-4-carboxylic acid methylester. This compound was also purified on a sep-pak silica column elutedwith 2%-10%

MeOH/CH₂Cl₂.

¹H-NMR (CDCl₃): δ 1.92-1.99 (2H, bd), 2.11-2.22 (2H, m), 2.73-3.03 (4H,m), 3.69 (3H, s), 3.94 (1H, s), 6.50-6.53 (2H, bd), 7.09-7.12 (2H, bd)

MS m/z: 269(M+1)

Step 4

The titled compound was prepared by following the procedure of Example464, step 3, but replacing4-(4-chlorophenylamino)-piperidine-4-carbonitrile with4-(4-Chloro-phenylamino)-piperidine-4-carboxylic acid methyl ester. Theresidue was purified by reverse phase HPLC to give the title compound(62 mg, 32%).

¹H-NMR (CDCl₃): δ 1.58 (6H, s) 2.09-2.20 (2H, m), 2.36-2.47 (2H, m),2.51-2.60 (2H, m), 2.85-3.02 (6H, m), 3.69 (3H, s), 5.19-5.41 (3H, bs),6.01-6.06 (1H, t), 6.51-6.54 (2H, d), 6.82-6.84 (1H, d), 7.10-7.13 (2H,d), 7.24-7.34 (2H, m), 7.43-7.44 (1H, d), 7.55-7.58 (1H, d), 8.26 (1H,s), 8.53-8.55 (1H, dd)

MS m/z: 562 (M)

Example 4664-(4-Chloro-phenylamino)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-4-carboxylicacid amide Step 1: 4-(4-Chloro-phenylamino)-piperidine-4-carboxylic acidamide

The titled compound was prepared by following the procedure of Example464, step 2, but replacing1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carbonitrile with1-Benzyl-4-(4-chloro-phenylamino)-piperidine-4-carboxylic acid amide.

¹H-NMR (CDCl₃): δ 1.82-1.92 (2H, bd), 2.10-2.37 (3H, m), 2.69-2.79 (2H,m), 2.89-3.03 (2H, m), 5.42-5.46 (1H, bs), 6.47-6.59 (2H, m), 6.76-6.82(1H, bs), 7.08-7.15 (2H, bd).

MS m/z: 254 (M+1)

Step 2

The titled compound was prepared by following the procedure of Example464, step 3, but replacing4-(4-chlorophenylamino)-piperidine-4-carbonitrile with4-(4-Chloro-phenylamino)-piperidine-4-carboxylic acid amide. The samplewas purified using reverse phase HPLC to give the title compound (25 mg,25%).

¹H-NMR (CDCl₃): δ 1.53-1.55 (7H, s), 1.97-2.07 (2H, m), 2.40-2.61 (3H,m), 2.67-2.76 (3H, m), 2.86-2.96 (2H, m), 5.20-5.38 (2H, bs), 6.04-6.09(1H, t), 6.51-6.54 (2H, bd), 6.77-6.80 (1H, bd), 7.08-7.11 (2H, bd),7.19-7.29 (2H, m), 7.42-7.43 (1H, bd), 7.51-7.55 (1H, dd), 8.18 (1H,bs), 8.48-8.50 (1H, dd)

MS m/z: 547 (M)

Example 4672-(5-{3-[4-(4-Chloro-phenyl)-4-fluoro-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1

To a cooled (0° C.) solution of hydrogen fluoride (65-70%) in pyridine(4 mL) was added 4-(4-chloro-phenyl)-piperidin-4-ol (500 mg, 2.36 mmol).The resulting solution was stirred at 0° C. for 15 min and then warmedto rt and stirred 1 h. The mixture was slowly poured into a saturatedaqueous sodium bicarbonate solution (30 mL) and extracted with methylenechloride (100 mL; ADD SOLVENT AND EXTRACT SLOWLY AND WITH CAUTION).

Excess hydrogen fluoride was neutralized with solid sodium carbonate.The organic phase was washed with brine, dried over magnesium sulfate,filtered and concentrated. The crude residue was purified by silica gelchromatography, eluting with a methylene chloride to methylenechloride/methanol/ammonium hydroxide (8.5/1/0.5) gradient to give4-(4-Chloro-phenyl)-4-fluoro-piperidine (260 mg, 52%).

¹H-NMR (CDCl₃, 300 MHz) δ: 2.98-3.14 (m, 4H), 1.87-2.10 (m, 4H),7.33-7.36 (m, 4H).

¹⁹F-NMR (CDCl₃, 282 MHz) d: −160.40-−160.20 (m).

MS m/z: 214 (M+1).

Step 2

To a solution of the product of Step 1 (252 mg, 1.18 mmol) in isopropylalcohol (5 mL) was added 2,6-lutidine (197 mg, 214 uL, 1.84 mmol) andpotassium iodide (few mg). The resulting suspension was warmed to 80° C.Solid2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(221 mg, 0.591 mmol) was added in approximately equal portions over 2 h.Stirring was continued an additional 20 h at 80° C. The mixture wasconcentrated and the resulting residue purified by silica gelchromatography (methylene chloride to methylene/methanol 95:5 gradient)to afford the title compound (160 mg, 54%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.57-1.66 (m, 8 H), 1.88-1.97 (m, 3H),2.31-2.46 (m, 4H), 2.52-2.62 (m, 2H), 2.67-2.76 (m, 2H), 5.20-5.45 (brs, 2H), 6.14, (t, 1 H), 6.83 (d, 1H), 7.22-7.37 (m, 6H), 7.45 (d, 1H),7.59 (dd, 1H), 8.51 (dd, 1H).

¹⁹F-NMR (CDCl₃, 282 MHz) δ: −160.30-−160.50 (m).

MS m/z: 507 (M+1).

Example 4684-(4-Chloro-phenyl)-4-fluoro-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-3-olStep 1

To a solution of4-(4-chloro-phenyl)-3,4-dihydroxy-piperidine-1-carboxylic acidtert-butyl ester (1.213 g, 3.34 mmol) in methylene chloride (30 mL) at−78° C. was added diethylaminosulfur trifluoride (DAST, 3 mL). Theresulting solution was stirred at −78° C. 4 h. Methanol (20 mL) wasadded to quench excess DAST and the mixture was allowed to remain at−78° C. 5 min before warming to rt. The mixture was concentrated andpurified by silica gel chromatography (80% hexanes/20% ethyl acetategradient) to afford 4-(4-chloro-phenyl)-4-fluoro-piperidin-3-ol (262 mg,24%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.48 (s, 9H), 1.84 (br dd, 1H), 2.50 (dddd,1H), 3.15 (br dd, 1H), 3.38 (d, 1H), 3.76 (s, 1H), 4.04-4.36 (m, 2H),7.33-7.44 (m, 4H).

¹⁹F-NMR (CDCl₃, 282 MHz) δ: −159.90 (d).

Step 2

4-(4-Chloro-phenyl)-4-fluoro-piperidin-3-ol was prepared as in step 3 ofExample 502, substituting4-(4-chloro-phenyl)-4-fluoro-3-hydroxy-piperidine-1-carboxylic acidtert-butyl ester for4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acidtert-butyl ester. Following isolation from the crude mixture, the freeamine was used immediately without further purification.

¹H-NMR (CDCl₃, 300 MHz). 4-(4-Chloro-phenyl)-4-fluoro-piperidin-3-olappears as the major constituent of a mixture of compounds.

MS m/z: 230 (M+1; major peak in chromatogram).

Step 3

The titled compound was prepared as in step 5 of Example 502,substituting 4-(4-chloro-phenyl)-4-fluoro-piperidin-3-ol forS-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.58 (s, 6H), 1.74-1.96 (m, 2H), 2.31-2.75(m, 8 H), 2.80 (br d, 1H), 3.06 (d, 1H), 3.67 (br d, 1H), 5.20-5.45 (brs, 2H), 6.11 (t, 1H), 6.84 (d, 1H), 7.22-7.36 (m, 4H), 7.39-7.47 (m,3H), 7.57 (d, 1H), 8.56 (dd, 1 H).

¹⁹F-NMR (CDCl₃, 282 MHz) δ: −158.30 (d).

MS m/z: 523 (M+1).

Example 4692-(5-{3-[4-(4-Chloro-phenyl)-4-fluoro-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1

4-(4-Chloro-phenyl)-4-fluoro-3-methyl-piperidine was prepared followingthe procedure in Step 1 in Example 467, replacing4-(4-chloro-phenyl)-piperidin-4-ol with4-(4-Chloro-phenyl)-3-methyl-piperidin-4-ol.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.67 (d, 3H), 1.91-2.26 (m, 2H), 2.84 (t,1H), 3.02 (dd, 1H), 3.06-3.21 (m, 2H), 3.33 (br s, 2H), 7.27 (d, 2H),7.34 (d, 2 H).

¹⁹F-NMR (CDCl₃, 282 MHz) δ: −180.60 (ddd).

MS m/z: 228 (M+1).

Step 2

The titled compound was prepared following the procedure step 2 ofExample 467, replacing 4-(4-chloro-phenyl)-4-fluoro-piperidine with4-(4-chloro-phenyl)-4-fluoro-3-methyl-piperidine.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.63 (d, 3H), 1.58 (s, 6H), 1.76-1.96 (m,2H), 2.09-2.52 (m, 6H), 2.55-2.88 (m, 4H), 5.18-5.50 (br s, 2H), 6.12(t, 1H), 6.83 (d, 1H), 7.22-7.36 (m, 6H), 7.46 (dd, 1H), 7.59 (d, 1H),8.51 (d, 1H).

MS m/z: 521 (M+1).

Example 4704-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidine-3,4-diolStep 1

To a suspension of 4-(4-Chloro-phenyl)-1,2,3,6-tetrahydro-pyridinehydrochloride (2 g, 8.73 mmol) in methylene chloride (50 mL) was addedtriethylamine (1.42 g, 1.95 mL, 14.0 mol). The resulting mixture wascooled to 0° C. and di-tert-butyl-dicarbonate (2.19 g, 10.0 mmol) wasadded in a single portion. After 10 min at 0° C., the mixture was warmedto rt and stirred 90 min. The contents of the flask were poured into 250mL methylene chloride and washed with 1 N hydrochloric acid/brine (3:1),saturated aqueous sodium bicarbonate and brine. The organic phase wasdried over magnesium sulfate, filtered, concentrated and the resultingoil filtered through a plug of silica with methylene chloride elution,to afford 2.88 g (>100%) of4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylester.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.49 (s, 9H), 2.45-2.52 (m, 2H), 3.63 (t,2H), 4.07 (q, 2H), 6.02 (br s, 1H), 7.29 (s, 4H).

Step 2

The product of step 1 (2.88 g, approx. 8.7 mmol) was dissolved in 15 mLof a 5:1 acetone:water solution. Osmium tetroxide (2.5% in tert-butylalcohol, 1 mL) was added followed by 4-methyl morpholine N-oxide (1.13g, 9.65 mmol). The mixture was stirred at rt 16 h. Saturated aqueoussodium bisulfite (5 mL) was added and the acetone was removed underreduced pressure. The resulting aqueous phase was extracted withmethylene chloride and the extracts washed with an aliquot of saturatedaqueous sodium bisulfite, 1 N hydrochloric acid, saturated aqueoussodium bicarbonate and brine. The extracts were then dried overmagnesium sulfate, filtered and concentrated to afford an oil which waspurified by silica gel chromatography (100% methylene chloride to 90:10methylene chloride:methanol gradient).4-(4-Chloro-phenyl)-3,4-dihydroxy-piperidine-1-carboxylic acidtert-butyl ester was afforded as an oil (2.64 g, 83%, 2 steps).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.44 (s, 9H), 1.62 (br d, 1H), 1.82 (br s,2H), 2.69 (br s, 1H), 2.99 (br t, 1H), 3.12 (br s, 1H), 3.90-4.30 (m,3H), 7.33 (d, 2H), 7.41 (d, 2H).

Step 3

The product of step 2 (500 mg, 1.37 mmol) was dissolved in methylenechloride (10 mL) and the resulting solution cooled to 0° C.Trifluoroacetic acid (3 mL) was slowly added and the reaction wasallowed to stir at 0° C. for 2 h, before concentration under reducedpressure. The trifluoroacetate salt was dissolved in tetrahydrofuran andexcess triethylamine was added. Solids generated were removed by suctionfiltration and the supernatant solution was concentrated to afford4-(4-chloro-phenyl)-piperidine-3,4-diol.

¹H-NMR (CD₃OD, 300 MHz) δ: 1.91 (ddd, 1H), 2.13 (ddd, 1H), 3.12-3.28 (m,4H), 4.08 (dd, 1H), 7.37 (ddd, 2H), 7.51 (ddd, 2 H).

Step 4

The titled compound was prepared following the procedure in step 2 ofExample 467, but replacing 4-(4-Chloro-phenyl)-4-fluoro-piperidine with4-(4-Chloro-phenyl)-piperidine-3,4-diol.

¹H-NMR (CD₃OD, 300 MHz) δ: 1.51 (s, 6H), 1.80 (br d, 1H), 2.03-2.11 (m,1H), 2.56 (q, 2H), 2.68-3.12 (m, 6H), 4.00 (dd, 1H), 5.00-5.50 (br s,2H), 6.17 (t, 1H), 6.76 (d, 2H), 7.27 (dd, 1H), 7.33 (ddd, 2H),7.44-7.49 (m, 4H), 7.80 (dd, 1H), 8.48 (dd, 1H).

MS m/z: 521 (M+1).

Example 4714-(4-Chloro-phenyl)-3-ethyl-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-ol Step 1

A solution of 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (5 g,25.1 mmol), pyrollidine (5 mL) and p-toluenesulfonic acid (25 mg) inbenzene (100 mL) was heated at reflux for 16 h with azeotropicdistillation of water. The resulting enamine solution was cooled to rtand concentrated. The crude enamine was dissolved in acetonitrile (50mL); iodoethane (4.67 g, 30.1 mmol.) was added and the mixture washeated at 100° C. for 0.5 h, cooled to rt and concentrated. The mixturewas dissolved in ethyl acetate (200 mL), washed with 1 N hydrochloricacid, saturated aqueous sodium bicarbonate, and brine. The extract wasdried over magnesium sulfate, filtered and concentrated. The crudecompound was purified by silica gel chromatography (80% hexanes/20%ethyl acetate) to afford 3-ethyl-4-oxo-piperidine-1-carboxylic acidtert-butyl ester (680 mg).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.95 (t, 3H), 1.26-1.42 (m, 1H), 1.50 (s,9H), 1.69-1.85 (m, 1H), 2.30 (br s, 1H), 2.43 (q, 2H), 2.90-4.36 (m,4H).

Step 2

4-(4-Chloro-phenyl)-3-ethyl-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester was prepared following the procedure in step 2 ofExample 502, substituting 3-ethyl-4-oxo-piperidine-1-carboxylic acidtert-butyl ester for 3,3-dimethyl-4-oxo-piperidine-1-carboxylic acidtert-butyl ester.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.80 (t, 3H), 0.91-1.13 (m, 2H), 1.18-1.28(m, 1H), 1.48 (s, 9H), 1.57-1.64 (br d, 1H), 1.75-1.91 (m, 2H), 2.79 (t,1H), 3.14 (ddd, 1 H), 4.02 (br d, 1H), 4.19 (br d, 1H), 7.28-7.37 (m,4H).

Step 3

4-(4-Chloro-phenyl)-3-ethyl-piperidin-4-ol was prepared according to theprocedure of step 3 in Example 502, substituting4-(4-chloro-phenyl)-3-ethyl-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester for4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acidtert-butyl ester.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.75 (t, 3H), 0.88-1.17 (m, 2H), 1.26 (t,1H), 1.65 (br d, 2H), 1.83-2.02 (m, 2H), 2.75 (t, 1H), 2.95-3.21 (m,3H), 7.32 (d, 2H), 7.40 (d, 2 H).

MS m/z: 240 (M+1).

Step 4

The titled compound was prepared following the procedure in step 5 ofExample 502, substituting 4-(4-chloro-phenyl)-3-ethyl-piperidin-4-ol for4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.70 (t, 3H), 0.81-1.11 (m, 3H), 1.56-1.64(m, 7H), 1.77-2.09 (m, 4H), 2.23-2.86 (m, 7H), 5.00-5.60 (m, 2H), 6.13(t, 1H), 6.83 (d, 1 H), 7.23-7.47 (m, 6H), 7.46 (d, 1H), 7.59 (dd, 1H),8.49 (dd, 1H).

MS m/z: 533 (M+1).

Example 4725-Chloro-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]-cyclohepten-5-ylidene}-propyl]-spiro[3-oxo-1,3-dihydroisobenzofuran-1,4′-piperidine]Step 1

To a suspension of 2-bromo-5-chlorobenzoic acid (1.5 g, 6.4 mmol) inmethylene chloride (15 mL) at room temperature was added oxalyl chloride(969 mg, 666 μL, 7.64 mmol) and 2 drops of dimethylformamide; bubblingcommenced and the mixture ultimately became homogenous. The mixture wasstirred at roorm temperature for 7 hours and concentrated. The resultingacid chloride residue was dissolved in methylene chloride (15 mL).Triethylamine (325 mg, 450 μL, 3.2 mmol) was added, followed by2-amino-2-methyl-1-propanol (627 mg, 672 μL, 7.04 mmol) and the reactionwas allowed to stir at rt 3 h. The mixture was poured into 1 Nhydrochloric acid (50 mL), extracted with methylene chloride (2×75 mL).The combined extracts were washed with saturated aqueous sodiumbicarbonate, brine and dried over magnesium sulfate, filtered andconcentrated and dried in vacuo. The crude amide residue was dissolvedin methylene chloride (15 mL) and thionyl chloride (1.29 g, 794 μL, 10.9mmol) was added. Stirring at room temperature was carried out for 4 hafter which the mixture was poured into saturated sodium bicarbonate (50mL). The pH was adjusted to 9 by the addition of solid sodiumbicarbonate and further basified by the addition of several millilitersof aqueous sodium hydroxide (5 N). The biphasic mixture was extractedwith methylene chloride (150+50 mL). The combined extracts were washedwith brine, dried over magnesium sulfate, filtered and concentrated toafford the crude residue which was purified by silica gel chromatography(80% hexanes/20% ethyl acetate gradient) to yield2-(2-bromo-5-chloro-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole (1.15 g,62%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.42 (s, 6H), 4.14 (s, 2H), 7.25 (dd, 1H),7.55 m (d, 1 H), 7.67 (d, 1H).

Step 2

To a cold (−78° C.) solution of the product of step 1 (1.09 g, 4.63mmol) in anhydrous tetrahydrofuran (10 mL) was added a solution ofn-butyllithium (1.6 M in hexanes, 2.89 mL, 4.63 mmol) and the contentsof the reaction were allowed to react for 0.5 h. A solution of4-oxo-piperidine-1-carboxylic acid tert-butyl ester (922 mg, 4.63 mmol)in tetrahydrofuran (10 mL) was added and the combined contents stirredfor 2 h at −78° C. Reaction was quenched by the addition of saturatedaqueous ammonium chloride (30 mL), followed by warming to rt. Thebiphasic mixture was extracted with ethyl acetate (150 mL); washed withwater and brine; dried over magnesium sulfate; filtered andconcentrated.4-[4-Chloro-2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-phenyl]-4-hydroxy-piperidine-1-carboxylicacid tert-butyl ester was isolated (412 mg, 22%) following silica gelchromatography (80% hexanes/20% ethyl acetate). ¹H-NMR (CDCl₃, 300 MHz,mixture; spectrum of major component:) δ: 1.36 (s, 6H), 1.50 (s, 9H),1.66 (d, 2H), 1.96 (dd, 2H), 3.19 (br d, 2H), 3.42 (d, 2H), 4.24 (br s,2H), 7.16 (d, 1H), 7.45 (dd, 1H), 7.71 (br s, 1H).

MS m/z: 409 (M+1).

Step 3

To a solution of the product of step 2 (200 mg, 0.49 mmol) intetrahydrofuran (5 mL) was added water (5 mL) and oxalic acid (300 mg).Stir at rt for about 4 days. The solids were separated and dissolved inethyl acetate (50 mL); the resulting solution was washed with saturatedaqueous sodium bicarbonate and brine. The extracts were dried overmagnesium sulfate; filtered and concentrated. The5-chlorospiro[3-oxo-1,3-dihydroisobenzofuran-1,4′-piperidine]-1-carboxylicacid tert-butyl ester thus afforded (100 mg, 61%) was used withoutfurther purification.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.49 (s, 9H), 1.67 (d, 2H), 2.04 (ddd, 2H),3.24 (dd, 2 H), 4.21 (br s, 2H), 7.32 (d, 1H), 7.64 (dd, 1H), 7.85 (d,1H).

MS m/z: 238 (M+1-100).

Step 4

5-Chlorospiro[3-oxo-1,3-dihydroisobenzofuran-1,4′-piperidine] wasprepared according to the procedure in step 3 of Example 502, using5-chlorospiro[3-oxo-1,3-dihydroisobenzofuran-1,4′-piperidine]-1-carboxylicacid tert-butyl ester instead of4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acidtert-butyl ester.

¹H-NMR (CDCl₃, 300 MHζ) δ: 1.71 (d, 2H), 2.09-2.22 (m, 2H), 3.13-3.28(m, 4 H), 7.37 (d, 1H), 7.64 (dd, 1H), 7.84 (d, 1H).

MS m/z: 238 (M+1).

Step 5

The titled compound was prepared according to the procedure in step 2 ofExample 467, substituting5-chlorospiro[3-oxo-1,3-dihydroisobenzofuran-1,4′-piperidine] for4-(4-chloro-phenyl)-4-fluoro-piperidine.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.58 (s, 6H), 1.64 (d, 2H), 2.04-2.15 (m,3H), 2.33-2.50 (m, 3H), 2.57 (t, 2H), 2.76 (d, 2H), 5.20-5.50 (br s,2H), 6.12 (t, 1H), 6.81 (d, 1H), 7.22-7.34 (m, 3H), 7.45 (d, 2H),7.55-7.63 (m, 2H), 7.81 (d, 1H), 8.48 (dd, 1H).

MS m/z: 531 (M+1).

Example 4734-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-4-methoxy-3-methyl-piperidin-3-olStep 1

To a suspension of 4-(4-chloro-phenyl)-1,2,3,6-tetrahydro-pyridinehydrochloride (5 g, 21.8 mmol) in methylene chloride (100 mL) was addedtriethylamine (3.6 g, 4.9 mL, 35 mmol). The resulting solution wascooled to 0° C. in an ice-water bath. Di-tert-butyl-dicarbonate (5.4 g,25 mmol) was added and the resulting reaction was allowed to warm to rtand stir over night. The mixture was poured into 100 mL of a 1:1 1 NHCl:brine solution and diluted with methylene chloride (300 mL). Theorganic phase was washed with saturated aqueous sodium bicarbonate andbrine, dried over magnesium sulfate, filtered and concentrated to afford4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylester (6.68 g, 93%) as a colorless oil, which was used without furtherpurification. ¹H-NMR (CDCl₃, 300 MHz) δ: 1.48 (s, 9H), 2.45-2.55 (m,2H), 3.63 (t, 2H), 4.07 (q, 2H), 6.03 (br s, 1H), 7.29 (m, 4H).

Step 2

To a cooled (0° C.) solution of4-(4-chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylester (7.10 g, approx. 24.1 mmol) in methylene chloride (150 mL) wasadded a solution of 3-chloroperbenzoic acid (75%, 8.34 g, 36.2 mmol) inmethylene chloride (120 mL) over 40 min. The mixture was warmed to rtand allowed to stir over night (16 h). The solution was washed twicewith a half-saturated aqueous solution of sodium bisfulfite to destroyexcess oxidant. The mixture was then twice washed with half-saturatedaqueous potassium carbonate, and brine. The extracts were dried overmagnesium sulfate, filtered and concentrated to afford a crude oil whichwas purified by silica gel chromatography (100% hexanes-80% hexanes/20%ethyl acetate gradient) to afford pure6-(4-Chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acidtert-butyl ester (5.34 g, 71%) as a clear, colorless oil whichsolidified on standing.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.48 (s, 9H), 2.06-2.22 (m, 1H), 2.42 (ddd,1H), 3.08-3.23 (m, 2H), 3.57-4.19 (m, 3H), 7.26-7.36 (m, 4H).

Step 3

To a solution of6-(4-Chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acidtert-butyl ester (2.4 g, 7.8 mmol) in methanol (100 mL) was added acatalytic amount of p-toluenesulfonic acid (ca. 50 mg). The resultingsolution was heated at reflux 24 h, cooled and concentrated. The cruderesidue was purified by silica gel chromatography (100% hexanes-80%hexanes/20% ethyl acetate gradient) to afford4-(4-chloro-phenyl)-3-hydroxy-4-methoxy-piperidine-1-carboxylic acidtert-butyl ester (2.05 g, 77%); note the diol moiety has thetrans-orientation.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.47 (s, 9H), 1.95 (d, 1H), 2.37 (ddd, 1H),2.97 (s, 3 H), 3.47 (d, 1H), 3.67 (br s, 1H), 3.98-4.17 (m, 3H),7.29-7.42 (m, 4H).

Step 4

A solution of4-(4-chloro-phenyl)-3-hydroxy-4-methoxy-piperidine-1-carboxylic acidtert-butyl ester (2.05 g, 6.0 mmol) in methylene chloride (75 mL) wascooled to 0° C. Dess-Martin periodinane (3.30 g, 7.8 mmol) was added,followed by water (200 uL) and the reaction allowed to stir at rt 2 h.The reaction was quenched by the addition of a solution consisting ofequal parts saturated aqueous sodium thiosulfate and saturated aqueoussodium bicarbonate; the resulting reaction was stirred until the mixtureformed two homogenous phases. The phases were separated and the aqueousphase was extracted with ethyl acetate. The combined organic phases werewashed with brine and dried over magnesium sulfate, filtered andconcentrated. The crude mixture was purified by silica gelchromatography to afford recovered starting material (1.17 g, 57%) and4-(4-chloro-phenyl)-4-methoxy-3-oxo-piperidine-1-carboxylic acidtert-butyl ester (540 mg, 27% (62% brsm)).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.43 (s, 9H), 2.16-2.40 (m, 2H), 3.12 (s,3H), 3.55 (ddd, 1H), 3.80 (br s, 1H), 3.96 (d, 1H), 4.34 (br s, 1H),7.23-7.40 (m, 4H).

Step 5

To a solution of4-(4-chloro-phenyl)-4-methoxy-3-oxo-piperidine-1-carboxylic acidtert-butyl ester (470 mg, 1.38 mmol) in anhydrous tetrahydrofuran (10mL) at 0° C. was added methylmagnesium bromide (1.4 M in diethyl ether,2.96 mL, 4.15 mmol) and the resulting mixture was stirred at thattemperature for 3 h. Excess organomagnesium was quenched by the additionof saturated aqueous ammonium chloride and the reaction was allowed towarm to rt. To the biphasic mixture was added water and ethyl acetate.The phases were separated and the organic phase washed with brine, driedover magnesium sulfate, filtered, dried and concentrated to afford acrude residue which was purified by silica gel chromatography (100%methylene chloride-97.5% methylene chloride/2.5% methanol gradient) toafford pure4-(4-chloro-phenyl)-3-hydroxy-4-methoxy-3-methyl-piperidine-1-carboxylicacid tert-butyl ester (269 mg, 58%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.97 (s, 3H), 1.50 (s, 9H), 1.81 (d, 1H),2.59 (ddd, 1 H), 2.96 (br t, 1H), 3.11 (s, 3H), 3.31 (s, 3H), 3.72-3.88(m, 1H), 7.27-7.37 (m, 4 H).

Step 6

4-(4-Chloro-phenyl)-3-hydroxy-4-methoxy-3-methyl-piperidine-1-carboxylicacid tert-butyl ester (260 mg, 0.74 mmol) was dissolved in methylenechloride (5 mL) and the resulting solution was cooled to 0° C.Trifluoroacetic acid (1 mL) was added and the mixture was stirred 2 h.Solvents were then removed under reduced pressure and the residuedissolved in ethyl acetate. Water and 6 N aqueous sodium hydroxide wereadded until the pH=10. The organic phase was washed with brine and driedover magnesium sulfate, filtered and concentrated to afford4-(4-chloro-phenyl)-4-methoxy-3-methyl-piperidin-3-ol.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.94 (s, 3H), 1.91 (d, 1H), 2.65-2.81 (m,2H), 2.94 (ddd, 1H), 3.13 (s, 3H), 3.25 (d, 1H), 3.30 (m, 1H), 7.37 (s,4H).

MS m/z: 256 (M+1).

Step 7

To a solution of 4-(4-chloro-phenyl)-4-methoxy-3-methyl-piperidin-3-01(206 mg, 1.24 mmol) in acetonitrile/water (4:1, 20 mL) was addedpotassium carbonate (171 mg, 1.24 mmol) followed by2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(417 mg, 1.12 mmol). The mixture was stirred at rt 40 h andconcentrated. The product residue was partitioned between ethyl acetateand water and the organic phase was washed with brine, dried overmagnesium sulfate, filtered and concentrated. The crude product waspurified by silica gel chromatography (100% methylene chloride-90%methylene chloride/10% methanol gradient) to afford the titled compound(232 mg, 35%) as an off-white solid.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.83 (s, 3H), 1.57 (s, 6H), 1.76-1.94 (m,2H), 2.20 (t, 1H), 2.29-2.72 (m, 7H), 3.06 (s, 3H), 3.39 (br s, 1H),5.19-5.54 (br s, 2H), 6.12 (t, 1H), 6.82 (d, 1H), 7.21-7.34 (m, 6H),7.46 (d, 1H), 7.58 (d, 1H), 8.51 (d, 1H).

MS m/z: 549 (M+1).

Example 4744-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-4-methoxy-piperidin-3-olStep 1

4-(4-Chloro-phenyl)-4-methoxy-piperidin-3-ol was prepared following theprocedure in Step 6 of Example 473, replacing4-(4-chloro-phenyl)-3-hydroxy-4-methoxy-3-methyl-piperidine-1-carboxylicacid tert-butyl ester with4-(4-chloro-phenyl)-3-hydroxy-4-methoxy-piperidine-1-carboxylic acidtert-butyl ester.

MS m/z: 242 (M+1).

Step 2

The titled compound was prepared following the procedure of Step 7 inExample 473, replacing4-(4-chloro-phenyl)-4-methoxy-3-methyl-piperidin-3-ol with the productof Step 1 in Example 474.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.58 (s, 6H), 1.63-1.82 (m, 3H), 1.95 (d,1H), 2.21-2.78 (m, 8 H), 2.91 (s, 3H), 3.63 (br s, 1H), 5.32 (br s, 2H),6.11 (t, 1H), 6.81 (d, 1 H), 7.21-7.37 (m, 6H), 7.44 (d, 1H), 7.57 (dd,1H), 8.51 (dd, 1H).

MS m/z: 535 (M+1).

Example 4752-(5-{3-[4-(4-Chloro-phenyl)-3,4-dimethoxy-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1

The product of Step 3 in Example 473 (259 mg, 0.76 mmol) was dissolvedin tetrahydrofuran (5 mL) and cooled to 0° C. Sodium hydride (60%dispersion in mineral oil, 46 mg, 1.15 mmol) was added in a singleportion and the mixture stirred 5 min. Methyl iodide was added and themixture was warmed to rt and stirred 48 h. Excess base was quenched bythe addition of saturated aq. NH₄Cl and water. The biphasic mixture wasextracted twice with ethyl acetate. The extracts were combined, washedwith brine and dried over sodium sulfate, filtered and concentrated. Thecrude residue was purified by silica gel chromatography (hexanes-80hexanes/20 ethyl acetate gradient) to afford4-(4-chloro-phenyl)-3,4-dimethoxy-piperidine-1-carboxylic acidtert-butyl ester (191 mg, 71%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.47 (s, 9H), 1.90 (d, 1H), 2.31 (ddd, 1H),2.91-3.38 (m, 9H), 3.93-4.37 (br m, 2H), 7.24-7.37 (m, 4H).

Step 2

4-(4-Chloro-phenyl)-3,4-dimethoxy-piperidine was prepared following theprocedure in Step 6 of Example 473, substituting the product of Step 1for4-(4-Chloro-phenyl)-3-hydroxy-4-methoxy-3-methyl-piperidine-1-carboxylicacid tert-butyl ester.

¹H-NMR (CD₃OD, 300 MHz) δ: 1.96 (d, 1H), 2.27 (dddd, 1H), 2.71-3.03 (m,9H), 3.04-3.15 (m, 2H), 7.30-7.41 (m, 4H).

MS m/z: 256 (M+1).

Step 3

The titled compound was prepared following the procedure in Step 7 ofExample 473, substituting the product of Step 2 for4-(4-chloro-phenyl)-4-methoxy-3-methyl-piperidin-3-ol.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.58 (s, 6H), 1.67 (br s, 2H), 1.77 (s, 1H),1.91 (d, 1H), 2.18-2.31 (m, 1H), 2.33-2.47 (m, 2H), 2.48-2.62 (m, 2H),2.65-2.75 (m, 1H), 2.83-2.90 (m, 4H), 2.92 (s, 3H), 3.07 (br s, 1H),5.06-5.57 (br s, 2H), 6.10 (t, 1H), 6.82 (d, 1H), 7.22-7.35 (m, 6H),7.44 (d, 1H), 7.59 (d, 1H), 8.50 (d, 1H).

MS m/z: 549 (M+1).

Example 4763-Azido-4-(4-chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene}-propyl}-piperidin-4-olStep 1: 4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acidtert-butyl ester

To a solution of di-tert-butyl-dicarbonate (9.96 g, 45.6 mmol) in CH₂Cl₂(500 mL) was added 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridinehydrochloride (10.00 g, 43.5 mmol) and triethylamine (12.42 mL, 89mmol). The solution was stirred at rt for 4 h. Gas evolution wasobserved. The reaction was quenched with 1N HCl and extracted withCH₂Cl₂ (3×), and the organic layers were collected together, dried overMgSO₄ and evaporated in vacuo. The residue was purified to yield thetitle compound as a colorless oil. ¹H-NMR (CDCl₃) δ: 1.50 (9H, s), 2.46(2H, br s), 3.62 (2H, br s), 4.05 (2H, br s), 6.01 (1H, br s), 7.25 (4H,s).

Step 2:6-(4-Chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acidtert-butyl ester

To a solution of4-(4-chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylester (4.0 g, 13.6 mmol) in CH₂Cl₂ (136 mL) cooled to 0° C.3-Chloroperbenzoic acid (4.07 g, 20.4 mmol) was dissolved in CH₂Cl₂ andadded portion wise over 45 min. A white precipitate was observed. Thesolution was allowed to stir at room temperature for 14 h. The reactionwas washed with 1×10% NaSO₃, 1×10% Na₂CO₃, 1× brine and dried overMg₂SO₄, filtered and evaporated in vacuo. The residue was purified byBiotage flash system (90% hexane/10% ethyl acetate to 80% hexane/20%ethyl acetate to yield the title compound as a colorless oil (2.75 g,65%).

¹H-NMR (CDCl₃) δ: 1.50 (9H, s), 2.15 (1H, m), 3.15 (2H, m), 3.6-4.2 (4H,m), 7.31 (4H, s).

Step 3: 4-Azido-4-(4-chloro-phenyl)-3-hydroxy-piperidine-1-carboxylicacid tert-butyl ester and3-azido-4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester

To a solution of6-(4-chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acidtert-butyl ester (0.960 g, 3.1 mmol) in 31 mL of DMSO was added sodiumazide (0.970 g, 14.9 mmol). The solution was allowed to heat at 100° C.for 24 h and cooled to room temperature. The reaction was washed withwater, dried over Mg₂SO₄, filtered and evaporated in vacuo. The residuewas purified by Biotage flash system (90% hexane/10% ethyl acetate to80% hexane/20% ethyl acetate to 70% hexane/30% ethyl acetate to yieldtwo compounds. The faster eluting isomer4-azido-4-(4-chloro-phenyl)-3-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.010 g, 9%)

¹H-NMR (CDCl₃) δ: 1.46 (s, 9H), 1.93 (d, 1H), 2.51 (dt, 1H), 3.10 (bt,1H), 3.34 (d, 1H), 3.80 (bs, 1H), 4.08 (m, 2H), 7.41 (s, 4H). The slowereluting isomer3-azido-4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.361 g, 33%) ¹H-NMR (CDCl₃) δ: 1.43 (s, 9H), 1.57 (m,1H), 2.40 (t, 1H), 2.93 (m, 1H), 3.11 (t, 1H), 3.50 (s, 1H), 3.56 (d,1H), 4.07 (m, 2H), 7.33 (d, 2H), 7.40 (d, 2H).

Step 4

The Boc-protected azido-alcohol (0.184 g, 0.5 mmol) was dissolved inCH₂Cl₂ (2 mL) and cooled to 0° C. and TFA (0.790 mL) was added. Thesolution was allowed to stir at 0° C. for 1 h. The solvent wasevaporated in vacuo and the residue was partitioned between NaHCO₃ andCH₂Cl₂. The aqueous solution was extracted (3×) and then washed withbrine and dried over Na₂SO₄. The residue was carried onto the next stepwithout further purification.

Step 5

To a solution of the azido piperidine (0.142 g, 0.56 mmol) inisopropanol (5.6 mL) was added 2,6-lutidine (0.066 mL, 0.8 mmol) andcatalytic potassium iodide. This mixture was heated to 80° C., andtreated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.025 g, 0.067 mmol), added in portions over 2 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Biotage flash chromatography (75% EtOAc/25%Hexane to 100% ethyl acetate) to yield the title compound (0.135 g,66%). ¹H-NMR (CDCl₃): δ 1.56 (6H, s), 1.65 (d, 1H), 1.85 (s, 1H), 2.13(s, 1H), 2.36-2.94 (m, 8H), 3.51 (s, 1H), 5.24 (bs, 2H), 6.16 (t, 1H),6.80 (d, 1H), 7.21-7.45 (m, 7H), 7.58 (d, 1H), 8.44 (d, 1H). ESI-MS m/z:546(M+1), retention time 1.55.

Example 4774-Azido-4-(4-chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-3-ol Step 1

The Boc-protected azido-alcohol (Example 476, step 3) (0.050 g, 0.2mmol) was dissolved in CH₂Cl₂ (2 mL) and cooled to 0° C. and TFA (0.2mL) was added. The solution was allowed to stir at 0° C. for 1 h. Thesolvent was evaporated in vacuo and the residue was partitioned betweenNaHCO₃ and CH₂Cl₂. The aqueous solution was extracted (3×) and thenwashed with brine and dried over Na₂SO₄. The residue was carried ontothe next step without further purification.

Step 2

To a solution of the azido piperidine (0.025 g, 0.1 mmol) in isopropanol(1.0 mL) was added 2,6-lutidine (0.012 mL, 0.1 mmol) and catalyticpotassium iodide. This mixture was heated to 80° C., and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.025 g, 0.067 mmol), added in portions over 2 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Biotage flash chromatography (100% ethylacetate) to yield the title compound (0.013 g, 36%). ¹H-NMR (CDCl₃): δ1.56 (s, 6H), 1.65 (d, 1H), 1.85 (s, 1H), 2.13 (s, 1H), 2.36-2.94 (m,8H), 3.51 (s, 1H), 5.24 (bs, 2H), 6.16 (t, 1H), 6.80 (d, 1H), 6.93 (d,1H), 7.21-7.46 (m, 8H), 7.58 (d, 1H), 8.42 (d, 1H). ESI-MS m/z:546(M+1), retention time 1.71.

Example 478N-[4-(4-Chloro-phenyl)-4-hydroxy-1-{3-[7-(hydroxyl-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-3-yl)-propionamideStep 1: 3-Amino-4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylicacid tert-butyl ester

3-azido-4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.67 g, 0.2 mmol) was dissolved in Et₂O (2 mL) andcooled to 0° C. and LiAlH₄ (0.280 mL, 0.23 mmol) was added. The solutionwas allowed to warm to room temperature and stir for 2 h. A whiteprecipitate formed. The reaction mixture was quenched with water andextracted with Et₂O (3×). The organic layers were collected together,dried over MgSO₄ and evaporated in vacuo to give the amino alcohol whichwas used directly in the next reaction.

Step 2: 4-(4-Chloro-phenyl)-4-hydroxy3-propionylamino-piperidine-1-carboxylic acid tert-butyl ester

3-Amino-4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.116 g, 0.35 mmol) was dissolved in CH₂Cl₂. Propionylchloride (0.034 mL, 0.39 mmol) and triethylamine (0.109 mL, 0.78 mmol)were added and the solution was stirred for 24 h at room temperature.The reaction was concentrated in vacuo, then purified by Biotage flashchromatography (30% ethyl acetate/70% hexane to 50% ethyl acetate/50%hexane) to yield the title compound (0.133 g, 97%). ¹H-NMR (CDCl₃): δ0.87 (t, 3H), 1.44 (s, 9H), 1.78-1.95 (m, 3H), 2.20 (dt, 1H), 3.24 (t,1H), 3.50 (d, 1H), 3.90 (t, 1H), 4.08 (q, 2H), 4.28 (d, 1H), 5.48 (bd,1H), 7.26 (d, 2H), 7.37 (d, 2H). ESI-MS m/z: 383 (M+1), retention time2.21.

Step 3

The Boc-protected 3-N-acyl-alcohol (0.180 g, 0.47 mmol) was dissolved inCH₂Cl₂ (5 mL) and cooled to 0° C. and TFA (2 mL) was added. The solutionwas allowed to stir at 0° C. for 1 h. The solvent was evaporated invacuo and the residue was partitioned between NaHCO₃ and CH₂Cl₂. Theaqueous solution was extracted (3×) and then washed with brine and driedover Na₂SO₄. The residue was carried onto the next step without furtherpurification.

Step 4

To a solution of theN-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-3-yl]-propionamide (0.133 g,0.47 mmol) in isopropanol (5.0 mL) was added 2,6-lutidine (0.055 mL,0.47 mmol) and catalytic potassium iodide. This mixture was heated to80° C., and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.176 g, 0.35 mmol), added in portions over 2 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by HPLC (acetonitrile/H₂O/Formic acid) to yieldthe title compound as a white formate salt (0.085 g, 27%). ¹H-NMR(CDCl₃): δ 0.780 (t, 3H), 1.55 (s, 6H), 1.90 (m, 3H), 2.60 (m, 2H),2.92-3.28 (m, 6H), 4.50 (d, 1H), 5.26 (bs, 2H), 6.00 (t, 1H), 6.82 (d,1H), 7.22-7.37 (m, 6H), 7.44 (s, 1H), 7.56 (d, 1H), 8.20 (d, 1H), 8.34(s, 1H), 8.47 (d, 1H). ESI-MS m/z: 576(M+1), retention time 1.43.

Example 479Trans-4-(4-Chloro-phenyl)-4-hydroxy-1-{3-[7-(1-hydroxyl-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-3-carbonitrileStep 1: Cis andtrans-4-(4-chloro-phenyl)-3-cyano-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester

Acetone cyanohydrin (0.917 mL, 10 mmol) was added to THF (22 mL) andcooled to 0° C. To the solution was added lithium hydride (0.077 g, 9.7mmol) in several portions over 20 min. and then stirred at roomtemperature for 1 h.6-(4-Chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acidtert-butyl ester (1.00 g, 3.2 mmol) dissolved in THF (10 mL) was addedto the above solution and heated to reflux for 7½ h. The reaction wasdiluted with H₂O and extracted (3×). The reaction was washed with water,dried over Mg₂SO₄, filtered and evaporated in vacuo. The residue waspurified by Biotage flash system (90% hexane/10% ethyl acetate to 80%hexane/20% ethyl acetate to 70% hexane/30% ethyl acetate to yield twocompounds. The faster eluting isomercis-4-(4-chloro-phenyl)-3-cyano-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.210 g, 19%) ¹H-NMR (CDCl₃): δ 1.35 (s, 9H),1.59-1.86 (m, 2H), 2.83-3.30 (m, 3H), 3.88 (bs, 2H), 4.16 (m, 1H), 7.23(d, 2H), 7.33 (d, 2H).

The second eluting isomer was thetrans-4-(4-chloro-phenyl)-3-cyano-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.560 g, 51%). ¹H-NMR (CDCl₃): δ 1.43 (s, 9H), 1.70(d, 1H), 2.47 (dt, 1H), 2.76 (bs, 2H), 3.10-3.54 (m, 2H), 4.18 (m, 2H),7.31 (d, 2H), 7.44 (d, 2H).

Step 2

Trans-4-(4-chloro-phenyl)-3-cyano-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.210 g, 0.62 mmol) was dissolved in CH₂Cl₂ (5 mL) andcooled to 0° C. and TFA (1.0 mL) was added. The solution was allowed tostir at 0° C. for 1 h. The solvent was evaporated in vacuo and theresidue was partitioned between NaHCO₃ and CH₂Cl₂. The aqueous solutionwas extracted (3×) and then washed with brine and dried over Na₂SO₄. Theresidue was carried onto the next step without further purification.

Step 3

To a solution of the trans-3-cyano-4-hydroxypiperidine (0.137 g, 0.58mmol) in isopropanol (5.7 mL) was added 2,6-lutidine (0.067 mL, 0.58mmol) and catalytic potassium iodide. This mixture was heated to 80° C.,and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.108 g, 0.29 mmol), added in portions over 2 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Biotage flash chromatography (50% ethylacetate/50% hexane to 75% ethyl acetate/25% hexane to 100% ethylacetate) to yield the title compound (0.040 g, 26%). ¹H-NMR (CDCl₃): δ1.50 (d, 6H), 1.63 (s, 1H), 1.78 (d, 1H), 2.08 (s, 1H), 2.35 (m, 2H),2.51-3.03 (m, 6H), 3.48 (s, 1H), 5.29 (bs, 2H), 6.42 (t, 1H), 6.79 (d,1H), 7.15 (d, 1H), 7.28 (m, 1H), 7.37 (d, 2H), 7.50 (d, 2H), 7.55 (s,1H), 7.58 (d, 1H), 8.46 (d, 1H). ESI-MS m/z: 530.2 (M+1), retention time1.50.

Example 480Cis-4-(4-Chloro-phenyl)-4-hydroxy-1-{3-[7-(1-hydroxyl-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-3-carbonitrileStep 1

Cis-4-(4-chloro-phenyl)-3-cyano-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.210 g, 0.62 mmol) was dissolved in CH₂Cl₂ (3 mL) andcooled to 0° C. and TFA (1 mL) was added. The solution was allowed tostir at 0° C. for 1 h. The solvent was evaporated in vacuo and theresidue was partitioned between NaHCO₃ and CH₂Cl₂. The aqueous solutionwas extracted (3×) and then washed with brine and dried over Na₂SO₄. Theresidue was carried onto the next step without further purification.

Step 2

To a solution of the cis-3-cyano-4-hydroxypiperidine (0.125 g, 0.53mmol) in isopropanol (5.8 mL) was added 2,6-lutidene (0.061 mL, 0.53mmol) and catalytic potassium iodide. This mixture was heated to 80° C.,and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.100g, 0.26 mmol), added in portions over 2 h. The solution was then stirredat 80° C. for an additional 14 h. The reaction was concentrated invacuo, then purified by Biotage flash chromatography (50% ethylacetate/50% hexane to 75% ethyl acetate/25% hexane to 100% ethylacetate) to yield the title compound (0.050 g, 35%). ¹H-NMR (CDCl₃): δ1.53 (d, 1H), 1.57 (s, 6H), 1.74 (d, 1H), 1.89 (s, 1H), 2.35-2.68 (m,7H), 2.88 (d, 1H), 3.11 (d, 1H), 5.30 (bs, 2H), 6.11 (t, 1H), 6.82 (d,1H), 7.23-7.45 (m, 7H), 7.57 (d, 1H), 8.48 (d, 1H). ESI-MS m/z: 530.2(M+1), retention time 1.58.

Example 4814-(4-Chloro-phenyl)-4-hydroxy-1-{3-[7-(hydroxyl-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene}-propyl]-3-methyl-piperidine-3-carboxylicacid methyl ester Step 1: 4-Oxo-piperidine-1,3-dicarboxylic acid1-tert-butyl ester 3-methyl ester

To a solution of di-tert-butyl-dicarbonate (3.08 g, 14.1 mmol) in CH₂Cl₂(134 mL) was added methyl-4-oxo-3-piperidine carboxylate HCl (2.6 g,13.4 mmol) and triethylamine (3.84 mL, 27.5 mmol). The solution wasstirred at rt for 12 h. Gas evolution was observed. The reaction wasquenched with 1N HCl and extracted with CH₂Cl₂ (3×), and the organiclayers were collected together, dried over MgSO₄ and evaporated invacuo. The residue was purified to yield the title compound as acolorless oil. ¹H-NMR (CDCl₃) δ: 1.46 (s, 9H), 2.36 (t, 2H), 3.55 (t,2H), 3.77 (s, 4H), 4.04 (s, 2H).

Step 2: 3-Methyl-4-oxo-piperidine-1,3-dicarboxylic acid-1-tert-butylester 3-methyl ester

4-Oxo-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester(2.00 g, 6.8 mmol) was dissolved in tetrahydrofuran and cooled to 0° C.To the solution was added NaH (0.300 g, 12.5 mmol) portionwise over 1 h.H_(2(g)) was evolved during the addition. The reaction was allowed tostir for 30 minutes at 0° C. and then methyl iodide (0.422 mL, 6.8 mmol)was added and allowed to stir at room temperature for 13 h. The reactionwas quenched with ice water and concentrated down. The residue waspartitioned between water and ethyl acetate. The aqueous layer wasextracted with EtOAc (3×), the organics were collected together driedover Mg₂SO₄, filtered and evaporated in vacuo, then purified by Biotageflash chromatography (10% ethyl acetate/90% hexane to yield the titlecompound (1.1 g, 52%). ¹H-NMR (CDCl₃): δ 1.29 (s, 3H), 1.47 (s, 9H),2.47 (dt, 1H), 2.76 (m, 1H), 3.07 (d, 1H), 3.33 (dt, 1H), 3.71 (s, 3H),4.11 (m, 1H), 4.50 (d, 1H).

Step 3:4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidine-1,3-dicarboxylic acid1-tert-butyl ester 3-methyl ester

3-Methyl-4-oxo-piperidine-1,3-dicarboxylic acid-1-tert-butyl ester3-methyl ester (1.1 g, 4.07 mmol) was dissolved in tetrahydrofuran andcooled to 0° C. To the solution was added 4-chlorophenyl magnesiumbromide (12.2 mL, 12.2 mmol) dropwise over ˜½ h and then stirred at 0°C. for 1 h. The reaction was quenched with saturated solution of NH₄Cland extracted with ethyl acetate (3×). The organics were collected,dried over Mg₂SO₄, filtered and evaporated in vacuo, then purified byBiotage flash chromatography (10% ethyl acetate/90% hexane to 20% ethylacetate/80% hexane) to yield the title compound (1.1 g, 70%). ¹H-NMR(CDCl₃): δ 1.17 (s, 3H), 1.44 (s, 9H), 1.55 (m, 1H), 1.96 (d, 1H) 3.00(m, 1H), 3.37 (m, 2H), 3.53 (s, 3H), 3.91 (m, 2H), 4.07 (d, 1H), 7.27(d, 2H), 7.43 (d, 2H). ESI-MS m/z: 384.1 (M+1), retention time 2.95.

Step 4

4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidine-1,3-dicarboxylic acid1-tert-butyl ester 3-methyl ester (1.1 g, 2.87 mmol) was dissolved inCH₂Cl₂ (35 mL) and cooled to 0° C. and TFA (8 mL) was added dropwise.The solution was allowed to stir at 0° C. for 1 h. The solvent wasevaporated in vacuo and the residue was partitioned between 1N NaOH andCH₂Cl₂. The aqueous solution was extracted (3×) and then washed withbrine and dried over Na₂SO₄. The residue was carried onto the next stepwithout further purification.

Step 5

To a solution of4-(4-chloro-phenyl)-4-hydroxy-3-methyl-piperidine-3-carboxylic acidmethyl ester (0.71 g, 2.5 mmol) in acetonitrile/water (8:2) (25 mL) wasadded K₂CO₃ (1.40 g, 10.0 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.937 g, 2.5 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (50% ethyl acetate/50%hexane to 75% ethyl acetate/25% hexane to 100% ethyl acetate) to yieldthe title compound (0.835 g, 58%). ¹H-NMR (CDCl₃): 1.30 (s, 3H), 1.57(s, 6H), 1.76 (d, 1H), 2.24-2.53 (m, 7H), 2.65 (d, 1H), 2.86 (d, 2H),3.44 (s, 3H), 5.30 (bs, 2H), 6.16 (d, 1H), 6.82 (d, 1H), 7.26 (m, 4H),7.45 (s, 1H), 7.53 (d, 1H), 7.58 (d, 1H), 8.49 (d, 1H). ESI-MS m/z: 577(M+1), retention time 1.50.

Example 4824-(4-Chloro-phenyl)-3-hydroxymethyl-1-{3-[7-(hydroxyl-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidine-4-ol

4-(4-Chloro-phenyl)-4-hydroxy-1-{3-[7-(hydroxyl-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidine-3-carboxylicacid methyl ester (0.250 g, 0.43 mmol) was dissolved in tetrahydrofuranand cooled to 0° C. To the solution was added LiAlH₄ (1.3 mL, 1.3 mmol)dropwise and the reaction was allowed to stir at 0° C. for 3 h. Thereaction was quenched with ice water slowly and diluted with ethylacetate. The reaction mixture was allowed to stir at room temperaturefor 45 min. to break up any aluminum complexes. The organics wereseparated and the aqueous layer was extracted (2×) more. All of theorganics were collected, dried over Mg₂SO₄, filtered and evaporated invacuo, then purified by Biotage flash chromatography (50% ethylacetate/50% hexane to 75% ethyl acetate/25% hexane) to yield the titlecompound (0.103 g, 43%). ¹H-NMR (CDCl₃): δ 0.53 (s, 3H), 1.55 (d, 6H),1.62 (m, 1H), 2.40 (q, 2H), 2.55 (q, 3H), 2.72-2.86 (m, 4H), 3.19 (dd,1H), 3.24 (d, 1H), 3.41 (d, 1H), 5.33 (bs, 2H), 6.17 (t, 1H), 6.44 (bs,1H), 6.79 (d, 1H), 7.17 (d, 1H), 7.26-7.59 (m, 7H), 8.50 (d, 1H). ESI-MSm/z: 549 (M+1), retention time 1.39.

Example 483-1, Example 483-2

Racemic4-(4-Chloro-phenyl)-3-hydroxymethyl-1-{3-[7-(hydroxyl-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidine-4-olwas resolved using a ChiralPak AD column eluting with 5/5/90methanol/ethanol/hexane. Peak One is the more active enantiomer, Example483-1. Peak Two is the less active enantiomer, Example 483-2.

Example 484 4-(4-Chloro-phenyl)-3-ethoxymethyl-1-{3[7-(-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidin-4-olStep 1

To a solution of4-(4-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3-methyl-piperidine-1-carboxylicacid-tert-butyl ester (0.270 g, 0.76 mmol) in THF (4.8 mL) was added NaH(0.075 g, 1.9 mmol) and stirred for 20 min at room temperature. Ethyliodide (0.066 mL, 0.83 mmol) was added and the solution was heated to50° C. for 1 h. The reaction was quenched with water and extracted withethyl acetate (3×). The organics were collected together dried overMg₂SO₄, filtered and evaporated in vacuo, then purified by Biotage flashchromatography (10% ethyl acetate/90% hexane to 20% ethyl acetate/80%hexane to 30% ethyl acetate/70% hexane) to yield the title compound(0.110 g, 37%). ¹H-NMR (CDCl₃): 0.79 (s, 3H), 1.10 (t, 3H), 1.26 (s,1H), 1.45 (s, 9H), 1.84 (s, 1H), 2.74 (m, 2H), 2.98 (d, 1H), 3.18 (m,1H), 3.28 (q, 2H), 3.97 (d, 2H), 7.26-7.39 (m, 4H).

Step 2

4-(4-Chloro-phenyl)-3-ethoxymethyl-4-hydroxy-3-methyl-piperidine-1-carboxylicacid-tert-butyl ester (0.052 g, 0.14 mmol) was dissolved in CH₂Cl₂ (3mL) and cooled to 0° C. and TFA (1 mL) was added. The solution wasallowed to stir at 0° C. for 1 h. The solvent was evaporated in vacuoand used directly in the next reaction.

Step 3

To a solution of4-(4-chloro-phenyl)-3-ethoxymethyl-3-methyl-piperidin-4-ol (0.038 g,0.13 mmol) in acetonitrile/water (8:2) (1.3 mL) was added K₂CO₃ (0.075g, 0.53 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.050 g, 0.13 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected, dried over MgSO₄, filtered and evaporated in vacuo, thenpurified by Biotage flash chromatography (75% ethyl acetate/25% hexane)to yield the title compound in 65% yield. ¹H-NMR (CDCl₃): δ 0.81 (s,3H), 0.98 (t, 3H), 1.58 (s, 6H), 1.84 (s, 1H), 2.31-2.49 (m, 5H), 2.58(d, 1H), 2.67 (s, 1H), 2.77 (d, 2H), 3.26 (q, 2H), 3.65 (d, 2H), 5.33(bs, 2H), 6.16 (t, 1H), 6.82 (d, 1H), 7.22-7.36 (m, 7H), 7.45 (d, 1H),7.60 (d, 1H).

ESI-MS m/z: 577 (M+1), retention time 1.58.

Example 485 (4-(4-Chloro-phenyl)-4-hydroxy-1-{3[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidin-3-ylmethoxy)-aceticacid ethyl ester Step 1

To a solution of4-(4-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3-methyl-piperidine-1-carboxylicacid-tert-butyl ester (0.080 g, 0.22 mmol) in THF (2.2 mL) was added NaH(0.031 g, 0.78 mmol) and stirred for 20 min at room temperature. Ethylbromoacetate (0.027 mL, 0.30 mmol) was added and the solution was heatedto 50° C. for 1 h. The reaction was quenched with water and extractedwith ethyl acetate (3×). The organics were collected together dried overMg₂SO₄, filtered and evaporated in vacuo, then purified by Biotage flashchromatography (10% ethyl acetate/90% hexane to 20% ethyl acetate/80%hexane) to yield the ethyl ester (0.050 g, 50%). ¹H-NMR (CDCl₃): 0.85(bs, 3H), 1.22 (t, 3H), 1.45 (s, 9H), 1.66 (s, 1 h), 2.64-3.39 (m, 6H),3.96 (d, 2H), 4.12 (q, 2H), 7.26-7.38 (m, 4H).

Step 2

4-(4-Chloro-phenyl)-3-ethoxycarbonylmethoxymethyl-4-hydroxy-3-methyl-piperidine-1-carboxylicacid-tert-butyl ester (0.060 g, 0.14 mmol) was dissolved in CH₂Cl₂ (3mL) and cooled to 0° C. and TFA (1 mL) was added. The solution wasallowed to stir at 0° C. for 1 h. The solvent was evaporated in vacuoand used directly in the next reaction.

Step 3

To a solution of4-(4-chloro-phenyl)-4-hydroxy-3-methyl-piperidin-3-ylmethoxy]-aceticacid ethyl ester (0.046 g, 0.13 mmol) in acetonitrile/water (8:2) (1.3mL) was added K₂CO₃ (0.075 g, 0.53 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.051 g, 0.13 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (75% ethyl acetate/25%hexane) to yield the title compound in 54% yield. ¹H-NMR (CDCl₃): δ 0.86(s, 3H), 11.16 (t, 3H), 1.57 (s, 6H), 1.78 (s, 1H), 2.37 (t, 1H),2.46-2.71 (m, 5H), 2.81 (t, 1H), 3.80 (d, 2H), 3.97 (d, 2H), 4.06 (q,2H), 5.30 (bs, 2H), 6.18 (t, 1H), 6.82 (d, 1H), 7.22 (dd, 1H), 7.26-7.36(m, 7H), 7.47 (d, 1H), 7.60 (d, 1H). ESI-MS m/z: 635 (M+1), retentiontime 1.62.

Example 4864-(4-Chloro-phenyl)-3-(2-diethylamino-ethoxymethyl)-4-hydroxy-3-methyl-piperidine-1-carboxylicacid-tert-butyl ester Step 1

To a solution of4-(4-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3-methyl-piperidine-1-carboxylicacid-tert-butyl ester (0.071 g, 0.15 mmol) in THF (1.5 mL) was added NaH(0.016 g, 0.39 mmol) and stirred for 20 min at room temperature.2-Bromo-N,N-diethylethylamine HBr (0.044 mL, 0.17 mmol) was added andthe solution was heated to 50° C. for 1 h. The reaction was quenchedwith water and extracted with ethyl acetate (3×). The organics werecollected, dried over MgSO₄, filtered and evaporated in vacuo, thenpurified by Biotage flash chromatography (10% ethyl acetate/90% hexaneto 20% ethyl acetate/80% hexane) to yield the diethylamine (0.035 g).

Step 2

4-(4-Chloro-phenyl)-3-(2-diethylamino-ethoxymethyl)-4-hydroxy-3-methyl-piperidine-1-carboxylicacid-tert-butyl ester (0.035 g, 0.62 mmol) was dissolved in CH₂Cl₂ (3mL) and cooled to 0° C. and TFA (1 mL) was added. The solution wasallowed to stir at 0° C. for 1 h. The solvent was evaporated in vacuoand used directly in the next reaction.

Step 3

To a solution of4-(4-chloro-phenyl)-3-(2-diethylamino-ethoxymethyl)-3-methyl-piperidin-4-olin acetonitrile/water (8:2) (3.2 mL) was added K₂CO₃ and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol.The solution was allowed to stir at room temperature for 48 h. Thereaction was concentrated down and partitioned between EtOAc/H₂O,extracted with EtOAc (3×). The organics were collected, dried overMgSO₄, filtered and evaporated in vacuo, then purified by Biotage flashchromatography (5% methanol/95% methylene chloride to 10% methanol/90%methylene chloride to 15% methanol/85% methylene chloride) to yield thetitle compound. ¹H-NMR (CDCl₃): 0.50 (s, 3H), 0.97 (t, 6H), 1.52 (s,6H), 2.40-2.66 (m, 12H), 3.16-3.30 (m, 6H), 5.32 (bs, 2H), 6.06 (t, 1H),6.80 (t, 1H), 7.20 (dd, 1H), 7.29 (dd, 1H), 7.29-7.31 (m, 6H), 7.58 (d,2H), 8.51 (d, 1H). δ ESI-MS m/z: 648 (M+1), retention time 1.19.

Example 4872-[5-(3-{4-[(4-Chloro-benzyl)ethyl-amino]-piperidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-olStep 1: 4-(4-Chloro-benzylamino)-piperidine-1-carboxylic acid tert-butylester

4-Amino-1-N-Boc piperidine (1.80 g, 8.9 mmol) was dissolved in CH₂Cl₂and 4-chlorobenzylbromide (1.84 g, 8.9 mmol) and triethylamine (1.25 mL,8.9 mmol) were added. The solution was allowed to stir for 14 h at roomtemperature and evaporated in vacuo and partitioned between ether/1NNaOH. The aqueous layer was removed and the ether was washed with brineand dried over MgSO₄, filtered and evaporated in vacuo, then purified byBiotage flash chromatography (5% methanol/95% methylene chloride) toyield the title compound (0.800 g, 27%). ¹H-NMR (CDCl₃): δ 1.26 (m, 1H),1.44 (s, 9H), 1.83 (d, 2H), 2.63 (t, 1H), 2.78 (t, 2H), 3.46 (s, 2H),3.78 (s, 2H), 4.00 (bs, 2H), 7.26 (bs, 4H). ESI-MS m/z: 325.1 (M+1),retention time 1.86.

Step 2

(4-Chloro-benzyl)-ethyl-amino]-piperidine-1-carboxylic acid tert-butylester (0.500 g, 1.4 mmol) dissolved in 4M HCl/Dioxane (100 mL). Thesolution was stirred at rt for 1 h. The solvent was removed in vacuo andthe mixture was carried on to the next step without further purificationas the hydrochloride salt.

Step 3: (4-Chloro-benzyl)-ethyl-piperidin-4-yl-amine

4-(4-Chloro-benzylamino)-piperidine-1-carboxylic acid tert-butyl esterwas dissolved in CH₂Cl₂ and acetaldehyde (0.678 g, 3.2 mmol), Na(OAc)₃BH(0.163 g, 3.7 mmol) and 1 drop of AcOH was added. The solution wasstirred in a sealed vessel for 10 h. The reaction mixture was washedwith 1N NaOH, brine and dried over Mg₂SO₄, filtered and evaporated invacuo, then purified by Biotage flash chromatography (15% ethylacetate/85% hexane) to yield the title compound (0.350 g, 40%).

Step 4

To a solution of (4-chloro-benzyl)-ethyl-piperidin-4-yl-aminehydrochloride (0.200 g, 0.83 mmol) in acetonitrile/water (8:2) (8 mL)was added K₂CO₃ (0.476 g, 3.4 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.282 g, 7.5 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected, dried over MgSO₄, filtered and evaporated in vacuo, thenpurified by Biotage flash chromatography (5% methanol/95% methylenechloride to 10% methanol/90% methylene chloride) to yield the titlecompound (0.240 g, 60%). ¹H-NMR (CDCl₃): δ 0.988 (t, 3H), 1.57 (s, 6H),1.67 (d, 2H), 1.85 (t, 2H), 2.32-2.46 (m, 5H), 2.51 (q, 2H), 2.84 (d,2H), 3.47 (s, 2H), 3.56 (s, 2H), 5.29 (bs, 2H), 6.07 (t, 1H), 6.80 (d,1H), 7.21-7.28 (m, 6H), 7.42 (s, 1H), 7.56 (d, 1H), 8.48 (d, 1H). ESI-MSm/z: 546 (M+1), retention time 1.87.

Example 4881-{3-[7-(1-Hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-4-phenyl-piperidin-4-ol

To a solution of the 4-phenyl-piperidin-4-ol (0.212 g, 1.2 mmol) inisopropanol was added 2,6-lutidine (0.240 mL, 2.1 mmol) and catalyticpotassium iodide. This mixture was heated to 80° C., and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.224 g, 0.6 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.140 g, 50%).

¹H-NMR (CDCl₃): δ 1.12 (t, 3H), 1.57 (s, 6H), 2.67-2.80 (m, 4H),1.95-2.11 (m, 2H), 2.34-2.41 (m, 2H), 2.43-2.54 (m, 2H), 2.88 (d, 2H),3.22 (q, 2H), 3.43 (m, 1H), 5.28 (bs, 2H), 6.12 (t, 1H), 6.60 (d, 2H),6.80 (d, 1H), 7.13 (d, 2H), 7.21-7.30 (m, 2H), 7.45 (s, 1H), 7.56 (d,1H), 8.48 (dd, 1H). ESI-MS m/z: 534 (M+1), retention time 2.47.

Example 4894-(2-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-azadibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-ol Step 1

To a 1-bromo-2-chloro-benzene (0.97 mL, 8.3 mmol) in ether was addedmagnesium (0.238 g, 9.8 mmol) and catalytic iodide at room temperaturefor 2 h. This mixture was cooled to 0° C., and treated with4-oxo-piperidine-1-carboxylic acid tert-butyl ester (1.5 g, 7.5 mmol)dissolved in ether (8 mL) and added to the reaction mixture slowly. Thereaction was heated to reflux for 1 h. The reaction was quenched withammonium chloride and the aqueous phase extracted with ethyl acetate.The organics were combined and dried over MgSO₄, filtered and evaporatedin vacuo. The residue was purified by Isco flash system (75% hexane/25%ethyl acetate) to yield the alcohol (0.600 g, 38%).

Step 2

4-(2-Chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butylester (0.600 g, 1.9 mmol) was dissolved in CH₂Cl₂ (19 mL) and cooled to0° C. and TFA (4 mL) was added. The solution was allowed to stir at 0°C. for 1 h. The solvent was evaporated in vacuo and the residue waspartitioned between NaHCO₃ and CH₂Cl₂. The aqueous solution wasextracted (3×) and then washed with brine and dried over Na₂SO₄. Theresidue was carried onto the next step without further purification.

Step 3

To a solution of the 4-(2-chloro-phenyl)-piperidin-4-ol (0.210 g, 1.0mmol) in isopropanol was added 2,6-lutidine (0.31 mL, 2.7 mmol) andcatalytic potassium iodide. This mixture was heated to 80° C., andtreated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.287 g, 0.77 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.200 g, 52%).

¹H-NMR (CDCl₃): δ 1.55 (s, 6H), 1.70 (d, 2H), 2.10-2.30 (m, 2H),2.36-2.54 (m, 2H), 2.57-2.92 (m, 6H), 5.30 (bs, 2H), 6.16 (t, 1H), 6.77(d, 1H), 7.16-7.36 (m, 5H), 7.48 (s, 2H), 7.58 (d, 1H), 8.37 (dd, 1H).ESI-MS m/z: 505 (M+1), retention time 1.48.

Example 4904-(4-Chloro-2-methyl-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-olStep 1

To 4-chloro-2-methylphenylmagnesium bromide (15 mL, 7.5 mmol) in ethercooled to 0° C. was added 4-oxo-piperidine-1-carboxylic acid tert-butylester (1.0 g, 5.0 mmol) over 30 min. The resulting solution was heatedto reflux for 1 h. The reaction was quenched with ammonium chloride andthe aqueous phase extracted with ethyl acetate. The organics werecombined and dried over MgSO₄, filtered and evaporated in vacuo. Theresidue was purified by Isco flash system (75% hexane/25% ethyl acetate)to yield the alcohol (0.534 g, 33%).

Step 2

4-(4-Chloro-2-methyl-phenyl)-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.534 g, 1.6 mmol) was dissolved in CH₂Cl₂ (16 mL) andcooled to 0° C. and TFA (3 mL) was added. The solution was allowed tostir at 0° C. for 1 h. The solvent was evaporated in vacuo and theresidue was partitioned between NaHCO₃ and CH₂Cl₂. The aqueous solutionwas extracted (3×) and then washed with brine and dried over Na₂SO₄. Theresidue was carried onto the next step without further purification.

Step 3

To a solution of the 4-(4-chloro-2-methyl-phenyl)-piperidin-4-ol (0.160g, 0.71 mmol) in isopropanol was added 2,6-lutidine (0.24 mL, 2.1 mmol)and catalytic potassium iodide. This mixture was heated to 80° C., andtreated with245-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.221 g, 0.59 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.130 g, 36%). ¹H-NMR(CDCl₃): δ 1.57 (s, 6H), 1.92 (d, 2H), 2.30 (t, 2H), 2.49 (s, 3H),2.48-2.63 (m, 2H), 2.74-3.11 (m, 6H), 3.40 (s, 1H), 5.21 (bs, 2H), 6.09(t, 1H), 6.75 (d, 1H), 7.06 (d, 1H), 7.08 (s, 1H), 7.20 (d, 2H),7.22-7.36 (m, 1H), 7.57 (d, 1H), 8.36 (dd, 1H). ESI-MS m/z: 519 (M+1),retention time 1.61.

Example 4914-(3,4-Dichloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-olStep 1

To 3,4-dichlorophenylmagnesium bromide (7.5 mL, 7.5 mmol) in ethercooled to 0° C. was added 4-oxo-piperidine-1-carboxylic acid tert-butylester (1.0 g, 5.0 mmol) over 30 min. The resulting solution was heatedto reflux for 1 h. The reaction was quenched with ammonium chloride andthe aqueous phase extracted with ethyl acetate. The organics werecombined and dried over MgSO₄, filtered and evaporated in vacuo. Theresidue was purified by Isco flash system (75% hexane/25% ethyl acetate)to yield the alcohol (0.630 g, 36%).

Step 2

4-(3,4-Dichloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acidtert-butyl ester (0.630 g, 1.8 mmol) was dissolved in CH₂Cl₂ and cooledto 0° C. and TFA (3 mL) was added. The solution was allowed to stir at0° C. for 1 h. The solvent was evaporated in vacuo and the residue waspartitioned between NaHCO₃ and CH₂Cl₂. The aqueous solution wasextracted (3×) and then washed with brine and dried over Na₂SO₄. Theresidue was carried onto the next step without further purification.

Step 3

To a solution of the 4-(4-chloro-2-methyl-phenyl)-piperidin-4-ol (0.140g, 0.57 mmol) in isopropanol was added 2,6-lutidine (0.23 mL, 2.0 mmol)and catalytic potassium iodide. This mixture was heated to 80° C., andtreated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.213 g, 0.57 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.110 g, 36%). (CDCl₃):δ 1.55 (s, 6H), 1.70 (d, 2H), 2.10-2.30 (m, 2H), 2.45 (m, 2H), 2.57-2.92(m, 6H), 5.30 (bs, 2H), 6.16 (t, 1H), 6.77 (d, 1H), 7.16-7.40 (m, 4H),7.08 (s, 1H), 7.57 (s, 2H), 8.36 (dd, 1H). ESI-MS m/z: 539 (M+1),retention time 1.72.

Example 4924-(4-Chloro-3-nitro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-olStep 1

To fuming nitric acid (20 mL) was added4-(4-chloro-phenyl)-piperidin-4-ol at 0° C. and stirred for 5 min. Thesolution was carefully neutralized with Na₂CO₃ and filtered. Theresulting solid was trituated with water and then filtered to give ayellow solid. The solid was dissolved in sat NaHCO₃ and extrated withethyl acetate (3×). The organics were collected together dried overMg₂SO₄, filtered and evaporated in vacuo to give the 4-chloro-3-nitrocompound (1.1 g, 18%).

Step 2

To a solution of the 4-(4-Chloro-3-nitro-phenyl)-piperidin-4-ol (0.295g, 1.2 mmol) in isopropanol was added 2,6-lutidine (0.225 mL, 2.1 mmol)and catalytic potassium iodide. This mixture was heated to 80° C., andtreated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.224 g, 0.6 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.100 g, 30%). ¹H-NMR(CDCl₃): δ 1.53 (s, 6H), 1.70 (d, 2H), 1.81-2.18 (m, 4H), 2.3-2.44 (m,4H), 2.56 (t, 2H), 2.69 (d, 2H), 5.32 (bs, 2H), 6.16 (t, 1H), 6.81 (d,1H), 7.28 (t, 2H), 7.48 (t, 2H), 7.58 (t, 2H), 8.06 (s, 1H). ESI-MS m/z:550 (M+1), retention time 1.51

Example 4932-[5-(3-{4-[(4-Chloro-phenyl)-ethyl-amino]-piperidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-olStep 1

4-Amino-piperidine-1-carboxylic acid tert-butyl ester (1.58 g, 7.9 mmol)and acetaldehyde (0.417 g, 9.48 mmol) were mixed with sodium triacetoxyborohydride (3.35, 15.8 mmol) in dichloroethane containing acetic acid(1%) and the resulting mixture was stirred at room temperatureovernight. The reaction mixture was diluted with CH₂Cl₂ and washed withsaturated aqueous sodium bicarbonate solution and brine and dried oversodium sulfate. The reaction was concentrated in vacuo, then purified byIsco flash chromatography (10% methanol/90% methylene chloride/ammoniumhydroxide) to yield the tert-butyl ester (0.71 g, 39%).

Step 2

4-Ethylamino-piperidine-1-carboxylic acid tert-butyl ester (0.694 g,3.04 mmol) and 1-Bromo-4-chloro-benzene (0.582, 3.04 mmol) was dissolvedin toluene along with sodium t-butoxide (0.41, 4.26 mmol), Pd₂(dba)₃(0.055 g, 0.061 mmol) and BINAP (0.037 g, 0.061 mmol). The solution washeated to 70° C. for 2 days and then filtered and the reaction wasconcentrated in vacuo, then purified by Isco flash chromatography (50%ethyl acetate/50% hexane) to yield the tert-butyl ester (0.25 g, 24%).

Step 3

4-(Ethyl-phenyl-amino)-piperidine-1-carboxylic acid tert-butyl ester(0.251 g, 1.0 mmol) was dissolved in 4M HCl/Dioxane (10 mL). Thesolution was stirred at rt for 1 h. The solvent was removed in vacuo andthe mixture was carried on to the next step without further purificationas the hydrochloride salt.

Step 4

To a solution of the (4-chloro-phenyl)-ethyl-piperidin-4-yl-amine (0.150g, 0.63 mmol) in isopropanol was added 2,6-lutidine (0.24 mL, 2.1 mmol)and catalytic potassium iodide. This mixture was heated to 80° C., andtreated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.221 g, 0.6 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.108 g, 34%). ¹H-NMR(CDCl₃): δ 1.12 (t, 3H), 1.57 (s, 6H), 2.67-2.80 (m, 4H), 2.00 (m, 2H),2.34-2.41 (m, 2H), 2.43-2.54 (m, 2H), 2.88 (d, 2H), 3.22 (q, 2H),3.37-3.51 (m, 1H), 5.28 (bs, 2H), 6.12 (t, 1H), 6.60 (d, 2H), 6.80 (d,1H), 7.13 (d, 2H), 7.21-7.30 (m, 2H), 7.45 (s, 1H), 7.56 (d, 1H), 8.48(dd, 1H). ESI-MS m/z: 532 (M+1), retention time 2.47.

Example 4942-(5-{3-[4-(4-Chloro-phenyl)-4-methoxy-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1

4-(4-Chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butylester (200 mg, 0.641 mmol) was added portionwise as a solid to asuspension of sodium hydride (0.018 g, 0.770 mmol) in dimethylformamide(6 mL) at room temperature. After 30 minutes, methyl iodide (0.109 g, 60uL, 0.770 mmol) was added and the mixture was stirred overnight. Themixture was poured into an equal volume of water and extracted withethyl acetate (2×10 mL). The ethyl acetate extracts were dried overmagnesium sulfate, filtered, and concentrated in vacuo to give a tanoil. The crude oil was purified by silica gel chromatography (hexane to60:40 hexane/ethyl acetate gradient) to afford4-(4-Chloro-phenyl)-4-methoxy-piperidine-1-carboxylic acid tert-butylester as a clear oil (108 mg, 52%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.45 (s, 9H), 1.80 (td, 2H), 1.97 (bd, 2H),2.96 (s, 3H), 3.16 (td, 2H), 3.90 (bd, 2H), 7.36 (s, 4H)

MS m/z: 326 (M+1)

Step 2

4-(4-Chloro-phenyl)-4-methoxy-piperidine-1-carboxylic acid tert-butylester (0.108 g, 0.331 mmol) was dissolved in methylene chloride (6 mL)and cooled in an ice bath. Trifluoroacetic acid (2 mL) was added slowlydropwise. The mixture was stirred for 2 hr as it warmed to roomtemperature. The reaction mixture was concentrated in vacuo and thenredissolved in methylene chloride and washed with saturated sodiumbicarbonate (2×10 mL). The pooled aqueous layers were extracted withmethylene chloride (2×10 mL). The methylene chloride extracts werepooled, dried over magnesium sulfate, filtered and concentrated in vacuoto give 4-(4-Chloro-phenyl)-4-methoxy-piperidine as a clear oil (72 mg,97%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.92 (m, 4H), 2.98 (s, 3H), 3.07 (m, 4H),4.50 (bs, 1H), 7.30 (s, 4H)

MS m/z: 226 (M+1)

Step 3

4-(4-Chloro-phenyl)-4-methoxy-piperidine (0.072 g, 0.319 mmol) wasdissolved in isopropanol (5 mL) and 2,6-lutidine (0.034 g, 37 uL, 0.319mmol) was added. Catalytic iodine was also added. The resultingsuspension was warmed to 80° C. Solid2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.060 g, 0.160 mmol) was added in approximately equal portions over 2h. Stirring was continued an additional 20 h at 80° C. The mixture wasconcentrated and the resulting residue purified by silica gelchromatography (ethyl acetate to 87/10/3 ethylacetate/methanol/triethylamine gradient) to afford the title compound(70 mg, 42%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.67 (s, 6H), 1.99-2.86 (m, 12H), 2.98 (s,3H), 5.32 (brs, 2H), 6.16 (t, 1H), 6.81 (d, 1H), 7.25-7.40 (m, 6H), 7.50(s, 1H), 7.66 (d, 1H), 7.59 (d, 1H)

MS m/z: 519 (M+1)

Example 4952-(5-{3-[4-(2-Chloro-phenoxy)-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

4-(2-Chloro-phenoxy)-piperidine hydrochloride (0.067 g, 0.268 mmol) wasdissolved in a mixture of acetonitrile (1.32 mL) and water (0.17 mL). Tothis mixture was added2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.050 g, 0.134 mmol) and potassium carbonate (0.074 g, 0.536 mmol). Themixture was stirred at room temperature for 24 hrs and then concentratedin vacuo. The resulting white solid was suspended in ethyl acetate (5mL) and an equal volume of water was added. The product was extractedinto ethyl acetate (2×5 mL). The pooled organic layers were dried overmagnesium sulfate, filtered and concentrated in vacuo to afford an oil.The residue was purified by silica gel chromatography (ethyl acetate to87/10/3 ethyl acetate/methanol/triethylamine gradient) to afford thetitle compound (46 mg, 68%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.58 (s, 6H), 1.7-2.9 (m, 12H), 4.42 (br s,1H), 5.34 (br s, 2H), 6.1 (t, 1H), 6.75 (d, 1H), 6.88 (d, 2H), 6.9-7.3(m, 4H), 7.32 (s, 1H), 7.58 (d, 1H), 8.55 (d, 1H); MS m/z: 506 (M+1)

Example 496(4-Chloro-phenyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-methanone

The title compound was prepared by following the procedure of Example494, Step 3, but replacing 4-(4-Chloro-phenyl)-4-methoxy-piperidine with(4-Chloro-phenyl)-piperidin-4-yl-methanone.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.45 (s, 6H), 2.05 (m, 2H), 2.55 (m, 2H),2.71 (m, 2H), 3.05 (m, 2H), 3.20 (m, 2H), 3.61 (m, 2H), 5.20 (m, 2H),6.05 (t, 1H), 6.77 (d, 1H), 7.35-7.60 (m, 6H), 7.82 (d, 1H), 8.35 (br s,1H), 8.52 (d, 1H); MS m/z: 517 (M+1)

Example 4972-(5-{3-[4-(4-trifluoromethyl-phenoxy)-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

The title compound was prepared by following the procedure of Example495, but replacing 4-(2-Chloro-phenoxy)-piperidine hydrochloride with4-(4-Trifluoromethyl-phenoxy)-piperidine.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.62 (s, 6H), 2.15 (br d, 2H), 2.60-3.15 (m,8H), 3.3 (br d, 2H), 4.74 (s, 1H), 6.07 (t, 1H), 6.84 (d, 1H), 6.91 (d,2H), 7.10-7.24 (m, 5H), 7.40 (s, 1H), 7.55 (m, 3H), 8.52 (d, 1H); MSm/z: 539 (M+1)

Example 4984-(4-Chloro-benzyl)-3-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-oxazolidin-2-oneStep 1

2-Amino-3-(4-chloro-phenyl)-propan-1-ol and4-oxo-piperidine-1-carboxylic acid tert-butyl ester were dissolved in 12ml of methylene chloride. Sodium triacetoxyborohydride (1.03 g, 0.00487mole) was added as a solid followed by catalytic acetic acid. Thereaction was stirred overnight at room temperature. The reaction wasquenched by adding 12 ml of 1N sodium hydroxide. The intermediatealcohol was extracted into methylene chloride (3×12 mL), the organicswere dried over magnesium sulfate, filtered and concentrated in vacuo togive the intermediate alcohol as a clear yellow oil (1.1 g, 86%). Thisoil was carried on without additional characterization.

4-[1-(4-Chloro-benzyl)-2-hydroxy-ethylamino]-piperidine-1-carboxylicacid tert-butyl ester, the intermediate alcohol was dissolved in 15 mLof methylene chloride. Triethylamine (0.423 g, 0.00418 mol, 583 uL 1.2equiv) was added followed by portionwise addition of carbonyldiimidazole (0.68 g, 0.00418 mol, 1.2 equiv). The mixture was stirred atroom temperature and then quenched with water (15 mL). The organiclayers were separated and the remaining aqueous layer was extracted withmethylene chloride (3×15 mL). The combined organics were dried overmagnesium sulfate, filtered and concentrated in vacuo to afford a yellowsolid. The crude oil was purified by silica gel chromatography(methylene chloride to 10% methanol in methylene chloride gradient) toafford4-[4-(4-chloro-benzyl)-2-oxo-oxazolidin-3-yl]-piperidine-1-carboxylicacid tert-butyl ester as a white solid (1.1 g, 80%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.40 (s, 9H), 1.70-2.10 (m, 4H), 2.75 (m,2H), 2.72 (td, 1H), 4.11 (m 3H), 4.15 (br t, 2H), 7.05 (d, 2H), 7.45 (d,2H); MS m/z: 395 (M+1)

Step 2

4-[4-(4-chloro-benzyl)-2-oxo-oxazolidin-3-yl]-piperidine-1-carboxylicacid tert-butyl ester (0.9 g, 0.002279 mole) was dissolved in methylenechloride (41 mL). The solution was cooled to ice bath temperature andtrifluoroacetic acid (14 mL) was added and the reaction mixture wasstirred for 2.5 hours. The reaction mixture was concentrated in vacuo togive the trifluoroacetate salt of the product as an oil. The salt wasfree based by adding saturated sodium bicarbonate (50 mL) and extractingwith methylene chloride (2×50 mL). The organic layers were pooled, driedover magnesium sulfate, filtered and concentrated in vacuo to give4-(4-chloro-benzyl)-3-piperidin-4-yl-oxazolidin-2-one as an off-whitefoam (560 mg, 84%).

¹H-NMR (CDCl₃, 300 MHz) δ: 1.70-2.15 (m, 4H), 2.60-2.80 (m, 4H),3.05-3.30 (m, 2H), 3.55 (br s, 1H), 3.71 (m, 1H), 3.87 (m, 2H), 7.01 (d,2H), 7.23 (d, 2H); MS m/z: 295 (M+1)

Step 3

The title compound was prepared by following the procedure of Example495, but replacing 4-(2-Chloro-phenoxy)-piperidine hydrochloride with4-(4-chloro-benxyl)-3-piperidin-4-yl-oxazolidin-2-one.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.60 (s, 6H), 1.97-3.10 (m, 14H), 3.75 (br s,2H), 4.10 (br s, 2H), 5.98 (t, 1H), 6.80 (d, 1H), 7.00-7.20 (m, 8H),7.40 (s, 1H), 7.62 (d, 1H), 8.60 (d, 1H); MS m/z: 590 (M+1)

Example 4991-{4-(4-Chloro-phenyl)-1-[3-(7-isopropenyl-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-piperidin-4-yl}-ethanol

The product of Example 457 (64 mg, 0.12 mmol) was dissolved in anhydrousmethanol (2.5 mL) and the resulting solution cooled to 0° C. Sodiumborohydride (37 mg, 1 mmol,) was added portionwise over 5 h. Thereaction was quenched with water and concentrated. The crude productresidue was purified by reverse phase HPLC (water, acetonitrile, formicacid gradient) to afford the titled compound (note elimination oftertiary benzylic alcohol).

MS m/z: 515 (m+1).

Example 500[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-amino]-aceticacid methyl ester Step 1

To a solution of 4-chlorobenzylamine (859 mg, 6.07 mmol) in1,2-dichloroethane (20 mL) was addedt-butyl-4-oxo-piperidine-1-carboxylate (1.451 g, 7.282 mmol), aceticacid (400 uL), and sodium triacetoxyborohydride (1.800 g, 8.497 mmol).The mixture was stirred at rt under nitrogen for 2 h, diluted with ethylacetate, washed thrice with saturated sodium bicarbonate solution anddried over magnesium sulfate. The extracts were filtered andconcentrated to afford 4-(4-chloro-benzylamino)-piperidine-1-carboxylicacid tert-butyl ester (2.49 g, >100%) as a yellow oil, which was ofsufficient purity by H-NMR to use without further purification.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.44 (s, 9H), 1.56-1.70 (br s, 2H), 1.81-1.90(br d, 2H), 2.63 (dddd, 1H), 2.78 (dd, 2H), 3.72 (s, 1H), 3.78 (s, 1H),4.00 (br s, 2H), 7.16-7.25 (m, 4H).

MS m/z: 325 (M+1).

Step 2

To a solution of the product from step 1 (620 mg, 1.91 mmol) intetrahydrofuran (20 mL) was added triethylamine (0.386 g, 532 uL, 3.82mmol) followed by methyl bromoacetate (0.584 g, 361 uL, 3.82 mmol). Theresulting mixture was heated at 55° C. for 2 d then rt for 3 days. Thereaction was diluted with ethyl acetate, washed twice with water andonce with brine, dried over magnesium sulfate, filtered andconcentrated. The resulting crude4-[(4-chloro-benzyl)-methoxycarbonylmethyl-amino]-piperidine-1-carboxylicacid tert-butyl ester (0.697 g, 92%) was of sufficient purity to usewithout further purification.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.44 (s, 9H), 1.78-1.95 (m, 2H), 2.60-2.83(m, 2 H), 3.3-4.2 (m, 12 H), 7.24-7.36 (m, 4H).

MS m/z: 397 (M+1).

Step 3

To a solution of the product of step 2 (0.270 g, 0.681 mmol) in methanol(6 mL) was added hydrogen chloride in dioxane (4.0 M, 340 uL, 1.36mmol). After stirring at rt 3 h, an additional 1 mL aliquot of the HClin dioxane solution was added and the mixture was allowed to stir at rtover night. The mixture was concentrated under reduced pressure toafford [(4-chloro-benzyl)-piperidin-4-yl-amino]-acetic acid methyl esterwhich was used without further purification.

MS m/z: 297 (M+1).

Step 4

To a solution of the product of step 3 (0.251 g, 0.680 mmol) inacetonitrile (4 mL) was added potassium carbonate (0.310 g, 2.24 mmol)in water (2 mL), followed by2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(170 mg, 448 mmol). The resulting orange solution was stirred at rt 13days. The mixture was diluted with ethyl acetate and washed with waterand brine. The washed extracts were dried over magnesium sulfate,filtered and concentrated. Pure titled compound was afforded by silicagel chromatography of the crude material (methylene chloride-98/2methylene chloride/methanol gradient); 107 mg, 41%.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.56 (s, 6H), 1.74-1.92 (m, 6H), 2.28-2.48(m, 4H), 2.53-2.66 (m, 2H), 2.82 (br d, 2H), 3.30 (s, 2H), 3.63 (s, 3H),3.77 (s, 2H), 5.21-5.39 (br s, 2H), 6.07 (t, 1H), 6.80 (d, 1H),7.21-7.32 (m, 6H), 7.42 (d, 1H), 7.55 (dd, 1H), 8.50 (dd, 1H).

MS m/z: 590.

Example 501[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-amino]-aceticacid

To a solution of the product of step 4 in Example 500 (209 mg, 0.353mmol) in dioxane (5 mL) and water (2.5 mL) was added lithium hydroxide(59 mg, 1.41 mmol). The reaction was allowed to stir at rt 24 h, wasconcentrated and purified by reverse-phase HPLC (water, acetonitrile,formic acid gradient) to afford the titled compound (44 mg, 22%) as awhite solid.

¹H-NMR (CDCl₃, 300 MHz) δ: 1.49 (s, 6H), 1.69 (d, 2H), 2.05 (d, 2H),2.28-2.53 (m, 5 H), 2.82 (m, 3H), 3.14-3.20 (4 H), 4.06 (s, 2H),5.18-5.36 (br d, 2H), 6.12 (t, 1H), 6.76 (d, 1H), 7.25 (dd, 1H),7.32-7.40 (m, 2H), 7.45-7.51 (m, 4H), 7.78 (dd, 1H), 8.49 (dd, 1H).

MS m/z: 576 (M+1).

Example 502S-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-olStep 1

To a dry, 2 L 2-neck, round-bottom flask equipped with a magneticstirrer, a condenser, and a large 10° C. water bath was added4-oxo-piperidine-1-carboxylic acid tert-butyl ester (125 g, 628 mmol)and anhydrous tetrahydrofuran (1 L). To the resulting yellow solutionwas added methyl iodide (85 mL, 1365 mmol). Sodium t-butoxide (150 g,1560 mmol) was then added portionwise over 30 minutes. An exotherm wasdetected, especially at the beginning of the addition. The reactionmixture did warm to a gentle reflux, the rate was controlled by thespeed of addition of base. The mixture was stirred an additional 30minutes. The solvent was removed in vacuo. The oily residue was treatedwith NH₄Cl/water (500 mL), and extracted with ether (3×200 mL). Thecombined organics were washed with brine, dried over Na₂SO₄, andfiltered through a short plug of silica gel. The solvent was removed invacuo, and the resulting yellow oil had started to ccrystallize. It wasleft under high vacuum overnight. The mixture was slurried in hexane(50-100 mL) and sonicated for one minute. The yellow solid was collectedby filtration and washed with hexane (100 mL). The first crop of3,3-dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester yieldeda yellow solid. (See, preparation of (37) in Vice, S. et al., J. Org.Chem., 66:2487-2492 (2001).)

¹H-NMR (CDCl₃, 300 MHz) δ: 1.13 (s, 6H), 1.49 (s, 9H), 2.49 (t, 2H),3.43 (br s, 2H), 3.73 (t, 2 H).

Step 2

A 2-neck, 2-L round bottom flask was fitted with 2 125 mL droppingfunnels and a stir bar. The assembly was flame-dried under dry nitrogen.The flask was charged with THF (700 mL) and 4-bromo-chlorobenzene (33.7g, 176 mmol, 2.5 eq.). The resulting solution was cooled to −78° C. in adry ice/acetone bath. To one of the dropping funnels was addedbutyllithium (2.5 M in hexanes, 70 mL, 175 mmol, 2.5 eq) via canula. Thebutyllithium solution was slowly added to the cold THF solution over 1h. Stirring continued for an additional 0.5 h affording a whitesuspension. A solution of 3,3-dimethyl-4-oxo-piperidine-1-carboxylicacid tert-butyl ester (16.0 g, 70.5 mmol, 1 eq.) in THF (100 mL) wasprepared and added to the reaction mixture via the second droppingfunnel over 1.75 h. The resulting mixture was stirred at −78° C. for 2h, at which time reaction appears to be essentially complete by TLCanalysis. Saturated aqueous NH₄Cl (150 mL) was added and the reactionwas allowed to warm to rt. Water (150 mL) was added and the mixtureextracted with ethyl acetate (2+1 L). The combined extracts were washedwith water and brine, dried over magnesium sulfate, filtered andconcentrated. The solid residue was triturated with ethyl acetate andfiltered. The supernatant was concentrated and triturated with ether.The resulting supernatant was then triturated with ether/petroleumether. The resulting solids were combined to afford4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acidtert-butyl ester (17.52 g, 51.6 mmol, 73%) as an off-white solid.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.82 (s, 6H), 1.34-1.44 (m, 2H), 1.49 (s,9H), 2.67 (ddd, 1H), 3.10-3.70 (m, 3H), 4.00-4.30 (m, 1H), 7.31 (d, 2H),7.39 (d, 2 H).

Step 3

To a cooled (0° C.) solution of the compound prepared in step 2 (10.42g, 30.7 mmol) in methylene chloride (300 mL) was slowly addedtrifluoroacetic acid (60 mL) over 1.25 h. The resulting yellow solutionwas stirred at 0° C. for an additional 1.5 h. The mixture wasconcentrated under reduced pressure and the residue dissolved in ethylacetate (1.2 L), washed with aqueous sodium hydroxide (1 N, 150 mL). Theaqueous layer was extracted with additional ethyl acetate (200 mL) andthe combined extracts were washed with brine, dried over sodium sulfate,filtered and concentrated. The resulting solid residue was trituratedwith ether to afford 4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol(6.94 g, 29.0 mmol, 94%) as an off-white solid.

¹H-NMR (CD₃OD, 300 MHz) δ: 0.73 (s, 3H), 0.85 (s, 3H), 1.42 (ddd, 1H),2.36 (d, 1 H), 2.61 (ddd, 1H), 2.91 (br dd, 1H), 3.08-3.19 (m, 2H),7.26-7.32 (m, 2H), 7.44-7.50 (m, 2 H).

MS m/z: 240 (M+1).

Step 4

A visibly clean 5 L, 3-neck flask was fitted with an overhead stirrerand flushed with nitrogen for 20 min.4-(4-Chloro-phenyl)-3,3-dimethyl-piperidin-4-ol (202 g, 843 mmol),L-(+)-tartaric acid (114 g, 759 mmol) and 4040 mL of a 9:1butanone:water mixture were added to the flask. The mixture was heatedto reflux. Water (202 mL) was added portionwise over 45 min (ratio ofbutanone to water: 6:1) to fully dissolve the solid mixture. Reflux wascontinued an additional 45 min, the heat source was then turned off andthe flask allowed to cool slowly to rt overnight. Solids were removedunder suction filtration and dried 3 d in vacuo to afford S-enantiomer(134.4 g, 41%) as the L-(+) tartrate salt.

The above salt was partitioned between 1 M NaOH and methylene chloride(brine washed and sodium sulfate-dried) to afford the free base.

¹H-NMR (CD₃OD, 300 MHz) δ: 0.73 (s, 3H), 0.85 (s, 3H), 1.42 (ddd, 1H),2.36 (d, 1 H), 2.61 (ddd, 1H), 2.91 (br dd, 1H), 3.08-3.19 (m, 2H),7.26-7.32 (m, 2H), 7.44-7.50 (m, 2 H).

MS m/z: 240 (M+1).

Step 5

To a solution of the homochiral product of step 4 (2.40 g, 10 mmol) inacetonitrile (80 mL) and water (20 mL) was added potassium carbonate(1.39 g, 10 mmol) followed by2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(2.49 g, 6.67 mmol). The biphasic mixture was stirred at rt 48 h.Acetonitrile was removed by rotary evaporation and the resulting slurrywas partitioned between ethyl acetate and brine. The organic phase wasdried over magnesium sulfate, filtered and concentrated to afford anoily solid which was purified by silica gel chromatography (methylenechloride—90/10 methylene chloride/methanol gradient) to afford the titlecompound as an off-white powder (2.63 g, 74%).

¹H-NMR (CD₃OD, 300 MHz) δ: 0.71 (s, 3H), 0.84 (s, 3H), 1.4-1.55 (m, 9H),2.18-2.81 (m, 9H), 5.15-5.40 (br s, 2H), 6.23 (t, 1H), 6.74 (d, 1H),7.23-7.31 (m, 3H), 7.42-7.50 (m, 4H), 7.80 (dd, 1H), 8.47 (dd, 1H).

MS m/z: 533 (M+1).

Example 503R-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-olStep 1

Racemic 4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol (0.500 g, 2.086mmol) was dissolved in minimal hot isopropyl alcohol (ca. 5 mL). The hotsolution was filtered through a plug of cotton and transferred to asolution of (1S)-(+)-10-camphorsulfonic acid (0.484 g, 2.086 mmol) inisopropyl alcohol (ca. 3 mL). The mixture was stirred vigorously forseveral minutes, during which a thick precipitate forms, and allowed tocool to rt over 0.25 h. The solids were removed by suction filtrationand dried in vacuo. The dried salt was dissolved in hot isopropylalcohol (ca. 50 mL), filtered thorugh a cotton plug, and allowed toslowly cool to rt, undisturbed, overnight. The solids that formed oncooling (95 mg, 19% of theoretical) were removed by suction filtrationand shown by analytical HPLC to be enantiomerically pure. The salt wassuspended in ethyl acetate and neutralized with sodium hydroxide (1 N).The homogenous organic phase was washed with water and brine, dried oversodium sulfate, filtered and dried to affordR-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol.

¹H-NMR (CD₃OD, 300 MHz) δ: 0.73 (s, 3H), 0.85 (s, 3H), 1.42 (ddd, 1H),2.36 (d, 1 H), 2.61 (ddd, 1H), 2.91 (br dd, 1H), 3.08-3.19 (m, 2H),7.26-7.32 (m, 2H), 7.44-7.50 (m, 2 H).

MS m/z: 240 (M+1).

Step 2

The titled compound was prepared following the procedure in step 5 ofExample 502, substitutingS-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol forR-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol.

¹H-NMR (CD₃OD, 300 MHz) δ: 0.71 (s, 3H), 0.84 (s, 3H), 1.4-1.55 (m, 9H),2.18-2.81 (m, 9H), 5.15-5.40 (br s, 2H), 6.23 (t, 1H), 6.74 (d, 1H),7.23-7.31 (m, 3H), 7.42-7.50 (m, 4H), 7.80 (dd, 1H), 8.47 (dd, 1H).

MS m/z: 533 (M+1).

Example 504S-1-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-ethanone

To a solution of S-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol (180mg, 0.75 mmol) in acetonitrile/water (4/1) was added potassium carbonate(120 mg, 0.86 mmol), followed by1-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-ethanone(214 mg, 0.6 mmol). The reaction mixture was stirred at 50° C. for 8hours and then concentrated in vacuo. The resulting residue was treatedwith water and extracted with ethyl acetate. Solvent was evaporated fromthe combined dried (MgSO₄) organic extracts, and the residue waspurified by column chromatography on silica gel using methylenechloride-methanol (96:4) to afford the title compound (217 mg, 70%).

¹H-NMR (CDCl₃) δ: 0.6-0.9 (6H, d), 1.2-1.6 (4H, m), 2.2-2.4 (4H, m),2.55 (3H, s), 2.8 (2H, d), 5.3 (2H, brs), 6.25 (1H, t), 6.85 (1H, d),7.27-7.4 (6H, m), 7.6-7.8 (2H, m), 8.0 (1H, d), 8.5 (1H, d).

MS m/z: 517 (M+1).

Example 505R-1-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-ethanone

To a solution of R-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol (100mg, 0.417 mmol) in acetonitrile/water (4/1) was added potassiumcarbonate (57 mg, 0.413 mmol), followed by1-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-ethanone(100 mg, 0.279 mmol). The reaction mixture was stirred at 50° C. for 8hours and then concentrated in vacuo. The resulting residue was treatedwith water and extracted with ethyl acetate. Solvent was evaporated fromthe combined dried (MgSO₄) organic extracts, and the residue waspurified by column chromatography on silica gel using methylenechloride-methanol (96:4) to afford the titled compound (102 mg, 71%).

¹H-NMR (CDCl₃) δ: 0.6-0.9 (6H, d), 1.2-1.6 (4H, m), 2.2-2.4 (4H, m),2.55 (3H, s), 2.8 (2H, d), 5.3 (2H, brs), 6.25 (1H, t), 6.85 (1H, d),7.27-7.4 (6H, m), 7.6-7.8 (2H, m), 8.0 (1H, d), 8.5 (1H, d).

MS m/z: 517 (M+1).

Example 506 Acetic acid2-(5-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-ethylester

To a solution of5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol(64.5 mg, 0.131 mmol) in N,N-dimethylormamide (2.5 ml) was added sodiumhydride (6 mg, 0.158 mmol), 60% dispersion in mineral oil, then aceticacid 2-bromo-ethyl ester (17 μl, 0.158 mmol). The reaction stirred atroom temperature overnight under a nitrogen atmosphere. The reaction wasquenched the following day with water and diluted with ethyl acetate.The organic layer was washed twice with water, then brine. After theorganic layer was dried over magnesium sulfate the solvent was distilledoff under reduced pressure to give the title compound, 132 mg (100%).

¹H-NMR (CDCl₃) δ: 1.73-1.90 (4H, m), 2.07-2.90 (4H, s), 2.29-2.79 (6H,m), 4.11-4.14 (2H, bt), 4.36-4.40 (2H, bt), 5.23-5.30 (2H, bs),6.10-6.15 (1H, t), 6.73-6.84 (3H, m), 7.24-7.39 (10H, m), 7.56-7.59 (1H,dd), 8.47-8.50 (1H, dd).

MS m/z: 577 (M)

Example 5074-(4-Chloro-phenyl)-1-{3-[7-(2-hydroxy-ethoxy)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol

To a solution of 75.8 mg (0.1314 mmol) Acetic acid2-(5-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-ethylester (example 10) in ethanol (5 ml) was added a 15% sodium hydroxide inwater (2 ml) solution. The reaction was heated to reflux for 30 minutes,at which time the LC/MS showed it to be complete. After cooling to roomtemperature the reaction was worked up by diluting with ethyl acetateand washing with water and brine. The combined aqueous layers were backextracted with ethyl acetate. The combined organics were dried overmagnesium sulfate and the solvent was distilled under reduced pressure.The residue was purified by reverse phase HPLC to give the titlecompound (42 mg, 60%).

¹H-NMR (CDCl₃) δ: 0.821 (3H, s), 0.975 (3H, s), 2.56-5.64 (2H, bq),2.68-2.74 (1H, bd), 2.80-3.08 (5H, m), 3.30-3.38 (1H, bd), 3.62-3.67(2H, t), 4.04-4.08 (2H, t), 5.19-5.32 (2H, bs), 5.94-6.00 (1H, t),6.79-6.87 (4H, m), 7.26-7.40 (4H, m) 7.56-7.60 (1H, bd), 8.35-8.37 (1H,s), 8.50-8.53 (1H, dd)

MS m/z: 535 (M)

Example 5084-(4-Chloro-phenyl)-1-{3-[7-(2-methoxy-ethoxy)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol

The titled compound was prepared by following the procedure of Example506, but replacing acetic acid 2-bromo-ethyl ester with1-Bromo-2-methoxy-ethane. The residue was purified by reverse phase HPLCto give the title compound (27 mg, 39%).

¹H-NMR (CDCl₃) δ: 0.79-0.085 (3H, s), 0.95-1.03 (3H, s), 2.55-3.12 (8H,m), 3.28-3.45 (2H, m), 3.48 (3H, bs), 3.70-3.78 (2H, bs), 4.06-4.13 (2H,bs), 5.18-5.28 (2H, bs), 5.92-6.01 (1H, bt), 6.75-6.88 (3H, m),7.25-7.43 (4H, m), 7.55-7.63 (1H, bd), 8.48-8.55 (2H, bd)

MS m/z: 549 (M)

Example 5095-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol

The titled compound was prepared following the procedure in step 5 ofExample 502, substituting5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclo-hepten-7-olfor2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]-cyclohepten-7-yl]-propan-2-oland racemic piperidine for the S-piperidine.

¹H-NMR (CDCl₃, 300 MHz) δ: 0.74 (s, 3H), 0.88 (s, 3H), 1.45 (m, 1H),2.20-2.54 (m, 7H), 2.66-2.77 (m, 2H), 5.27 (br s, 2H), 6.11 (t, 1H),6.67 (dd, 1H), 6.74-6.79 (m, 2H), 7.25-7.31 (m, 3H), 7.36-7.42 (m, 2H),7.59 (d, 1H), 8.50 (dd, 1H).

MS m/z: 491 (M+1).

Example 5102-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-2-methyl-propionicacid ethyl ester

To a cooled (0° C.) solution of5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol(250 mg, 0.51 mmol) in dimethylformamide (7 mL) was added sodium hydride(60% dispersion in oil, 31 mg, 0.76 mmol). The resulting mixture wasstirred at 0° C. for 10 min. Ethyl 2-bromo-2-methyl propionate (149 mg,0.76 mmol) was added. Stirring at 0° C. was continued 10 min before themixture was warmed to rt and stirred 4 h. The reaction was thenpartitioned between ethyl acetate and water; the aqueous phase wasback-extracted with additional ethyl acetate. The combined organicphases were washed thrice with water, brine and dried over magnesiumsulfate, filtered and concentrated. The crude residue was purified bysilica gel chromatography (methylene chloride-95:5 methylenechloride:methanol gradient) to afford the titled compound (233 mg, 76%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.74 (s, 3H), 0.87 (s, 3H), 1.27 (t, 3H),1.41 (d, 1H), 1.50 (br s, 1H), 1.55 (s, 6H), 2.18-2.56 (m, 7H),2.64-2.78 (m, 2H), 4.24 (q, 2H), 5.27 (br s, 1H), 6.09 (t, 1H),6.67-6.76 (m, 2H), 6.87 (d, 1H), 7.25-7.31 (m, 2H), 7.37-7.42 (m, 2H),7.57 (d, 2H), 8.01 (s, 1H), 8.50 (d, 1H).

MS m/z: 605 (M+1).

Example 5114-(4-Chloro-phenyl)-1-{3-[7-(2-hydroxy-1,1-dimethyl-ethoxy)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol

To a cooled (0° C.) solution of2-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-2-methyl-propionicacid ethyl ester (117 mg, 0.193 mmol) in tetrahydrofuran (5 mL) wasadded lithium aluminum hydride (1.0 M solution in tetrahydrofuran, 0.39mL, 0.39 mmol). The reaction was allowed to stir at 0° C. for 2 h.Excess hydride was quenched by the addition of a saturated aqueouspotassium/sodium tartrate solution. The mixture was stirred at rt untiltwo clear phases formed. The mixture was diluted with ethyl acetate andshaken. The extracts were dried over magnesium sulfate, filtered andconcentrated. The crude residue was purified by silica gelchromatography (methylene chloride—90:10 methylene chloride/methanolgradient) to afford the titled compound (102 mg, 94%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.74 (s, 3H), 0.87 (s, 3H), 1.25 (s, 6H),1.41 (d, 1H), 2.18-2.55 (m, 9H), 2.65-2.79 (m, 2H), 3.58 (d, 2H),5.20-5.40 (br s, 2H), 6.12 (t, 1H), 6.74-6.84 (m, 2H), 6.92 (d, 1H),7.25-7.32 (m, 3H), 7.36-7.42 (m, 2H), 7.60 (dd, 1H), 8.51 (dd, 1H).

MS m/z: 563 (M+1).

Example 5122-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-2-methyl-propionicacid

To a solution of2-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-2-methyl-propionicacid ethyl ester (158 mg, 0.261 mmol) in methanol (3 mL) was addedsodium hydroxide (1 N in water, 1 mL). Following a slight exotherm, themixture clarified. An additional aliquot of sodium hydroxide (1 N, 1 mL)was added after 1 h and the mixture was allowed to stir an additional 1h at rt. The solvents were evaporated under reduced pressure and theresidue dissolved in water (2.5 mL). The basic solution was neutralized(pH=7) with hydrochloric acid (1 N) and the titled compound wasprecipitated and collected by suction filtration (86 mg, 57%).

¹H-NMR (CD₃OD, 300 MHz) δ: 0.80 (s, 3H), 0.91 (s, 3H), 1.47 (s, 6H),1.72 (d, 1H), 2.56-2.72 (m, 2H), 2.83-3.00 (m, 2H), 3.15-3.24 (m, 3H),3.32-3.48 (m, 2H), 5.18 (br s, 2H), 6.04 (t, 1H), 6.69-6.84 (m, 2H),6.97 (d, 1H), 7.28-7.37 (m, 3H), 7.40-7.47 (m, 2H), 7.67 (dd, 1H), 8.42(dd, 1 h).

MS m/z: 577 (M+1).

Example 5132-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-2-methyl-propionamide

To a solution of2-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-2-methyl-propionicacid (72 mg, 0.125 mmol) in dimethyl formamide (3 mL) was added1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (48 mg, 0.25mmol), 1-hydroxybenzotriazole (34 mg, 0.25 mmol), and ammonium hydroxide(170 μL, 0.50 mmol) and triethylamine (100 μL). Stir at rt 48 h. Themixture was poured into chloroform and washed with water. The organicphase was washed with additional water and brine; dried over magnesiumsulfate, filtered and concentrated. The crude residue was purified bysilica gel chromatography (methylene chloride—90:10 methylenechloride/methanol gradient) to yield the titled compound (22 mg, 31%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.74 (s, 3H), 0.87 (s, 3H), 1.42 (br d, 1H),1.49 (s, 6 H), 2.16-2.61 (m, 7H), 2.63-2.78 (m, 2H), 5.20-5.40 (br s,2H), 5.50 (br s, 1H), 6.11 (t, 1 h), 6.68-6.82 (m, 3H), 6.91 (dd, 1H),7.26-7.33 (m, 4H), 7.36-7.43 (m, 2 H), 7.60 (dd, 1H), 8.51 (dd, 1H).

MS m/z: 576 (M+1).

Example 514(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-aceticacid methyl ester

5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol(0.4 g, 0.814 mmol) was dissolved in dimethyl formamide (10 mL). Sodiumhydride (0.029 g, 1.22 mmol, 1.5 equiv, 48 mg of a 60% suspension inmineral oil) was added at room temperature and gas evolution wasvisible. Methyl bromoacetate (0.187 g, 1.22 mmol, 116 uL) was added andthe mixture was stirred at room temperature. After stirring overnight atroom temperature, the reaction was quenched with water (10 mL). Theresulting suspension was extracted with ethyl acetate (3×10 mL). Thecombined ethyl acetate extracts were dried over magnesium sulfate,filtered and concentrated in vacuo to give an oil. The crude oil waspurified by silica gel chromatography (methylene chloride to 10%methanol in methylene chloride gradient) to afford the title compound asa white solid (222 mg, 48%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.7 (s, 3H), 1.2 (s, 3H), 1.30-1.70 (m, 3H),2.62-3.51 (m, 9H), 3.82 (s, 3H), 4.55 (s, 2H), 5.22 (br s, 1H), 5.88 (t,1H), 6.85 (m, 2H), 7.15-7.33 (m, 6H), 7.62 (d, 1H), 8.43 (d, 1H); MSm/z: 564 (M+1)

Example 515(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-aceticacid

(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-aceticacid methyl ester (0.060 g, 0.107 mmol) was dissolved in methanol (1.5mL). Sodium hydroxide (150 uL, 1N stock solution) was added and theresulting mixture was stirred at room temperature. After stirringovernight at room temperature, the reaction mixture was concentrated invacuo to give a yellow oil. The oil was suspended in water (2 mL) andthen washed with ethyl acetate (3×3 mL). The aqueous layer was thenacidified to pH=2 and extracted with ethyl acetate (3×5 mL). The pooledorganic layers were dried over magnesium sulfate, filtered andconcentrated in vacuo to afford a white solid (55 mg, 94%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.8 (s, 3H), 0.92 (s, 3H), 1.12-1.31 (m, 6H),2.68 (br d, 2H), 3.89 (m, 1H), 2.95 (d, 1H), 3.10-3.36 (m, 2H), 4.45 (s,1H), 5.20 (br s, 2H), 5.98 (t, 1H), 6.81 (m, 2H), 6.96 (d, 1H), 7.40 (d,2H), 7.40 (m, 3H), 7.83 (d, 1H), 8.44 (d, 1H); MS m/z: 550 (M+1)

Example 5162-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-acetamide

The title compound was prepared by following the procedure of Example514, but replacing methyl bromoacetate with bromoacetamide. This yielded58 mg of the title compound after chromatography (52%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.5 (br s, 6H), 0.78-2.90 (m, 10 H), 4.35 (s,1H), 5.22 (br s, 2H), 5.74 (br s, 1H), 6.11 (br s, 1H), 6.55 (br s, 1H),6.82 (m, 3H), 7.33 (d, 3H), 7.25 (d, 2H), 7.65, (d, 1H), 8.55 (d, 1H);MS m/z: 549 (M+1)

Example 5174-(4-Chloro-phenyl)-1-{3-[7-(2-hydroxy-2-methyl-propoxy)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol

(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-aceticacid methyl ester (52 mg, 0.0923 mmole) was dissolved in tetrahydrofuran(2 mL). The resulting solution was cooled to ice bath temperatures andmethylmagnesium bromide (0.369 mmol, 264 uL of 1.4 M solution intoluene/tetrahydrofuran) was added dropwise. The reaction was stirredfor 4 hrs at ice bath temperature and then warmed to room temperatureovernight. Tetrahydrofuran was removed by concentration in vacuo. Theresulting solid was dissolved in ethyl acetate (10 mL) and washed withsaturated ammonium chloride (10 mL). The ethyl acetate extracts weredried over magnesium sulfate, filtered and concentrated in vacuo to givean oil. The crude oil was purified by silica gel chromatography(methylene chloride to 10% methanol in methylene chloride gradient) toafford the title compound as a white solid (40 mg, 77%).

¹H-NMR (CDCl₃, 300 MHz) δ: 0.92 (d, 6H), 1.34 (s, 6H), 1.62, (br s, 2H),2.24 (m, 9H), 3.78 (s, 2H), 6.82 (m, 3H), 7.22-7.41 (m, 7H), 7.62 (d,1H), 8.52 (d, 1H); MS m/z: 564 (M+1)

Example 5183-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)propane-1,2-diol

1-[3-(Allyl-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol(0.044 g, 0.08 mmol) was dissolved THF (2 mL)/H₂O (0.5 mL) and cooled to0° C. To the solution was added OsO₄ (1.07 mL-2.5% OsO₄ in t-butanol)and stirred at room temperature for 4 h. The reaction was diluted withsat. sodium bisulfite, the organics were removed dried over Mg₂SO₄,filtered and evaporated in vacuo, then purified by Biotage flashchromatography (5% methanol/95% methylene chloride to 7.5%methanol/92.5% methylene chloride to 15% methanol/85% methylenechloride) to yield the title compound (0.025 g, 53%). ¹H-NMR (CDCl₃): δ0.74 (ss 3H), 0.87 (s, 3H), 1.22 (d, 1H), 1.41 (s, 1H), 1.44 (d, 1H),2.26-2.77 (m, 9H), 3.53 (d, 1H), 3.70 (dd, 1H), 3.93 (s, 1H), 5.30 (bs,2H), 6.14 (t, 1H), 6.79 (d, 1H), 7.02 (d, 1H), 7.16 (s, 1H), 7.27 (d,3H), 7.37 (d, 2H), 7.58 (d, 1H), 8.48 (dd, 1H). ESI-MS m/z: 515 (M+1),retention time 1.72.

Example 5192-(5-{3-[4-(4-Chloro-phenyl)-3-methyl-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: 4-(4-Chloro-phenyl)-3-methyl-piperazine-1-carboxylic acidtert-butyl ester

To a solution of 3-Methyl-piperazine-1-carboxylic acid tert-butyl ester(1.0 g, 5 mmol) and 4-bromochlorobenzene (0.77 g, 4 mmol) was addedsodium tert-butoxide (0.96 g, 10 mmol), palladium(II)dibenzylideneacetone (Pd₂DBA₃, 0.09 g, 0.1 mmol), and BINAP (0.19 g, 0.3mmol). The suspension was stirred at 120° C. for 10 hours. The reactionwas filtered through celite and evaporated in vacuo. The residue waspurified by silica gel chromatography (hexane→ethyl acetate) to yield0.84 g (68%) of the title compound. ¹H-NMR (CDCl₃): δ 1.00 (3H, m), 1.74(9H, s), 3.10 (3H, m), 3.30 (1H, m), 3.80 (2H, m), 4.10 (1H, brs), 6.85(2H, d), 7.20 (2H, d).

Step 2: 1-(4-Chloro-phenyl)-2-methyl-piperazine

4-(4-Chloro-phenyl)-3-methyl-piperazine-1-carboxylic acid tert-butylester (0.83 g, 0.68 mmol) was dissolved in HCl/dioxane (4M, 8 mL) andstirred for 2 hr at rt. The mixture was then evaporated in vacuo,basified with aqueous sodium hydroxide (1M, 50 mL), and extracted withethyl acetate (3×100 mL). The organic layers were evaporated and thecrude residue used in the next step, (0.56 g, brown oil)

Step 3:2-(5-{3-[4-(4-Chloro-phenyl)-3-methyl-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

A solution of2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.24 g, 0.64 mmol) in isopropanol (5 mL) was treated with1-(4-Chloro-phenyl)-2-methyl-piperazine (0.25 g, 1.2 mmol) and catalyticpotassium iodide. The solution was stirred at 80° C. for 5 hr, andevaporated in vacuo. The residue was purified by silica gelchromatography (ethyl acetate→87:10:3 ethylacetate/methanol/triethylamine) to yield 0.22 g (69%) of the titlecompound, ¹H-NMR (CDCl₃) δ: 1.00 (3H, m), 1.60 (6H, s), 2.20-2.70 (8H,m), 3.10 (2H, m), 3.75 (1H, m), 5.30 (2H, brs), 6.12 (1H, t), 6.87 (4H,d), 7.18-7.32 (3H, m), 7.45 (1H, s), 7.70 (1H, d), 8.55 (1H, d).

ESI-MS m/z: 504 [M+1].

The freebase was converted to the formate salt with formicacid/methanol. CHN passed, 0.4 formic acid.

Example 5202-(5-{3-[6-chloro-1,2-dihydro-2-oxo-spiro[4H-3,1-benzoxazin-4,4′-piperidin]-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

A solution of6-chloro-1,2-dihydro-2-oxo-spiro[4H-3,1-benzoxazin-4,4′-piperidine](Made by the procedure of Bock, et al. GB2,355,465, 0.25 g, 0.7 mmol) inisopropanol (5 mL) was treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.19 g, 0.50 mmol) and catalytic potassium iodide. The solution wasstirred at 80° C. for 5 hr, and evaporated in vacuo. The residue waspurified by reverse-phase preparative HPLC to yield 0.029 g (10%) of thetitle compound, ¹H-NMR (CD₃OD) δ: 1.50 (3H, s), 2.18 (2H, brs), 2.95-3.2(6H, m), 5.30 (2H, brs), 6.18 (1H, t), 6.79 (1H, m), 6.92 (1H, m), 7.12(1H, m), 7.38 (2H, m), 7.48 (2H, m), 7.81 (2H, m), 8.31 (1H, m), 8.55(1H, d).

ESI-MS m/z: 546 [M+1].

Example 5212-(5-{3-[4-(2-Chloro-phenyl)-4-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: 1-Benzyl-4-methyl-piperidin-4-ol

A solution of 1-benzyl-4-piperidone (4.9 mL, 26.5 mmol) in anhydrousdiethyl ether (50 mL) was cooled to −78° C. and treated withmethyllithium (1.4 M, 21 mL, 29 mmol). This mixture was stirred for 2.5hr at −78° C., then quenched with aqueous brine, and extracted withethyl acetate (3×100 mL). The combined organics were dried over sodiumsulfate and evaporated in vacuo. The residue was purified by silica gelchromatography (CH₂Cl₂→90:10:1 CH₂Cl₂/methanol/NH₄OH) to yield 4.5 g(83%) of the title compound, ESI-MS m/z: 206 [M+1].

Step 2: 1-Benzyl-4-(2-chloro-phenyl)-4-methyl-piperidine

A solution of 1-Benzyl-4-methyl-piperidin-4-ol (4.5 g, 22 mmol) inchlorobenzene (60 mL) was treated with anhydrous AlCl₃ (15 g, 110 mmol).This mixture was stirred for 3 hr at reflux, then quenched into ice (250g), basified with sodium hydroxide, and extracted with ethyl acetate(3×100 mL). The combined organics were dried over sodium sulfate andevaporated in vacuo. The residue was purified by silica gelchromatography (CH₂Cl₂→490:10 CH₂Cl₂/methanol) to yield 0.59 g (10%) ofthe title compound, ESI-MS m/z: 300 [M+1].

Step 3: 4-(2-Chloro-phenyl)-4-methyl-piperidine

A solution of 1-benzyl-4-(2-chloro-phenyl)-4-methyl-piperidine (0.59 g,1.95 mmol) in 1,2-dichloroethane (10 mL) was treated with 1-chloroethylchloroformate (0.28 mL, 2.6 mmol). This mixture was stirred for 12 hr atreflux, then evaporated in vacuo. The residue was redissolved inmethanol (10 mL) and heated to reflux for 1 hr, then evaporated invacuo. The resulting brown solid (the hydrochloric salt) was washed withethyl acetate, then freebased with ethyl acetate/sodium hydroxide toyield 0.30 g (72%) of the title compound, ESI-MS m/z: 246 [M+1].

Step 4:2-(5-{3-[4-(2-Chloro-phenyl)-4-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

A solution of 4-(2-Chloro-phenyl)-4-methyl-piperidine (0.29 g, 1.38mmol) in isopropanol (5 mL) was treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.19 g, 0.50 mmol) and catalytic potassium iodide. The solution wasstirred at 80° C. for 12 hr, and evaporated in vacuo. The residue waspurified by silica gel chromatography (ethyl acetate→87:10:3 ethylacetate/methanol/triethylamine) to yield 0.062 g (25%) of the titlecompound, ¹H-NMR (CDCl₃) δ: 1.10 (3H, s), 1.58 (6H, s), 1.78 (2H, m),1.90 (1H, m), 2.10 (2H, m), 2.40 (8H, m), 5.30 (2H, brs), 6.18 (1H, t),6.79 (1H, m), 6.92 (1H, m), 7.19-7.39 (6H, m), 7.42 (1H, m), 7.55 (1H,m), 8.55 (1H, d).

ESI-MS m/z: 503 [M+1].

Example 5224-(4-Chloro-phenyl)-1-{3-[7-(2-hydroxy-2-methyl-propoxy)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidin-4-olStep 1:(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-aceticacid methyl ester

A solution of5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol(0.14 g, 0.28 mmol) in dimethylformamide (3 mL) was treated with sodiumhydride (60% in mineral oil, 0.016 g, 0.4 mmol) and methyl bromoacetate(0.038 mL, 0.4 mmol). The mixture was allowed to stir at rt for 2 hr,then quenched with aqueous brine, and extracted with ethyl acetate (3×10mL). The combined organics were washed several time with water, driedover sodium sulfate, and evaporated in vacuo. The residue was purifiedby silica gel chromatography (ethyl acetate→87:10:3 ethylacetate/methanol/triethylamine) to yield 0.07 g (50%) of the titlecompound, ESI-MS m/z: 549 [M+1].

Step 2:4-(4-Chloro-phenyl)-1-{3-[7-(2-hydroxy-2-methyl-propoxy)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3-methyl-piperidin-4-ol

A solution of(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yloxy)-aceticacid methyl ester (0.07 g, 0.13 mmol) in THF (3 mL) was treated withmethylmagnesium bromide (3M, 0.15 mL, 0.45 mmol). The solution wasstirred at rt for 2 hr, and quenched with brine. The aqueous residue wasextracted with ethyl acetate (3×10 mL), and the combined organics wereevaporated in vacuo. The residue was purified by silica gelchromatography (ethyl acetate→87:10:3 ethylacetate/methanol/triethylamine) to yield 0.038 g (50%) of the titlecompound, ¹H-NMR (CDCl₃) 0: 0.6 (3H, s), 1.37 (6H, s), 1.66 (2H, m),1.99-2.80 (9H, m), 3.78 (2H, s), 5.30 (2H, brs), 6.18 (1H, t), 6.79-6.89(3H, m), 6.92 (1H, m), 7.25-7.45 (6H, m), 7.55 (1H, m), 8.55 (1H, d).

ESI-MS m/z: 549 [M+1].

Example 5234-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-1-oxy-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-olStep 1:1-[5-(3-Bromo-propylidene)-1-oxy-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-ethanone

A solution of1-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-ethanone(1.5 g, 4.2 mmol) in CH₂Cl₂ (10 mL) was treated with m-chloroperbenzoicacid (77%, 1.2 g, 5.0 mmol). The mixture was allowed to stir at rt for12 hr, then quenched with aqueous brine and extracted with CH₂Cl₂ (3×30mL). The combined organics were dried over sodium sulfate and evaporatedin vacuo. The resulting brown foam, 1.5 g (95%), was carried on to thenext step crude. ESI-MS m/z: 374 [M+1].

Step 2:1-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-1-oxy-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-ethanone

A solution of1-[5-(3-Bromo-propylidene)-1-oxy-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-ethanone(1.4 g, 3.8 mmol) in acetonitrile/water (12 mL/3 mL) was treated with4-(4-Chloro-phenyl)-3,3-dimethyl-piperidin-4-ol (1.0 g, 4.2 mmol) andpotassium carbonate (1.1 g, 7.6 mmol). The suspension was stirred at rtfor 72 hr, and evaporated in vacuo. The residue was purified by silicagel chromatography (ethyl acetate→87:10:3 ethylacetate/methanol/triethylamine) to yield 1.2 g (58%) of the titlecompound, ESI-MS m/z: 533 [M+1].

Step 3:4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-1-oxy-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol

A solution of1-(5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-1-oxy-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-ethanone(0.43 g, 0.81 mmol) in THF (3 mL) was treated with methylmagnesiumbromide (1.4M, 0.74 mL, 1.0 mmol). The solution was stirred at rt for 48hr, and quenched with brine. The aqueous residue was extracted withethyl acetate (3×10 mL), and the combined organics were evaporated invacuo. The residue was purified by silica gel chromatography (ethylacetate→87:10:3 ethyl acetate/methanol/triethylamine) to yield 0.10 g(25%) of the title compound, ¹H-NMR (CDCl₃) δ: 0.6 (3H, s), 0.9 (3H, s),1.55 (6H, s), 1.99-2.80 (10H, m), 5.30 (2H, brs), 6.18 (1H, br), 6.89(1H, m), 7.25-7.45 (7H, m), 7.50 (1H, m), 8.55 (1H, d).

ESI-MS m/z: 549 [M+1].

Example 524(R)-2-[5-(3-{3-[(4-Chloro-benzyl)-ethyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol

(R)-Pyrrolidin-3-yl-carbamic acid tert-butyl ester (7.85 g, 42.1 mmol)was dissolved in methylene chloride at 0° C. and triethylamine (11.72mL, 84.3 mmol) and ethyl chloroformate (8.06 mL, 84.3 mmol) were added.The solution was warmed to room temperature and stirred for 30 min, thereaction was washed with NaHCO₃. The organics were combined and driedover MgSO₄, filtered and evaporated in vacuo. The residue was purifiedby Isco flash system (70% hexane/30% ethyl acetate) to yield the ester(7.73 g, 71%).

Part 2:

(R)-3-tert-Butoxycarbonylamino-pyrrolidine-1-carboxylic acid ethyl ester(7.73 g, 29.9 mmol) was dissolved in 4M HCl/dioxane. The solution wasstirred at rt for 1 h. The solvent was removed in vacuo and the mixturewas carried on to the next step without further purification as thehydrochloride salt.

Part 3:

(R)-3-Amino-pyrrolidine-1-carboxylic acid ethyl ester and acetaldehyde(1.76 mL, 31.43 mmol) were mixed with sodium triacetoxyborohydride (9.54g, 45 mmol) in dichloroethane (200 mL) containing acetic acid (1%) andthe resulting mixture was stirred at room temperature overnight. Thereaction mixture was diluted with CH₂Cl₂ and washed with 1 N NaOHsolution and brine and dried over magnesium sulfate. The reaction wasconcentrated in vacuo. The residue was used directly in the nextreaction (4.0 g, 72%)

Part 4:

(R)-3-Ethylamino-pyrrolidine-1-carboxylic acid ethyl ester (1.00 g, 5.4mmol) was dissolved in acetonitrile (100 mL) and potassium carbonate(3.7 g, 27 mmol), KI (0.050 mg) and 1-bromomethyl-4-chloro-benzene (1.1g, 5.4 mmol) were added. The solution was heated at 60° C. for 20 h. Thereaction mixture was filtered and concentrated in vacuo. The residue waspurified by Isco flash system (75% hexane/25% ethyl acetate) to yieldcoupled product (0.410 g, 25%).

Part 5:

(R)-3-[(4-Chloro-benzyl)-ethyl-amino]-pyrrolidine-1-carboxylic acidethyl ester (4.00 g, 1.29 mmol) was dissolved in 15 mL of ethanol andpotassium hydroxide (1.5 g, 26.7 mmol) in water (8 mL) was added. Thesolution was heated to reflux for 14 h and the ethanol was removed invacuo. The residue was partitioned between water and methylene chloride.The organics were removed and washed with sat'd solution of NaHCO₃ andbrine, then dried over magnesium sulfate. The reaction was concentratedin vacuo (0.253 g, 82%).

Part 6:

To a solution of the (R)-(4-chloro-benzyl)-ethyl-pyrrolidin-3-yl-amine(0.253 g, 1.06 mmol) in isopropanol was added 2,6-lutidine (0.225 g, 2.1mmol) and catalytic potassium iodide. This mixture was heated to 80° C.,and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.224 g, 0.6 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.100 g, 31%). ¹H-NMR(MeOD): δ 0.94 (t, 3H), 1.40 (s, 6H), 1.88-2.01 (m, 1H), 2.02-2.18 (m,1H), 2.42-2.67 (m, 4H), 3.03-3.36 (m, 7H), 3.56 (d, 1H), 3.72 (d, 1H),5.16 (bs, 2H), 6.03 (t, 1H), 6.77 (d, 1H), 7.22-7.37 (m, 4H), 7.38-7.47(m, 2H), 7.69 (d, 1H), 8.30 (s, 1H), 8.37 (dd, 1H). ESI-MS m/z: 534(M+1), retention time 1.22.

Example 525(R)-2-[5-(3-{3-[(4-Chloro-phenyl)-ethyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-olPart 1:

(R)-3-Ethylamino-pyrrolidine-1-carboxylic acid ethyl ester (2.0 g, 10.8mmol) and 1-bromo-4-chloro-benzene (2.06 g, 10.8 mmol) was dissolved intoluene along with sodium t-butoxide (1.45 g, 15.12 mmol), Pd₂(dba)₃(0.195 g, 0.21 mmol) and BINAP (0.13 g, 0.21 mmol). The solution washeated to 100° C. for 2 days, then filtered, and the reaction wasconcentrated in vacuo, and then purified by Isco flash chromatography(50% ethyl acetate/50% hexane) to yield the product (0.536 g, 17%).

Part 2:

(R)-3-[(4-Chloro-phenyl)-ethyl-amino]-pyrrolidine-1-carboxylic acidethyl ester (0.536 g, 1.8 mmol) was dissolved in 15 mL of ethanol andpotassium hydroxide (2.05 g, 36.2 mmol) in water (8 mL) was added. Thesolution was heated to reflux for 14 h and the ethanol was removed invacuo. The residue was partitioned between water and methylene chloride.The organics were removed and washed with sat'd solution of NaHCO₃ andbrine, then dried over magnesium sulfate. The reaction was concentratedin vacuo (0.273 g, 67%).

Part 3:

To a solution of the (R)-(4-Chloro-phenyl)-ethyl-pyrrolidin-3-yl-amine(0.270 g, 1.2 mmol) in isopropanol was added 2,6-lutidine (0.20 g, 1.7mmol) and catalytic potassium iodide. This mixture was heated to 80° C.,and treated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.180 g, 0.48 mmol), added in portions over 1 h. The solution was thenstirred at 80° C. for an additional 14 h. The reaction was concentratedin vacuo, then purified by Isco flash chromatography (15% methanol/85%methylene chloride) to yield the title compound (0.180 g, 72%). ¹H-NMR(CDCl₃): δ 1.08 (t, 3H), 1.54 (s, 6H), 1.68-1.92 (m, 2H), 2.08-2.25 (m,1H), 2.36-2.92 (m, 7H), 3.26 (q, 2H), 42.8 (t, 1H), 5.29 (bs, 2H), 6.12(t, 1H), 6.74 (d, 2H), 6.82 (d, 1H), 7.08 (d, 2H), 71.3-7.31 (m, 2H),7.44 (s, 1H), 7.52 (d, 1H), 8.48 (dd, 1H). ESI-MS m/z: 520 (M+1),retention time 2.01.

Example 526(R)-2-{5-[3-(3-{[(4-Chloro-benzyl)-ethyl-amino]-methyl}-pyrrolidin-1-yl)-propylidene]5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl}-propan-2-olPart 1:

(R)-3-Aminomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (0.385g, 1.92 mmol) and 1-bromomethyl-4-chloro-benzene (0.395 g, 1.92 mmol)were dissolved in acetonitrile at 0° C. (10 mL) and triethyl amine(0.793 mL, 5.76 mmol) was added. The solution was allowed to warm toroom temperature and stir overnight. The reaction was concentrated downand partitioned between 1N NaOH and extracted with CH₂Cl₂ (3×). Theorganics were collected together and dried over MgSO₄, filtered andevaporated in vacuo. The residue was purified by Isco flash system (20%hexane/80% ethyl acetate) to yield the product (0.35 g, 57%).

Part 2:

(R)-3-[(4-Chloro-benzylamino)-methyl]-pyrrolidine-1-carboxylic acidtert-butyl ester (0.35 g, 0.1 mmol) and acetaldehyde (0.15 mL, 0.15mmol) were mixed with sodium triacetoxyborohydride (0.35 g, 0.15 mmol)in dichloroethane (15 mL) containing acetic acid (1%) and the resultingmixture was stirred at room temperature overnight. The reaction mixturewas diluted with CH₂Cl₂ and washed with 1 N NaOH solution and brine anddried over magnesium sulfate. The reaction was concentrated in vacuo.The residue was used directly in the next reaction (0.34 g, 100%)

Part 3:

3-{[(4-Chloro-benzyl)-ethyl-amino]-methyl}-pyrrolidine-1-carboxylic acidtert-butyl ester (0.34 g, 0.98 mmol) was dissolved in 4M HCl/dioxane.The solution was stirred at rt for 1 h. The solvent was removed in vacuoand the mixture was carried on to the next step without furtherpurification as the hydrochloride salt.

Part 4:

To a solution of (R)-(4-Chloro-benzyl)-ethyl-pyrrolidin-3-ylmethyl-aminein acetonitrile/water (8:2) (10 mL) was added K₂CO₃ (0.54 g, 3.9 mmol)and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.368 g, 0.98 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Isco flash chromatography (5% methanol/95% methylenechloride/ammonium hydroxide) to yield the title compound (0.110 g, 33%).¹H-NMR (CDCl₃): δ0.94 (t, 3H), 1.37 (m, 1H), 1.48 (s, 6H), 1.76-2.15 (m,4H), 2.22-2.68 (m, 10H), 3.41 (d, 1H), 3.52 (d, 1H), 5.28 (bs, 2H), 6.11(t, 1H), 6.82 (d, 1H), 7.14-7.32 (m, 6H), 7.48 (s, 1H), 7.54 (d, 1H),8.51 (dd, 1H). ESI-MS m/z: 548 (M+1), retention time 1.02.

Example 527(R)-5-(3-{3-[(4-Chloro-benzyl)-ethyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cycloheptene-7-carboxylicacid Part 1:

To a solution of (R)-(4-Chloro-benzyl)-ethyl-pyrrolidin-3-yl-amine (0.43g, 1.8 mmol) in acetonitrile/water (8:2) was added K₂CO₃ (0.99 g, 7.2mmol) and1-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-ethanone(0.65 g, 1.8 mmol). The solution was allowed to stir at room temperaturefor 48 h. The reaction was concentrated down and partitioned betweenEtOAc/H₂O, extracted with EtOAc (3×). The organics were collectedtogether dried over Mg₂SO₄, filtered and evaporated in vacuo, thenpurified by Isco flash chromatography (5% methanol/95% methylenechloride/ammonium hydroxide) to yield the ketone tricycle (0.683 g,73%). ¹H-NMR (MeOD): δ 0.96 (t. 3H), 1.39 (dd, 1H), 1.48 (dd, 1H), 1.84(s, 1H), 1.81 (m, 1H), 1.94 (m, 1H), 2.33-2.47 (m, 2H), 2.53 (s, 3H),2.58-2.66 (m, 2H), 2.68-2.86 (m, 4H), 5.42 (bs, 2H), 6.24 (t, 1H), 6.81(d, 1H), 7.17-7.32 (m, 4H), 7.46 (dd, 1H), 7.77 (t, 2H), 7.96 (s, 1H),8.48 (d, 1H). ESI-MS m/z: 517 (M+1), retention time 2.61.

Part 2:

Bromine (0.13 mL, 2.5 mmol) was added dropwise to a solution of NaOH(0.332 g, 8.3 mmol) in water (3 mL) at 10° C. The solution was cooled to0° C. and(R)-1-[5-(3-{3-[(4-Chloro-benzyl)-ethyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-ethanone(0.43 g, 0.83 mmol) dissolved in dioxane (8 mL) was added to thesolution dropwise. The reaction was allowed to warm to room temperatureand stirred for 3 h. The reaction was evaporated in vacuo and purifiedby HPLC. ¹H-NMR (MeOD): δ 0.96 (t. 3H), 1.37 (m, 1H), 1.48 (m, 1H), 1.95(s, 1H), 1.94 (m, 1H), 2.10 (m, 1H), 2.42-2.63 (m, 3H), 2.90 (t, 1H),2.97-3.23 (m, 3H), 5.82 (bs, 2H), 6.26 (t, 1H), 6.65 (d, 1H), 7.13-7.31(m, 4H), 7.39 (t, 1H), 7.61 (d, 1H), 7.67 (d, 1H), 7.86 (s, 1H), 8.37(d, 1H). ESI-MS m/z: 519 (M+1), retention time 1.91.

Example 5282-{5-[3-(3-[2-(4-Chloro-phenyl)-ethyl]-ethyl-amino}-pyrrolidin-1-yl)-propylidene]-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl}-propan-2-olPart 1:

To a solution of 3-amino-pyrrolidine-1-carboxylic acid tert-butyl ester(0.300 g, 1.37 mmol) dissolved in dimethylformamide was added K₂CO₃(0.567 g, 4.11 mmol) and 1-(2-bromo-ethyl)-4-chloro-benzene (0.30 g,1.37 mmol). The solution was heated to 60° C. for 2 d and thenconcentrated down and partitioned between EtOAc/H₂O, extracted withEtOAc (3×). The organics were collected together dried over Mg₂SO₄,filtered and evaporated in vacuo, then purified by Isco flashchromatography (60% ethyl acetate/40% hexane) to yield the intermediatecompound (0.263 g, 59%).

Part 2:

(R)-3-[2-(4-Chloro-phenyl)-ethylamino]-pyrrolidine-1-carboxylic acidtert-butyl ester (0.263 g, 0.81 mmol) and acetaldehyde (0.068 mL, 1.2mmol) were mixed with sodium triacetoxyborohydride (0.25 g, 1.2 mmol) indichloroethane containing acetic acid (1%) and the resulting mixture wasstirred at room temperature overnight. The reaction mixture was dilutedwith CH₂Cl₂ and washed with 1 N NaOH solution and brine and dried overmagnesium sulfate. The reaction was concentrated in vacuo. The residuewas used directly in the next reaction (0.24 g, 85%)

Part 3:

(R)-3-{[2-(4-Chloro-phenyl)-ethyl]-ethyl-amino}-pyrrolidine-1-carboxylicacid tert-butyl ester (0.242 g) was dissolved in 4M HCl/dioxane. Thesolution was stirred at rt for 1 h. The solvent was removed in vacuo andthe mixture was carried on to the next step without further purificationas the hydrochloride salt.

Part 4:

To a solution of(R)-[2-(4-Chloro-phenyl)-ethyl]-ethyl-pyrrolidin-3-yl-amine (0.100 g,0.39 mmol) in acetonitrile/water (8:2) (10 mL) was added K₂CO₃ (0.837 g,6.06 mmol) and2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.100 g, 0.26 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Isco flash chromatography (5% methanol/95% methylenechloride/ammonium hydroxide) to yield the title compound (0.048 g, 33%).¹H-NMR (CDCl₃): δ 1.06 (t, 3H), 1.52 (s, 6H), 1.58 (m, 1H), 2.10 (m,1H), 2.20-2.78 (m, 13H), 3.30 (m, 1H), 5.28 (bs, 2H), 6.12 (t, 1H), 6.80(d, 1H), 7.06 (d, 2H), 7.14-7.30 (m, 4H), 7.46 (s, 1H), 7.52 (d, 1H),8.52 (dd, 1H). ESI-MS m/z: 548 (M+1), retention time 1.35

Example 529(S)-2-(5-{3-[3-(4-Chloro-benzyloxy)-pyrrolidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

To a solution of (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butylester (0.5 g, 2.67 mmol) in THF (10 mL) was added NaH (0.128 g, 3.2mmol) (60% dispersion in oil). The resulting solution was stirred for 5min. and 1-bromomethyl-4-chloro-benzene (0.658 g, 3.2 mmol) dissolved inTHF (5 mL) was added. The reaction mixture was stirred overnight. Thereaction was quenched with water and extracted with ethyl acetate (3×).The organics were collected together dried over Mg₂SO₄, filtered andevaporated in vacuo, then purified by Isco flash chromatography (15%ethyl acetate/85% hexane) to yield the intermediate compound (0.48 g,58%).

Part 2:

(S)-3-(4-Chloro-benzyloxy)-pyrrolidine-1-carboxylic acid tert-butylester (0.48 g) was dissolved in 4M HCl/dioxane. The solution was stirredat rt for 1 h. The solvent was removed in vacuo and the mixture wascarried on to the next step without further purification as thehydrochloride salt.

Part 3:

To a solution of (S)-3-(4-chloro-benzyloxy)-pyrrolidine (0.38 g, 1.54mmol) in acetonitrile/water (8:2) (10 mL) was added K₂CO₃ (0.85 g, 6.15mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.575 g, 1.54 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Isco flash chromatography (5% methanol/95% methylenechloride/ammonium hydroxide) to yield the title compound (0.112 g, 14%).¹H-NMR (CDCl₃): δ 1.54 (s, 6H), 1.81 (m, 1H), 1.94-2.12 (m, 2H), 2.31(t, 3H), 2.48-2.72 (m, 4H), 4.10 (m, 1H), 4.38 (q, 2H), 5.28 (bs, 2H),6.12 (t, 1H), 6.84 (d, 1H), 7.16-7.30 (m, 6H), 7.48 (s, 1H), 7.56 (d,1H), 8.52 (dd, 1H). ESI-MS m/z: 507 (M+1), retention time 1.56.

Example 5301-{3-[7-(1-Hydroxy-1-methyl-ethyl-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidine-3-carboxylic acid4-chloro-benzyl amide3-(4-Chloro-benzylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butylester

To a solution of di-tert-butyl-dicarbonate (1.86 g, 8.5 mmol) in dioxane(100 mL) was added 3-pyrrolidine carboxylic acid (1.0 g, 8.5 mmol) and 1N NaOH (5 mL). The solution was stirred at rt for 12 h. The reaction wasconcentrated down and partitioned between EtOAc/1N HCl. The reaction wasquenched with 1N HCl and extracted with EtOAc (3×), and the organiclayers were collected together, dried over MgSO₄ and evaporated invacuo. The residue was used directly in the next reaction.

Step 2

Pyrrolidine-1,3-dicarboxylic acid (1.59 g, 7.3 mmol) was dissolved inCH₂Cl₂ and EDCI (2.53 g, 13.2 mmol), HOBt (1.48 g, 10.9 mmol) and4-chlorobenzylamine (0.97 mL, 8.05 mmol) was added. The solution wasallowed to stir at room temperature for 10 h and then washed 1N NaOH(1×), 1N HCl (1×) and brine (1×). The organic layers was dried overMgSO₄ and evaporated in vacuo, then purified by Biotage flashchromatography (50% ethyl acetate/50% hexane) to yield the titlecompound (1.50 g, 62%). ¹H-NMR (CDCl₃): δ 1.43 (s, 9H), 2.07 (m, 2H),2.85 (pentet, 1H), 3.30 (q, 1H), 3.49 (q, 1H), 3.55 (q, 2H), 4.38 (d,2H), 6.16 (bs, 1H), 7.17 (d, 2H), 7.27 (d, 2H).

3-(4-Chloro-benzylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butylester (0.707 g, 2.07 mmol) was dissolved in 4M HCl/Dioxane (5 mL). Thesolution was stirred at rt for 1 h. The solvent was removed in vacuo andthe mixture was carried on to the next step without further purificationas the hydrochloride salt.

To a solution of pyrrolidine-3-carboxylic acid 4-chloro-benzylamidehydrochloride (0.2 g, 0.83 mmol) in acetonitrile/water (8:2) (8 mL) wasadded K₂CO₃ (0.476 g, 3.4 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.282 g, 0.83 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (5% methanol/95% methylenechloride to 10% methanol/90% methylene chloride) to yield the titlecompound (0.240 g, 60%). ¹H-NMR (CDCl₃): 1.54 (s, 6H), 1.93 (m, 1H),2.12 (m, 2H), 2.29-2.82 (m, 10H), 4.26 (bs, 2H), 5.26 (BS, 1h), 6.05 (t,1H), 6.79 (d, 1H), 7.03 (d, 2H), 7.19-7.26 (m, 4H), 7.42 (s, 1H), 7.51(d, 1H), 8.46 (d, 1H). ESI-MS m/z: 532.05 (M+1), retention time 1.68.

Example 5311-{3-[7-(1-Hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidine-3-carboxylicacid (4-chloro-phenyl)-ethyl-amide3-[(4-Chloro-phenyl)-ethyl-carbamoyl)]-pyrrolidine-1-carboxylic acidtert-butyl ester

To a solution of di-tert-butyl-dicarbonate (1.86 g, 8.5 mmol) in dioxane(100 mL) was added 3-pyrrolidine carboxylic acid (1.0 g, 8.5 mmol) and 1N NaOH (5 mL). The solution was stirred at rt for 12 h. The reaction wasconcentrated down and partitioned between EtOAc/1N HCl. The reaction wasquenched with 1N HCl and extracted with EtOAc (3×), and the organiclayers were collected together, dried over MgSO₄ and evaporated invacuo. The residue was used directly in the next reaction.

Step 2

Pyrrolidine-1,3-dicarboxylic acid (0.300 g, 1.4 mmol) was dissolved inCH₂Cl₂ and EDCI (0.477 g, 2.4 mmol), HOBt (0.280 g, 2.1 mmol) andN-ethyl-4-chloro aniline (0.236 g, 1.5 mmol) was added. The solution wasallowed to stir at room temperature for 24 h and then washed 1N NaOH(1×), 1N HCl (1×) and brine (1×). The organic layers was dried overMgSO₄ and evaporated in vacuo, then purified by Biotage flashchromatography (30% ethyl acetate/70% hexane to 40% ethyl acetate/60%hexane) to yield the title compound 0.040 g, 8%). ¹H-NMR (CDCl₃): δ 1.08(t, 3H), 1.41 (s, 9H), 1.78 (m, 1H), 2.13 (m, 1H), 2.76 (pentet, 1H),3.10 (q, 1H), 3.36 (pentet, 2H), 3.50 (t, 1H), 3.73 (m, 2H), 7.09 (d,2H), 7.42 (d, 2H).

3-[(4-Chloro-phenyl)-ethyl-carbamoyl)]-pyrrolidine-1-carboxylic acidtert-butyl ester (0.040 g, 0.1 mmol) was dissolved in 4M HCl/Dioxane (2mL). The solution was stirred at rt for 1 h. The solvent was removed invacuo and the mixture was carried on to the next step without furtherpurification as the hydrochloride salt.

To a solution of pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-ethyl-amide hydrochloride (0.033 g, 0.11 mmol) inacetonitrile/water (8:2) (2 mL) was added K₂CO₃ (0.125 g, 0.89 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.042 g, 0.11 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (2½% methanol/97½%methylene chloride to 5% methanol/95% methylene chloride) to yield thetitle compound (0.028 g, 46%). ¹H-NMR (CDCl₃): δ 1.07 (t, 3H), 1.55 (6H,s), 1.62 (m, 1H), 1.99 (m, 3H), 2.30 (pentet, 3H), 2.47-2.77 (m, 5H),3.68 (m, 2H), 5.26 (bs, 2H), 6.09 (t, 1H), 6.79 (d, 1H), 7.03 (d, 2H),7.24 (m, 2H), 7.37 (d, 2H), 7.42 (s, 1H), 7.52 (d, 1H), 8.47 (d, 1H).ESI-MS m/z: 546.04 (M+1), retention time 1.44.

Example 532(R)-2-(5-{3-[3-(5-Chloro-1,3-dihydro-isoindol-2-yl)-pyrrolin-1-y;]-propylidene-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl-propan-2-ol(R)-3-(5-Chloro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester

4-Chlorophthalic acid monosodium (2.00 g, 8.9 mmol) and PCl₅ (5.61 g,26.9 mmol) were added neat to a flask and heated to 180° C. (caution theinitial mixture of the acid and PCl₅ was very exothermic). The mixturewas heated for 3 h and then the suspension was diluted with toluene andfiltered. The reaction was concentrated down and used without furtherpurification.

Part 2:

(R)-4-Chloro-phthaloyl dichloride (0.556 g, 2.3 mmol) and(R)-3-amino-1-N-Boc-pyrrolidine (0.400 g, 2.1 mmol) were dissolved in 21mL of pyridine and heated to 80° C. for 2½ h. The solution was dilutedwith water and extracted with EtOAc. The organic were collected togetherand washed with 1N HCl, 1N NaOH, brine and dried over Mg₂SO₄, filteredand evaporated in vacuo, then purified by Biotage flash chromatography(5% methanol/95% methylene chloride to 10% ethyl acetate/90% hexane to20% ethyl acetate/80% hexane) to yield the title compound (0.200 g,26%). ¹H-NMR (CDCl₃): δ 1.46 (s, 9H), 2.12 (m, 1H), 2.59 (pentet, 1H),3.38 (quartet, 1H), 3.71 (m, 3H), 4.83 (pentet, 1H), 7.69 (d, 1H), 7.77(d, 1H), 7.80 (s, 1H). ESI-MS m/z: 351 (M+1), retention time 2.73.

(R)-3-(5-Chloro-1,3-dihydro-isoindol-2-yl)-pyrrolidine-1-carboxylic acidtert-butyl ester

(R)-3-(5-Chloro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester (0.200 g, 0.57 mmol) was dissolved in ether andcooled to 0° C. and LiAlH₄ (2.85 mL, 2.8 mmol) was added dropwise,followed by AlCl₃ (0.380 g, 2.8 mmol). The solution was allowed to stirat 0° C. for 1½ h and then slowly quenched with water and extracted withethyl acetate (3×). The organic were collected together and dried overMg₂SO₄, filtered and evaporated in vacuo, to yield the title compound(0.076 g, 41%) without further purification. ESI-MS m/z: 323 (M+1),retention time 1.27.

(R)-3-(5-Chloro-1,3-dihydro-isoindol-2-yl)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.076 g, 0.23 mmol) was dissolved in 4M HCl/Dioxane (2mL). The solution was stirred at rt for 1 h. The solvent was removed invacuo and the mixture was carried on to the next step without furtherpurification as the hydrochloride salt.

Step 2

To a solution of (R)-5-chloro-2-pyrrolin-3-yl-2,3-dihydro-1H-isoindolehydrochloride (0.052 g, 0.23 mmol) in acetonitrile/water (8:2) (2 mL)was added K₂CO₃ (0.215 g, 1.5 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.079 g, 0.21 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (5% methanol/95% methylenechloride to 10% methanol/90% methylene chloride to 15% methanol/85%methylene chloride) to yield the title compound (0.055 g, 55%). ¹H-NMR(CDCl₃): δ 1.55 (s, 9H), 1.77 (m, 1H), 2.02 (m, 2H), 2.37 (pentet, 3H),2.42-2.64 (m, 4H), 2.81 (t, 1H), 3.17 (pentet, 1H), 3.43 (s, 3H), 3.84(s, 4H), 5.26 (bs, 2H), 6.11 (t, 1H), 6.79 (d, 1H), 7.08-7.28 (m, 5H),7.43 (s, 1H), 7.56 (d, 1H), 8.46 (d, 1H). ESI-MS m/z: 516.02 (M+1),retention time 1.26.

Example 533(R)-1-(4-Chloro-benzyl)-1-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)urea

(R)-1-(4-Chloro-benzyl)-1-pyrrolidin-3-yl-urea

(R)-3-(4-Chloro-benzylamino)-pyrrolidine-1-carboxylic acidtert-butylester (0.690 g, 2.2 mmol) was dissolved in CH₂Cl₂ with a fewdrops of isopropanol and trimethylsilylisocyanate (0.365 mL, 2.6 mmol)were added. The solution was allowed to stir at room temperature for 12h, the reaction was concentrated down and used directly in the nextreaction. ESI-MS m/z: 354 (M+1), retention time 2.15.

Part 2:

(R)-3-[1(4-Chloro-benzyl)-ureido]-pyrrolidine-1-carboxylic acidtert-butyl ester (0.300 g, 0.84 mmol) was dissolved in 4M HCl/Dioxane (2mL). The solution was stirred at rt for 1 h. The solvent was removed invacuo and the mixture was carried on to the next step without furtherpurification as the hydrochloride salt.

To a solution of (R)-1-(4-Chloro-benzyl)-1-pyrrolidin-3-yl-urea (0.200g, 0.78 mmol) in acetonitrile/water (8:2) (8 mL) was added K₂CO₃ (0.449g, 3.2 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.267 g, 0.71 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (5% methanol/95% methylenechloride to 10% methanol/90% methylene chloride) to yield the titlecompound (0.231 g, 60%). ¹H-NMR (CDCl₃): δ 1.55 (s, 6H), 1.88 (pentet,1H), 2.01-2.28 (m, 5H), 2.53 (pentet, 6H), 3.12 (t, 1H), 3.14 (t, 1H),3.83 (q, 1H), 4.37 (s, 1H), 4.53 (s, 2H), 5.28 (bs, 2H), 6.18 (t, 1H),6.78 (d, 1H), 7.11 (dd, 1H), 7.16 (s, 1H), 7.18-7.27 (m, 4H), 7.49 (d,1H), 7.51 (s, 1H), 8.47 (dd, 1H).

ESI-MS m/z: 547.06 (M+1), retention time 1.65.

Example 534(R)-8-Chloro-4-(1-{3-[7-(-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidine-3-yl)-1,3,4,5-tetrahydro-benzo[e][1,4]diazepin-2-oneStep 1: 3-(4-Chloro-2-nitro-benzylamino)-pyrrolidine-1-carboxylic acidtert-butyl ester

To a solution of 3-Amino-pyrrolidine-1-carboxylic acid tert-butyl ester(2 g, 10.7 mmol) in methanol (20 mL) was added4-Chloro-2-nitro-benzaldehyde (1.98 g, 10.7 mmol). The resultantsolution was heated at 60° C. overnight. The reaction mixture was cooledto 0° C. and to it was added NaBH₄ (629 mg, 10 mmol). After 1 h, thereaction solution was quenched with saturated NaHCO₃ solution andextracted with ethyl acetate. The organic extract was dried over MgSO₄,filtered and concentrated to provide the crude product as an oil. Thecrude product was used in the subsequent reaction without furtherpurification. LCMS (retention time=1.28, ES+; 356)

Step 2:3-[(4-Chloro-benzyl)-methoxycarbonylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of3-(4-Chloro-2-nitro-benzylamino)-pyrrolidine-1-carboxylic acidtert-butyl ester (3.8 g, 10.7 mmol) in DMF (40 mL) was addedBromo-acetic acid methyl ester (1.01 mL, 10.7 mmol) and K₂CO₃ (1.48 g,10.7 mmol). The resultant suspension was stirred at 70° C. overnight.The reaction mixture was diluted with water and ethyl ether. The organicextract was dried over MgSO₄, filtered and concentrated to provide thedesired product as an oil. The crude product was purified on SiO₂ andconcentrated to provide the desired product as an oil (2 g, 44%). LCMS(retention time=3.03, ES+428)

Step 3:3-(8-Chloro-2-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of3-[(4-Chloro-2-nitro-benzyl)-methoxycarbonylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (1.04 g, 2.4 mmol) in ethyl acetate (20 mL) wasadded 10% Pd/C. Hydrogenolysis of the reaction solution at rt underatmospheric pressure provided the desired product after 1.5 h. Thereaction mixture was filtered through a pad of celite and concentrated.The crude product (662 mg, 1.7 mmol) was dissolved in DMF (5 mL) and toit was added 60% NaH (100 mg, 2.5 mmol). The resultant solution wasstirred at rt overnight. The reaction was quenched with water andextracted with ethyl ether. The organic extract was dried over MgSO₄,filtered and concentrated to get the crude product. Purification on SiO₂provided the desired product. LCMS (retention time=1.89, ES+; 310)

(R)-3-(8-Chloro-2-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)pyrrolidine-1-carboxylicacid tert-butyl ester (0.210 g, 0.57 mmol) was dissolved in 4MHCl/Dioxane (5.7 mL). The solution was stirred at rt for 1 h. Thesolvent was removed in vacuo and the mixture was carried on to the nextstep without further purification as the hydrochloride salt.

Step 2

To a solution of(R)-8-chloro-4-pyrrolidin-3-yl-1,3,4,5-tetrahydro-benzo[e][1,4]diazepin-2-one(0.198 g, 0.58 mmol) in acetonitrile/water (8:2) (5.8 mL) was addedK₂CO₃ (0.655 g, 4.6 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.183 g, 0.48 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (5% methanol/95% methylenechloride to 10% methanol/90% methylene chloride to 15% methanol/85%methylene chloride) to yield the title compound (0.077 g, 28%). ¹H-NMR(CDCl₃): δ1.55 (s, 6H), 1.74 (septet, 1H), 2.01 (sextet, 1H), 2.32-2.60(m, 6H), 2.76 (t, 1H), 3.26 (pentet, 1H), 3.43 (d, 1H), 3.46 (s, 2H),3.74 (s, 2H), 5.27 (bs, 2H), 6.12 (t, 1H), 6.78 (d, 1H), 6.96 (s, 1H),7.06 (dd, 1H), 7.13 (d, 1H), 7.19-7.27 (m, 2H), 7.44 (d, 1H), 7.55 (dd,1H), 8.47 (dd, 1H), 8.49 (s, 1H). ESI-MS m/z: 559 (M+1), retention time1.24.

Example 535(R)-8-Chloro-1-ethyl-4-(1-{3[7-(-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidine-3-yl)-1,3,4,5-tetrahydro-benzo[e][1,4]diazepin-2-one(R)-3-(8-Chloro-1-ethyl-2-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)pyrrolidine-1-carboxylicacid tert-butyl ester

(R)-3-(8-Chloro-2-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)pyrrolidine-1-carboxylicacid tert-butyl ester (0.258 g, 0.70 mmol) was dissolved in THF (7 mL)and cooled to 0° C. To the solution was added NaH (0.042 g, 1.0 mmol)and stirred for 15 min, followed by ethyl iodide (0.085 mL, 1.0 mmol).The solution was allowed to warm to room temperature slowly and stir atroom temperature for 14 h. The reaction was quenched with water andextracted with EtOAc (3×). The organics were collected together driedover Mg₂SO₄, filtered and evaporated in vacuo, then purified by Biotageflash chromatography (75% ethyl acetate/25% ethyl acetate to 100% ethylacetate) to yield the title compound (0.130 g, 47%). ¹H-NMR (CDCl₃): δ1.16 (t, 3H), 1.43 (s, 9H), 1.75 (sextet, 1H), 2.18 (pentet, 1H),3.05-3.9 (m, 1H), 7.20 (m, 3H). ESI-MS m/z: 394 (M+1), retention time2.25.

(R)-3-(8-Chloro-1-ethyl-2-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)pyrrolidine-1-carboxylicacid tert-butyl ester (0.130 g, 0.32 mmol) was dissolved in 4MHCl/Dioxane (3.2 mL). The solution was stirred at rt for 1 h. Thesolvent was removed in vacuo and the mixture was carried on to the nextstep without further purification as the hydrochloride salt.

Step 2

To a solution of(R)-8-chloro-1-ethyl-4-pyrrolidin-3-yl-1,3,4,5-tetrahydro-benzo[e][1,4]diazepin-2-one(0.121 g, 0.32 mmol) in acetonitrile/water (8:2) (3.2 mL) was addedK₂CO₃ (0.368 g, 2.6 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.102 g, 0.27 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated down and partitionedbetween EtOAc/H₂O, extracted with EtOAc (3×). The organics werecollected together dried over Mg₂SO₄, filtered and evaporated in vacuo,then purified by Biotage flash chromatography (5% methanol/95% methylenechloride to 10% methanol/90% methylene chloride to 15% methanol/85%methylene chloride) to yield the title compound (0.033 g, 21%). ¹H-NMR(CDCl₃): δ1.17 (t, 3H), 1.55 (s, 6H), 1.73 (septet, 1H), 2.08 (m, 1H),2.34 (pentet, 2H), 2.43-2.61 (m, 4H), 2.85 (t, 1H), 2.92 (d, 1H), 3.10(q, 1H), 3.22 (m, 1H), 3.52 (q, 2H), 3.91 (septet, 2H), 5.29 (bs, 2H),6.12 (t, 1H), 6.79 (dd, 1H), 7.15-7.28 (m, 5H), 7.44 (s, 1H), 7.56 (d,1H), 8.47 (d, 1H). ESI-MS m/z: 587 (M+1), retention time 1.37.

Example 536[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-aceticacid methyl ester Step 1:3-(4-Chloro-benzylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester

To a solution of 3-Amino-pyrrolidine-1-carboxylic acid tert-butyl ester(2 g, 10.7 mmol) in methanol (20 mL) was added 4-Chloro-benzaldehyde(1.5 g, 10.7 mmol). The resultant solution was heated at 60° C.overnight. The reaction mixture was cooled to 0° C. and to it was addedNaBH₄ (629 mg, 10 mmol). After 1 h, the reaction solution was quenchedwith saturated NaHCO₃ solution and extracted with ethyl acetate. Theorganic extract was dried over MgSO₄, filtered and concentrated toprovide the crude product as an oil. The crude product was used in thesubsequent reaction without further purification. LCMS (retentiontime=1.27, ES+311)

Step 2:3-[(4-Chloro-benzyl)-methoxycarbonylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of 3-(4-Chloro-benzylamino)-pyrrolidine-1-carboxylic acidtert-butyl ester (3.3 g, 10.7 mmol) in DMF (40 mL) was addedBromo-acetic acid methyl ester (1.01 mL, 10.7 mmol) and K₂CO₃ (1.48 g,10.7 mmol). The resultant suspension was stirred at 70° C. overnight.The reaction mixture was diluted with water and ethyl ether. The organicextract was dried over MgSO₄, filtered and concentrated to provide thedesired product as an oil. The crude product was purified on SiO₂ andconcentrated to provide the desired product as an oil (3.5 g, 87%). LCMS(retention time=2.96, ES+383)

Step 3: [(4-Chloro-benzyl)-pyrrolidin-3-yl-amino]-acetic acid methylester

3-[(4-Chloro-benzyl)-methoxycarbonylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (3.5 g, 9.1 mmol) was dissolved in 4N HCl indioxane (60 mL). The resultant solution was stirred for 2 h at rt thenconcentrated to provide the desired product as a white solid. LCMS(retention time=1.26, ES+283)

Step 4:[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-aceticacid methyl ester

To a solution of [(4-Chloro-benzyl)-pyrrolidin-3-yl-amino]-acetic acidmethyl ester (188 mg, 0.67 mmol) in isopropanol (5 mL) was added2,6-lutidine (186 uL, 1.6 mmol), and a catalytic amount of potassiumiodide. The resultant solution was heated at 80° C. and to it was added2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(149 mg, 0.4 mmol) portionwise over 0.5 h. The reaction solution washeated overnight then partitioned between water and ethyl acetate. Theproduct was purified on SiO₂ (ethyl acetate: Methanol: triethylamine95:4.5:0.4) and isolated as a film. LCMS (retention time=1.84, ES+;576); ¹H NMR (CD₃OD): δ 8.46 (1H, d), 7.76 (1H, d), 7.45 (2H, m), 7.23(5H, m), 6.74 (1H, d), 6.15 (1H, m), 3.72 (2H, m), 3.60 (4H, s), 3.30(6H, m), 2.78 (4H, m), 2.42 (2H, m), 2.05 (1H, m), 1.82 (1H, m), 1.50(6H, s).

Example 537[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-aceticacid Step 1:[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-aceticacid

To a solution of[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-aceticacid methyl ester (116 mg, 0.2 mmol) in THF:H₂O (4:1, 10 mL totalvolume) was added lithium hydroxide monohydrate (17 mg, 0.4 mmol). Theresultant solution was stirred at rt for 3 h. The reaction solution wasquenched with 1N HCl and extracted with ethyl ether, dried over MgSO₄,filtered and concentrated. The final product was filtered through filterpaper and re-concentrated. This product was submitted without furtherpurification. LCMS (retention time=1.72, ES+562); ¹H NMR (CD₃OD): δ 8.48(1H, d), 7.78 (1H, d), 7.48 (2H, m), 7.31 (5H, m), 6.76 (1H, d), 6.15(1H, t), 3.85 (2H, dd), 3.60 (2H, m), 3.30 (7H, m), 3.24 (1H, s), 3.18(1H, m), 3.06 (1H, m), 2.58 (1H, m), 2.48 (1H, t), 2.06 (2H, m), 1.50(6H, s).

Example 5382-(5-{3-[4-(3,4-Dichloro-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

To a solution of 1-(3,4-dichloro-phenyl)-piperazine (0.14 g, 0.601 mmol)in isopropanol (6.0 mL) was added 2,6-lutidine (95 uL, 0.802 mmol) andcatalytic potassium iodide. This mixture was heated to 80° C. andtreated with2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol (0.37 g, 1.0 mmol), added in threeportions over 2 h. The reaction was then stirred at 80° C. for 18 hours.The reaction was concentrated in vacuum, then purified by flashchromatography on silica gel (gradient elution from 95% ethyl acetate/5%methanol to 90% ethyl acetate/10% methanol) to yield the title compoundas a white solid (0.15 g, 69%). ¹H-NMR (MeOD) δ: 1.55 (6H, s), 2.35-2.65(8H, m), 3.15-3.25 (4H, m), 5.30 (2H, br s), 6.20 (1H, t), 6.82 (1H,dd), 7.23-7.55 (5H, m), 7.59 (1H, d), 8.50 (1H, dd).

ESI-MS m/z: 524 (M+1), UV retention time: 1.66 min.

Example 5392-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: 4-(4-Chloro-2-methyl-phenyl)-piperazine-1-carboxylic acidtert-butyl ester

2-Bromo-5-chlorotoluene (0.82 g, 4 mmol) and tert-Butyl 1-piperazinecarboxylate (0.89 g, 2.32 mmol) were added to a solution of tri-t-butylphosphine (0.033 g, 4 mmol %), tris(dibenzylideneacetone) dipalladium(0)(0.075 g, 2.0 mmol %) and cesium carbonate (1.95 g, 6.0 mmol) in tolueneand heated to 80° C. overnight. The reaction mixture was filteredthrough celite and concentrated in vacuo. The crude product was purifiedon silica gel (gradient elution from 20% ethyl acetate/hexane to 50%ethyl acetate/hexane) to give the title compound in 20% yield. ESI-MSm/z: 311 (M+1), UV retention time: 3.49 min.

Step 2: 1-(4-Chloro-2-methyl-phenyl)-piperazine

A solution of 4-(4-chloro-2-methyl-phenyl)-piperazine-1-carboxylic acidtert-butyl ester (0.26 g, 0.837 mmol) in dichloromethane cooled at 0° C.was treated with trifluoroacetic acid (20%) and warmed to roomtemperature and stirred for 2 hours. The reaction mixture wasconcentrated in vacuo, diluted with ethyl acetate and free based with10% aqueous sodium bicarbonate. The organics were separated and driedover sodium sulfate and concentrated. The product was used withoutfurther purification ESI-MS m/z: 211 (M+1), UV retention time: 1.25 min.

Step 3.2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

To a solution of 1-(4-chloro-2-methyl-phenyl)-piperazine (0.13 g, 0.6mmol) in isopropanol (6.0 mL) was added 2,6-lutidine (95 uL, 0.802 mmol)and catalytic potassium iodide. This mixture was heated to 80° C., andtreated with2-[5-(3-Bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.15 g, 0.4 mmol), added in portions over 2 h. The solution was thenstirred at 80° C. for an additional 12 h. The reaction mixture wasconcentrated in vacuo, then purified by flash chromatography on silicagel (gradient elution from 95% ethyl acetate/5% methanol to 90% ethylacetate/10% methanol) to yield the title compound (0.11 g, 54%). ¹H-NMR(DMSO) δ: 1.45 (6H, s), 2.30-2.65 (8H, m), 2.75-2.85 (4H, m), 3.30 (3H,d), 5.30 (2H, br s), 6.20 (1H, t), 6.75 (1H, d), 7.00-7.47 (6H, m), 7.80(1H, dd), 8.50 (1H, dd). ESI-MS m/z: 504 (M+1), UV retention time: 1.65min.

Example 5405-Chloro-2-(4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazin-1-yl)-benzonitrileStep 1: 4-(2-Cyano-phenyl)-piperazine-1-carboxylic acid tert-butyl ester

To a solution of 2-piperazin-1-yl-benzonitrile (1.1 g, 5.87 mmol) indichloromethane (10 mL) was added diisopropylethylamine (3.1 mL, 17.62mmol) followed by di-tert-butyl-dicarbonate (1.28 g, 5.87 mmol) andreaction mixture was stirred at room temperature for 20 hours. Thereaction mixture was concentrated in vacuo, dissolved in ethyl acetateand washed with saturated aqueous sodium bicarbonate solution. Theaqueous layer was back extracted twice with ethyl acetate. The organiclayers were combined, dried over sodium sulfate and concentrated invacuo. The crude product was purified using a short plug of silica gelusing hexane/ethyl acetate (50%) ¹H-NMR (CDCL₃) δ: 1.47 (9H, s),3.12-3.16 (4H, m), 3.61-3.65 (4H, m), 6.90-7.05 (2H, m), 7.47-7.70 (2H,m). ESI-MS m/z: 288 (M+1), UV retention time: 2.75 min.

Step 2 4-(4-Chloro-2-cyano-phenyl)-piperazine-1-carboxylic acidtert-butyl ester

To a solution of 4-(2-cyano-phenyl)-piperazine-1-carboxylic acidtert-butyl ester (7.1 g, 24.72 mmol) in acetonitrile (120 ml) was addedN-chlorosuccinimide (3.96 g, 29.66 mmol) and the resulting mixture wasslowly heated to 80° C. and stirred for 1.5 h. The reaction mixture wascooled to room temperature, concentrated in vacuo diluted withdichloromethane and extracted with saturated aqueous sodium bicarbonatesolution. The aqueous layer was back extracted twice withdichloromethane. The organic layers were combined, dried over sodiumsulfate and concentrated in vacuo. The crude product was purified usinga short plug of silica gel using gradient elution from hexane/ether(10%) to hexane/ether (40%) to give the p-chloro isomer in 50% yield.¹H-NMR (CDCL₃) δ: 1.48 (9H, s), 3.10-3.38 (4H, m), 3.60-3.70 (4H, m),6.85-7.18 (1H, m), 7.40-7.60 (2H, m). ESI-MS m/z: 322 (M+1), UVretention time: 3.07 min.

Step 3: 5-Chloro-2-piperazin-1-yl-benzonitrile

A solution of 4-(4-chloro-2-cyano-phenyl)-piperazine-1-carboxylic acidtert-butyl ester (0.32 g, 1 mmol) in dichloromethane cooled at 0° C. wastreated with trifluoroacetic acid (20%) and warmed to room temperatureand stirred for 2 h. The reaction mixture was concentrated in vacuo,diluted with ethyl acetate and free based with 10% aqueous sodiumbicarbonate. The organic layers were separated and dried over sodiumsulfate and concentrated in vacuo. The product used without furtherpurification.

ESI-MS m/z: 222 (M+1), UV retention time: 1.05 min.

Step 45-Chloro-2-(4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-azadibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazin-1-yl)-benzonitrile

To a solution of 5-chloro-2-piperazin-1-yl-benzonitrile (0.22 g, 1 mmol)in isopropanol (8 mL) was added 2,6-lutidine (0.16 mL, 1.33 mmol) andcatalytic potassium iodide. This mixture was heated to 80° C. andtreated with2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.26 g, 0.67 mmol) in portions over 2 h. The solution was then stirredat 80° C. for an additional 18 h. The reaction mixture was concentratedin vacuo, then purified by flash chromatography on silica gel (gradientelution from 95% ethyl acetate/5% methanol to 90% ethyl acetate/10%methanol) to yield the title compound (0.11 g, 54%). ¹H-NMR (MeOD) δ:1.40 (6H, s), 2.30-2.58 (8H, m), 3.00-3.15 (4H, m), 5.20 (1H, br s),6.18 (1H, t), 6.70 (1H, dd), 7.18-7.84 (7H, m), 8.50 (1H, dd). ESI-MSm/z: 515 (M+1),

UV retention time: 1.75 min.

Example 5415-Chloro-2-(4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazin-1-yl)-benzoicacid methyl ester Step 1:4-(2-Carboxy-4-chloro-phenyl)-piperazine-1-carboxylic acid tert-butylester

To a solution of 4-(4-chloro-2-cyano-phenyl)-piperazine-1-carboxylicacid tert-butyl ester (0.6 g, 1.86 mmol) in methanol (4.0 mL) was added1.0 N NaOH (4.0 mL, 4.0 mmol) and the resulting mixture was heated toreflux at 80° C. for 36 h. Additional 1.0 N NaOH (2.0 ml, 2.0 mmol) wasadded to the reaction mixture and refluxed further for 18 hrs. Thereaction mixture was concentrated and acidified to pH 4.0-5.0 using 1.0N HCl and extracted with chloroform (5×). The combined organics weredried over sodium sulfate, concentrated and dried in vacuo overnight.The product contained approximately 20% amide and was separated afteresterification in the next step. ESI-MS m/z: 341(M+1), UV retentiontime: 2.33 min.

Step 2: 4-(4-Chloro-2-methoxycarbonyl-phenyl)-piperazine-1-carboxylicacid tert-butyl ester

To a solution of 4-(2-Carboxy-4-chloro-phenyl)-piperazine-1-carboxylicacid tert-butyl ester (0.64 g, 1.88 mmol) in toluene:methanol (9:1) wasadded a trimethylsilyldiazomethane (2.0 M in hexanes) (1.05 mL, 2.07mmol) and the resulting mixture was stirred at room temperature for 1 h.The reaction mixture was concentrated in vacuo and purified usinggradient elution from hexane/ethyl acetate (10%) to hexane/ethyl acetate(50%). ¹H-NMR (CDCL₃) δ: 1.45 (9H, s), 2.90-3.00 (4H, m), 3.50-3.60 (4H,m), 3.90 (3H, s), 6.90-7.00 (1H, d), 7.35-7.45 (1H, dd), 7.80 (1H, d).

ESI-MS m/z: 355 (M+1), UV retention time: 3.11 min.

Step 3: 5-Chloro-2-piperazin-1-yl-benzoic acid methyl ester

A solution of4-(4-chloro-2-methoxycarbonyl-phenyl)-piperazine-1-carboxylic acidtert-butyl ester (0.32 g, 0.92 mmol) in dichloromethane (5.0 mL) cooledat 0° C. was treated with trifluoroacetic acid (20%) and warmed to roomtemperature and stirred for 2 h. The reaction mixture was concentratedin vacuo, diluted with ethyl acetate and free based with 10% aqueoussodium bicarbonate. The organics were separated and dried over sodiumsulfate and concentrated in vacuo. The product used without any furtherpurification. ESI-MS m/z: 255 (M+1), UV retention time: 1.14 min.

Step 4:5-Chloro-2-(4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazin-1-yl)-benzoicacid methyl ester

To a solution of 5-chloro-2-piperazin-1-yl-benzoic acid methyl ester(0.23 g, 0.916 mmol) in isopropanol (8.0 mL) was added 2,6-lutidine(0.16 mL, 1.33 mmol) and catalytic potassium iodide. This mixture washeated to 80° C. and treated with2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.26 g, 0.67 mmol) in portions over 2 h. The solution was then stirredat 80° C. for an additional 18 h. The reaction mixture was concentratedin vacuo, then purified by flash chromatography on silica gel (gradientelution from 95% ethyl acetate/5% methanol to 90% ethyl acetate/10%Methanol) to yield the title compound.

¹H-NMR (DMSO) δ: 1.40 (6H, s), 2.15-2.55 (8H, m), 2.75-2.95 (4H, m),3.75 (3H, s), 5.20 (2H, br s), 6.10 (1H, t), 6.65 (1H, dd), 7.00-7.60(6H, m), 7.70 (1H, dd), 8.50 (1H, dd). ESI-MS m/z: 548 (M+1), UVretention time: 1.56 min.

Example 5422-(4-Chloro-phenyl)-N-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-azadibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-acetamideStep 1: 4-[2-(4-Chloro-phenyl)-acetylamino]-piperidine-1-carboxylic acidtert-butyl ester

To a solution of 4-amino-piperidine 1-carboxylic acid tert-butyl ester(0.44 g, 2.2 mmol) and 4-chlorophenyl acetic acid (0.34 g, 2 mmol) indichloromethane (10 mL) were added EDCI (0.55 g, 2.8 mmol), HOBT (0.42g, 2.8 mmol) and N-methylmorpholine (0.6 g, 6 mmol) and the resultingmixture was stirred at room temperature overnight. The reaction mixturewas concentrated in vacuo, diluted with dichloromethane and extractedwith saturated aqueous sodium bicarbonate solution. The aqueous layerwas back extracted twice with dichloromethane. The combined organicswere dried over sodium sulfate and concentrated in vacuo. Crude productwas purified using a short plug of silica gel using ethyl acetate togive the desired product ¹H-NMR (CDCL₃) δ: 1.15-1.25 (2H, m), 1.40 (9H,s), 1.80-1.90 (2H, m), 2.85 (2H, dd), 3.5 (2H, s), 4.00 (1H, br s), 5.20(1H, d), 7.15-7.35 (4H, m). ESI-MS m/z: 353 (M+1), UV retention time:2.47 min.

Step 2: 2-(4-Chloro-phenyl)-N-piperidin-4-yl-acetamide

A solution of4-[2-(4-chloro-phenyl)-acetylamino]-piperidine-1-carboxylic acidtert-butyl ester (0.55 g, 1.54 mmol) in dichloromethane (8.0 mL) cooledat 0° C. was treated with trifluoroacetic acid (20%) and warmed to roomtemperature and stirred for 2 h. The reaction mixture was concentratedin vacuo, diluted with ethyl acetate and free based with 10% aqueoussodium bicarbonate. The combined organic layers were dried over sodiumsulfate and concentrated in vacuo. The crude product was purified onsilica using gradient elution from ethyl acetate/methanol (2%) to ethylacetate/methanol (20%). ¹H-NMR (CDCL₃) δ: 1.15-1.25 (2H, m), 1.80-1.90(2H, m), 2.60-2.75 (2H, m), 2.90-3.10 (2H, m), 3.5 (2H, s), 3.85 (1H,m), 5.20 (1H, d), 7.15-7.35 (4H, m). ESI-MS m/z: 253 (M+1), UV retentiontime: 0.87 min.

Step 3:2-(4-Chloro-phenyl)-N-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-yl)-acetamide

To a solution of 2-(4-chloro-phenyl)-N-piperidin-4-yl-acetamide (0.2 g,0.8 mmol) in isopropanol (6.0 mL) was added 2,6-lutidine (0.095 mL, 0.8mmol) and catalytic potassium iodide. This mixture was heated to 80° C.and treated with2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.15 g, 0.4 mmol) in portions over 2 h. The solution was then stirredat 80° C. for an additional 18 h. The reaction mixture was concentratedin vacuo, then purified by flash chromatography on silica gel (gradientelution from 95% ethyl acetate/5% methanol to 90% ethyl acetate/20%methanol) to yield the title compound.

¹H-NMR (CDCL₃) δ: 1.15-1.50 (4H, m), 1.60 (6H, s), 1.80-2.85 (8H, m),3.50 (2H, s), 3.70-3.90 (1H, m), 5.20 (2H, br s), 6.05 (1H, t), 6.80(1H, d), 7.20-7.40 (7H, m) 7.60 (1H, dd), 8.50 (1H, dd). ESI-MS m/z: 546(M+1), UV retention time: 1.24 min.

Example 5432-{5-[3-({2-[(4-Chloro-phenyl)-ethyl-amino]-ethyl}-ethyl-amino)-propylidene]-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl}-propan-2-olStep 1:2-(5-{3-[2-(4-Chloro-phenylamino)-ethylamino]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

To a solution of N-(4-chloro-phenyl)-ethane-1,2-diamine (0.68 g, 3.96mmol) in isopropanol (8.0 mL) was added 2,6-lutidine (0.31 mL, 2.64mmol) and catalytic potassium iodide. This mixture was heated to 80° C.and then treated with2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.15 g, 0.4 mmol) in portions over 2 h. The solution was then stirredat 80° C. for an additional 18 h. The reaction mixture was concentratedin vacuo, then purified by flash chromatography on silica gel (gradientelution from 95% ethyl acetate/5% methanol to 90% ethyl acetate/20%methanol) to yield the title compound. ¹H-NMR (DMSO) δ: 1.40 (6H, s),2.20-2.40 (2H, m), 2.70-2.90 (3H, m), 3.10-3.30 (3H, m), 5.20 (2H, br,s), 5.80 (1H, m), 6.15 (1H, t), 6.60-6.70 (1H, m), 7.10-7.30 (4H, m)7.50 (2H, m), 7.80 (1H, dd), 8.50 (1H, dd). ESI-MS m/z: 464 (M+1), UVretention time: 1.40 min.

Step 2:2-{5-[3-({2-[(4-Chloro-phenyl)-ethyl-amino]-ethyl}-ethyl-amino)-propylidene]-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl}-propan-2-ol

To a solution of2-(5-{3-[2-(4-chloro-phenylamino)-ethylamino]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol(0.13 g, 0.27 mmol) in dichloroethane (5.0 mL) was added acetaldehyde(0.045 mL, 0.81 mmol), sodium triacetoxy borohydride (0.17 g, 0.81 mmol)and catalytic acetic acid and stirred at room temperature overnight. Thereaction mixture was concentrated and the residue was dissolved indichloromethane and washed with saturated aqueous sodium bicarbonate.The combined organics were washed with brine, dried over sodium sulfateand concentrated in vacuo. The crude product was purified on silicausing gradient elution from ethyl acetate (100%) to ethylacetate/methanol (5%). ¹H-NMR (CDCL₃) δ: 0.90-1.20 (6H, 2×t), 1.60 (6H,s), 2.20-2.40 (2H, m), 2.45-2.65 (6H, m), 3.20-3.40 (4H, 2×q), 5.30 (2H,br, s), 6.10 (1H, t), 6.50 (2H, dd), 6.80 (1H, d), 7.10 (2H, dd)7.20-7.35 (2H, m), 7.45 (1H, dd), 7.55 (1H, dd), 8.50 (1H, dd). ESI-MSm/z: 520 (M+1), UV retention time: 1.51 min.

Example 5441-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazine-2-carboxylic acid amide Step 1:1-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazine-2-carbonitrile

To a solution of2-(5-{3-[2-(4-chloro-phenylamino)-ethylamino]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol(0.4 g, 0.86 mmol) in toluene (6 mL) was added triethylamine (0.48 mL,3.44 mmol) and 2,3-dibromopropionitrile (0.19 mL, 1.72 mmol) andreaction mixture was heated to 110° C. (reflux) and stirred overnightfor 18 h. The reaction mixture was concentrated in vacuo and the residuewas diluted with ethyl acetate and extracted with 1.0N NaOH solution.The aqueous layer was back extracted twice with ethyl acetate. Thecombined organics were dried over sodium sulfate and concentrated. Thecrude product was purified using a short plug of silica gel using ethylacetate to give the title compound. ¹H-NMR (CDCl₃) δ: 1.05 (6H, s),2.20-2.70 (8H, 2×m), 3.00 (1H, m), 3.10-3.40 (3H, 2×m), 4.50 (1H, br,s), 5.30 (2H, br, s), 6.20 (1H, t), 6.70-6.90 (3H, 2×d), 7.10-7.35 (4H,m), 7.50 (2H, d), 8.50 (1H, dd). ESI-MS m/z: 515 (M+1), UV retentiontime: 2.36 min.

Step 2:1-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazine-2-carboxylicacid amide

To a solution of1-(4-chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazine-2-carbonitrile(0.12 g, 0.23 mmol) in methanol (0.5 mL) and THF (0.5 mL) was added 1.0N NaOH (0.5 mL, 0.5 mmol) and the resulting mixture was heated to refluxat 80° C. for 18 h. Additional 2.0 N NaOH (0.5 mL, 0.5 mmol) was addedto the reaction mixture and refluxed further for 18 h. The reactionmixture was concentrated, acidified to pH 5.0 using 1.0 N HCl andextracted with ethyl acetate(3×). The combined organics were dried oversodium sulfate and concentrated. The crude product was purified on ashort plug of silica gel using gradient elution from ethylacetate/methanol (2-10%) to give the title compound. ¹H-NMR (CDCl₃) δ:1.05 (6H, s), 2.20-2.70 (8H, 2×m), 3.00 (1H, m), 3.10-3.40 (3H, 2×m),4.50 (1H, br, s), 5.30 (2H, br, s), 6.00 (1H, br, s), 6.20 (1H, t), 6.40(1H, br, s), 6.70-6.90 (3H, 2×d), 7.10-7.35 (4H, m), 7.50 (2H, d), 8.50(1H, dd).

ESI-MS m/z: 515 (M+1), UV retention time: 1.32 min.

Example 5451-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazine-2-carbonitrile

To a solution of2-(5-{3-[2-(4-chloro-phenylamino)-ethylamino]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol(0.4 g, 0.87 mmol) in toluene (6 mL) was added triethylamine (0.48 mL,3.44 mmol) and 2,3-dibromopropionitrile (0.19 mL, 1.72 mmol) andreaction mixture was heated to 110° C. (reflux) and stirred overnightfor 18 h. The reaction mixture was concentrated in vacuo and the residuewas diluted with ethyl acetate and extracted with 1.0N NaOH solution.The aqueous layer was back extracted twice with ethyl acetate. Thecombined organics were dried over sodium sulfate and concentrated. Thecrude product was purified using a short plug of silica gel using ethylacetate to give the desired product. ¹H-NMR (CDCl₃) δ: 1.05 (6H, s),2.20-2.70 (8H, 2×m), 3.00 (1H, m), 3.10-3.40 (3H, 2×m), 4.50 (1H, br,s), 5.30 (2H, br, s), 6.20 (1H, t), 6.70-6.90 (3H, 2×d), 7.10-7.35 (4H,m), 7.50 (2H, d), 8.50 (1H, dd). ESI-MS m/z: 515 (M+1), UV retentiontime: 2.36 min.

Example 5461-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazine-2-carboxylicacid methyl ester Step 1: piperazine-1,2,4-tricarboxylic acid1-tert-butyl ester 4-(9H-fluoren-9-ylmethyl) ester 2-methyl ester

To a solution of piperazine-1,2,4-tricarboxylic acid 1-tert-butyl ester4-(9H-fluoren-9-ylmethyl) ester (2.21 mmol) in toluene:methanol (9:1)was added equimolar trimethylsilyldiazomethane (2.0 M in hexanes) andthe resulting mixture was stirred overnight at room temperature. Thereaction mixture was concentrated in vacuo and purified using gradientelution from hexane/ethyl acetate (5%) to hexane/ethyl acetate (30%).ESI-MS m/z: 467 (M+1), UV retention time: 3.04 min.

Step 2: piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methylester

To a solution of piperazine-1,2,4-tricarboxylic acid 1-tert-butyl ester4-(9H-fluoren-9-ylmethyl) ester 2-methyl ester (2.03 mmol) in DMF (4.0mL) was added diethylamine (5%) and the resulting solution was stirredat room temperature overnight. The reaction mixture was concentrated invacuo and purified using ethyl acetate/methanol (10%). ESI-MS m/z:245(M+1), UV retention time: 0.78 min.

Step 3: 4-(4-Chloro-phenyl)-piperazine-1,3-dicarboxylic acid1-tert-butyl ester 3-methyl ester

4-Chloro phenyl boronic acid (2.0 equiv, 3.68 mmol) andpiperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester (1.0equiv, 1.84 mmol) were dissolved in dichloromethane followed by theaddition of copper acetate (1.0 equiv), 4 Å molecular sieves andpyridine (2.0 equiv). The reaction mixture was stirred at roomtemperature for 72 h. The reaction mixture was concentrated in vacuo,dissolved in ethyl acetate, filtered through celite and concentrated.The crude product was purified using gradient elution from hexane/ethylacetate (5%) to hexane/ethyl acetate (20%).

ESI-MS m/z: 354 (M+1), UV retention time: 2.88 min.

-   Reference: Tetrahedron Letters, 2001, 42, 3415-3418

Step 4: 1-(4-Chloro-phenyl)-piperazine-2-carboxylic acid methyl ester

A solution of 4-(4-chloro-phenyl)-piperazine-1,3-dicarboxylic acid1-tert-butyl ester 3-methyl ester (0.4 g, 1.13 mmol) in dichloromethane(5.0 mL) cooled at 0° C. was treated with trifluoroacetic acid (20%) andwarmed to room temperature and stirred for 2 h. The reaction mixture wasconcentrated in vacuo, diluted with ethyl acetate and free based with10% aqueous sodium bicarbonate. The combined organics were dried oversodium sulfate and concentrated. The product was used without anyfurther purification. ESI-MS m/z: 254 (M+1), UV retention time: 1.01min.

Step 5:1-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]propyl}-piperazine-2-carboxylicacid methyl ester

To a solution of 1-(4-chloro-phenyl)-piperazine-2-carboxylic acid methylester (0.14 g, 0.53 mmol) in acetonitrile:water (4:1) was addedpotassium carbonate (0.083 g, 0.6 mmol) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(150 mg, 0.4 mmol) and the resulting mixture was stirred at 50° C. for 5hours. The reaction mixture was concentrated in vacuo, diluted withethyl acetate, and dried over sodium sulfate. The crude product waspurified by flash chromatography on silica using gradient elution fromethyl acetate (100%) to ethyl acetate/methanol (5%). ¹H-NMR (CDCl₃) δ:1.05 (6H, s), 2.20-2.70 (8H, 2×m), 3.00 (1H, m), 3.10-3.40 (3H, 2×m),3.55 (3H, s), 4.50 (1H, br, s), 5.30 (2H, br, s), 6.20 (1H, t),6.70-6.90 (3H, 2×d), 7.10-7.35 (4H, m), 7.50 (2H, d), 8.50 (1H, dd).ESI-MS m/z: 548 (M+1), UV retention time: 1.62 min.

Example 547 Isopropyl-carbamic acid5-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ylester

5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol(0.27 mmol, 1.0 equiv) was dissolved in tetrahydrofuran and treated withtriethylamine (1.50 equiv) and isopropyl isocyanate (0.4 mmol, 1.50equiv). The resulting mixture was heated to 50° C. for 18 h. Thereaction mixture was concentrated and crude product was purified onsilica using gradient elution from ethyl acetate (100%) and ethylacetate/methanol (5%).

¹H-NMR (CDCl₃) δ: 0.70 (3H, s), 0.90 (3H, s), 1.1 (3H, d), 1.25 (3H, d),1.4 (1H, m), 1.6 (1H, m), 2.30-2.50 (8H, m), 2.70 (2H, m), 3.80-4.00(3H, m), 3.55 (3H, s), 4.85 (1H, m), 5.30 (2H, br, s), 6.20 (1H, t),6.80-7.00 (2H, dd), 7.20-7.45 (6H, m), 7.60 (1H, dd), 8.50 (1H, dd).ESI-MS m/z: 576 (M+1), UV retention time: 1.58 min.

Example 5483-(4-Chloro-phenyl)-1-ethyl-1-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-ureaStep 1: 3-Ethylamino-pyrrolidine-1-carboxylic acid tert-butyl ester

To a solution of (R)-3-amino-1-N-Boc pyrrolidine (1 eq, 5.37 mmol) inmethanol (20 mL) was added acetaldehyde (0.95 eq) and the resultingmixture was heated to 80° C. and stirred for 2 h., then stirred at roomtemperature overnight. Sodium borohydride (0.95 eq, 5.1 mmol) was addedand reaction mixture was stirred for an additional 2 h. The reactionmixture was concentrated, dissolved in ethyl acetate and washed withsaturated aqueous sodium bicarbonate. The combined organics were washedwith brine and dried over sodium sulfate. The crude product was purifiedon silica using hexane/ethyl acetate (10%) to hexane/ethyl acetate(50%). ¹H-NMR (CDCL₃) δ: 1.05 (3H, t), 1.45 (9H, s), 1.60-1.75 (1H, m),2.00-2.10 (1H, m), 2.68 (4H, q), 2.90-3.15 (1H, m), 3.25-3.65 (4H, m).ESI-MS m/z: 215 (M+1), UV retention time: 0.75 min.

Step 2: 3-[3-(4-Chloro-phenyl)-1-ethyl-ureido]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of 3-ethylamino-pyrrolidine-1-carboxylic acid tert-butylester (0.33 g, 1.5 mmol) in DMF (5.0 mL) was added drop wise a solutionof 4-chlorophenyl isocyanate (0.23 g, 1.51 mmol) in DMF (2.5 mL) at roomtemperature and the resulting mixture was stirred for 3 h. The reactionmixture was concentrated in vacuo and the crude product was purified onsilica using hexane/ethyl acetate (50%) followed by ethyl acetate (100%)to give the desired product as white foamy solid.

ESI-MS m/z: 368 (M+1), UV retention time: 2.61 min.

Step 3: 3-(4-Chloro-phenyl)-1-ethyl-1-pyrrolidin-3-yl-urea

A solution of3-[3-(4-chloro-phenyl)-1-ethylureido]-pyrrolidine-1-carboxylic acidtert-butyl ester (0.4 g, 1.08 mmol) in dichloromethane (5.0 ml) cooledat 0° C. was treated with trifluoroacetic acid (20%) and warmed to roomtemperature and stirred for 2 h. The reaction was concentrated in vacuo,diluted with ethyl acetate and free based with 10% aqueous sodiumbicarbonate. The combined organics were dried over sodium sulfate. Theproduct was used without any further purification. ESI-MS m/z: 268(M+1), UV retention time: 1.02 min.

Step 4:3-(4-Chloro-phenyl)-1-ethyl-1-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-urea

To a solution of 3-(4-chloro-phenyl)-1-ethyl-1-pyrrolidin-3-yl-urea(0.21 g, 0.8 mmol) in acetonitrile:water (4:1) was added potassiumcarbonate (0.16 g, 0.8 mmol) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.15 g, 0.4 mmol) and the resulting mixture was stirred at 50° C. for24 h. The reaction mixture was concentrated in vacuo, diluted with ethylacetate, and dried over sodium sulfate. The crude product was purifiedby flash chromatography on silica using gradient elution from ethylacetate/methanol (5%) to ethyl acetate/methanol (10%) to give thedesired product as yellow solid. ¹H-NMR (CDCl₃) δ: 1.05 (3H, t), 1.40(6H, s), 1.80 (1H, m), 2.20-2.40 (3H, m), 2.50-3.00 (8H, m), 3.40 (4H, qand m), 4.20 (1H, m), 5.20 (2H, br, s), 6.20 (1H, t), 6.65 (1H, d), 7.00(2H, dd), 7.20-7.40 (5H, m), 7.70 (1H, dd), 8.50 (1H, dd) 9.80 (1H, brs). ESI-MS m/z: 561 (M+1), UV retention time: 1.45 min.

Example 5492-(5-{3-[3-(4-Chloro-benzyloxy)-pyrrolidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: (R)-3-(4-Chloro-benzyloxy)-pyrrolidine-1-carboxylic acidtert-butyl ester

A solution of (R)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butylester (1.14 mmol, 1.0 eq) in THF (2.5 mL) was added to a suspension ofsodium hydride (1.15 eq) in THF (2.5 mL) cooled at 0° C. and theresulting mixture was stirred for 45 min. A solution of 4-chlorobenzylbromide (1.31 mmol, 1.15 eq) in THF (2.0 mL) was then added drop wiseand reaction mixture was slowly warmed to room temperature and stirredfor 18 h. The reaction mixture was quenched with water (1.0 ml) anddiluted with ethyl acetate. The combined organics were dried over sodiumsulfate. The crude product was purified on silica using gradient elutionfrom hexane/ethyl acetate (10%) to hexane/ethyl acetate (30%). ¹H-NMR(CDCL₃) δ: 1.45 (9H, s), 1.80-2.05 (2H, m), 3.30-3.55 (4H, m), 4.05 (1H,m), 4.45 (2H, s), 7.15-7.30 (4H, m). ESI-MS m/z: 311 (M+1), UV retentiontime: 2.94 min.

Step 2: (R)-3-(4-Chloro-benzyloxy)-pyrrolidine

A solution of (R)-3-(4-chlorobenzyloxy)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.88 mmol) in dichloromethane cooled at 0° C. wastreated with trifluoroacetic acid (20%) and warmed to room temperatureand stirred for 2 h. The reaction mixture was concentrated in vacuo,diluted with ethyl acetate and free based with 10% aqueous sodiumbicarbonate. The combined organics were dried over sodium sulfate. Theproduct was used without any further purification. ESI-MS m/z: 211(M+1),UV retention time: 0.97 min.

Step 3:2-(5-{3-[3-(4-Chloro-benzyloxy)-pyrrolidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

To a solution of (R)-3-(4-chloro-benzyloxy)-pyrrolidine (0.88 mmol, 2.0eq) in acetonitrile:water (4:1) was added potassium carbonate (0.88mmol, 2.0 eqv) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-oland the resulting mixture was stirred at room temperature for 24 h. Thereaction mixture was concentrated in vacuo, diluted with ethyl acetate,and dried over sodium sulfate. The crude product was purified by ReversePhase HPLC. ¹H-NMR (CDCl₃) δ: 1.40 (6H, s), 1.15-1.35 (1H, m), 1.85-2.05(1H, m), 2.20-2.40 (1H, m), 2.35-2.65 (8H, m), 3.90-4.10 (1H, m),4.30-4.50 (2H, d), 5.10-5.30 (2H, br, s), 6.05 (1H, t), 6.50 (1H, dd),7.10-7.50 (4H, m), 7.70 (1H, dd), 8.50 (1H, dd). ESI-MS m/z: 505 (M+1),UV retention time: 1.52 min.

Example 5502-[5-(3-{3-[(4-Chloro-benzyl)-isobutyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-olStep 1: 3-(4-Chloro-benzylamino)-pyrrolidine-1-carboxylic acidtert-butyl ester

(R)-3-amino-1-N-Boc pyrrolidine (1.0 eq, 2.68 mmol), 4-chlorobenzylbromide (1.0 eq, 2.68 mmol), and potassium carbonate (1.75 eq) weremixed in ethanol (10 mL) and the resulting mixture was stirred at roomtemperature overnight. The reaction mixture was concentrated in vacuo,taken up in ethyl acetate, filtered and concentrated. The crude productwas purified by flash chromatography on silica using ethyl acetate.

ESI-MS m/z: 311 (M+1), UV retention time: 1.18 min.

Step 2: 3-[(4-Chloro-benzyl)-isobutyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of 3-(4-chloro-benzylamino)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.4 g, 1.28 mmol) and isobutyraldehyde (0.14 g, 1.92mmol) in dichloroethane was added sodium triacetoxy borohydride (0.81 g,3.85 mmol) and catalytic acetic acid. The resulting reaction mixture wasstirred at room temperature overnight. The reaction mixture wasconcentrated, dissolved in dichloromethane and washed with saturatedaqueous sodium bicarbonate. The combined organics were washed with brineand dried over sodium sulfate. The crude product was purified on silicausing gradient elution from hexane/ethyl acetate (10%) to hexane/ethylacetate (50%). ¹H-NMR (CDCl₃) δ: 0.80 (6H, 2×d), 1.45 (9H, s), 1.60-1.90(2H, m), 2.20 (2H, d), 3.00-3.70 (7H, m), 7.20 (4H, s). ESI-MS m/z: 367(M+1), UV retention time: 1.89 min.

Step 3: (4-Chloro-benzyl)-isobutyl-pyrrolidin-3-yl-amine

To a solution of3-[(4-chloro-benzyl)-isobutyl-amino]-pyrrolidine-1-carboxylic acidtert-butyl ester in dichloromethane cooled at 0° C. was addedtrifluoroacetic acid (20%) and warmed to room temperature and stirredfor 2 h. The reaction mixture was concentrated in vacuo, diluted withethyl acetate and free based with 10% aqueous sodium bicarbonate. Thecombined organics were dried over sodium sulfate and concentrated. Theproduct was used without any further purification.

ESI-MS m/z: 267(M+1), UV retention time: 0.93 min.

Step 4:2-[5-(3-{3-[(4-Chloro-benzyl)-isobutyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol

To a solution of (4-chloro-benzyl)-isobutyl-pyrrolidin-3-yl-amine (0.16g, 0.6 mmol) in acetonitrile:water (4:1) was added potassium carbonate(0.8 mmol) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.15 g, 0.4 mmol) and the resulting mixture was stirred at 50° C. for24 h. The reaction was concentrated, diluted with ethyl acetate, anddried over sodium sulfate. The crude product was purified by flashchromatography using ethyl acetate/methanol (5%). ¹H-NMR (CDCl₃) δ: 0.80(6H, d), 1.55 (6H, s), 1.60-1.90 (4H, m), 2.15 (1H, d), 2.20-2.60 (6H,m), 3.25-3.60 (2H, m), 5.30 (2H, br, s), 6.10 (1H, t), 6.80 (1H, dd),7.15-7.30 (6H, m), 7.40 (1H, d), 7.55 (1H, dd), 8.45 (1H, dd). ESI-MSm/z: 560 (M+1), UV retention time: 1.66 min.

Example 5512-[5-(3-{3-[(4-Chloro-benzyl)-isopropyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-olStep 1: 3-Isopropylamino-pyrrolidine-1-carboxylic acid tert-butyl ester

To a solution of (R)-3-amino-1-N-Boc pyrrolidine (1.0 eq, 2.68 mmol) inmethanol (15 mL) was added acetone (1.07 eq), sodium cyano borohydride(2.0 eq) and few drops of acetic acid and the resulting mixture wasstirred at room temperature overnight. The reaction mixture wasconcentrated dissolved in dichloromethane and washed with saturatedaqueous sodium bicarbonate. The combined organics were washed with brineand dried over sodium sulfate. The crude product was purified on silicausing gradient elution from hexane/ethyl acetate (5%) to hexane/ethylacetate (30%). ¹H-NMR (CDCl₃) δ: 1.05 (6H, d), 1.45 (9H, s), 1.60 (1H,m), 2.80-3.00 (2H, m), 3.20-3.70 (4H, m). ESI-MS m/z: 229 (M+1), UVretention time: 0.77 min.

Step 2: 3-[(4-Chloro-benzyl)-isopropyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of isopropyl-pyrrolidin-3-yl-amine (0.3 g, 1.31 mmol) indichloroethane (5.0 ml) was added 4-chlorobenzaldehyde (0.22 g, 1.57mmol), sodium triacetoxy borohydride (0.83 g, 3.93 mmol) and catalyticacetic acid and the resulting reaction mixture was stirred at roomtemperature overnight. The reaction mixture was concentrated, dissolvedin dichloromethane and washed with 10% aqueous sodium bicarbonate. Thecombined organics were washed with brine and dried over sodium sulfate.The crude product was purified on silica using hexane/ethyl acetate(50%). ¹H-NMR (CDCl₃) δ: 1.05 (6H, d), 1.45 (9H, s), 1.60 (1H, m),2.80-3.00 (2H, m), 3.20-3.70 (4H, m), 7.20 (4H, m). ESI-MS m/z:353(M+1), UV retention time: 1.49 min.

Step 3: (4-Chloro-benzyl)-isopropyl-pyrrolidin-3-yl-amine

A solution of3-[(4-chloro-benzyl)-isopropyl-amino]-pyrrolidine-1-carboxylic acidtert-butyl ester in dichloromethane cooled at 0° C. was treated withtrifluoroacetic acid (20%) and warmed to room temperature and stirredfor 2 hours. The reaction mixture was concentrated in vacuo, dilutedwith ethyl acetate and free based with 10% aqueous sodium bicarbonate.The combined organics were dried over sodium sulfate. The product wasused without any further purification. ESI-MS m/z: 253 (M+1, UVretention time: 0.59 min.

Step 4:2-[5-(3-{3-[(4-Chloro-benzyl)-isopropyl-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol

To a solution of (4-chloro-benzyl)-isopropyl-pyrrolidin-3-yl-amine (0.68mmol, 1.7 eq) in acetonitrile:water (4:1) was added potassium carbonate(0.8 mmol, 2 eq) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.4 mmol, 1.0 eq) and the resulting mixture was stirred at 50° C. for24 h. The reaction mixture was concentrated in vacuo, diluted with ethylacetate, and dried over sodium sulfate. The crude product was purifiedby flash chromatography using ethyl acetate/methanol (5%). ¹H-NMR(CDCl₃). δ: 0.85 (6H, d), 1.50-1.90 (10H, m), 2.10-2.60 (8H, m), 3.50(3H, m), 5.30 (2H, br, s), 6.10 (1H, t), 6.80 (1H, dd), 7.10-7.40 (8H,m), 7.50 (1H, d), 8.50 (1H, dd). ESI-MS m/z: 546 (M+1), UV retentiontime: 1.40 min.

Example 5522-[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-azadibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-acetamide Step 1:3-(Carbamoylmethyl-amino)-pyrrolidine-1-carboxylic acid tert-butyl ester

To a solution of (R)-3-amino-1-N-Boc pyrrolidine (0.5 g, 2.68 mmol) and2-bromo acetamide (0.44 g, 3.21 mmol) in DMF (6.0 mL) was addedpotassium carbonate (1.11 g, 8.04 mmol) and the reaction mixture wasstirred at room temperature overnight. The reaction mixture wasconcentrated and re-dissolved in dichloromethane. Potassium carbonatewas filtered off and filtrate was concentrated and purified using ethylacetate/methanol (5%). ¹H-NMR (CDCl₃) δ: 1.50 (9H, s), 1.60-1.80 (2H,m), 2.10 (1H, m), 3.10-3.60 (6H, m), 5.65 (1H, br, s), 6.90 (1H, br, s).ESI-MS m/z: 367(M+1), UV

retention time: 0.61 min.

Step 2:3-[Carbamoylmethyl-(4-chloro-benzyl)-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of 3-(carbamoylmethyl-amino)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.49 g, 2.03 mmol) in dichloroethane (5.0 mL) wasadded 4-chlorobenzaldehyde 0.34 g, 2.44 mmol), sodium triacetoxyborohydride (0.86 g, 4.06 mmol) and catalytic acetic acid and theresulting mixture was stirred at room temperature overnight. Thereaction mixture was concentrated, dissolved in dichloromethane andwashed with 10% aqueous sodium bicarbonate. The combined organics werewashed with brine and dried over sodium sulfate. The crude product waspurified on silica using ethyl acetate. ¹H-NMR (CDCl₃) δ: 1.50 (9H, s),1.60-1.80 (2H, m), 2.10 (1H, m), 3.10-3.60 (8H, m), 5.65 (1H, br, s),6.90 (1H, br, s) 7.20-7.40 (4H, m). ESI-MS m/z: 367(M+1), UV retentiontime: 1.94 min.

Step 3: 2-[(4-Chloro-benzyl)-pyrrolidin-3-yl-amino]-acetamide

A solution of3-[carbamoylmethyl-(4-chloro-benzyl)-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (0.49 g, 1.32 mmol) in dichloromethane cooled at0° C. was treated with trifluoroacetic acid (20%). The resulting mixturewas warmed to room temperature and stirred for 2 h. The reaction mixturewas concentrated in vacuo, diluted with ethyl acetate and free basedwith 10% aqueous sodium bicarbonate. The combined organics were driedover sodium sulfate. The product was used without any furtherpurification ESI-MS m/z: 267 (M+1), UV retention time: 0.82 min.

Step 4:2-[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-azadibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-acetamide

To a solution of 2-[(4-chloro-benzyl)-pyrrolidin-3-yl-amino]acetamide(0.21 g, 0.8 mmol) in acetonitrile:water (4:1) was added potassiumcarbonate (0.6 mmol) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.15 g, 0.4 mmol) and the resulting mixture was stirred at 50° C. for24 h. The reaction mixture was concentrated in vacuo, diluted with ethylacetate, and dried over sodium sulfate. The crude product was purifiedby HPLC. ¹H-NMR (CDCl₃) δ: 1.35 (6H, s), 1.55-1.75 (1H, m), 1.80-2.00(1H, m), 2.20-2.85 (8H, m), 2.90-3.10 (2H, d), 3.30-3.50 (1H, m), 3.60(1H, d), 4.80-5.30 (2H, br, s), 6.10 (1H, t), 6.70 (1H, dd), 7.00-7.45(7H, m), 7.70 (1H, dd), 8.50 (1H, dd). ESI-MS m/z: 562 (M+1), UVretention time: 1.31 min.

Example 5532-[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-N-ethyl-acetamideStep 1: 3-(Methoxycarbonylmethyl-amino)-pyrrolidine-1-carboxylic acidtert-butyl ester

To a solution of (R)-3-amino-1-N-Boc pyrrolidine (0.5 g, 2.68 mmol) andmethyl bromo acetate (0.49 g, 2.95 mmol) in DMF (6.0 mL) was addedpotassium carbonate (1.11 g, 8.04 mmol) and the reaction mixture wasstirred at room temperature overnight. The reaction mixture wasconcentrated and re-dissolved in dichloromethane. Potassium carbonatewas filtered off and filtrate was concentrated and purified usinggradient elution from hexane/ethyl acetate (10%) to hexane/ethyl acetate(50%). H-NMR (CDCl₃) δ: 1.40 (9H, s), 1.70 (2H, m), 2.00 (1H, m),3.20-3.60 (5H, m), 3.79 (3H, br s). ESI-MS m/z: 258(M+1), UV retentiontime: 0.74 min.

Step 2:3-[(4-Chloro-benzyl)-methoxycarbonylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of3-(methoxycarbonylmethyl-amino)-pyrrolidine-1-carboxylic acid tert-butylester (0.5 g, 2.03 mmol) in dichloroethane (5.0 mL) was added4-chlorobenzaldehyde (0.34 g, 2.44 mmol), sodium triacetoxy borohydride(0.86 g, 4.06 mmol) and catalytic acetic acid and the resulting mixturewas stirred at room temperature overnight. The reaction mixture wasconcentrated, dissolved in dichloromethane and washed with 10% aqueoussodium bicarbonate. The combined organics were washed with brine anddried over sodium sulfate. The crude product was purified on silicausing ethyl acetate. ¹H-NMR (CDCl₃) δ: 1.40 (9H, s), 1.80 (1H, m), 2.10(1H, m), 3.00-3.80 (7H, m), 4.70 (1H, br, s), 7.20 (4H, m). ESI-MS m/z:383(M+1), UV retention time: 2.91 min.

Step 3:3-[Carboxymethyl-(4-chloro-benzyl)-amino]-pyrrolidine-1-carboxylic acidtert-butyl ester

A solution of3-[(4-chloro-benzyl)-methoxycarbonylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (0.5 g, 1.31 mmol) in methanol (4.00 mL) and 1.0 NNaOH (aqueous) (4.00 mL) was heated to reflux at 80° C. for 2.5 h. Thereaction mixture was concentrated, acidified to pH 5.0 using 1.0 N HCland extracted with dichloromethane(3×). The product was used for thenext step without further purification. ESI-MS m/z: 369(M+1), UVretention time: 1.85 min.

Step 4:3-[(4-Chloro-benzyl)-ethylcarbamoylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of3-[carboxymethyl-(4-chloro-benzyl)-amino]-pyrrolidine-1-carboxylic acidtert-butyl ester (0.48 g, 1.30 mmol) in tetrahydrofuran (10 mL) wasadded EDCI (0.39 g, 1.95 mmol), HOBT (0.26 g, 1.95 mmol), and stirredfor 30 min., followed by the addition of N-methyl morpholine (0.43 mL,3.90 mmol) and N-ethyl amine (0.1 mL, 1.95 mmol). The reaction mixturewas stirred at room temperature for 18 h. Upon concentration, theresidue was dissolved in ethyl acetate and washed with saturated aqueoussodium bicarbonate. The combined organics were washed with brine anddried over sodium sulfate. The crude product was purified on silicausing gradient elution from hexane/ethyl acetate (50%) to ethyl acetate(100%).

ESI-MS m/z: 396 (M+1), UV retention time: 2.18 min.

Step 5: 2-[(4-Chloro-benzyl)-pyrrolidin-3-yl-amino]-N-ethyl-acetamide

A solution of3-[(4-chloro-benzyl)-ethylcarbamoylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (0.12 g, 0.31 mmol) in dichloromethane cooled at0° C. was treated with trifluoroacetic acid (20%) The resulting mixturewas warmed to room temperature and stirred for 2 hours. The reactionmixture was concentrated in vacuo, diluted with ethyl acetate and freebased with 10% aqueous sodium bicarbonate. The combined organics weredried over sodium sulfate. The product was used without any furtherpurification. ESI-MS m/z: 296 (M+1), UV retention time: 1.02 min.

Step 6:2-[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-N-ethyl-acetamide

To a solution of2-[(4-chloro-benzyl)-pyrrolidin-3-yl-amino]-N-ethyl-acetamide (0.09 g,0.31 mmol) in acetonitrile:water (4:1) was added potassium carbonate(0.07 g, 0.51 mmol) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.095 g, 0.25 mmol) and the resulting mixture was stirred at 50° C. for24 h. The reaction mixture was concentrated in vacuo, diluted with ethylacetate, and dried over sodium sulfate. The crude product was purifiedon silica using ethyl acetate. ¹H-NMR (CDCl₃) δ: 0.90 (3H, t), 1.40 (6H,s), 1.60 (1H, m), 1.85 (1H, m), 2.10-2.55 (8H, m), 2.90-3.10 (4H, m),3.25-3.40 (4H, m), 3.55 (2H, d), 4.95 (2H, s), 5.10 (2H, br, s), 6.10(1H, t), 6.70 (1H, dd), 7.15-7.25 (1H, dd), 7.25-7.45 (4H, m), 7.55-7.75(2H, m), 8.50 (1H, dd). ESI-MS m/z: 589 (M+1), UV retention time: 1.42min.

Example 5542-[5-(3-{3-[(4-Chloro-benzyl)-(2-hydroxy-ethyl)-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-olStep 1:3-[(4-Chloro-benzyl)-(2-hydroxy-ethyl)-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of3-[(4-chloro-benzyl)-methoxycarbonylmethyl-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (0.44 g, 1.15 mmol) in methanol cooled to 0° C.was added sodium borohydride (0.13 g, 3.45 mmol) and the resultingmixture was heated to 65° C. for 16 h. Additional sodium borohydride(0.26 g, 6.90 mmol) was added to the reaction mixture and stirredfurther at 65° C. for 18 h. The reaction mixture was concentrated,dissolved in ethyl acetate and washed with saturated aqueous sodiumbicarbonate. The aqueous layer was extracted with ethyl acetate. Thecombined organics were dried over sodium sulfate. The crude product waspurified on silica using gradient elution from hexane/ethyl acetate(50%) to ethyl acetate (100%). ESI-MS m/z:355 (M+1), UV retention time:1.27 min.

Step 2: 2-[(4-Chloro-benzyl)-pyrrolidin-3-yl-amino]ethanol

A solution of3-[(4-chloro-benzyl)-(2-hydroxy-ethyl)-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (0.22 g, 0.6 mmol) in dichloromethane cooled at 0°C. was treated with trifluoroacetic acid (20%). The resulting mixturewas warmed to room temperature and stirred for 2 h. The reaction mixturewas concentrated in vacuo, diluted with ethyl acetate and free basedwith 10% aqueous sodium bicarbonate. The combined organics were driedover sodium sulfate. The product was used without any furtherpurification. ESI-MS m/z:255 (M+1), UV retention time: 0.34 min.

Step 3:2-[5-(3-{3-[(4-Chloro-benzyl)-(2-hydroxy-ethyl)-amino]-pyrrolidin-1-yl}-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol

To a solution of 2-[(4-chloro-benzyl)-pyrrolidin-3-yl-amino]-ethanol(0.15 g, 0.6 mmol) in acetonitrile:water (4:1) was added potassiumcarbonate (0.11 g, 0.8 mmol) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.15 g, 0.4 mmol) and the resulting mixture was stirred at 50° C. for24 h. The reaction mixture was concentrated in vacuo, diluted with ethylacetate and dried over sodium sulfate. The crude product was purified onsilica. ¹H-NMR (CDCl₃) δ: 1.40 (6H, s), 1.60 (1H, m), 1.80 (1H, m),2.10-2.60 (8H, m), 3.20-3.40 (6H, m), 3.50 (2H, m), 5.20 (2H, br, s),6.15 (1H, t), 6.70 (1H, t), 7.18-7.42 (7H, m), 7.70 (1H, dd), 8.50 (1H,dd). ESI-MS m/z: 548 (M+1), UV retention time: 1.26 min.

Example 5553-[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-propionic acid methylester Step 1: 3-(2-Methoxycarbonyl-ethylamino)-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of (R)-3-amino-1-N-Boc pyrrolidine (0.5 g, 2.68 mmol) and3-bromo propionate (0.49 g, 2.95 mmol) in DMF (6.0 mL) was addedpotassium carbonate (1.11 g, 8.04 mmol) and the resulting mixture wasstirred at room temperature overnight. The reaction mixture wasconcentrated and re-dissolved in dichloromethane. Potassium carbonatewas filtered off and filtrate was concentrated and crude product wasused further in the next step. ESI-MS m/z: 272 (M+1), UV retention time:1.28 min.

Step 2:3-[(4-Chloro-benzyl)-(2-methoxycarbonyl-ethyl)-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester

To a solution of3-(2-methoxycarbonyl-ethylamino)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.73 g, 2.68 mmol) in dichloroethane (10.0 mL) wasadded 4-chlorobenzaldehyde (0.42 g, 2.95 mmol), sodium triacetoxyborohydride (1.71 g, 8.04 mmol) and catalytic acetic acid and theresulting mixture was stirred at room temperature overnight. Thereaction mixture was concentrated, dissolved in dichloromethane andwashed with saturated aqueous sodium bicarbonate. The combined organicswere washed with brine and dried over sodium sulfate. The crude productwas purified on silica using gradient elution from hexane/ethyl acetate(15%) to hexane/ethyl acetate (50%). ¹H-NMR (CDCl₃) δ: 1.35 (9H, s),1.80 (1H, m), 1.90 (1H, m), 2.40 (2H, t), 2.85 (2H, t), 3.00-3.80 (7H,m), 4.70 (1H, d), 7.20 (4H, m). ESI-MS m/z: 397 (M+1), UV retentiontime: 1.99 min.

Step 3: 3-[(4-Chloro-benzyl)-pyrrolidin-3-yl-amino]-propionic acidmethyl ester

A solution of3-[(4-chloro-benzyl)-(2-methoxycarbonyl-ethyl)-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (0.08 g, 0.2 mmol) in dichloromethane cooled at 0°C. was treated with trifluoroacetic acid (20%). The resulting mixturewas warmed to room temperature and stirred for 2 h. The reaction mixturewas concentrated in vacuo, diluted with ethyl acetate and free basedwith 10% aqueous sodium bicarbonate. The combined organics were driedover sodium sulfate. The product was used without any furtherpurification. ESI-MS m/z: 297 (M+1), UV retention time: 1.05 min.

Step 4:3-[(4-Chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amino]-propionicacid methyl ester

To a solution of 3-[(4-chloro-benzyl)-pyrrolidin-3-yl-amino]-propionicacid methyl ester (0.06 g, 0.2 mmol) in acetonitrile:water (3:1) wasadded potassium carbonate (0.056 g, 0.4 mmol) and(E)-2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.065 g, 0.17 mmol) and reaction stirred at 50° C. for 24 h. Thereaction mixture was concentrated in vacuo, diluted with ethyl acetateand dried over sodium sulfate. The crude product was purified by flashchromatography on silica using ethyl acetate/methanol (5%). ¹H-NMR(CDCl₃) δ: 1.40 (6H, s), 1.60 (1H, m), 1.80 (1H, m), 2.10-2.60 (8H, m),3.20-3.40 (6H, m), 3.50 (2H, m; 2H, s), 5.20 (2H, br s), 6.15 (1H, t),6.70 (1H, t), 7.18-7.42 (7H, m), 7.70 (1H, dd), 8.50 (1H, dd). ESI-MSm/z: 590 (M+1), UV retention time: 1.51 min.

Example 5562-(5-{3-[4-(4-Chloro-phenyl)-3-(S)-methyl-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: 3-(S)-Methyl-piperazine-1-carboxylic acid tert-butyl ester

Triethylamine (3 g, 4.2 mL, 30 mmol) was added to a solution of2-(S)-methyl piperazine (2 g, 20 mmol) in dichloromethane (40 mL)followed by di-tert-butyl-dicarbonate (4.8 g, 22 mmol). The reactionmixture was stirred at room temperature for 20 h. The mixture wasdiluted with dichloromethane and washed with saturated aqueous sodiumbicarbonate and brine and dried over sodium sulfate. The crude productwas purified using a short plug of silica gel using hexane/ethyl acetate(1:1).

¹H-NMR (CDCl₃) δ: 1.03 (3H, d), 1.45 (9H, s), 1.65 (1H, s), 2.35-2.42(1H, m), 2.66-2.80 (3H, m), 2.92-2.95 (1H, m), 3.92 (2H, br s). ESI-MSm/z: 201(M+1).

Step 2: 4-(4-Chloro-phenyl)-3-(S)-methyl-piperazine-1-carboxylic acidtert-butyl ester

To a mixture of 4-chlorobromobenzene (1.05 g, 5.5 mmol) and3-(S)-Methyl-piperazine-1-carboxylic acid tert-butyl ester (1 g, 5 mmol)in toluene (30 mL) was added tris(dibenzylideneacetone) dipalladium(0)(0.057 g, 0.063 mmol), BINAP (0.12 g, 0.19 mmol) and sodium-t-butoxide(2.02 g, 21 mmol). The resulting mixture was heated 110° C. for 20 h.The solvent was evaporated and the residue was taken up in ethyl acetateand washed with saturated aqueous sodium bicarbonate and brine and driedover magnesium sulfate. Column chromatography (10% ethyl acetate/hexane)provided 0.79 g (51%) of the title compound.

¹H-NMR (CDCl₃) δ: 0.97 (3H, d), 1.48 (9H, s), 3.00-3.24 (3H, m),3.32-3.38 (1H, m), 3.72-3.79 (2H, m), 3.88-4.05 (1H, m), 6.81 (2H, d),7.21 (2H, d). ESI-MS m/z: 311(M), UV retention time: 3.2 min.

Step 3:2-(5-{3-[4-(4-Chloro-phenyl)-3-(S)-methyl-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

4-(4-Chloro-phenyl)-3-(S)-methyl-piperazine-1-carboxylic acid tert-butylester (0.79 g, 2.6 mmol) was treated with 4M HCl/Dioxane (20 mL) at roomtemperature for 3 h. The solvent was evaporated and the residue wastaken up in dichoromethane and washed several times with saturatedsodium bicarbonate. The combined organic phases were dried over sodiumsulfate. The residue was carried to the next step without furtherpurification.

To a solution of 4-(4-chloro-phenyl)-3-(S)-methyl-piperazine (0.56 g,2.6 mmol) in isopropanol (20 mL) was added 2,6-lutidine (0.305 mL, 2.6mmol) and catalytic potassium iodide. This mixture was heated to 80° C.,and then treated with2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.64 g, 1.7 mmol), added in portions over 2 h. The solution was thenstirred at 80° C. for an additional 20 h. The reaction was concentratedin vacuo and purified by flash chromatography (100% dichloromethane to2% methanol/dichloromethane) to yield the title compound (0.151 g, 18%).¹H-NMR (CDCl₃) δ: 1.0 (3H, d), 1.57 (6H, s), 1.79 (s, 1H), 2.25-2.52(7H, m), 2.66-2.69 (1H, m), 2.98-3.12 (2H, m), 3.68-3.73 (1H, m), 5.32(2H, br s), 6.17 (1H, t), 6.82 (3H, d), 7.18-7.31 (4H, m), 7.44 (1H, d),7.56-7.60 (1H, m), 8.50 (1H, dd). ESI-MS m/z: 504 (M), UV retentiontime: 1.49 min.

Example 5572-(5-{3-[4-(4-Chloro-phenyl)-3-(R)-methyl-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-olStep 1: 3-(R)-Methyl-piperazine-1-carboxylic acid tert-butyl ester

Triethylamine (3 g, 4.2 mL, 30 mmol) was added to a solution of(R)-2-methyl piperazine (2 g, 20 mmol) in dichloromethane (40 mL)followed by di-tert-butyl-dicarbonate (4.8 g, 22 mmol). The reactionmixture was stirred at room temperature for 20 h. The mixture wasdiluted with dichloromethane and washed with saturated aqueous sodiumbicarbonate and brine and dried over sodium sulfate. The crude productwas purified using a short plug of silica gel using hexane/ethyl acetate(1:1).

¹H-NMR (CDCl₃) δ: 1.05 (3H, d), 1.45 (9H, s), 2.11 (1H, s), 2.37-2.44(1H, m), 2.66-2.79 (3H, m), 2.93-2.96 (1H, m), 3.93 (2H, br s). ESI-MSm/z: 201(M+1).

Step 2: 4-(4-Chloro-phenyl)-3-(R)-methyl-piperazine-1-carboxylic acidtert-butyl ester

To a mixture of 4-chlorobromobenzene (0.53 g, 2.75 mmol) and3-(R)-Methyl-piperazine-1-carboxylic acid tert-butyl ester (0.5 g, 2.5mmol) in toluene (20 mL) was added tris(dibenzylideneacetone)dipalladium(0) (0.029 g, 0.032 mmol), BINAP (0.058 g, 0.093 mmol) andsodium-t-butoxide (1.01 g, 10.5 mmol). The resulting mixture was heated110° C. for 20 h. The solvent was evaporated and the residue was takenup in ethyl acetate and washed with saturated aqueous sodium bicarbonateand brine and dried over magnesium sulfate. Column chromatography (10%ethyl acetate/hexane) provided the title compound.

¹H-NMR (CDCL₃) δ: 0.98 (3H, d), 1.48 (9H, s), 3.04-3.21 (3H, m),3.34-3.38 (1H, m), 3.72-3.76 (2H, m), 3.80-4.05 (1H, m), 6.81 (2H, d),7.21 (2H, d). ESI-MS m/z: 311(M), UV retention time: 3.21 min.

Step 3:2-(5-{3-[4-(4-Chloro-phenyl)-3-(R)-methyl-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol

4-(4-Chloro-phenyl)-3-(R)-methyl-piperazine-1-carboxylic acid tert-butylester (0.36 g, 2.6 mmol) was treated with 4M HCl/Dioxane (10 mL) at roomtemperature for 3 h. The solvent was evaporated and the residue wastaken up in dichloromethane and washed several times with saturatedsodium bicarbonate. The combined organic phases were dried over sodiumsulfate. The residue was taken to the next step without furtherpurification.

To a solution of 4-(4-chloro-phenyl)-3-(R)-methyl-piperazine (0.2 g,0.95 mmol) in isopropanol (20 mL) was added 2,6-lutidine (0.11 mL, 0.94mmol) and catalytic potassium iodide. This mixture was heated to 80° C.and then treated with2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.24 g, 0.63 mmol), added in portions over 2 h. The solution was thenstirred at 80° C. for an additional 20 h. The reaction was concentratedin vacuo and purified by flash chromatography (100% dichloromethane to2% methanol/dichloromethane) to yield the title compound.

¹H-NMR (CDCl₃) δ: 1.0 (3H, d), 1.57 (6H, s), 1.72 (s, 1H), 2.25-2.55(7H, m), 2.61-2.73 (1H, m), 2.96-3.17 (2H, m), 3.66-3.77 (1H, m), 5.3(2H, br s), 6.16 (1H, t), 6.77-6.87 (3H, m), 7.17-7.31 (4H, m), 7.45(1H, d), 7.59 (1H, dd), 8.51 (1H, dd). ESI-MS m/z: 504 (M), UV retentiontime: 1.50 min.

Example 558(1-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazin-2-yl)-aceticacid methyl ester Step 1:4-(4-Chloro-phenyl)-3-methoxycarbonylmethyl-piperazine-1-carboxylic acidtert-butyl ester

4-Chlorophenyl boronic acid (1.08 g, 6.97 mmol) and3-methoxycarbonylmethyl-piperazine-1-carboxylic acid tert-butyl ester(0.9 g, 3.48 mmol) were dissolved in dichloromethane. To this mixturewas added copper acetate (0.63 g, 3.48 mmol), 4 Å molecular sieves andpyridine (0.56 mL, 6.97 mmol) and the reaction mixture was stirred atroom temperature for 72 h. The reaction mixture was concentrated invacuo and dissolved in ethyl acetate, filtered through celite andconcentrated. The crude product was purified using gradient elution fromhexane/ethyl acetate (5%) to hexane/ethyl acetate (20%). ESI-MS m/z: 369(M+1), UV retention time: 2.97 min.

Step 2:(1-(4-Chloro-phenyl)-4-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperazin-2-yl)-aceticacid methyl ester

4-(4-Chloro-phenyl)-3-methoxycarbonylmethyl-piperazine-1-carboxylic acidtert-butyl ester (0.19 g, 0.5 mmol) was treated with 4M HCl/Dioxane (10mL) at room temperature for 3 h. The solvent was evaporated and theresidue was taken up in dichloromethane and washed several times withsaturated sodium bicarbonate. The combined organic phases were driedover sodium sulfate. The residue was taken to the next step withoutfurther purification.

To a solution of 4-(4-Chloro-phenyl)-3-methoxycarbonylmethyl-piperazine(0.13 g, 0.5 mmol) in acetonitrile/water (8:2) (10 mL) was added K₂CO₃(0.2 g, 0.42 mmol) and2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(0.16 g, 0.42 mmol). The solution was allowed to stir at roomtemperature for 48 h. The reaction was concentrated, partitioned betweenEtOAc/H₂O, and extracted with EtOAc (3×). The organics were combined,dried over Mg₂SO₄, filtered and evaporated in vacuo, then purified byBiotage flash chromatography (50% ethyl acetate/50% hexane to 75% ethylacetate/25% hexane to 100% ethyl acetate) to yield the title compound.

¹H-NMR (CDCl₃) δ: 1.57 (6H, s), 2.16-2.49 (8H, m), 2.78-3.01 (4H, m),3.22 (1H, d), 3.54 (3H, s), 4.21-4.24 (1H, m), 5.29 (2H, br s), 6.19(1H, t), 6.77-6.82 (3H, m), 7.17-7.30 (4H, m), 7.48 (1H, d), 7.58 (1H,dd), 8.51 (1H, dd). ESI-MS m/z: 562 (M), UV retention time: 1.63 min.

Example 5594-(4-Chloro-phenyl)-3,3-dimethyl-1-{3-[7-(2-morpholin-4-yl-ethoxy)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-piperidin-4-ol

To a solution of5-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-ol(0.15 g, 0.28 mmol) in DMF (1.5 mL) was added NaH (0.034 g, 0.84 mmol)and stirred for 20 min. at room temperature.4-(2-Chloro-ethyl)-morpholine HCl (0.063 g, 0.34 mmol) was added and thesolution was heated to 50° C. for 16 h. The reaction was quenched withwater and extracted with ethyl acetate (3×). The organics were combined,dried over Mg₂SO₄, filtered and concentrated, then purified by Biotageflash chromatography (5-10% methanol/dichloromethane) to yield the titlecompound (0.050 g). ¹H-NMR (MeOD) δ: 0.73 (3H, s), 0.85 (3H, s),2.39-2.90 (11H, m), 3.29-3.31 (3H, m), 3.69-3.72 (4H, m), 4.1 (2H, t),5.20 (2H, br s), 6.18 (1H, t), 6.74-6.79 (2H, m), 6.89 (1H, d),7.27-7.30 (2H, m), 7.43-7.47 (3H, m), 7.79 (1H, dd), 8.46 (1H, dd).ESI-MS m/z: 604 (M), UV retention time: 1.20 min.

Examples 560-571 General Procedures

The N-BOC protected amine (0.0565-0.6911 mmol) was subjected to 1N NaOH,extracted with dichloromethane, washed with brine, dried over magnesiumsulfate and filtered. The solution was evaporated via steady N₂ airflow.To the residue was added the corresponding bromide (0.8 eq), potassiumcarbonate (1.0 eq), 11 mLs of acetonitrile and 2.75 mLs water. Theresulting solution was agitated via and orbital shaker for 48 hours. Thevials were transferred to a heating plate and stirred at 50° C. for 48hours. The solutions were quenched with a 1:1 brine/water mixture,washed with 1N NaOH, dried over magnesium sulfate, filtered andconcentrated via steady N₂ airflow. The residue was dissolved indichloromethane and subjected to column chromatography (SiO₂, Biotage12M column, 95% dichloromethane/5% methanol with 0.1% triethyl amine) toafford the desired product.

Example 560

N-(4-Chloro-benzyl)-N-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-2-methyl-butyramide

To a heated (77° C.) stirring solution of1-(4-chloro-phenyl)-2-imidazolidin-1-yl-4-methyl-hexan-3-one (110 mg,0.374 mmol), 2,6-lutidiene (130_L, 11.229 mmol) and 5 mL isopropanol wasadded2-[5-(3-bromo-propylidene)-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl]-propan-2-ol(70 mg, 0.187 mmol) portion-wise over a 30 minute period. The resultingsolution was monitored using thin layer chromatography and allowed tostir at 77° C. for 16 hours. The solution was concentrated in vacuo at35° C. The residue was dissolved in ethyl acetate and subjected tocolumn chromatography (SiO₂, Biotage 12M column, gradient elution 100%ethyl acetate→92% ethyl acetate/8% methanol with 1% triethyl amine) toafford 54 mg of1-(4-chloro-phenyl)-2-(3-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-imidazolidin-1-yl)-4-methyl-hexan-3-oneas a tan foam. LC/MS: t_(UV)=1.68 min, M/Z=588 amu.

Example 561

N-(4-Chloro-benzyl)-N-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-acetamide.

LC/MS: t_(UV)=1.66 min, M/Z=546 amu. ¹H NMR((CD₃)₂SO): δ 8.54 (1H, d),7.70 (1H, m), 7.44 (3H, m), 7.28 (3H, m), 7.13 (1H, m), 6.76 (1H, d),6.12 (1H, d), 5.21 (3H, m), 5.00 (1H, s), 4.63 (2H, m), 4.50 (2H, m),3.12 (2H, d), 2.39 (4H, m), 2.27 (2H, m), 2.18 (3H, s), 1.90 (5H, m),1.60 (2H, m), 1.43 (6H, s), 1.21 (2H, t), 0.92 (1H, m).

Example 562

N-(4-Chloro-benzyl)-N-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-isobutyramide.

LC/MS: t_(UV)=1.56 min, M/Z=574 amu. ¹H NMR((CD₃)₂SO): δ 8.51 (1H, d),7.66 (1H, d), 7.42 (3H, m), 7.25 (2H, t), 7.12 (1H, m), 7.04 (1H, d),6.74 (1H, d), 6.11 (1H, m), 5.18 (2H, m), 4.98 (2H, s), 4.91 (2H, m),4.48 (1H, s), 3.04 (1H, m), 2.40 (5H, m), 2.14 (4H, m), 1.40 (6H, s),1.04 (3H, d), 0.90 (3H, m).

Example 563

N-(4-Chloro-benzyl)-N-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-propionamide.

LC/MS: t_(UV)=1.49 min, M/Z=560 amu. ¹H NMR((CD₃)₂SO): δ 8.48 (1H, d),7.64 (1H, d), 7.40 (3H, m), 7.27 (2H, t), 7.07 (2H, m), 6.72 (1H, d),6.10 (1H, m), 5.17 (3H, m), 4.96 (2H, s), 4.52 (4H, m), 2.35 (3H, m),2.12 (5H, m), 1.52 (1H, m), 1.34 (6H, s), 1.00 (2H, t), 0.89 (1H, m).

Example 564

Cyclopentanecarboxylic acid(4-chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amide.

LC/MS: t_(UV)=1.73 min, M/Z=600 amu. ¹H NMR((CD₃)₂SO): δ 8.50 (1H, d),7.65 (1H, d), 7.40 (3H, m), 7.24 (2H, t), 7.11 (1H, m), 7.02 (1H, d),6.72 (1H, d), 6.11 (1H, m), 5.14 (3H, m), 4.96 (1H, s), 4.82 (1H, m),4.64 (2H, m), 4.46 (1H, s), 3.13 (1H, m), 2.34 (3H, t), 2.19 (2H, m),2.06 (2H, m), 1.71 (2H, m), 1.57 (7H, m), 1.39 (6H, s).

Example 565

Cyclohexanecarboxylic acid(4-chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amide.

LC/MS: t_(UV)=1.79 min, M/Z=614 amu. ¹H NMR((CD₃)₂SO): δ 8.48 (1H, d),7.64 (1H, d), 7.39 (3H, m), 7.23 (2H, t), 7.10 (1H, m), 7.00 (1H, d),6.69 (1H, d), 6.08 (1H, m), 5.13 (2H, m), 4.95 (1H, s), 4.58 (2H, m),4.43 (1H, s), 2.73 (1H, m), 2.34 (3H, m), 2.12 (4H, m), 1.67 (7H, m),1.38 (6H, s), 1.29 (3H, m), 1.03 (3H, m),.

Example 566

2-Ethyl-hexanoic acid(4-chloro-benzyl)-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-amide.

LC/MS: t_(UV)=1.92 min, M/Z=630 amu. ¹H NMR ((CD₃)₂SO): δ 8.44 (1H, m),7.61 (1H, m), 7.35 (3H, m), 7.20 (2H, m), 7.11 (1H, m), 7.02 (1H, d),6.68 (1H, d), 6.05 (1H, m), 5.10 (3H, m), 4.91 (1H, s), 4.61 (2H, m),4.44 (1H, s), 2.66 (3H, m), 2.32 (3H, m), 2.07 (4H, m), 1.46 (3H, m),1.34 (6H, s), 1.17 (4H, m), 0.94 (2H, m), 0.75 (4H, m), 0.60 (1H, m).

Example 567

1-(4-Chloro-benzyl)-1-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-3-isopropyl-urea.

LC/MS: t_(UV)=1.53 min, M/Z=589 amu. ¹H NMR((CD₃)₂SO): δ 8.50 (1H, m),7.69 (1H, d), 7.40 (2H, m), 7.32 (2H, d), 7.19 (3H, m), 6.71 (1H, d),6.09 (1H, m), 5.17 (2H, m), 4.95 (1H, s), 4.41 (2H, s), 4.12 (1H, m),3.69 (1H, m), 3.05 (2H, m), 2.78 (2H, m), 2.58 (1H, m), 2.26 (2H, m),1.91 (2H, m), 1.61 (1H, m), 1.38 (6H, s), 1.16 (1H, m), 0.92 (6H, m).

Example 568

1-(4-Chloro-benzyl)-3-cyclohexyl-1-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-urea.

LC/MS: t_(UV)=1.70 min, M/Z=629 amu. ¹H NMR((CD₃)₂SO): δ 8.50 (1H, d),7.69 (1H, d), 7.40 (2H, m), 7.32 (4H, m), 7.18 (3H, m), 6.70 (1H, d),6.10 (1H, m), 5.16 (2H, m), 4.95 (1H, s), 4.43 (2H, m), 4.02 (1H, m),3.14 (1H, m), 2.71 (3H, m), 2.22 (3H, m), 1.87 (2H, m), 1.62 (5H, m),1.38 (6H, s), 0.98 (8H, m).

Example 569

1-(4-Chloro-benzyl)-3-ethyl-1-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-urea.

LC/MS: t_(UV)=1.46 min, M/Z=5.75 amu. ¹H NMR((CD₃)₂SO): δ 8.52 (1H, d),7.70 (1H, d), 7.43 (2H, m), 7.33 (2H, d), 7.23 (1H, dd), 7.17 (2H, d),6.73 (1H, d), 6.13 (1H, t), 5.19 (2H, m), 4.98 (1H, s), 4.43 (2H, s),4.20 (1H, m), 2.96 (4H, m), 2.71 (2H, m), 2.26 (3H, m), 1.95 (2H, m),1.61 (1H, m), 1.41 (6H, s), 1.19 (1H, m), 1.01 (1H, m), 0.85 (2H, m).

Example 570

1-(4-Chloro-benzyl)-1-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-3-(1,1,3,3-tetramethyl-butyl)-urea.LC/MS: t_(UV)=2.05 min, M/Z=659 amu.

Example 571

N-(4-Chloro-benzyl)-N-(1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-pyrrolidin-3-yl)-methanesulfonamide.

LC/MS: t_(UV)=1.49 min, M/Z=582 amu.

Additional compounds of the invention can be prepared by the schemes setforth in FIGS. 1-5, 7, 8A-8C, 9A-9E, 10A-10 d and 12-19 and by theprocedures described herein.

Those skilled in the art will be able to recognize, or be able toascertain, using no more than routine experimentation, many equivalentsto the specific embodiments of the invention described herein. Suchequivalents are intended to be encompassed by the following claims.

What is claimed:
 1. A compound having the formula:

or physiologically acceptable salt thereof, wherein: n is one to four; Mis >NR² or >CR¹R²; R¹ is —H, —OH, —N₃, a halogen, an aliphatic group, asubstituted aliphatic group, an aminoalkyl group, —O-(aliphatic group),—O-(substituted aliphatic group), —SH, —S-(aliphatic group),—S-(substituted aliphatic group), —OC(O)-(aliphatic group),—O—C(O)-(substituted aliphatic group), —C(O)O-(aliphatic group),—C(O)O-(substituted aliphatic group), —COOH, —CN, —CO—NR³R⁴, —NR³R⁴ orR¹ is a covalent bond between the ring atom at M and an adjacent carbonatom in the ring which contains M; R² is —OH, a halogen, an acyl group,a substituted acyl group, —NR⁵R⁶, an aliphatic group, a substitutedaliphatic group, an aromatic group, a substituted aromatic group, abenzyl group, a substituted benzyl group, a non-aromatic heterocyclicgroup, a substituted non-aromatic heterocyclic group, —O-(substituted orunsubstituted aromatic group), —O-(substituted or unsubstitutedaliphatic group), —C(O)-(substituted or unsubstituted aromatic group) or—C(O)-(substituted or unsubstituted aliphatic group); R³, R⁴, R⁵ and R⁶are independently —H, an acyl group, a substituted acyl group, analiphatic group, a substituted aliphatic group, an aromatic group, asubstituted aromatic group, a benzyl group, a substituted benzyl group,a non-aromatic heterocyclic group or a substituted non-aromaticheterocyclic group; or R¹ and R², R³ and R⁴, or R⁵ and R⁶ taken togetherwith the atom to which they are bonded, form a substituted orunsubstituted non-aromatic carbocyclic or heterocyclic ring; R⁷⁰ and R⁷¹are independently —H, —OH, —N₃, a halogen, an aliphatic group, asubstituted aliphatic group, an aminoalkyl group, —O-(aliphatic group),—O-(substituted aliphatic group), —SH, —S-(aliphatic group),—S-(substituted aliphatic group), —OC(O)-(aliphatic group),—O—C(O)-(substituted aliphatic group), —C(O)O-(aliphatic group),—C(O)O-(substituted aliphatic group), —COOH, —CN, —CO—NR³R⁴, —NR³R⁴, anacyl group, a substituted acyl group, a benzyl group, a substitutedbenzyl group, a non-aromatic heterocyclic group, a substitutednon-aromatic heterocyclic group, —O-(substituted or unsubstitutedaromatic group); R⁷² and R⁷³ are independently —OH, —N₃, a halogen, analiphatic group, a substituted aliphatic group, an aminoalkyl group,—O-(aliphatic group), —O-(substituted aliphatic group), —SH,—S-(aliphatic group), —S-(substituted aliphatic group),—O—C(O)-(aliphatic group), —O—C(O)-(substituted aliphatic group),—C(O)O-(aliphatic group), —C(O)O-(substituted aliphatic group), —COOH,—CN, —CO—NR³R⁴, —NR³R⁴, an acyl group, a substituted acyl group, abenzyl group, a substituted benzyl group, a non-aromatic heterocyclicgroup, a substituted non-aromatic heterocyclic group, —O-(substituted orunsubstituted aromatic group); Z is

X₁ is —CH₂—O—, —O—CH₂—, —S—, —CH₂—, —CH₂—CH₂—, —CH₂—S—, —S—CH₂—,—NR_(c)—CH₂—, —SO—CH₂—, —CH₂—SO—, —S(O)₂—CH₂—, —CH₂—S(O)₂—, —CH═CH—,—NR_(c)—CO—, a bond, —O—, or —CO—NR_(c)—; R_(c) is —H, an aliphaticgroup, a substituted aliphatic group, an aromatic group, a substitutedaromatic group, a benzyl group or a substituted benzyl group; Rings Aand B are independently unsubstituted or substituted; said acyl group isan aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl or aromaticsulfonyl; said aliphatic group is a C₁-C₆ alkyl, alkenyl or alkynyl;said aromatic group is selected from the group consisting of phenyl,1-naphthyl, 2-naphthyl, 1-anthracyl, 2-anthracyl, N-imidazolyl,2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-thienyl, 3-thienyl,2-furanyl, 3-furanyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl,4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl,4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl,2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2-oxazolyl,4-oxazolyl, 5-oxazolyl, tetrahydronaphthyl, 2-benzothienyl,3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl,2-quinolinyl, 3-quinolinyl, 2-benzothiazolyl, 2-benzooxazolyl,2-benzimidazolyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl,3-isoindolyl, acridinyl, 3-benzisoxazolyl, benzocyclopentyl,benzocyclohexyl; said non-aromatic heterocyclic group is a five toeight-membered non-aromatic ring which contains one or more heteroatomsindependently selected from the group consisting of nitrogen, oxygen orsulfur; said substituted aliphatic group is substituted with one or moresubstitutents selected from the group consisting of oxo group, epoxygroup, non-aromatic heterocyclic ring, benzyl group, substituted benzylgroup, aromatic group or substituted aromatic group electron withdrawinggroup, halo, azido, —CN, —CONR²⁴R²⁵, —NR²⁴R²⁵, —OS(O)₂NR²⁴R²⁵,—S(O)₂NR²⁴R²⁵, —SO₃H, guanidino, oxalo, —C(═NR⁶⁰)NR²¹R²², ═NR⁶⁰,—(O)_(u)—(CH₂)_(t)—C(O)OR²⁰, —(O)_(u)—(CH₂)_(t)—OC(O)R²⁰,—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²², —(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H,-Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl),-Q-(aromatic group), -Q-(substituted aromatic group),-Q-(CH₂)_(p)-(substituted or unsubstituted aromatic group),-Q-(non-aromatic heterocyclic group) or -Q-(CH₂)_(p)-(non-aromaticheterocyclic group); said substituted non-aromatic heterocyclic ring issubstituted with one or more substitutents selected from the groupconsisting of ═O, ═S, electron withdrawing group, halo, azido, —CN,—CONR²⁴R²⁵, —NR²⁴R²⁵, —OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, guanidino,oxalo, —C(═NR⁶⁰)NR²¹R²², —NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²²,—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphatic group),-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group),-Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or-Q-(CH₂)_(p)-(non-aromatic heterocyclic group); said substitutedaromatic group, substituted benzyl group, Ring A when substituted andRing B when substituted, are substituted with one or more substitutentsselected from the group consisting of electron withdrawing group, halo,azido, —CN, —CONR²⁴R²⁵, —NR²⁴R²⁵, —OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H,guanidino, oxalo, —C(═NR⁶⁰)NR²¹R²², ═NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²²,—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphatic group),-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic gout)),-Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or-Q-(CH₂)_(p)-(non-aromatic heterocyclic group); Q is —O—, —S—, —S(O)—,—S(O)₂—, —OS(O)₂—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)C(O)—O—, —O—C(O)C(O)—,—NHC(O)—, —OC(O)NH—, —NH—C(O)—NH—, —S(O)₂NH—, —NHS(O)₂—, —C(NR²³)NHNH—,—NHNHC(NR²³)—, —NR²⁴C(O)— or —NR²⁴S(O)₂—; R²⁰, R²¹ and R²² areindependently —H, an aliphatic group, an aromatic group, a non-aromaticheterocyclic group, —NHC(O)—O-(aliphatic group), —NHC(O)—O-(aromaticgroup) or —NHC(O)—O-(non-aromatic heterocyclic group) or R²¹ and R²²,taken together with the nitrogen atom to which they are bonded, can forma substituted or unsubstituted non-aromatic heterocyclic ring; R²³ is—H, an aliphatic group, a benzyl group, an aryl group or non-aromaticheterocyclic group; R²⁴ and R²⁵ are independently —H, an aliphaticgroup, a substituted aliphatic group, a benzyl group, an aryl group,non-aromatic heterocyclic group or R²⁴ and R²⁵ taken together with thenitrogen atom to which they are bonded can form a substituted orunsubstituted non-aromatic heterocyclic ring. R⁶⁰ is a —H, —OH, —NH₂, anaromatic group or a substituted aromatic group. t is zero to three; u iszero or one; p is one to five.
 2. The compound of claim 1 wherein Ring Ais unsubstituted and B is substituted para to the carbon atom of ring Bthat is bonded to X₁ in ring C, and Z is represented by the structuralformula:

wherein R⁴⁰ is —OH, —COOH, —NO₂, halogen, aliphatic group, substitutedaliphatic group, an aromatic group, a substituted aromatic group,—NR²⁴R²⁵, —CONR²⁴R²⁵, —NR²⁴C(O)-(aliphatic group),—NR²⁴C(O)-(substituted aliphatic group), —NR²⁴S(O)₂-(aliphatic group),—NR²⁴S(O)₂-(substituted aliphatic group), —C(O)O-(aliphatic group),—C(O)O-(substituted aliphatic group), —C(O)-(aliphatic group),—C(O)-(substituted aliphatic group), —O-(aliphatic group),—O-(substituted aliphatic group), —O-(aromatic group), —O-(substitutedaromatic group), an electron withdrawing group,—(O)_(u)—(CH₂)_(t)—C(O)OR²⁰, —(O)_(u)—(CH₂)_(t)—OC(O)R²⁰,—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²² or —(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰; R²⁰,R²¹ or R²² are independently —H, an aliphatic group, a substitutedaliphatic group, an aromatic group, a substituted aromatic group or anon-aromatic heterocyclic group; or R²¹ and R²², taken together with thenitrogen atom to which they are bonded, form a non-aromatic heterocyclicring; R²⁴ and R²⁵ are independently —H, an aliphatic group or asubstituted aliphatic group; u is zero or one; and t is an integer fromzero to
 3. 3. The compound of claim 2 wherein M is >CR¹R²; R¹ is —H or—OH; and R² is a substituted aromatic group, wherein said substitutedaromatic group is 4-halophenyl.
 4. The compound of claim 3 wherein said4-halophenyl is selected from the group consisting of 4-chlorophenyl,4-bromophenyl and 4-fluorophenyl.
 5. The compound of claim 4 whereinsaid 4-halophenyl is 4-chlorophenyl.
 6. The compound of claim 3 whereinX_(i) is —CH₂—O—.
 7. The compound of claim 2 wherein at least one ofR⁷⁰, R⁷¹, R⁷² and R⁷³ is an aliphatic group or a substititued aliphaticgroup; wherein said aliphatic group is a C₁-C₆ alkyl and saidsubstituted aliphatic group is a C₁-C₆ alkyl substituted with asubstitutent selected from the group consisting of —OH,—(O)_(u)—(CH₂)_(t)—C(O)OR₂₀ and —O-(aliphatic group); t is zero tothree; u is zero or one; and R²⁰ is C₁-C₆ alkyl.
 8. The compound ofclaim 7 wherein R⁷⁰ and R⁷¹ are both —H; R⁷² and R⁷³ are independentlyselected from the group consisting of C₁-C₆ alkyl and substititued C₁-C₆alkyl.
 9. The compound of claim 8 wherein R⁷² is —CH₃.
 10. A method fortreating a disease associated with aberrant leukocyte recruitment,aberrant leukocyte activation or aberrant leukocyte recruitment andactivation, comprising administering to a subject in need thereof aneffective amount of a compound according to claim
 1. 11. Apharmaceutical composition comprising a compound according to claim 1and a physiologically acceptable carrier.
 12. A compound having theformula:

or physiologically acceptable salt thereof, wherein: n is one to four; Mis >CR¹R²; R¹ is —OH; R² is 4-halophenyl; R⁷⁰ and R⁷¹ are —H, and R⁷²and R⁷³ are —CH₃; or R⁷⁰ and R⁷¹ are —CH₃, and R⁷² and R⁷³ are —H; Z is

X₁ is —CH₂—O—; and R⁴⁰ is selected from the group consisting of:


13. The compound of claim 12 wherein R⁴⁰ is


14. The compound of claim 12 wherein said 4-halophenyl is selected fromthe group consisting of 4-chlorophenyl, 4-bromophenyl and4-fluorophenyl.
 15. The compound of claim 14 wherein said 4-halophenylis 4-chlorophenyl.
 16. The compound of claim 15 wherein R⁷⁰ and R⁷¹ are—H, R⁷² and R⁷³ are —CH₃, n is two, and the compound has the structure:


17. A method for treating a disease associated with aberrant leukocyterecruitment, activation or recruitment and activation, comprisingadministering to a subject in need thereof an effective amount of acompound of claim
 12. 18. A pharmaceutical composition comprising acompound of claim 12 and a physiologically acceptable carrier.
 19. Acompound having the structure:

or a physiologically acceptable salt thereof, wherein R² is4-halophenyl; and R⁴⁰ is selected from the group consisting of:


20. The compound of claim 19 wherein R⁴⁰ is


21. The compound of claim 19 wherein R² is selected from the groupconsisting of 4-chlorophenyl, 4-bromophenyl and 4-fluorophenyl.
 22. Thecompound of claim 21 wherein R² is 4-chlorophenyl.
 23. A pharmaceuticalcomposition comprising the compound of claim 18 and a physiologicallyacceptable carrier.
 24. A method for treating a disease associated withaberrant leukocyte recruitment, aberrant leukocyte activation oraberrant leukocyte recruitment and activation, comprising administeringto a subject in need thereof an effective amount of a compound of claim18.
 25. The method of claim 24 wherein said disease is selected from thegroup consisting of arthritis, atherosclerosis, arteriosclerosis,restenosis, ischemia/reperfusion injury, diabetes mellitus, psoriasis,multiple sclerosis, inflammatory bowel diseases, rejection of atransplanted organ or tissue, graft versus host disease, allergy andasthma.
 26. The method of claim 25 wherein said disease is multiplesclerosis.
 27. The method of claim 25 wherein said disease is arthritis,and said arthritis is rheumatoid arthritis.
 28. A compound having theformula:

or physiologically acceptable salt thereof, wherein: n is an integerfrom one to four; M is >NR², >CR¹R², —O—CR¹R²—O— or —CH₂—CR¹R²—O—; q¹ isan integer from zero to three; q² is zero or one; R¹ is —H, —OH, —N₃, ahalogen, an aliphatic group, a substituted aliphatic group, anaminoalkyl group, —O-(aliphatic group), —O-(substituted aliphaticgroup), —SH, —S-(aliphatic group), —S-(substituted aliphatic group),—OC(O)-(aliphatic group), —O—C(O)-(substituted aliphatic group),—C(O)O-(aliphatic group), —C(O)O-(substituted aliphatic group), —COOH,—CN, —CO—NR³R⁴, —NR³R⁴ or R¹ is a covalent bond between the ring atom atM and an adjacent carbon atom in the ring which contains M; R² is —OH, ahalogen, an acyl group, a substituted acyl group, —NR⁵R⁶, an aliphaticgroup, a substituted aliphatic group, an aromatic group, a substitutedaromatic group, a benzyl group, a substituted benzyl group, anon-aromatic heterocyclic group, a substituted non-aromatic heterocyclicgroup, —O-(substituted or unsubstituted aromatic group) or—O-(substituted or unsubstituted aliphatic group); R³, R⁴, R⁵ and R⁶ areindependently —H, an acyl group, a substituted acyl group, an aliphaticgroup, a substituted aliphatic group, an aromatic group, a substitutedaromatic group, a benzyl group, a substituted benzyl group, anon-aromatic heterocyclic group or a substituted non-aromaticheterocyclic group; or R¹ and R², R³ and R⁴, or R⁵ and R⁶ taken togetherwith the atom to which they are bonded, form a substituted orunsubstituted non-aromatic carbocyclic or heterocyclic ring; Z is:

X₁ is —S—, —CH₂—, —CH₂—CH₂—, —CH₂—S—, —S—CH₂—, —O—CH₂—, —CH₂—O—,—NR_(c)—CH₂—, —CH₂—NR_(c)—, —SO—CH₂—, —CH₂—SO—, —S(O)₂—CH₂—,—CH₂—S(O)₂—, —CH═CH—, —NR_(c)—CO—, a bond, —O—, or —CO—NR_(c)—; R_(c) is—H, an aliphatic group, a substituted aliphatic group, an aromaticgroup, a substituted aromatic group, a benzyl group or a substitutedbenzyl group; said acyl group is an aliphatic carbonyl, aromaticcarbonyl, aliphatic sulfonyl or aromatic sulfonyl said aliphatic groupis a C₁-C₆ alkyl, alkenyl or alkynyl; said aromatic group is selectedfrom the group consisting of phenyl, 1-naphthyl, 2-naphthyl,1-anthracyl, 2-anthracyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl,5-imidazolyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyrrolyl,3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl,5-pyrimidyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl,5-pyrazolyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl,5-tetrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, tetrahydronaphthyl,2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl,2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazolyl,2-benzooxazolyl, 2-benzimidazolyl, 1-isoquinolinyl, 3-quinolinyl,1-isoindolyl, 3-isoindolyl, acridinyl, 3-benzisoxazolyl,benzocyclopentyl, benzocyclohexyl; said non-aromatic heterocyclic groupis a five to eight-membered non-aromatic ring which contains one or moreheteroatoms independently selected from the group consisting ofnitrogen, oxygen or sulfur; said substituted aliphatic group issubstituted with one or more substitutents selected from the groupconsisting of oxo group, epoxy group, non-aromatic heterocyclic ring,benzyl group, substituted benzyl group, aromatic group or substitutedaromatic group electron withdrawing group, halo, azido, —CN, —CONR²⁴R²⁵,—NR²⁴R²⁵, —OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, guanidino, oxalo,—C(═NR⁶⁰)NR²¹R²², —NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)C(O)—NR²¹R²²,—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphatic group),-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group),-Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or-Q-(CH₂)_(p)-(non-aromatic heterocyclic group); said substitutednon-aromatic heterocyclic ring is substituted with one or moresubstitutents selected from the group consisting of ═O, ═S, electronwithdrawing group, halo, azido, —CN, —CONR²⁴R²⁵, —NR²⁴R²⁵,—OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, guanidino, oxalo,—C(═NR⁶⁰)NR²¹R²², ═NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²²,—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphatic group),-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group),-Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or-Q-(CH₂)_(p)-(non-aromatic heterocyclic group); said substitutedaromatic group and substituted benzyl group are substituted with one ormore substitutents selected from the group consisting of electronwithdrawing group, halo, azido, —CN, —CONR²⁴R²⁵, —NR²⁴R²⁵,—OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, guanidino, oxalo,—C(═NR⁶⁰)NR²¹R²², ═NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰,—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphaticgroup), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromaticgroup), -Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or-Q-(CH₂)_(p)-(non-aromatic heterocyclic group); Q is —O—, —S—, —S(O)—,—S(O)₂—, —OS(O)₂—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)C(O)—O—, —O—C(O)C(O)—,—NHC(O)—, —OC(O)NH—, —NH—C(O)—NH—, —S(O)₂NH—, —NHS(O)₂—, —C(NR²³)NHNH—,—NHNHC(NR²³)—, —NR²⁴C(O)— or —NR²⁴S(O)₂—; R²⁰, R²¹ and R²² areindependently —H, an aliphatic group, an aromatic group, a non-aromaticheterocyclic group, —NHC(O)—O-(aliphatic group), —NHC(O)—O-(aromaticgroup) or —NHC(O)—O-(non-aromatic heterocyclic group) or R²¹ and R²²,taken together with the nitrogen atom to which they are bonded, can forma substituted or unsubstituted non-aromatic heterocyclic ring; R²³ is—H, an aliphatic group, a benzyl group, an aryl group or non-aromaticheterocyclic group; R²⁴ and R²⁵ are independently —H, —OH, an aliphaticgroup, a substituted aliphatic group, a benzyl group, an aryl group,non-aromatic heterocyclic group or R²⁴ and R²⁵ taken together with thenitrogen atom to which they are bonded can form a substituted orunsubstituted non-aromatic heterocyclic ring; R⁶⁰ is a —H, —OH, —NH₂, anaromatic group or a substituted aromatic group; t is zero to three; u iszero or one; p is one to five; and R⁴⁰ is selected from the groupconsisting of


29. The compound of claim 28 wherein: q¹ is one; q² is one; M is >CR¹R²;R¹ is —H or —OH; and R² is a substituted aromatic group.
 30. Thecompound of claim 29 wherein R² is phenyl substituted with a halogen.31. The compound of claim 30 wherein R² is 4-chloropheynl.
 32. Thecompound of claim 31 wherein n is 2, X₁ is —CH₂—O—, and R¹ is —OH.
 33. Amethod for treating a disease associated with aberrant leukocyterecruitment, activation or recruitment and activation, comprisingadministering to a subject in need thereof an effective amount of acompound of claim
 28. 34. A pharmaceutical composition comprising acompound of claim 28 and a physiologically acceptable carrier.
 35. Acompound having the formula:

or physiologically acceptable salt thereof, wherein: n is one to four;R² is —OH, a halogen, an acyl group, a substituted acyl group, —NR⁵R⁶,an aliphatic group, a substituted aliphatic group, an aromatic group, asubstituted aromatic group, a benzyl group, a substituted benzyl group,a non-aromatic heterocyclic group, a substituted non-aromaticheterocyclic group, —O-(substituted or unsubstituted aromatic group) or—O-(substituted or unsubstituted aliphatic group); R⁵ and R⁶ areindependently —H, an acyl group, a substituted acyl group, an aliphaticgroup, a substituted aliphatic group, an aromatic group, a substitutedaromatic group, a benzyl group, a substituted benzyl group, anon-aromatic heterocyclic group or a substituted non-aromaticheterocyclic group; or R⁵ and R⁶ taken together with the atom to whichthey are bonded, form a substituted or unsubstituted non-aromaticcarbocyclic or heterocyclic ring; Z is:

X₁ is —S—, —CH₂—, —CH₂—CH₂—, —CH₂—S—, —S—CH₂—, —O—CH₂—, —CH₂—O—,—NR_(c)—CH₂—, —CH₂—NR_(c)—, —SO—CH₂—, —CH₂—SO—, —S(O)₂—CH₂—,—CH₂—S(O)₂—, —CH═CH—, —NR_(c)—CO—, a bond, —O—, or —CO—NR_(c)—; R_(c) is—H, an aliphatic group, a substituted aliphatic group, an aromaticgroup, a substituted aromatic group, a benzyl group or a substitutedbenzyl group; Rings A and B are independently unsubstited orsubstituted; said acyl group is an aliphatic carbonyl, aromaticcarbonyl, aliphatic sulfonyl or aromatic sulfonyl; said aliphatic groupis a C₁-C₆ alkyl, alkenyl or alkynyl; said aromatic group is selectedfrom the group consisting of phenyl, 1-naphthyl, 2-naphthyl,1-anthracyl, 2-anthracyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl,5-imidazolyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyrrolyl,3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl,5-pyrimidyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl,5-pyrazolyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl,5-tetrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, tetrahydronaphthyl,2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl,2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazolyl,2-benzooxazolyl, 2-benzimidazolyl, 1-isoquinolinyl, 3-quinolinyl,1-isoindolyl, 3-isoindolyl, acridinyl, 3-benzisoxazolyl,benzocyclopentyl, benzocyclohexyl; said non-aromatic heterocyclic groupis a five to eight-membered non-aromatic ring which contains one or moreheteroatoms independently selected from the group consisting ofnitrogen, oxygen or sulfur; said substituted aliphatic group issubstituted with one or more substitutents selected from the groupconsisting of oxo group, epoxy group, non-aromatic heterocyclic ring,benzyl group, substituted benzyl group, aromatic group or substitutedaromatic group electron withdrawing group, halo, azido, —CN, —CONR²⁴R²⁵,—NR²⁴R²⁵, —OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, guanidino, oxalo,—C(═NR⁶⁰)NR²¹R²², ═NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)—(CH₂)_(t)—OC(O)R²⁰, —(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²²,—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphatic group),-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group),-Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or-Q-(CH₂)_(p)-(non-aromatic heterocyclic group); said substitutednon-aromatic heterocyclic ring is substituted with one or moresubstitutents selected from the group consisting of ═O, ═S, electronwithdrawing group, halo, azido, —CN, —CONR²⁴R²⁵, —NR²⁴R²⁵,OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, guanidino, oxalo, —C(═NR⁶⁰)NR²¹R²²,═NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰, —(O)_(u)—(CH₂)_(t)—OC(O)R²⁰,—(O)_(u)—(CH₂)_(t)—C(O)—NR²¹R²², —(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H,-Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl),-Q-(aromatic group), -Q-(substituted aromatic group),-Q-(CH₂)_(p)-(substituted or unsubstituted aromatic group),-Q-(non-aromatic heterocyclic group) or -Q-(CH₂)_(p)-(non-aromaticheterocyclic group); said substituted aromatic group, substituted benzylgroup, Ring A when substituted and Ring B when substituted, aresubstituted with one or more substitutents selected from the groupconsisting of electron withdrawing group, halo, azido, —CN, —CONR²⁴R²⁵,—NR²⁴R²⁵, —OS(O)₂NR²⁴R²⁵, —S(O)₂NR²⁴R²⁵, —SO₃H, guanidino, oxalo,—C(═NR⁶⁰)NR²¹R²², ═NR⁶⁰, —(O)_(u)—(CH₂)_(t)—C(O)OR²⁰,—(O)_(u)(CH₂)_(t)—C(O)R²⁰, —(O)_(u)(CH₂)_(t)—C(O)—NR²¹R²²,—(O)_(u)—(CH₂)_(t)—NHC(O)O—R²⁰, -Q-H, -Q-(aliphatic group),-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group),-Q-(substituted aromatic group), -Q-(CH₂)_(p)-(substituted orunsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or-Q-(CH₂)_(p)-(non-aromatic heterocyclic group); Q is —O—, —S—, —S(O)—,—S(O)₂—, —OS(O)₂—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)C(O)—O—, —O—C(O)C(O)—,—NHC(O)—, —OC(O)NH—, —NH—C(O)—NH—, —S(O)₂NH—, —NHS(O)₂—, —C(NR²³)NHNH—,—NHNHC(NR²³)—, —NR²⁴C(O)— or —NR²⁴S(O)₂—; R²⁰, R²¹ and R²² areindependently —H, an aliphatic group, an aromatic group, a non-aromaticheterocyclic group, —NHC(O)—O-(aliphatic group), —NHC(O)—O-(aromaticgroup) or —NHC(O)—O-(non-aromatic heterocyclic group) or R²¹ and R²²,taken together with the nitrogen atom to which they are bonded, can forma substituted or unsubstituted non-aromatic heterocyclic ring; R²³ is—H, an aliphatic group, a benzyl group, an aryl group or non-aromaticheterocyclic group; R²⁴ and R²⁵ are independently —H, —OH, an aliphaticgroup, a substituted aliphatic group, a benzyl group, an aryl group,non-aromatic heterocyclic group or R²⁴ and R²⁵ taken together with thenitrogen atom to which they are bonded can form a substituted orunsubstituted non-aromatic heterocyclic ring; R⁶⁰ is a —H, —OH, —NH₂, anaromatic group or a substituted aromatic group; t is zero to three; u iszero or one; p is one to five.
 36. The compound according to claim 35wherein R² is —NR⁵R⁶.
 37. The compound of claim 36 wherein: R⁵ isaliphatic group or substituted aliphatic group; and R⁶ is benzyl orsubstituted benzyl; or R⁵ and R⁶ taken together with the atom to whichthey are bonded, form a substituted or unsubstituted non-aromaticcarbocyclic or heterocyclic ring.
 38. The compound of claim 37 whereinR⁵ is ethyl, and R⁶ is substituted benzyl, wherein said substitutedbenzyl is substituted with a halogen.
 39. A method for treating adisease associated with aberrant leukocyte recruitment, activation orrecruitment and activation, comprising administering to a subject inneed thereof an effective amount of a compound according to claim 35.40. A pharmaceutical composition comprising a compound according toclaim 35 and a physiologically acceptable carrier.
 41. A prodrug of thecompound of claim 12.